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 I 
Abstract 
HOX genes encode a family of transcription factors that play an essential role in embryonic patterning during foetal development. These genes are reported to be aberrantly expressed in numerous cancers, including glioblastoma (GBM). Previous research indicates that HOX genes are overexpressed in GBM tumours compared to normal human astrocytes (NHA). Three Amino Acid Loop Extension Homeobox (TALE) proteins act as important co-factors for HOX proteins, modulating their binding affinities to genomic targets. TALE members Pre-B-cell 
leukaemia homeobox (PBX) 1-4, bind anterior HOX proteins, facilitating cellular entry, while also limiting their degradation. HXR9, a small hexapeptide drug, has previously been shown to inhibit HOX-PBX dimers, causing rapid cell death in numerous solid and haemopoietic malignancies both in vitro and in vivo. HTL00-1 is a 2nd generation peptide based on HXR9, while ICT9119 is a small molecular inhibitor with the same binding site as the peptide inhibitors. 
We found clear evidence of overexpression of both HOX and TALE genes, in both adult and paediatric GBM cell lines. A further elevation in expression of these genes was visible in GBM cancer stem cells (CSCs). Normal adult brain tissue expressed low to undetectable levels of HOX genes, while paediatric brains expressed high levels between 0-4 years of age, before dramatically reducing from ages 5 onwards. HOX-PBX inhibitors are shown to be both cytostatic and cytotoxic when used to treat adult and paediatric GBM cells both in vitro and in vivo. GBM CSCs were more sensitive to HOX-PBX inhibition, alluding to their increased reliance on these genes. HTL00-1 and ICT9119 were shown to provide improved pharmacological effects compared to their predecessor HXR9. All HOX-PBX 
 II 
inhibitors cause apoptosis through induction of Fos Proto-Oncogene AP-1 
Transcription Factor Subunit (C-Fos) expression, which results in the dimerization of C-Fos and Jun Proto-Oncogene AP-1 Transcription Factor Subunit (C-Jun) to form the Activator protein 1 (AP-1) complex. This directly and indirectly represses B-cell lymphoma 2 (Bcl-2) expression leading to the release, and subsequent cleavage of caspase 3 and 7. This triggers the caspase cascade that concludes with cellular apoptosis. 
Radiotherapy (RT), combined with ICT9119 treatment proved highly synergistic in terms of cell kill when applied in combination when cancer cells were exposed to RT 24 hours prior to ICT9119. When ICT9119 was delivered 24 hours prior to RT antagonistic effects were observed. Attempts to identify the molecular mechanisms behind differing sequential treatment outcomes proved inconclusive. However, our work did suggest a mixture of cell cycle sequestration, C-Jun induction and the opposing effects of dual specific phosphatase 1 (DUSP1) and Mitogen-activated protein kinases (MAPK) were at least partly involved. 
This study highlights the important role of HOX genes in paediatric and adult gliomas, the potential utility of HOX/TALE gene expression in the identification of CSC population in patients and potential for HOX-PBX inhibition as a highly targeted effective treatment for adult and paediatric GBM patients. This treatment can be administered in the form of a peptide, as in HXR9 or HTL00-1, or as a small molecular agent in the form of ICT9119, either as single agents, or in combination with RT. HOX-PBX disruption as described in this thesis could potentially be moved rapidly into the clinic, in an area of very high unmet need. 
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Thesis Introduction 
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1 Thesis Introduction 
1.1 Cancer  Cancer is defined as an uncontrolled division of abnormal cells, which can arise in the various organs or tissues of the body, but has the potential to invade or metastasis to local and/or distal sites. Cancer is a major global health dilemma, bridging people of all socio-economic groups, unlike any other disease. This dilemma is worsening at an alarming rate, with incidence rates and cancer associated deaths increasing over the last century.  The global burden cancer carries has seen billions of pounds spent on research and treatment over the last decade alone, with an increase in cancer related spending only set to continue to increase. In 2014 the UK alone had 356,860 new cases of cancers being diagnosed, with 163,444 cancer associated deaths [1]. The NHS spent £6.01 billion on cancer treatment, with this being the second highest area of NHS spending across all disease related expenditures.   
1.1.1 Hallmarks of Cancer Cancer is a highly complex disease, with a single tumour aberrantly expressing thousands of genes at any one given time. This is all while modulating neighbouring aberrant and healthy cells, while manipulating it’s microenvironment and the host’s immune system. These complex processes can be simplified and grouped into the ‘hallmarks’ of cancer as initially proposed by Hanahan and Weinberg and later revised [2, 3]. It is proposed that normal cells evolve to a malignant state by acquiring malignant traits that are defined by the 10 hallmarks of cancer. Figure 1.1 [3] lists the 10 hallmarks of cancer.  
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Figure 1.1: An illustration of the 10 hallmarks of cancers. The 10 hallmarks of cancer are commonly 
shared between all different cancer types and are seen as key progression checkpoints reached by 
malignantly developing cancer cells. Adapted from Hanahan et al (2011). 
The 10 hallmarks of cancer can be used to explain key events in the initiation, promotion and progression of cancer. Initiation of cancer is caused by genomic instability, which induces mutations that permits cells to proliferate rapidly, circumvent cell cycle checkpoints, and other internal and external growth suppression signals. The newly formed aberrant mass must then acquire replication immortality, and resistance to cell death signals, as well as reprogramming energy metabolism to meet an increased demand. The promotion of cancer is then characterised by modulation of the tumour microenvironment, tumour promoted inflammation, and the formation of new blood vessels through angiogenesis. This is also accompanied by evasion of the immune system. Progression is represented by further genomic mutations allowing cancer cells to undergo epithelial-mesenchymal transition (EMT) that allow for invasion and metastasis.  
10 
Hallmarks 
of Cancer 
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These hallmarks are reached by a series of somatic mutations that can be broadly grouped into two classifications: driver and passenger mutations. Driver mutations are positively selected during cancer development and provide growth advantages to cancer cells harbouring them [4]. The acquisition of single or multiple driver mutations are essential for the transition of cancer cells through initiation, promotion, and progression of cancer. Passenger mutations can be by-products of cancer cell development, and do not directly contribute to cancer development. These mutations can be directly associated to driver mutations, and are in general more frequent. Figure 1.2 [4] depicts the process of somatic mutations leading to cancer formation.  
 
Figure 1.2: A diagram showing how somatic and passenger mutations are acquired. Somatic mutations 
are acquired post- and prenatally. These mutations can be induced by intrinsic cellular processes, or 
by external environmental mutagens. Passenger mutations can be acquired without phenotypically 
changing the host cell. However, driver mutations lead to irreversible changes in genomic phenotype, 
causing malignant cellular characteristics. Chemotherapy, as well as radiotherapy (RT), can lead to 
additional driver mutations that are specific to treatment resistance. Adapted from Stratton et al 
(2009).  
Epigenetic changes influence the spatial and temporal expression of genes during cellular cycles. In tumour evolution, epigenetic regulators can be broadly classified into three groups: epigenetic modulators, epigenetic modifiers and epigenetic mediators [5]. Epigenetic modulators are genes, which mutated or not, 
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are able to repress or activate epigenetic machinery in cancer cells. Epigenetic modifiers are mutated or un-mutated genes that modify DNA methylation, chromatin structure or transcriptional interpretation of DNA in cancer cells. Lastly, epigenetic mediators are genes directly regulated by one or more epigenetic modifiers, promoting cancer cells to increase pluripotency and survival. This is key for cells to obtain stem cell like phenotypes. 
1.2 Epidemiology of Brain and Central Nervous System 
Tumours Brain tumours are one of the rarest cancers and account for 3% of the overall cancer occurrences in the UK [6]. These tumours populate various areas of the brain and central nervous system (CNS). Currently there are more than 120 brain and CNS tumour sub-types. However, this number is consistently being revised as new sub-groups are being defined with new genomic and histological markers being identified.  
In 2013, 10,624 people in the UK were diagnosed with a brain or CNS tumour, with 4,973 of these cases found to be malignant [6]. 94% of all malignant CNS tumours are from tumours residing in the brain itself. It has been estimated that there are on average 6-11 new cases of primary intracranial tumours, which include meningiomas, per 100,000 population per year in men, and 4–11 new cases in women, in Western Europe, North America and Australia [7]. A visible trend also shows that incidences of brain tumours are higher in developed, industrialised countries [7]. In the UK malignant brain tumour prevalence has risen by 39% since the 1970s. This is mainly due to increased access to diagnostic scanning machines, 
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as well as improvements in scanning techniques. In children, brain tumours claim more lives than leukaemia, which is the second highest paediatric related cancer.  
1.2.1 Brain tumour Classification Brain tumours can be initially divided into two major groups, primary and secondary. Primary brain tumours are tumours that have originated from cells that are native to the brain. Secondary brain tumours are caused by metastasis of tumours from other sites of the body. The main contributors to secondary brain tumours are: lung, breast, skin, kidney and gastrointestinal tract cancer [8]. There are numerous sub-classes of primary brain tumours including: meningioma, medulloblastoma, acoustic neuroma, pineal region tumours, ependymomas and gliomas.  
Gliomas have been shown to account for over half of all primary brain tumours, and are the most prevalent brain tumour sub-type. Gliomas arise from glial cells, which have a multitude of functions in the brain. These functions range from the production and maintenance of cerebrospinal fluid (CSF), myelination of neurons, and the absorption and secretion of ions in the brain to maintain homeostasis.  In additon to this they are integral to a fully functioning blood brain barrier (BBB), and provide pathogenic defence. Glial cells are best described as ‘supportive tissue’. There are four different types of glial cells, which are listed in Table 1.1. 
Figure 1.3 [9] showing the structural arrangement of glial cells in the brain. Some gliomas present with distinct morphological subpopulations characterised by cells that arise from different glial types. These gliomas are referred to as mixed gliomas.   
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Table 1.1: Table showing the main functions of the different types of glial cells found in the brain. 
Glial Cell Types Cell Function 
Astrocytes 
Provides the neurons and various vessels of the brain with ‘molecular scaffolding’ and helps control brain plasticity. Also helps exert homeostatic control in the brain. 
Oligodendrocyte 
Main function is to provide insulation to neurones in the brain through multiple processes that extend out from the main body of the oligodendrocyte to the neurone. These processes wrap around the neurones creating multiple myelin sheathes, which in turn allow for fast and more efficient transduction of electrical signals in the brain. 
Ependymal Cells 
These cells line the cavities of the brain. They help protect the brain and also maintain the correct level of CSF and its constant movement. The function is mediated by the ependymal cells’ ability to produce CSF and absorb it though their many microvilli. The beating of cilia on the ependymal cells causes the movement of CSF. 
Microglial 
Microglial cells are the resident macrophages of the CNS, providing first line active immune defence.   
 
 
 
 
 
 
 
 
 
Figure 1.3: Structure and arrangement of astrocytes, oligodendrocytes and ependymal cells in the 
brain. Astrocytes and oligodendrocytes provide structural support to neurons, as well as myelination 
to provide faster transmission of electrical impulses. Additionally, they are integral to the structural 
integrity of BBB. Astrocytes also provide nutrients to neurones, while also maintaining an optimum 
extracellular environment. Ependymal cells secret and absorb CSF to maintain optimal levels, while 
also insuring its constant circulation via its microvilli.  Microglial cells scavenge dead cells, in addition 
to phagocytosis of pathogens. Adapted from Neurones and Glias Cells (2013). 
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1.3 Glioblastoma  Astrocytomas are the malignant progeny of astrocytes, and make up 35% of all brain tumours [10]. Asrocytomas are graded in order of increasing malignancy from I-IV [11]. Table 1.2 lists the different types of astrocytoma and their malignancy grade [11]. A grade IV astrocytoma is commonly referred to as a glioblastoma (GBM) [11, 12]. Initially GBM was called Glioblastoma multiforme because of its pleomorphic appearance but now the multiforme part of their name has been dropped [13].  
Table 1.2: Table showing the different grades of astrocytoma’s, their prevalence and medial survival. 
Adapted from [12]. 
Grade WHO Designation Percentage of all gliomas Median Survival (years) 
I Pilocytic astrocytoma <5% >10 
II Well-differentiated astrocytoma 25-30% >5 
III Anaplastic astrocytoma 25-30% 3 
IV Glioblastoma 40-50% 1  GBM is the most common and malignant sub-type of brain and CNS tumour. With its aggressive nature, its propensity to invade neighbouring tissue, heterogeneous cellular population and it’s highly specialised survival mechanisms, it is seen as one of the greatest treatment challenges in oncology [10, 14]. GBM’s are believed to have two distinct initiation pathways, which form two different sub-classes [12]. One of these sub classes is de novo (primary) GBMs that account for 60% of all cases [15]. The second sub-class is referred to as secondary GBMs, and make up the remaining 40% [15]. The current consensus is that de novo GBMs originate from astrocytes or from astrocytic precursor cells. The latter notion is strengthened by the discovery of cancer stem cells (CSCs) found within GBM 
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tumours [16, 17]. In contrast secondary GBMs are derived from low grade astrocytomas which slowly progress through the grades until they reach grade IV, GBM [18]. De novo GBMs can develop in a matter of months whilst secondary GBMs can take as long as 10 years to develop. Figure 1.4 [19] lists the common genetic mutations that leads to the formation of primary and secondary GBMs. 
 
Figure 1.4: A schematic representing of glioma development. PTENPA (Pilocytic astrocytoma), PXA 
(Pleomorphic xanthoastrocytoma), GBM (Glioblastoma), A (Astrocytoma), DA (Diffuse astrocytoma), 
AA (Anaplastic astrocytoma), OA (Oligoastrocytoma), AOA (Anaplastic oligoastrocytoma), O 
(Oligodendroglioma), AO (Anaplastic oligodendroglioma). Ichimura et al (2012). 
There are various challenges that face neuro-oncologists in the treatment and research of GBM. One of these is the complex tumour microenvironment present in the brain. It has been generally accepted that the tumour microenvironment is critical in influencing both tumour and non-tumorigenic cell behaviour and evolution [20]. GBM tumours are complex ‘ecosystems’ that dynamically adjust over time in response to changes in their microenvironment including genotoxic stress, immune responses, metabolic demands and vascular supply. These are 
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seen as major contributing factors in the heterogeneous nature of GBM [21]. Initially the central nervous system (CNS) was deemed to be an immune privileged area of the body. This was be due to the lack of lymphatic drainage, the apparent immunoincompetance of microglial cells, and the isolatory effects of the BBB segregating the CNS from the immune system [22]. This viewpoint has dramatically altered in light of new experimental data, highlighting that the CNS is neither passive nor isolated in it interactions with the immune system. This is indicated by the ability of peripheral immune cells to cross an intact BBB, CNS glial and neurones to actively regulate macrophage and lymphocyte responses, and the realisation that microglia are in fact immunocompetent.    
1.3.1 Glioblastoma Epidemiology  The prognosis for GBM patients is extremely dire, with only on average 2% of patients aged 65 or older, and around 30% of those under the age of 45 years at diagnosis surviving for 2 or more years [23]. Furthermore, the five-year survival rate of GBM is only 10%. The median survival time for patients receiving adjuvant temozolomide and radiotherapy (RT) is 15 months [24, 25].  
Though children can develop GBMs, they are more prevalent in the elderly with 60% of cases diagnosed in patients aged between 55-75 years of age [18]. Reports are also showing an increasing trend in incidences [26, 27]. GBM occurs in both men and women but are 1.5 times more likely in men [28]. However, de novo GBMs are more common in men, while secondary GBMs are more common in women [23]. The aggressive and fast developing nature of de novo GBMs is reflected in the short survival time of 4.7 months [29]. This is significantly shorter then secondary GBM patients who had a survival time of 7.8 months [29].  Currently there are 
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studies looking into variations between GBM prevalance between developed and non-developed countries, which have seen as much as a threefold difference. Also there is gathering evidence that differences are apparent between ethnic groups within the same country. Such differences show GBM is more prevalent in white populations than in black populations [30].   
GBMs primarily develop in the white matter of the cerebral hemispheres, but have also been diagnosed in other parts of the brain, as well as in the brainstem or the spinal cord [11]. Though spinal cord GBMs are rare, they are more frequent in children than adults. Cerebellum GBM is also an extremely rare neoplasm. GBMs are often found near the corpus callosum which allows for tumour invasion from one hemisphere to another presenting a ‘butterfly’ tumour appearance [11]. These tumours are normally CSC enriched due to their close proximity to the ventricles of the brain which are stem cell production and maturation sites [31]. GBMs are highly invasive and aggressively spread into surrounding brain parenchyma. Surprisingly even with this invasive nature they are confined to the CNS and do not metastasise to distal organs or tissue [30].  
1.3.2 Glioblasoma Risk Factors There are various risk factors associated with GBM. They can be characterised into three categories: chemical, biological or physical [28]. These all contribute to increased GBM risk as they cause deoxyribonucleic acid (DNA) damage, by one mechanism or another. This DNA damage results in an accumulation of genetic mutations which leads to the acquisition of a malignant phenotype. This malignant phenotype allows cells to evade their cellular constraints, permitting them the 
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ability to divide uncontrollably, invade neighbouring tissue and establish their own microenvironment.    
1.3.2.1 Ionising Radiation The best-established risk factor, which is unanimously accepted between researchers, is exposure to therapeutic or high-dose radiation [23, 30]. RT on children with skin disorders, now discontinued, and leukaemia has been shown to increase glioma risk well into adulthood [28]. Diagnostic x-rays do not appear to have a link with increased brain tumours, but in contrast mouth dental x-rays has in a small number of studies [28]. Hiroshima atomic bomb survivors were shown to have an increased risk of brain tumours in proportion to their radiation exposure [28]. Surprisingly there is no evidence to show an increased risk due to 
in utero exposure to radiation by a developing foetus [28].    
1.3.2.2 Chemicals N-nitroso compounds are naturally occurring compounds that get maximum exposure to humans through foods such as vegetables and cured meats [23, 28]. These compounds are alkylating agents with the ability to produce free radicals, and have a high penetration potential to cross the BBB. This ability coupled with their cacogenic properties make them ideal candidates as tumorigenic initiators. Numerous studies have looked at the effects of dietary and environmental N-nitroso compounds in humans, and the potential protective effect of consuming antioxidants. Antioxidants are compounds that limit/stop oxidation reactions, which produce free radicals. Sources of antioxidants include fresh fruit and vegetables, supplements and endogenous metabolic pathways [28]. As there is a conflict between N-nitroso compounds as well as antioxidants consumed, causing 
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inaccurate study findings [24]. This has led to many researchers discrediting its actual neuro-carcinogenic potential [24].  
Aspartame is a common low calorie sweetener first discovered in 1965. Aspartame is used in a number of products ranging from beverages, chewing gum, yogurt, cooking sauces, cereals and many more. Aspartame has come under scrutiny as a possible neuro-carcinogen, but there is much controversy over study’s findings [24]. This has meant that aspartame is in a state of limbo over its carcinogenic abilities and is still to this day banned in certain countries.   
Adult smoking and maternal smoking during pregnancy is another possible neuro-carcinogen that has shown no association with increased GBM risk [32-34]. This can be due to many of the constituents not being able to pass through the blood-brain barrier [28]. Similarly, there is no correlation seen between GBM and alcohol consumption. Other studies point to an increased glioma risk, including GBM, with the use of plastics, rubber products, arsenic, mercury and petroleum products [35, 36]. This can confidently be linked to the known carcinogens that these products possess or are used during their production. 
1.3.2.3 Genetics and Diseases There are certain inherited syndromes that provide a genetic predisposition to developing GBM. These rare hereditary syndromes include familiar schwannomatosis, Li-fraumeni, neurofibromatosis type 1 and 2, Turcot, tuberous sclerosis and Cowden [37, 38]. It must be noted that these disorders account for less than 2% of GBM [28].  
However, some diseases show an inverse correlation with glioma risk. These include chicken pox, asthma, eczema, hay fever, other allergies, IgG antibodies to 
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varicella-zoster virus and high levels of IgE antibody [39-41]. This inverse correlation alludes to an influence of immunological factors on the development of gliomas.  
1.3.2.4 Occupation Epidemiology studies have shown that certain occupations provide an increased risk of gliomas. These occupations include anatomists, pathologists and embalmers [42-45]. This increased risk was accredited to the use of formaldehyde, although its use in an industrial setting did not show an increased risk of gioma. Other studies have looked at the various industries that expose their employees to certain known neurotoxins. This includes organic solvents, polycyclic aromatic hydrocarbons, phenols and lubricating oils [28]. Despite a vast and diverse set of studies there has been no consistent data showing any of the aforementioned chemicals posing an increased risk [28]. However, these studies did show that employees in the petrochemical and oil industry did have an increased risk, but the underlying reason is still yet to be discovered. Other associated occupations include fire fighters and farmers but again there is no understanding as for the reason [46-48].  
1.3.2.5 Mobile Phones Mobile phones operate using radio frequencies, part of the electromagnetic spectrum, and are located between FM radio waves and waves occupied by microwave ovens, satellite stations and radar. This close proximity to microwave oven frequencies is the bases of many concerns and generated a considerable amount of media and public attention [49-52]. To date there is a considerable amount of data that shows mobile phone usage does not increase risk of glioma, 
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and the few studies that have shown a correlation have many discrepancies in their methodology making their data moot. It is also important to note that with the explosion of mobile phone usage and sales, there has not been a proportional rise, in the slightest, of brain tumour incidences. This means this issue is still in a state of limbo as research findings between groups remain inconsistent [53].  
1.3.2.6 Low Frequency Electromagnetic Fields Low frequency electromagnetic fields (LF-EF) are defined as frequencies between 50-60 Hz. These frequencies are used in domestic and industrial electrical supply. This is an intriguing potential risk factor as it has virtually universal exposure to the population. The theory behind the possible risk factor of LF-EF is that cellular metabolic pathways and DNA may be affected. Like many epidemiology studies, there has been contrasting results. Some studies show a weak association between LF-EF and brain tumours [54, 55]. On the other hand, other studies fail to prove a significant correlation [56-58]. Variations can in part be explained by varying methodologies and sample sizes [28]. This makes comparisons and interpretation of results extremely problematic, producing dubious conclusions. Similarly, to adult brain tumours, paediatric brain tumours have shown no link to LF-EF [59-61].  
1.3.2.7 Head Trauma Head trauma is another contentious risk factor for glioma. There has been cases reporting the development of glioma at the site of head injury [7]. Most cases reporting head trauma as a risk factor do so on the caveat that it is only effective in the presence of elevated carcinogens [62]. The biological basis of this is that once glial cells undergo severe kinetic trauma, they undergo gliosis, which causes 
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oedema, and thus hypertrophy [63]. This hypertrophy is believed to exert its influence on the BBB, causing its protection potential to be altered. As the cerebrovascular architecture of the brain is altered, there is a potential influx of carcinogens normally excluded by the BBB to enter the brain [63]. Another plausible risk is that as the BBB is breached, the brain is exposed to an elevated level of growth factors leading to uncontrolled division. Some studies have shown that head trauma elevated the risk of males developing any type of brain tumour by over four times [62, 64]. Several other studies have shown that repeated head trauma in males increased risk of glioma. Other epidemiology studies have found, in contrast, that a weak but inconsistant or insignificant association between head trauma and head injury [41, 65, 66]. An explanation for this variation could be because of ‘recall bias’ caused by the likelihood of brain tumour patients recalling head trauma more frequently than the general population. This alone renders most studies unfactual, without considering other their methodology deficiencies.  
1.3.2.8 Risk Factor Shortcomings As is apparent there is a failure to find statistically significant and consistent, findings for brain tumour risk factors. This can be due to a number of reasons including: small sample size, imprecise or invalid exposure measures, differential diffusion of chemicals across the BBB, disease heterogeneity, false positive results, inherited or developmental variations in metabolic and repair pathways, differentially expressed metabolic and repair pathways and unaccounted protection from unrelated disorders, such as allergies [67, 68].  
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1.3.3 Glioblastoma Symptoms  GBM patients can present with a multitude of symptoms with a high degree of variation between patients. This in most is due to different spatial placement of tumours, size of tumour and amount of oedema. It must also be noted that some patients do not present with any brain tumour specific symptoms and are only diagnosed with a brain tumour at autopsy.  
The most common symptom, which is present in 50% of patients at diagnosis, is headaches [69]. Intriguingly, headaches present with a nonspecific pattern and do not coordinate with tumour position. One of the most common symptoms in brain tumours is seizures [70]. These are normally focal-onset seizures and overall around 20-40% of brain tumour patients are affected [71, 72]. Other symptoms include cognitive difficulties and personality changes. Worryingly these are mistaken for psychiatric disorders or dementia, particularly in elderly patients [13, 30]. Incontinence and gait imbalance can also be present, and usually accompany large tumours. Depending on tumour location hemiparesis, sensory loss or visual field disturbance is not uncommon. Papilledema is also associated with severe oedema and thus raised intracranial pressure, caused by a brain tumour [30]. Thankfully this is becoming a rarity because of more effective imaging being performed early on in tumour development. Other focal signs include hemiparesis, sensory loss, palsy, speech disorders and visual field disturbances [30, 70]. As these symptoms can have a rapid onset, they can mimic, and in return be mistaken as a stroke. Speech disorders can also be wrongly diagnosed as confusion or delirium. Generalised cancer symptoms such as vomiting, loss of appetite, changes in mood and personality can also be observed.  
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1.3.4 Glioblastoma Histology and Immunohistochemical Markers The histological hallmarks of glioblastoma include diffuse infiltration, robust angiogenesis, resistance to apoptosis, genomic instability, a necrotic core and cellular proliferation [18, 73]. Other common histological features include vascular proliferation, peritumoral vasogenic edema, and leaky and chaotic blood vessel arrangement [30, 70, 74-76]. These tumours are normally focal but can present as multifocal lesions [30].  
Recently there has been a rapid rise in the use of immunohistochemical markers in the diagnosis and classification of gliomas. Glioblastomas can be diagnosed using various markers. These markers include glial fibrillary acidic protein (GFAP), oligodendrocyte transcription factor 2 (OLIG2) and S100 calcium-binding protein B (S100B). GFAP is expressed in both normal and malignant astrocytes, but is rarely expressed in oligodendroglial lineages [18].  OLIG2 is another glial marker, which is expressed in both GBM, and glioma cancer stem cells (GSCs) [77, 78]. S100B is a cellular marker that is shared between astrocytes, oligodendrocytes and glial precursor cells.  
1.3.5 Molecular Genetics Genetic profiling of cancer has become part of the foundation of developing new drugs as it unveils new treatment targets. Like other cancers, GBM is caused by numerous genetic alterations including: DNA mutations, copy number aberrations, DNA and histone epigenetic modifications and chromosomal rearrangements [79]. This genetic profiling has shown that primary and secondary GBMs can be distinguished by ‘hallmark’ mutations, providing distinct phenotypes [80]. De Novo’s key distinguishing mutations are epithelial growth 
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factor receptor (EGFR) amplification, mouse double minute 2 (MDM2) amplification and phosphate and tensin homolog (PTEN) mutation [81]. Secondary GBMs can be defined by tumour protein 53 (p53) mutation, overexpression of platelet-derived 
growth factor receptor (PDGFR) and loss of heterozygosity (LOH) of 17p and 19q [81]. It must be stressed that these genetic abnormalities are not strictly confined to their sub-class, but are used as an indicator.   
Recently 4 transcriptional subclasses in GBM have been discovered using genome-wide expression studies. These subclasses are known as Classical, Mesenchymal, Proneural and Neural [82, 83]. The Classical GBM subclass displays chromosome 10 deletion, Ink4a/ARF locus deletion, chromosome 7 amplification, EGFR amplification and EGFR mutations [13]. The Mesenchymal subclass is characterised by having a high frequency of neural-specific neurofibromatosis type 
1 gene (NF1) mutation/deletion and high expression of MET, Chitinase-3-Like protein 1 (CHI3L1) and genes involved in the tumour necrosis factor and nuclear factor- Kappa B (NF-κB) pathways [13]. Typically Proneural GBMs display 
PDGFRA alterations and mutations in isocitrate dehydrogenase 1 (IDH1) and P53 [13]. The Neural subclass is simply represented as GBMs which display neuronal markers [13]. While to date there has been many reported alterations in signalling pathways including Wingless-Type MMTV Integration Site Family Member 1 (Wnt), Neurogenic Locus Notch Homologue Protein (Notch) and sonic hedgehog (Shh), which are extremely relevant to CSCs, the most frequent alterations occur in the retinoblastoma (Rb), p53 and phosphatidylinositol 3-kinase (PI3K)/ 
PTEN/RAC-alpha serine/threonine-protein kinase B (AKT) pathways [79, 84, 85].  
Figure 1.5 [86] lists the main genetical differences between Classical, Mesenchymal, Proneural and Neural GBM subtypes.  
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Figure 1.5: Diagram showing differential gene expression in the 4 main GBM subtypes. Adapted from 
Van Meir et al (2010). 
1.3.5.1 p16INK4a/ Retinoblastoma (Rb) Pathway Rb is a critical element in the cell cycle and its mechanism is essential for permitting the cell to progress past its restriction point and exit Gap 1 (G1) phase into Synthesis (S) phase. If p53 is seen as the guardian of the genome, then Rb is the metaphorical ‘gate’. It has been shown that cells require several hours of serum mitogen stimulus to enter G1 from mitosis (M) and progress to the restriction point [87]. Once a cell progresses past the restriction point it becomes relatively serum independent [88]. After passing through the restriction point the cell is committed to pass through the full cell cycle and divide, unless exonerated due to cellular stress such as DNA or mitochondrial damage.  Hypophosphorylated Rb has been shown to bind and suppress the functions of E2 Factor (E2F), an important transcription factor which transcribes genes critical 
 21 
for cell cycle progression [89]. When Rb is hyperphosphorylated it loses its ability to bind, and thus suppress, E2F (Figure 1.6) [87, 90]. This phosphorylation ‘opens the gate’ allowing the cell to move into late G1 and into S phase. The hyperphosphorylation of Rb is initially mediated by the cyclin D classes (D1, D2 and D3) bound to cyclin-dependent kinases (CDK) 4 or 6. In late G1 phase cyclin E is bound to its partner CDK2 which further phosphorylates Rb. These cyclin-CDK complexes are believed to direct enzymes which cause the phosphorylation of Rb.  GBMs being an extremely aggressive neoplasm have devised numerous ways to evade the control of Rb mediated cell cycle control [91]. In around 25% of high grade astrocytes the Rb1 gene, found on chromosome 13q14, is mutated/methylated or deleted because of loss of 13q, which is seen as a crucial step in the transition from a low to high grade astrocytoma [92, 93]. Other genomic changes which can be seen in approximately 15% of GBMs is the amplification of the CDK4 gene on chromosome 12q13-14, and the amplification of CDK6, but at a lower frequency, causing the functional inactivation of Rb [94, 95]. Rb function can also be hindered by the inactivation of a crucial protein, cyclin-dependent kinase inhibitor 2A, multiple tumor suppressor 1 (p16INK4a), which acts as a negative regulator of CDK4 and CDK6 [96]. This is caused by either allelic loss or hypermethylation of the gene cyclin-dependent kinase Inhibitor 2A (CDKN2A), locus situated on chromosome 9p21. This is seen in 50-70% of primary high grade gliomas, and approximately 90% of cultured glioma cell lines [97-101]. Dual functionality can be seen with p16INK4a, as it serves as a crucial inhibitor of progenitor cell renewal in the subventricular zone of the brain [102].  
Though this pathway is almost universally evident in both De Novo and secondary GBM subsets, it is not seen as a fundamental mutation [98, 103]. Extensive 
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research has been performed in vitro and in vivo showing that mutations affecting the Rb pathway is not sufficient alone to cause gliomagenesis, and rather a supportive role from other cell cycle regulatory pathways is required [104-110].  
  
 
 
 
 
 
 
 
 
Figure 1.6: Diagram illustrating the p16INK4a/Rb pathway. p16INK4a inhibits Cyclin D-CDK4/6 binding, 
thus inhibiting phosphorylation of Rb. Hypophosphorylated Rb binds and inhibits E2F, suppressing 
its transcriptional activating ability. Once Rb is hyperphosphorylated (P) it loses its ability to bind 
E2F. This allows E2F to translocate to the cells nucleus and promote transcription of pro-proliferative 
genes. 
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1.3.5.2 p14ARF/MDM2/p53 Pathway The p53 tumour suppressor is regarded by many as one of the most important genes present in multicellular organisms. It elicits its function on controlling the cell cycle and preventing propagation of cells with genetically unstable genomes. This is mediated by p53’s ability to halt a potential precancerous cell in the G1 phase of its cell cycle, and then divert the cell towards apoptosis or quiescence [111]. The mechanism by which this is achieved is through p53’s ability to act as a transcription factor. This is activated in response to various genotoxic and cytotoxic stress-sensing agents, leading to the stabilisation of p53, which then allows binding to the promoters of over 2500 potential effector genes [112, 113].  The p53 pathway is frequently altered in GBM and is reported as an early event in the progression of secondary GBM [114, 115]. However, it must be noted that p53 mutations also occur in De Novo GBMs at a low frequency, estimated at 30% [29]. The importance of p53 in gliomagenesis can be supported by the correlation between gliomas and Li-Fraumeni syndrome, which is associated with germline 
p53 mutations [116, 117]. This association has been proven by genetical engineering the commonly caused Li-Fraumeni p53 mutations in mice, which led to the formation of gliomas [118]. The function of p53 is altered through either loss of chromosome 17p or a point mutation which prevents DNA binding [114]. 
As previously described, the gene CDKN2A is the locus for the protein p16INK4a, but through an alternate secondary promoter, an alternatively spliced transcript produces an additional tumour suppressor, p14ARF tumour suppressor (p14ARF) [119]. This splice variant has the ability to inhibit MDM2, thus neutralising its ability to ubiquitinate p53, and allow p53 to promote the activation of p21, an inhibiter of CDK2 (Figure 1.7) [120-125]. Similar to its sister protein, p16INK4a, 
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p14ARF can be absent due to allelic loss or hypermethylation of the gene CDKN2A, which is a frequent event in GBM [126]. While p14ARF can be lost in GBM, its inhibition target, MDM2, has been shown to be amplified in approximately 10% of primary GBM’s [94]. An additional related protein, MDM4, has been shown to be amplified in GBM, and has been shown to inhibit p53 transcription, while also enhancing the ubiquitin ligase action of MDM2 [78, 127-129].  
 
 
 
 
 
  
 
 
Figure 1.7: Diagram depicting the p14ARF/MDM2/p53 pathway. In the absence of p14ARF, MDM2 
ubiquitinates (Ub) p53, leading to its degradation by the proteasome. This leads to a loss of p21 
expression, and subsequent loss of CDK2 suppression, causing uncontrolled cellular proliferation. 
p14ARF represses MDM2, inhibiting p53 degradation. p53 in turn up-regulates p21 leading to 
suppression of CDK2 activity.  
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1.3.5.3 MAPK Pathway Mitogen-activated protein kinases (MAPK) are a family of serine /threonine/ tyrosine-specific protein kinases that are related to CDKs. The MAPK pathway can be activated by the mitogenic transduction of integrins and receptor tyrosine kinases (RTKs).  
Integrins are important membrane-bound extracellular matrix (ECM) receptors, which allow the cell to anchor itself to the ECM. This process involves the binding of integrins to actin filaments forming a focal adhesion complex. This acts as a beacon, attracting multiple focal adhesion kinases (FAKs), which cluster and become activated through cross-phosphorylation. A signal transduction cascade ensues after FAK activation, leading to MAPK phosphorylation either through Ras activation, facilitated by growth factor receptor-bound 2 (Grb2) and Son of Sevenless (SOS) recruitment, or through Src-dependent phosphorylation of p130Cas [130]. Phosphorylation of MAPK leads to further phosphorylation of nuclear transcription factors leading to expression of cell cycle progression genes.  
RTKs can activate MAPK pathway when activated by growth factor binding, receptor mutation or overexpression of receptors. These events cause RTK activation through dimerization and cross-phosphorylation, which provides binding sites for proteins such as Grb2 and SOS, which then go on to activate Ras.  
Though Ras mutations are common in many forms of cancers, it is however, not a pre-dominate mutation target in GBM. This finding suggests that MAPK dependent tumour growth is caused further upstream of Ras, and most likely by inappropriate activation of integrins and/or RTKs [18].  
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1.3.5.4 EGFR/PI3K/PTEN/AKT The EGFR/PI3K/PTEN/AKT pathway has been reported to be a key signalling pathway in the development of De Novo GBMs [131]. Amplification of EGFR occurs in approximately 40% of all De Novo GBMs, but is rarely witnessed in secondary GBMs [81, 132-134]. A similar pattern can be seen with EGFR overexpression, where it is present in over 60% of primary GBMs, compared to only less than 10% of secondary GBMs [132]. EGFRs, especially variant 3, are also prone to mutations, with exons 2 or 7 deletions the most common [135]. These mutations are associated with continual activation of the receptor and an inability to attenuate signalling through receptor down regulation, leading to unceasing internal mitogenic signalling [136]. Continued activation of EGFR leads to enhanced cellular proliferation by down regulating p27 through the activation of PI3K/AKT pathway [137].  
EGFR is activated normally through the binding of growth factors, such as epidermal growth factor (EGF), transforming growth factor-alpha (TGF-α), to its extracellular domains, culminated in the localisation of PI3K to the cell membrane.  This is followed by phosphorylation of phosphatidynositol-4,5-bisphophate (PIP2) to phosphatidynositol-3,4,5-triphophate (PIP3). Production of PIP3 results in activation of AKT and mammalian target or rapamycin (mTOR). AKT and mTOR are both potent blockers of apoptosis and stimulators of proliferation (Figure 
1.8).  PI3K gain-of-function point mutation has also been reported in GBM [138-140].  AKT activation can become dysregulated in GBM through additional, PI3K independent, mechanisms. One of these mechanisms is modulated through the GTPase, PIKE-A, which is highly expressed in GBM, and directly binds to phosphorylated AKT, enhancing its anti-apoptotic potentials [141, 142].  
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PTEN is a gene, which is located at 10q23.3, and encodes a major tumour suppressor, that has been shown to regulate proliferation and migration [143, 144]. PTEN is important in controlling the PI3K signalling pathway and its loss of function leads to an inability to dephosphorylate PIP3, leading to uncontrolled proliferation and robust anti-apoptotic characteristics [29, 142]. PTEN has also been shown to exert control over cell migration and invasion by dephosphorylating focal adhesion kinases [145]. PTEN inactivation by mutations or epigenetic mechanisms can be seen in 50% of all high grade gliomas [29]. 
 
 
 
 
 
 
 
 
    
Figure 1.8: Diagram showing the EGFR/PI3K/PTEN/AKT pathway. Binding of EGF to EGFR leads to the 
localisation, and activation, of PI3K to the cellular membrane. PI3K phosphorylates PIP2 to form PIP3. 
This phosphorylation can be inhibited by PTEN. PIP3 activates AKT and mTOR, which are both potent 
anti-apoptosis, and pro-proliferative transcription factors.  
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1.3.5.5 H3F3A/ATRX/DAXX Chromatin Remodelling Paediatric GBM have a distinctly different molecular signature compared to their adult counterparts with the most frequent mutations involving the 
H3.3/ATRX/DAXX chromatin remodelling pathway [19]. Heterozygous mutations in H3 histone, family 3A (H3F3A) gene that causes amino acid changes in residues important for repression and activation functions. The mutation is almost universally accompanied by mutations in α-thalassaemia/mental retardation 
syndrom X-linked (ATRX) and/or death-domain associated protein (DAXX) [146].  ATRX and DAXX dimerise to form a chaperone protein for H3.3 and facilitate its incorporation at telomeres and pericentric heterochromatin [147]. Mutation in one or more of these genes leads to reduced H3.3 depositions in telomeres causing alternative lengthening of chromosomes. Telomeres are essential for maintaining the structural integrity of chromosomes and loss of telomere function leads to genomic instability [148, 149]. The dysregulation of telomere shortening, and its subsequent genomic instability, has been directly linked to the initiation of human disease [150, 151].  
1.3.6 Glioblastoma Treatments Improvement in the treatment of GBM over the past 4 decades has been minimal, and for many patients and clinicians the potential for new innovations, seen in other cancer models, looks bleak. Still to this day GBM is seen as an incurable disease with palliative care being the main focus. This care is purely aimed at improving quality of life while prolonging life expectancy.  
The standard therapy for newly diagnosed malignant gliomas consists of maximal safe surgical resection followed by fractionated focal conformal RT with adjuvant 
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oral temozolomide (TMZ) [25, 152]. The use of this treatment regime has seen a modest improvement in survival time of patients with a mean life expectancy of 15 months for GBM patients. The worldwide adoption of this treatment regime is based on the use of surgery to de-bulk the tumour while the adjuvant RT and chemotherapy is designed to slow tumour re-invasion of the resection cavity while also targeting tumour cells that have disseminated deep into healthy brain tissue. GBMs present unique treatment challenges for oncologists who have to navigate difficulties such as migration of tumour cells, tumour capillary leakage, neurotoxicity, poor drug delivery because of abnormal vascularity, limited capacity of the brain to heal itself and the protective effect of the BBB. However, this treatment strategy has clear fundamental flaws, which highlight the need for new, specialised, and cancer specific drugs.  
1.3.6.1 Neurosurgery  Unlike chemotherapy, neuro-surgery has seen a marked improvement with new techniques allowing surgeons to operate on a greater number of patients due to their ability to access and remove previously inaccessible tumours or tumours located in perceived precarious regions of the brain. The use of image-guided surgical techniques, including intraoperative magnetic resonance imaging (MRI), cortical mapping, and stereotactic surgery in GBM treatment has helped to maximise the area of safe tumour resection and allow for a more complete restoration of neurological function. One major weakness of surgery is its inability to be used on tumours that are situated in or invade into certain regions of the brain. This is due to the risk of cognitive impairment and potential alterations to areas of the brain that control homeostatic functions such as heart rate, breathing, 
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hormone release and many more. Examples of these cases are when GBMs invade into areas such as motor cortex or cerebellum. Invasion is also the reason why total resection of GBM tumours is impossible, as GBM tumours cells penetrate deep into healthy tissue evading the resection margins [10, 153, 154]. This problem is highlighted by the fact that 90% of GBMs recur at the primary site [76]. This means that surgery alone will never cure GBM but is useful in de-bulking tumour mass and as such provides a platform for RT and chemotherapy. Its use in alleviating cognitive symptoms, caused by raised intracranial pressure leading to potential loss of sight, hearing and movement is invaluable and provides an obvious improvement to these patients. It also allows for a more aggressive use of RT and chemotherapy, and a reduced need for steroids. This is because potential oedema in the brain is decreased by allowing fluid to drain into tumour resection site, which reduces the potential rise in intracranial pressure.  
1.3.6.2 Chemotherapy  Though there is a vast amount of chemotherapeutic drugs at the disposal of clinicians, the amount that can be used to treat intracranial tumours is significantly reduced. This is mainly because of poor drug delivery to the brain, attributed mainly to the protective effects of the BBB, and the sensitivity of the brain to toxicity [155, 156].  
One drug used is 1,3-bis(2-chloroethyl)-1-nitrosourea (Carmustine). Carmustine covalently bonds a chloroethyl group to the O6 position of guanine, causing cross-linkage of DNA strands, leading to impairment of DNA duplication and transcription [157]. Carmustine can be administered as either an oral tablet or as a wafer directly next to the tumour site. The wafer is normally implanted after 
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surgery and is used to target tumour cells that have evaded the resection margins. The advantage of the use of wafers is that they bypass the BBB, allowing for direct delivery of carmustine to the target site, and the avoidance of systemic toxicity. This refferable means a higher dosage can be permitted compared to oral delivery. GBM’s are prone to abnormal and leaky tumour vasculature, caused by high hydrostatic pressure in the tumour, which can reduce drug delivery to the tumour. The use of carmustine wafers can be used to overcome this impairment [158, 159]. The use of carmustine has been shown to improve overall survival benefit in GBM patients [160, 161]. Carmustine’s main toxicities are pulmonary toxicity and cumulative myelosuppression. An additional chloroethylating agent used in the treatment of GBM is lomustine (CCNU). This is normally taken in an oral form at a 40 mg dosage. Meta-analysis has shown that the use of CCNU increases the median survival time of patients when combined with other cytoxic drugs, though only marginally [162]. CCNU and carmustine are the current drugs used for recurrent GBM [163]. CCNU’s main toxicities are pulmonary toxicity, induced anaemia and myelosuppression. Another drug used in the treatment of GBM is vincristine (VCR). VCR is a vinca alkaloid first produced from the Catharanthus roseus, Madagascan periwinkle, and is known as a mitotic inhibitor. Its mechanism of action is to bind to tubulin dimers, which inhibits the assembly of microtubule structures resulting in mitotic arrest in metaphase. VCR is available in liquid form and is administered intravenously and normally in combination with other cytotoxic drugs [164-166]. Frequently used combinations combining VCR is VCR with CCNU and procarbazine (PRC), which has been shown to be an effective combination in the treatment of high grade gliomas [164]. Side effects of VCR 
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treatment include systemic damage to bone marrow and intestinal epithelium, anaemia and myelosuppression.  
1.3.6.3 Temozolomide (TMZ) The current ‘gold standard’ for GBM is the chemotherapeutic drug temozolomide (TMZ). TMZ is an imidazotetrazine second-generation alkylating agent, with a molecular weight of 194 Daltons (Da). TMZ is normally taken in an oral form but can be delivered intravenously. TMZ was first approved for use because of its small size and highly lipophilic nature. TMZ is rapidly absorbed through the digestive tract, and passes across the BBB, providing 100% bioavailability [167].  Plasma concentrations within the CNS is approximately 30-40% making it an ideal candidate for use in treating CNS neoplasms [167]. Added to this is a plethora of evidence showing evidence of tumour localisation of the drug [168]. Also unlike nitrosoureas and other alkylating agents that chemically cross-link DNA, TMZ is not associated with cumulative haematological toxicity, shown to be between 5-10%, and only has mild myelosuppression [167, 169]. To date TMZ is commonly used to treat high grade glioma and melanoma, however, can be used to treat other solid neoplasms [170-172]. Trials have shown that the addition of temozolomide to RT increased median survival to 15 months vs the 12 months with RT alone [152].   
Beyond the mild myelosuppression and the low haematologic toxicity, TMZ has the same adverse effects frequently shared by chemotherapeutics such as, moderate nausea, vomiting, headaches and constipation. More serious adverse effects that need constant monitoring are for signs of neutropenia and thrombocytopenia. Results of trials have demonstrated that temozolomide has 
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low toxicity and is generally well tolerated by adults when administered at a dose of 150 to 200 mg/m2 per day for five consecutive days of a 4-week cycle. 
1.3.6.3.1 TMZ Chemical Structure and Mechanism of Action TMZ is classed as an imidazotetrazine because it contains an imidazole ring. Structurally and functionally TMZ and dacarbazine (DTIC) are very similar and both share the secondary metabolite 3-methyl-(triazen-1-yl)imidazole-4-carboxamide  (MTIC). TMZ is robustly stable in the pH of the stomach but once it has entered the slightly basic pH of the blood stream and tissue, it spontaneously undergoes hydrolysis to form the secondary active metabolite MTIC [173, 174]. MTIC is unstable and rapidly degrades to the reactive end metabolite methyldiazonium ion [173]. The structure of TMZ and its metabolites can be seen in Figure 1.9 [173]. The methyldiazonium ion is cytotoxic because of its ability to methylate guanine residues in the DNA strands, resulting in the formation of O6- and N7-methylguanine [175, 176]. From these methylation products, it is O6-methylguanine that is accredited to TMZ and DTIC’s cytotoxic potential. This is due to the actions of DNA mismatch repair enzymes which attempt to excise O6-methylguanine. This attempted repair mechanism generates single and double strand breaks in the DNA. The formation of double and single strand breaks ceases the cell-cycle at the Gap phase 2 (G2)/M boundary, causing cell-cycle arrest, therefore triggering the apoptotic pathway leading to cell death. In comparison the cell reacts more efficiently in repairing N7-methylguanine and does not cause DNA damage during the repair process. A major benefit of TMZ and DTIC is that their cytotoxic effects do not cause chemical cross-linking of DNA strands [167]. This is a major perk over other chemotherapeutics such as carmustine, CCNU, PRC 
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and platinum compounds which do cause cross-linkage in DNA leading to a higher toxicity to haematopoietic progenitor cells in the bone marrow.  
                
Figure 1.9: Chemical structure of temozolomide (TMZ). TMZ has a molecular formula of C6H6N6O2 with 
an average mass of 194.150803 Da. In neutral to basic conditions in the presence of CO2, TMZ forms 
MTIC which degrades into the active metabolite Diazomethane. TMZ systematic name is 3-Methyl-4-
oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide. Adapted from Newlands et al 
(1997) 
1.3.6.4 Radiotherapy (RT) Post surgical RT is universally used whenever possible in the treatment of GBM. The currently accepted treatment regime is based on fractionated focal external radiation beam therapy (EBRT) delivered by a linear accelerator.  This allows high-energy photons to be delivered accurately to the resection cavity maximising dose delivery to cancer cells while minimising exposure to surrounding normal cells.  Hyperfractionated radiation therapy (HRT) is the most common RT regime. This delivers 60 grays (Gy) of radiation, administered in 30 fractions of 2 Gys over 
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a period of 4 to 6 weeks starting 2 weeks post surgery [177]. A Gy is defined as the absorption of one joule of ionising radiation by one kilogram (Kg) of matter (1 J/Kg). Escalating doses beyond 60Gy has shown to provide minimal survival benefit but causes significant cognitive impartment due to increased cytotoxicity [178]. Though less frequent, whole brain RT and brachytherapy, where radioactive wafers are placed within the resection cavity, can be employed in certain circumstances and normally in very elderly patients. Patients with inoperable brain tumours, in highly sensitive areas of the brain, can be treated with Stereotactic body radiation therapy (SBRT) treatment. CyberKnife® is a SBRT treatment which precisely targets tumour tissue with minimal damage to healthy adjacent tissue. This is crucial to targeting tumours in areas associated with cognitive and homeostatic functions. 
1.3.6.4.1 Radiotherapy Mechanism of Action Ionising radiation is defined as electromagnetic waves or particles with sufficient energy to remove orbiting electrons from atoms resulting in the atom becoming highly charged, ‘excited’, or ionised. Ionisation produces excited atoms and molecules, which causes the formation of reactive ions and free radicals. Cytotoxicity of ionising radiation is induced by direct energy deposition in cellular DNA or by the formation of reactive oxygen species (ROS) and/or reactive nitrogen species (RNS), commonly referred to as hydroxyl radicals, which indirectly damage DNA. This direct and indirect radiation based DNA damage leads to single and double strand breaks causing genomic instability. Genomic instability can lead to numerous types of cellular death, but can be overcome by the use of DNA repair pathways or further genomic mutations. Figure 1.10 [179] 
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and Figure 1.11 highlights the important events that ensue after ionising radiation is administered to cells. 
 
 
 
 
 
 
 
 
 
Figure 1.10: Diagram showing how ionising radiation causes DNA damage. Cluster damage of DNA is 
caused where ionisation/excited particles are high, while isolated damage is found at low ionisation 
sites. This damage leads to double and single strand breaks in the DNA. Adapted from Shikazono et al 
(2015)  
 
Figure 1.11: An illustration showing the effects of ionising radiation on cells at varying time frames. 
Ionisation damage is rapidly induced and persists for days and weeks after treatment. Cells can 
undergo multiple rounds of division before its cellular fate is determined.  
Cluster of DNA 
damage  
Isolated DNA 
damage  
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1.3.7 Treatment Resistance in Glioblastoma  
1.3.7.1 Blood-Brain Barrier (BBB) One of the major culprits for the lack of advances in therapeutic agents in neuro-oncology is the BBB. Many drugs have been shown to have promising treatment potential in GBM, but have failed to even reach clinical trials once their inability to cross the BBB has been realised. The BBB is formed by a complex mesh of various neural cell types that line the blood vessels of the CNS. The BBB protects the brain by regulating the passage of materials into and out of the brain, allowing essential molecules such as glucose and amino acids into the CNS, while preventing xenotoxins, ranging from bacteria to toxic substances, and large molecules from entering [180, 181]. Molecules with a molecular mass less than 300 Da, and lipophilic in nature, are able to passively cross the BBB. However, the vast majority of molecules greater than this 300 Da limit are prevented from crossing the BBB [182].   In addition to this size exclusion ability, the BBB uses efflux pumps such as P-glycoprotein (P-gp) and multi-drug resistance associated protein family (MRP) that actively transport unwanted molecules back into vascular system [183, 184]. 
1.3.7.1.1 Multidrug Resistance Associated Protein (MRP) The MRP family consists of 9 members, MRP1-9, which are classified as organic ion transport proteins. Various normal tissue types including muscle, lung, spleen, bladder, adrenal glands, gall bladder and the brain contain MRP1-9 expression. MRP1 is the most prevalently expressed MRP in the brain and blood capillaries of the BBB. The MRP family are part of ATP-binding cassette (ABC) super family. These transporters are composed of four domains, two membrane spanning, and two that remain in the cytoplasm. These cytoplasmic domains are known as 
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nucleotide binding domains, which function as the transporters ‘motor’, hydrolysing ATP to derive energy [185]. Their normal functions involves the transportation of sugars, amino acids, ions and small peptides across membranes, but have efflux potential against organic anion conjugates as well as intact anticancer drugs [186-188]. MRP1 is a 190kDa protein with certain similarity to P-gp. MRP1 can target anthracylines, antifolates and vinca alkaloids, with tissue expression levels directly correlating with GBM chemoresistance [189, 190]. Other MRP family members have been shown to provide resistance to a variety of drugs in GBM treatment [191-193].  
1.3.7.1.2 P-Glycoprotein (P-gp) Like the MRP family, P-gp expression is found in various tissues including capillaries, kidneys’, liver, intestines, adrenal glands, the brain and the BBB. P-gp is encoded by the ABCB1 gene, which produces a 170kDa transmembrane glycoprotein and is part of the ABC transporter family [194]. The N-terminus has an ATP-binding site used to hydrolyse ATP for energy to actively transport organic as well as some inorganic molecules. Drug acquired resistance has been accredited in part to up-regulation of P-gp [185, 195, 196]. P-gp has a wide spectrum of anticancer drug targets, able to efflux vinca alkaloids, anthracyclines, alkylating agents such as temozolomide, and an array of taxanes including vincristine, doxorubicin, vinblastine, paclitaxel, cytarabine etc [197, 198].  
1.3.7.2 DNA Damage Repair Mechanisms The most important responsibility of any living organism, right down to its cellular levels, is preservation of its genomic stability. Though mutational changes lead to genetic evolution this process is slow and tightly controlled and any genetic 
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lesions are quickly detected and repaired by a variety of specialised DNA repair mechanisms. Cells are constantly under a bombardment of endogenous and exogenous genotoxic stress, causing an estimated 105, spontaneous or induced, DNA lesions per day per cell [199]. Endogenous genomic damage can be a result of deamination, depurination, depyrimidination, alkylation or oxidation by ROS and or RNS [200]. Exogenous damage can be a result of ultraviolet (UV) light resulting in the formation of cyclobutane pyrimidine dimers (CPDs) and pyrimidine-(6-4)-pyrimidone photoproducts (6-4PPs), IRs and thermal damage causing double and single strand breaks or intra and interstrand DNA crosslinks induced by chemotherapy or industrial chemicals or cigarette smoke [201]. Once DNA damage is detected cells undergo cell cycle arrest while repair mechanisms amend the mutation before division. Failure to repair DNA will either lead to cellular death, normally via apoptosis, or aberrant division leading to daughter cells inheriting the same genetic mutation. Acquiring multiple unresolved mutations can lead to various cancers.  The vast majority of GBM tumours are treated with a combination of chemo and RT, leading to GBM cells overexpressing and relying heavily on the use of DNA repair mechanisms to survive. Table 1.3 lists important repair mechanisms utilised by GBM cells and the type of damage they repair. 
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Table 1.3: Table listing DNA repair systems used against IR and chemotherapy treatment, and the 
lesion types they repair.  
Repair Mechanism Treatment Lesion Type 
Base excision repair (BER) Ionising Radiation, Chemotherapy Oxidative lesion, Single strand breaks Homologous recombination (HR) Ionising Radiation, Chemotherapy Double strand breaks Non-homologous end joining (NHEJ) Ionising Radiation, Chemotherapy Double strand breaks Mismatch repair (MMR) Chemotherapy Replication O6-alkylguanine DNA alkyltransferase (MGMT) Chemotherapy Intrastrand crosslinks  
1.3.7.2.1 Base Excision Repair Pathway  Chemotherapy, such as TMZ, and RT causes methylation, deamination and hydroxylation of DNA, triggering the base excision repair system (BER). Poly-ADP-ribose polymerase-1/2 (PARP1/PARP2) are two enzymes important in the detection of DNA damage and coordinating DNA repair through the BER and mismatch repair (MMR) pathways. The BER system has a two-step process involving the removal and replacement of the aberrant nucleotide before reattachment of the DNA strand [202]. GBM tissue has been shown to increase PARP and BER associated proteins post treatment with TMZ [175, 203, 204]. The inhibition of PARP has been shown to suppress BER activation, sensitising GBM tumours to chemotherapy [205].  
1.3.7.2.2 Mismatch Repair (MMR) Pathway Mismatch repair (MMR) pathway is an important proof reading process to detect replication errors produced by DNA polymerase replicating DNA during DNA synthesis [206]. MMR acts as an important tumour suppresser, and its inactivation due to mutations reduces the effectiveness of chemotherapy induced cytotoxicity 
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as DNA damage will be undetected. During TMZ treatment DNA polymerase mispairs O6-meG with thymine. If repair mechanism such as O6-alkylguanine DNA alkyltransferase (MGMT) cannot repair the damage, and further cycles of MMR are activated, double strand breaks will be induced and cells with be forced into apoptosis [207].  This highlights the importance of a functional MMR pathway in the treatment of GBM with TMZ [208].  
1.3.7.2.3 O6-alkylguanine DNA Alkyltransferase (MGMT) MGMT plays an essential role in the treatment resistance against alkylating agents, including TMZ. MGMT repairs methylated DNA adducts by forming a covalent bond between its internal active cysteine and the alkylated base. This removes the alkyl group from the DNA base while it remains on MGMT’s internal cysteine [209]. Once this has occurred the MGMT protein is inactivated and degrades [210]. GBM tumours with low MGMT activity are significantly more sensitive to TMZ treatment compared to tumours with high MGMT expression [211]. MGMT methylation status has been shown to correlate with tumour grade and aggressiveness.  
1.3.7.2.4 Apoptosis Resistance Mechanisms Apoptosis can be triggered by intrinsic and extrinsic mechanisms, with cross-talk common, both leading to loss of mitochondrial membrane potential and the activation of the cysteine-aspartic acid proteases (caspase) cascade. The extrinsic apoptotic pathway is mediated by membrane death receptors such as, Fas receptor or tumour necrosis factor (TNF) receptor. Once a death factor has bound to its’ respective receptor, it causes a cascade reaction in which procaspases are cleaved to form their activated forms. These activated caspases cleave specific 
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protein targets within the cell causing apoptosis. The intrinsic pathway is not dependent on external stimuli but rather stimuli from inside the cell. Cellular stress causes BH3 interacting-domain death agonist (BID) protein to translocate and bind to B-cell lymphoma 2 associated X protein (Bax). This binding event causes a conformational change in Bax, which allows it to insert itself into the outer mitochondria membrane. Bax oligomerises (6-8 molecules) to produce its final form. This final form of Bax allows cytochrome C and procaspase 9 to be released from the mitochondria into the cytosol [212, 213]. In the cytosol molecules of cytochrome C, procaspase 9 and apoptotic protease activating factor 1 (Apaf-1) bind together to form the wheel-like complex known as apoptosome. The newly formed apoptosome triggers a caspase cascade reaction which ends with cell apoptosis. Members of the IAP family inhibit apoptosis by binding, and inactivating, caspases 3, 7 and 9 [214]. During the release of cytochrome C from the mitochondria, two other proteins known as Smac and DIABLO are also liberated. Smac and DIABLO act as inhibitors to members of the inhibitor of apoptosis (IAP) family. B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-XL) can inhibit Bax and thus stop it from being inserted into the mitochondrial membrane. However, Bcl-2 and Bcl-XL can both be inhibited themselves by the inhibitor Bad. Figure 1.12 [215] illustrates key proteins needed in the intrinsic and extrinsic apoptosis pathways. GBM tumours have been shown to have aberrant expression of key pro and anti-apoptotic proteins either by direct activation/suppression or by inactivation of p53. Inactivation of P53 has been shown to be associated with an up-regulation of Bcl-2 and Bcl-XL leading to increased resistance to chemo and RT.   
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Figure 1.12: Schematic illustration of the intrinsic and extrinsic apoptosis pathway. Though apoptotic 
stimuli are a key difference, both pathways converge at the mitochondria leading to the release of 
cytochrome C and caspase cascade. Adapted from De Vries et al (2006).  
1.4 Stem Cells Stem cells are defined as undifferentiated biological cells able to replicate indefinitely, and possess the ability to differentiate into various specialised cells. These cells represent minor subpopulations compared to their terminal differentiated progeny, which forms the various organs and tissues in the human body.  Though various tissues contain stem cells, the largest repository is found in the bone marrow.  Stem cells have a hierarchal potency structure with zygote cells being the only mammalian cell to be totipotent. Totipotent stem cells are formed by the fusion of male and female gametes to produces zygotes with the potential 
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to produce any cell type in the body. Clonal expansion of these cells is followed by differentiation into blastocyst, pluripotent stem cells, able to form the 3 germ layers, endoderm, ectoderm and mesoderm. Mulipotent stem cells have a more defined differentiation potential. Under various conditions and with specialised signals stem cells will commit to various cell fates until they reach a unipotent state such as heart cells, skin cells, nerve cells or any of the other 200 cell types present in the adult body [216]. Figure 1.13 [217] shows the different potency states of stem cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.13: Diagram showing the varying stages of stem cell differentiation. Totipotent stem cells 
have the ability to differentiate into any cell type found in the body. Pluripotent and multipotent stem 
cells have a more restrictive differentiation potential. Unipotent cells are terminally differentiated 
cells with a finite division potential known as the Hayflick limit. Adapted from Anatomy and 
Physiology (2015). 
Adult 
Stem 
cells  
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1.4.1 Neural Stem Cells In 1960, neurogenesis was described for the first time in adult mammalian CNS [218, 219]. Later in 1992, Reynolds and Weiss were the first to isolate neural stem cells (NSCs) from adult mice [220]. Until this time it was believed that brain tissue contained no stem cells and had no ability to replenish lost cells after initial childhood development. This hypothesis is derived from the ‘no new neuron’ dogma proposed in 1928 [221]. This is now known to be incorrect. Recent discoveries have shown that the brain possesses certain regions such as the subventricular zone (SVZ) of the forebrain lateral ventricles, and the subgranular zone (SGZ) in the dentate gyrus of the hippocampus, in which NSC and progenitor cells reside [222, 223]. The SVZ and SGZ provide NSCs that are crucial for the maintenance of brain integrity, plasticity and optimal function [224]. These cells have been shown to express a multitude of markers, such as GFAP, glutamane aspartate transporter (GLAST), brain lipid binding protein (BLBP), Nestin, sex determining region Y-box 2 (SOX2), and have been shown to express more linear specific markers once they differentiate [225]. These GFAP expressing stem cells have been shown to be able to reconstruct the entire neurogenic structure when all other cells types have been ablated [31]. Figure 1.14 [31] lists the different types of neuro precursor cells and their organisation in the SVZ. NSCs provide evidence that neogenesis of mature cells persists throughout adult life in these discrete areas of the brain [31]. The discovery of neural stem cells in the SVZ, and the frequency of gliomas in the regions surrounding this area, has meant that the SVZ has emerged as the most likely source of gliomas [223, 226-228]. Figure 1.15 [31] shows the anatomy and cells present in the SVZ and SGZ in humans and rodents.  
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Figure 1.14: Diagram depicting the various stem cell types, and their arrangement in the SVZ. A| Stem 
cells undergo self-renewal with rounds of asymmetric divisions yielding a new stem cell and a 
differentiated progenitor cell. Multiple rounds of asymmetric division eventually forms terminally 
differentiated ‘mature’ cells.  B| There are 3 main precursor cell types found in the brain that can be 
classified by their unique expression marker combinations. Type B cells are more prevalent within 
these stem cell active zones of the brain. As mature precursors cells migrate to distal parts of the brain 
they mature and terminally differentiate. C| The SVZ is comprised of different cell types from stem 
cells to progenitor cells. Cells provide cell-to-cell signalling as well as secrete factors to help maintain 
the right balance of cell types in the SVZ. Adapted from Vescovi et al (2006).  
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Figure 1.15: An illustration showing the location of the SVZ and SGZ in the brain. A| The SVZ is located 
between the lateral ventricles and the parenchyma of the striatum. The SVZ is comprised of the 
multipotent type B stem cells, which gives rise to type C precursor cells that, in turn, differentiate into 
type A cells. B| The SGZ is located within the dentate gyrus of the hippocampus. In a similar manner 
to the SVZ, type B cells produce unique precursor cells, type D, which differentiates into type G cells. 
C| A distinct ribbon of astrocytes lines the ventricles to form the SVZ (red line) which provides 
structural support and essential signalling stimuli for NSC. D| The SGV is located in the hippocampus, 
between the hippocampus granular layer and the hilus. Adapted from Vescovi et al (2006). 
The easiest way to differentiate cell types in the SVZ, without the use of gene expression assays or immunohistochemistry (IHC), is by discriminating using division time. Type B neural stem cells have a cell cycle time of 28 days, while type C and type D, found in the SGZ, progenitor cells have a cycle time of 12 hours. Furthermore, only type B, C and D cells can form neurospheres, which is seen as a putative stem cell test.  
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1.4.2 Cancer Stem Cell Model Cancer is a direct result of aberrant genetic alteration accompanied by epigenetic modifications that result in the loss of cell cycle control and maintenance of DNA damage checkpoints, leading to uncontrolled cellular proliferation. There are generally two distinct cancer models proposed to explain how tumours are initiated and progress [229]. The Stochastic model proposes that all cells in a tumour have equal tumourgenic potential and the ability to form a new tumour. The Hierarchical model is based around the presence of a rare subset of cells that have extensive tumourgenic and differentiation potential. These cells are able to form tumours by asymmetric division generating new tumour initiating cell (TIC) and a differentiated tumour cell. The Hierarchal model helps explain the vast cellular heterogeneity of tumours and is the basis of the CSC hypothesis as these TIC cells share many properties reserved only to embryonic and adult stem cells. 
Figure 1.16 [230] visually represents both proposed cancer initiation models. These CSC’s are seen as vital to the continued growth and ultimate existence of the tumour as these cells alone have the ability of self renewal, unlimited proliferation and the ability to form differentiated cancer cells.  
 
 
 
 
Figure 1.16: Diagram of the two hypothesised CSC models. A| The Stochastic model proposes all cells 
have tumour initiating potential and can equally form a new tumour. B| The Hierarchical model 
implies only a small population of CSC have the ability to form a new tumour, while their differentiated 
progeny do not posses this ability. Adapted from Reya et al (2001). 
Stochastic Hierarchic
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1.4.2.1 Evidence of Cancer Stem Cells The first major documentation of CSC’s was reported in leukaemia and multiple myeloma. Mouse myeloma cells obtained from ascites and CSC purified, had a 1 in 10,000 to 1 in 100 cancer colony forming potential in vitro [231]. Furthermore, when leukaemia cells were injected in vivo in mice, only 1-4% of cells could form splenic colonies [232]. These findings could only be explained with the Hierarchical models, and as clonogeniticity mirrored that of normal haematopoietic stem cells, the TIC’s were classified loosely as CSC’s. Following on from these studies, acute myeloid leukaemia (AML) CSC’s were purified by using the pluripotent haematopoietic stem cells markers CD34+CD38- from patient samples. These cells only accounted for 0.2% of the tumour population and were the only tumourigenic cells, when injected in vivo into severely compromised immune deficient (SCID) mice, could recapitulate human AML conditions in mice [233].  
The CSC hypothesis was quickly widened to encompass solid cancers with the identification of a subset of stem like cells in numerous cancers. It was shown that like AML, only a small subpopulation ranging from 1 in 1000 to 1 in 5000 lung carcinoma, ovarian or neuroblastoma cells had the potential to form 3D colonies in soft agar [234]. To further strengthen the hypothesis that the TIC’s in solid cancers originate from CSC’s, stem cell markers such as Prominin-1 (CD133), Cluster of differentiation 44 (CD44), Cluster of differentiation 24 (CD24), glioma-associated oncogene protein 1 (GLI1) and other stem cell membrane markers have been used to identify the tumourgenic subset of cells (Table 1.4).  
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Table 1.4: Table listing the reported CSC markers in prevalent solid tumours.   
CSC Marker Cancer Expression References 
Cluster of Differentiation 24 (CD24) Breast, Liver, Pancreatic, Ovarian [235-237] Cluster of Differentiation 44 (CD44) Bladder, Breast, Colorectal, Head & Neck, Lung, Ovarian, Pancreatic, Prostate [235, 237-244] Prominin-1 (CD133) Breast, Colorectal, Melanoma, Lung, Ovarian, Pancreatic, Prostate [239-245] Aldehyde dehydrogenase (ALDH) Bladder, Breast, Colorectal, Glioma, Head & Neck, Lung, Pancreatic, Prostate [235, 239-244, 246] Octamer-binding transcription factor 4 (Oct4) Colorectal, Lung, Head & Neck [239, 240, 247] ATP-binding cassette sub family G member 2 (ABCG2) Head & Neck, Lung, Melanoma, Prostate [240, 243, 244, 248] B lymphoma Mo-MLV insertion region 1 homolog (BMI1) Breast, colorectal, Glioma, Head & Neck, Lung, Pancreatic, Prostate [239, 240, 242] Epithelial cell adhesion molecule (EpCAM) Breast, Colorectal, Lung, Pancreatic [239-242, 244] C-X-C chemokine receptor 4 (CXCR4) Breast, Lung, Pancreatic, prostate [241, 244, 249, 250]  A genetically engineered mouse model of glioma, utilising a nestin promoter driven transgene coding green fluorescent protein (GFP) and the herpes simplex virus tyrosine kinase, which was specifically expressed in quiescent NSC of the SVZ provided evidence of CSC driven GBM reoccurrence [251]. These cells formed spontaneous tumours and once treated with TMZ an initial tumour reduction was followed by recurrent tumour growth driven by GFP labelled CSC’s. However, tumours treated with ganciclovir, which is toxic to cells expressing the herpes simplex virus tyrosine kinase, and temozolomide resulted in inhibition of tumour development.  
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1.4.3 Glioblastoma Cancer Stem Cells Though adult NSC’s normally exist in a state of quiescence, they are subjected to a potent cocktail of transcription factors, growth factors and potential carcinogens, meaning they form an attractive target for gliomagenesis. The existence of CSCs would also go a long way to explaining the highly heterogeneous nature of GBM and their frequency to develop near stem cell rich areas. The occurrence of GBMs in areas located away form these stem cell rich areas can be explained by stem cell migration. This is when neural stem cells migrate out away from the periventricular regions to distal regions of the brain [252, 253]. Another possibility is that asymmetric divisions of a CSC generates a new CSC that remains in the SVZ, while a GBM precursor cell migrates out to form the tumour mass [254]. For brain tumour cells to be accredited to the CSC family they must have three fundamental characteristics:  1. The ability to self-renew [31, 230, 255]. 2. Potential to initiate brain tumours [31, 230, 255]. 3. Capacity to differentiate into cells of neural, astrocytic and oligodendroglial lineage [31, 230, 255]. In neuro-oncology literature these cells have been referred to as ‘cancer stem-like cells’, ‘glioma stem cells’ (GSC), ‘glioma initiating cells’, ‘tumour-propagating cells’, and ‘cancer stem cells’. For simplicity and clarity, for the reminder of this thesis they will be referred to as CSC’s.  
GBM was the first solid tumour type to have a recognised CSC subpopulation present. This was discovered by isolating clonogenic, neurosphere forming precursor cells from human post-surgery GBM tumours [256]. In addition to their neurosphere forming potential, these CSC, also expressed neuronal and astroglial 
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markers upon differentiation.  Following this, an independent group validated these findings, showing a small subset of neurosphere forming cells were able to differentiate into neuronal and astroglial-like cells [257].  These cells were also shown to express many genes expressed by NSC, such as SOX2, B lymphoma Mo-MLV insertion region 1 homolog (BMI1) and Musashi1. These findings have great relevance as they confirm that GBM tumours contain a subpopulation of transformed, undifferentiated neural stem cells that can be cultured under similar conditions and mitogens as adult NSC’s, as well as share molecular similarities.   
These findings prove the presence of CSC’s in GBM tumour and their advanced tumourgenicity. However, they do not prove that CSC’s are the original TIC. A study using a double mutant allele TP53 and Nf1 in mice cells was used to link CSCs and TICs. This double mutant allele combination causes activation of Ras signalling leading to astrocytoma lesions within the SVZ, alluding to the transformation of CSC as the TIC’s [258]. Additional studies have shown that activation of Ras and AKT signalling in undifferentiated nestin expressing cells result in a higher frequency of tumour lesions, compared to the same alterations in mature astrocytes [259]. Furthermore, the overexpression of platelet-derived growth factor (PDGF) in nestin expressing precursor cells caused a significant increase in glioma formation compared to overexpression in astrocytes [260].  
1.4.3.1 Glioblastoma Cancer Stem Cell Culture Methods Historically all solid tumour cells grown in vitro have been cultured as adherent cells in a two-dimension monolayer in media containing serum. Cell lines, in particular GBM cell lines, express high differentiation markers when cultured in serum containing media. With the identification of CSCs in GBM, and our increased 
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understanding of their importance in cancer biology, these serum culture conditions alone are unsuitable for translational GBM research [261].  Reynolds and Weiss first discovered NSCs, when they cultured these cells as non-adherent spheres, later coined neurospheres, in serum-free media with the addition of growth factors [220]. This lead to the demonstration that GBM cells, isolated from paediatric brains, and cultured in similar serum-free media containing growth factors could form neurospheres [257]. These neurospheres were shown to be heterogeneous aggregations of cells derived clonally from a single CSC or early progenitor cells. Once dissociated, these neurospheres, are capable of continued generation of neurospheres following serial plating. Furthermore, these cells under special stimulus are capable of differentiation into multiple glial and neuronal lineages [257]. In addition to this, the introduction of serum to neurospheres leads to astroglial differentiation, and the expression of differentiation markers such as GFAP. This is accompanied by the loss of neurosphere formation potential and an increase in adherent culture colonies. Neurosphere have been shown to be highly tumourgenic in vivo, recapitulate the tumour architecture and possess the genetic and phenotypic characteristics of the primary tumour they were derived from [262-264]. It is important to note that not just primary tumour cells can form neurospheres. Adherent long passaged GBM cell lines can derive CSCs and form neurospheres, with characteristic stem cell marker profiles, when cultured in serum-free media with the addition of growth factors [265].  
Though neurosphere culturing provides the ability to expand CSCs population of cell lines, their physical structure provides many complications for researchers. Reproducibility of results using neurospheres is difficult as premature splitting of 
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spheres can lead to an increase in progenitor cells and an incomplete formation of the tumour hierarchy. While over growth of neurospheres can lead to sphere aggregation and fusion which can lead to necrosis within the neurosphere, caused by the inability of growth factors and supplements to diffuse into the core of the sphere [266, 267].  
Laminin an ECM protein has been shown to help anchor NSCs and progenitor cells in the SVZ [268]. In addition, laminin-stem cell contact signalling has been shown to promote their survival. This knowledge has lead to the use of laminin-coated plates to be used to culture GBM CSCs as adherent monolayers in serum-free media. This adherent monolayer culture allows for equal distribution of growth factors to cells, leading to a reduction in differentiation and apoptosis. Cells cultured under these conditions express stem cell markers, low differentiation markers and have potent tumourgenic potential (Figure 1.17 [261]). A benefit of this model is the ability to complete high through put assays and increase reproducibility of results.  
A third culture method uses hypoxic condition to induce and enrich stem cells. This can be utilized with either a neurosphere or adherent model. Hypoxia causes the stabilisation of hypoxia inducible factors 1-3 alpha (HIF1-3α). Stabilisation of HIF proteins leads to the dimerization and subsequent activation of target genes. Though the cells produced express stem cell markers, their relevance is limited to a niche sub set of GBM CSCs and are not appropriate for universal GBM CSC research. Table 1.5 list key strengths and weaknesses of each culture condition. 
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Figure 1.17: Diagram showing the effects of different medium on cell populations. Cells grown in 
serum-free media on laminin form purer cancer stem cell populations compared to neurospheres and 
serum media conditions. Adapted from Gilbert et al (2009). 
Table 1.5: Table listing the key strength and weakness of each culture condition. Adapted from Gilbert 
et al (2009). 
 Media with Serum Serum free media Serum free media with laminin 
Culture type Adherent  Neurosphere Adherent 
Stem Cell Marker 
Expression 
Weak Strong Very Strong 
Differentiation 
Marker expression 
Strong  Weak Very Weak 
Tumourgenic 
Potential 
Low High High 
Gene expression 
Profile 
Weak homology to parent tumour Strong homology to parent tumour Strong homology to parent tumour 
1.4.3.2 Glioblastoma Cancer Stem Cell Markers With the importance of CSC in GBM being realised, a robust identification process is key to the longevity of CSC research. The main hurdle to CSC research is the lack of definitive stem cell markers. GBM cells found to have a negative expression profile for one stem cell marker might express another further complicating 
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identification. This highlights, that much like the tumours they form, CSC’s are highly heterogeneous in nature, with the additional complexity of phenotypic plasticity. With this in mind it is common to assess multiple stem cell markers in association with neurosphere formation assays [269, 270].  
1.4.3.2.1 Prominin-1 (CD133) Prominin-1 (CD133) was first used to isolate NSC’s in the brain, and was soon predicted to be a possible CSC marker in GBM [271].  This potential was realised when CD133 was shown to be present in GBM samples. However, the use of CD133 has been marred in controversy ever since. CD133 as a CSC marker was first utilised in the hematopoietic system. In this model it has been shown that CD133 is expressed in hematopoietic CSCs but is down regulated during cellular differentiation. CD133 cells have been reported in a range of cancerous tissues including prostate, breast, lung, colon and brain tumours. CD133 is a 120 kDa transmembrane spanning glycoprotein comprised of two N-glycosylated extracellular loops, two intracellular loops, a cytoplasmic C- terminal domain and an extracellular N-terminal domain [272-274].  
The tumorigenic capacity of CD133+ GBM cells has been shown to be higher than their CD133- counterparts. It was shown that as little as 100 CD133+ cells transplanted into SCID mice brain can form a new GBM tumour [16, 257]. In comparison, 106 CD133- cells cannot reproduce the same tumour size [16, 257]. Tumours formed by CD133+ cells were found to better represent the parental tumour both morphologically and molecularly. Silencing CD133 expression using lentivirus mediated short harpin RNA in GBM neurosphere cells causes significant loss of self-renewal and tumourigenic capacity [275].  
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Embryonic stem cells use multiple genes to retain their undifferentiated state and their capacity to self-renew. BMI1, Shh, octamer-binding transcription factor 4 (Oct4) and Snail are expressed in both normal stem cells and GBM CSCs, but are not expressed in CD133- GBM cells [276].  
1.4.3.2.2 Sex determining region Y-box 2 (SOX2) 
Sex Determining Region Y Box 2 (SOX2) is an intronless, single exon gene with its loci on chromosome 3q26.3 and encodes a 317 amino acid protein [277]. SOX2 has been shown to be highly expressed in embryonic stem cells and is down regulated when neural cells exit the cell cycle and differentiate [278]. SOX2 is known to control the expression of several major developmental genes and to play a role in both neurogenesis and gliogenesis [279-281].  
During embryogenesis, SOX2 is present in neural tube cells and in NSCs, but as the embryo develops SOX2 expressing cells become confined to the SVZ and SGV. Thus 
SOX2 is considered to be a marker of stem cells in adults. During astrogenesis, NSCs and progenitor cells lose their SOX2 expression once they have differentiated into astrocytes. SOX2 has been shown to up regulate the Notch signalling pathway, a known and very important developmental pathway that has been implicated in many cancers [282]. With the exception of the SVZ and the SGZ, SOX2 expression in the adult brain is almost undetectable [282, 283].  It has been shown that expression of SOX2 increases with GBM tumour grade [284]. Recent research has shown that the in vitro knockdown of SOX2 in GBM cells causes a marked reduction in proliferation, and up-regulation of two tumour suppressors, brain expressed X-linked 1 (BEX1) and brain expressed X-linked 2 (BEX2) [285]. While 
in vivo SOX2 silencing inhibits tumour growth in SCID mice [286].  
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1.4.3.2.3 Nestin Nestin is an intermediate filament protein (IFP) expressed in proliferating cells during embryonic and foetal development in a range of tissues [287].  Once differentiation starts, cells down-regulate nestin while up-regulating alternative IFPs, such as GFAP in glial precursors [288]. Nestin has been accredited with a multitude of cellular functions including organisation of the cytoskeleton, metabolism, attenuation of proliferation and migration, as well as cell signalling organogenesis of multi-lineage progenitor cells [289]. Nestin has been detected in varying levels in gliomas, including GBM [290-293], and is co-expressed with other putative CSC markers such as CD133 and SOX2 [284]. Nestin has also been shown to have a positive correlation with glioma tumour grade [294]. Various astrocytoma cell lines show a positive correlation between nestin expression and a migratory phenotype with increased motility and invasiveness [291]. 
1.4.3.2.4 B-lymphoma Mo-MLV insertion region 1 homolog (BMI1) BMI1 is a member of the polycomb ring finger group shown to regulate two major tumour suppressor pathways, INK4a and ARF [295, 296]. The regulation of these genes has been shown to govern self-renewal and proliferation of NSC and CSC [102, 297]. BMI1 has also been shown to silence genes including CDKN2A and cyclin-dependent kinase Inhibitor 1A (CDKN1A) shown to be important in differentiation and senescence [297]. BMI1 expression in NSC’s and CSC’s has a direct correlation to the micro ribonucleic acid-128 (miRNA-128) expression, with the silencing of miRNA-128 leading to a loss of BMI1 expression and the loss of self-renewal [298]. BMI1 has been shown to be co-expressed with CD133, SOX2 and nestin, and that post-transcriptional silencing in CD133+ cells leads to loss of neurosphere formation potential and self-renewal [299, 300].   
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1.4.3.2.5 Neurogenic Locus Notch Homologue Protein 1 (Notch1) The Neurogenic Locus Notch Homologue Protein 1 (Notch1) gene encodes a type 1 single-pass transmembrane receptor with a molecular weight of 300 kDa. Notch signalling is an evolutionarily well-conserved developmental pathway that influences cell differentiation, proliferation and apoptosis [301, 302]. The Notch pathway is important in the maintenance and self-renewal of NSC and essential for the proper formation of glial cells in the developing brain [303-305]. Notch expression has been shown to have higher expression in neurosphere forming, as well as being co-expressed with other stem cell markers such as CD133, SOX2, BMI1 and nestin. Notch signalling has been shown to de-differentiate astrocytes back to a stem like state, and silencing Notch will reverse this effect [306]. Further to this, tumours treated with Notch inhibitors have a reduction in CSC’s and leads to reduced tumour growth [307]. This could be due to the ability of Notch expressing CSC’s to stimulate angiogenesis being lost [229, 308].  
1.4.3.2.6 Maternal Embryonic Leucine Zipper Kinase (MELK) The Maternal Embryonic Leucine Zipper Kinase (MELK) gene encodes a serine/threonine kinase with a functional leucine-zipper domain. MELK is a member of the snf1/AMPK family known to be important tumour survival factors under nutrient starvation conditions [309]. MELK has been shown to have high expression in embryonic and adult NSC’s regulating self-renewal and maintenance of a stem-like phenotype [309]. MELK expression has been identified in numerous cancer models and was initially linked to the regulation of cell cycle progression [310].  One of these cancer models is GBM, with high MELK expression in GBM CSC’s [311].  MELK has been shown to be co-expressed with CD133 and its expression has an inverse correlation with GBM patient survival [312]. Studies 
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have shown that small interfering ribonucleic acid (siRNA) knockdown of MELK induces apoptosis in GBM CSC’s both in vitro and in vivo [313]. MELK has been implicated in tumour initiation with the silencing of MELK in CSC’s shown to reduce tumour formation in vivo [314].  
1.4.3.2.7 Additional Cancer Stem Cell Markers A definitive CSC marker is yet to be identified in the context of neuro-oncology, and has meant that the identification of this sub-population of cells depends on the use of multiple CSC markers. Additional markers include OLIG2, Musashi-1 (Msi1), CD90, CD44 and CD15 [222, 311, 315-321]. Another novel marker for CSCs in GBM is aldehyde dehydrogenase (ALDH). ALDH are a family of enzymes that are important in alcohol metabolism as they oxidise aldehydes formed during this process [322]. Elevated levels of ALDH1 were found to be associated with CSCs and could be a novel marker used to identify a particular CSC niche [323, 324]. It has also been shown that ALDH enzymes can help provide cells with resistance to many cytostatic drugs [325-327]. ALDH enzymes have been found in numerous cellular compartments including the cytosol, nucleus, mitochondria and endoplasmic reticulum of CSCs [328]. Table 1.6 list key regulators and markers of GBM CSC’s.  
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Table 1.6: Table listing the key regulators and markers of cancer stem cells in glioblastoma. Adapted from Cruceru et al (2013).  
Name/ Abbreviation Function Role Involvement in tumourgenesis Reference 
B-lymphoma Mo-MLV insertion 
region 1 homolog (BMI1) 
Polycomb complex protein. Gene transcription regulator  Important for proliferation of neural and haematopoietic stem cells. Overexpressed in brain tumours. Required for CSC proliferation and survival.  [295] 
Maternal Embryonic Leucine 
Zipper Kinase (MELK) Protein kinase Regulator of transcription factors Overexpressed in GBM CSC’s. Helps cells maintain stemness and survive nutrient starvation.  [330, 331] 
Sex Determining Region Y Box 2 
(SOX2) Transcription factor Involved in proliferation and maintenance of stemness Expressed in adult and paediatric GBM CSC’s. [283, 332, 333] 
Neurogenic Locus Homologue 
Protein 1 (Notch1) 
Membrane receptor for jagged1, jagged2 and Delta1 Involved in NSC stemness maintenance Promotes tumour formation by silencing retinoblastoma protein [334] 
Prominin-1 (CD133) Membrane Protein Suppressor of differentiation in NSC’s  Lost during CSC differentiation. Unique glycosylation pattern in GBM CSC’s [335] 
Nestin Intermediate filament protein Trafficking and distribution of factor in NSC Expression correlated with tumour grade [294] 
Sonic Hedgehog (Shh) Signalling protein Provides stimulus for proliferation of NSC Activated in GBM CSC’s [336] 
Musashi (Msi1) Regulates the expression of mRNAs at transcription level Represses differentiation in NSC’s  Helps GBM CSC’s maintain a stem-like phenotype [337] 
Protein Patch Homologue 1 
(Ptch) Shh Receptor Important for NSC proliferation Highly expressed in astrocytoma, increasing with grade [338] 
Epidermal growth factor receptor 
(EGFR), Fibroblast growth factor 
Receptor (FGFR) 
Membrane receptors with tyrosine kinase activity EGF/FGF dependent NSC proliferation Amplified in gliomas and mutated in GBM. High expression on GBM CSC’s [339-341] 
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1.4.3.2.8 Pitfalls of Glioblastoma Cancer Stem Cell Markers The lack of a definitive CSC marker in GBM has long eluded researchers. As a consequence, the validity of the current CSC literature has been called into question due to ineffective classification of cells as CSC’s. CD133 is the most widely used CSC marker in GBM but alone this marker has many drawbacks. Firstly, CD133 has been shown to have both cytoplasmic and nucleolus distribution in GBM cells [275]. Though reports of cytoplasmic distribution of CD133 have been published since 2013, extracellular targeting of CD133 is still the primary method of CD133 analysis. In addition to this, 4 commonly used commercial anti-CD133 antibodies have been shown to have varied staining distribution when compared [342]. This has been proposed to be caused by the different antibodies targeting different CD133 splice variants with potentially frail epitopes with unique glycosylation statuses. This may be why various studies using CD133+ populations as prognosis factors provide vastly different results. This also could be the reason why CD133- cell fractions have been shown to have stem-like phenotypes and properties [343]. A further complexity is the observation that CD133 has varying expression during the cell cycle with NSC’s and CSC’s lacking expression during G0/G1 cell cycle phase [344]. Potentially the main issue with identifying CSC population is the inherent phenotypic plasticity GBM cells possess. Normal differentiated epithelial cells have been shown to de-differentiate into functional stem cells under certain conditions [345]. Numerous studies have shown how various stimuli such as changes in tumour microenvironment, cellular stress upon chemotherapy and cell-to-cell signalling can induce cells to fluctuate between CSC and non-CSC phenotypes [346].   
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1.4.3.3 Treatment Resistance of Glioblastoma Cancer Stem Cells Rapidly gathering evidence proposes that the eradication of CSCs is essential for curing patients of GBM [347]. It is also suggested that these CSCs are accredited to the high resistance that GBMs have to conventional treatment [347].  
Tumours with high CD133+ expression levels have been shown to be associated with poor patient prognosis in numerous cancers including GBM [348], and CD133+ cells have been shown to be more resistant to RT and conventional chemotherapy compared to CD133- cells [276, 349, 350]. Reasons behind this are the increased levels of certain proteins in correlation to CD133 expression. Studies have shown that CD133+ cells have higher expression of ATP-binding cassette sub family G member 2 (ABCG2), an important drug efflux pump, combined with increased MGMT, FAS-associating death domain-like antiapoptotic molecule (FLIP), Bcl-2 and Bcl-xL [322, 351-353]. Studies have shown that elevated levels of Bcl-2 are associated with resistance to chemotherapy, RT and decreased overall survival [354, 355]. Other anti-apoptotic genes up regulated in CD133+ cells include baculoviral IAP repeat-containing protein 3 (c-IAP2), X-linked inhibitor of apoptosis protein (XIAP), baculoviral IAP repeat-containg protein 1 (NAIP) and survivin [276, 319]. These proteins are part of the IAP family and prevent apoptosis by binding and inhibiting caspases 3, 7 and 9 [356]. The IAP family has also been implicated in regulating cell division and cell cycle progression [356]. These anti-apoptotic proteins are over expressed, whilst expression of the pro-apoptotic protein Bax is three-fold lower in CD133+ GBM cells compared to CD133- cells [276].  
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In addition to resistance to chemotherapy, GBM CSC’s have been shown to have resistance to IR. Many intrinsic resistance mechanisms such as, up-regulation of Bcl-2, Bcl-XL and numerous DNA damage repair pathway proteins are utilised by CSC’s in resisting IR mediated death. However, extrinsic factors such as the perivascular niche of the tumour have also been implicated. Tumour microvascular endothelial cells (tMVEC) isolated and co-cultured with GBM tumours were shown to promote proliferation and inhibit apoptosis in CD133+ cells following IR treatment [357]. These tMVECs continued to provide stimulus to CD133+ cells to clonally expand following IR, suggesting that these cells not only provide a survival benefit against IR treatment but maintenance of a CSC population in GBM tumours. Furthermore, tMVECs provided a survival benefit to CSC’s when treated with TMZ by regulating MGMT expression as well as physically shielding cells from chemotherapy and RT [357].  
The expression of BMI1 has been shown to also contribute to GBM CSC IR resistance [358]. BMI1 was shown to be enriched in CD133+ CSCs and mediate cell cycle checkpoints and DSB repair following IR. Knockdown of BMI1 resulted in S phase arrest and sensitised cells to IR induced apoptosis [358]. Recent studies have shown that NOTCH1 receptor and it’s functioning NOTCH1 intracellular domain (NICD), which following NOTCH1 activation translocate to the nucleus and promotes targeted gene expression, mediates IR resistance. CD133+ CSC isolated from GBM tumours and treated with IR showed a significant increase in NOTCH1 transcription and NICD target gene expression. Knockdown of NOTCH1 in these cells, followed by IR, lead to a decrease in proliferation and clonogenicity, while increasing apoptosis [359]. Radioresistance of GBM cells can also be attributed to MELK expression. GBM CSCs expressing MELK were shown to be 
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resistant to IR while parental tumour cells, with low MELK expression were sensitive [360].  
An inherent property of NSCs shared by CSCs are their ability to modulate their cell cycle rate, including the ability to enter and exit senescence. As IR and chemotherapy are designed to target and kill rapidly proliferating cells, GBM CSCs are naturally resistant to these treatments. While under xenotoxic stress from treatments or nutrient deprivation, CSCs are able to slow their cell cycle in response and escape cellular death [251]. Once these stimuli pass, CSCs can either re-enter the cell cycle or increase cell cycle rate repopulating the tumour mass. Another inherent stem cell property is their migratory phenotype. C-X-C chemokine receptor 4 (CXCR4) has been shown to be highly expressed in NSCs, and is important in directing their migration during Neural development. CD133+ cells have been shown to have a 337.8 fold increase in the expression of CXCR4, compared to CD133- and is seen as one of the key factors behind their aggressive migratory phenotype [276]. This migratory phenotype CXCR4 is seen as one of the main reasons why GBM recurrence occurs after tumour resection as they penetrate deep into healthy brain tissue, evading the resection boundary made by the surgeon. This notion is further strengthened by the increase in the CD133+ cell population found in the recurring tumour compared to the parental tumour [319]. This CD133 enrichment can also be observed after RT [319, 350]. 
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1.4.3.4 Clinical Relevance of Glioblastoma Cancer Stem Cells With CSC’s implicated in the initiation, promotion, progression and reoccurance of GBM, the importance of targeting this subpopulation is critical for any newly proposed treatment. Current therapies treat tumours as a homogenous cellular mass and don’t take into account the vast heterogeneity that tumours actually possess. In clinical practise many GBM patients experience a complete response to treatment before relapsing months or even years after treatment. This can in part be explained by the presence of CSCs.  This pseudo regression is due to conventional treatments targeting ‘bulk tumour cells’, while leaving the CSC population mainly untouched. For true complete tumour response, the proper targeting and eradication of this population is essential. Figure 1.18 [230] illustrates this concept.  
 
 
 
 
 
 
 
 
 
Figure 1.18: Diagram showing the effects of conventional therapies on tumour cell population. 
Conventional therapies shrink tumours by targeting rapidly proliferating cells. As CSCs have a slower 
cell cycle, and advanced resistance mechanisms, they survive treatment and cause subsequent 
tumour reoccurrence. However, if CSCs are targeted this can lead to full tumour regression. Adapted 
from Reya et al (2001).   
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1.5 Homeobox Genes 
Homeobox genes are essential for the proper formation and patterning of the human body during embryogenesis. There is an estimated 235 functional and 65 pseudo homeobox genes in humans spread across multiple chromosome loci [361]. Homeobox genes can be subdivided into gene families based on their level of similarity. These families include: ANTP, PRD, LIM, POU, HNF, SINE, TALE, CUT, 
PROS and ZF. Homeoproteins posses a 180 base pair long segment that encodes a 60 amino acid helix-turn-helix protein, though the size can be slightly varied, known as the homeodomain [362]. Figure 1.19 [363] illustrates the sequence diversity of homeoproteins homeodomains. 
Figure 1.19: Diagram depicting the similarities and differences of homeoproteins. Homeodomains 
show a high level of sequence diversity between different homeoprotein classes. These differences 
are the main contributors to different classes unique functional properties. Adapted from Abate-Shen 
(2002).  
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The homeodomain protein forms a tertiary structure consisting of three alpha helices coiled around a hydrophobic core. The longer C-terminal helix directly interacts with DNA, while the N-terminal helices provide structural support, as well as facilitating secondary and tertiary co-factor binding sites [364]. The homeodomain binds sequence-specific DNA elements, primarily elements containing a TAAT core Motif [363]. This function means primarily homeoproteins are transcription activators or repressors, however, some function as cell signalling proteins. Figure 1.20 [363] illustrates the structure of the homeodomain and its interactions with DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.20: Diagram illustration of the interaction between homeodomain and DNA. Helix 1 (N-
terminal) inserts into the minor groove of the DNA while Helix 3 (C-terminal) lies directly in the major 
groove. This binding will either activate or repress the target gene. Adapted from Abate-Shen (2002).  
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1.5.1 Three Amino Acid Loop Extension Homeobox (TALE) Genes Three Amino Acid Loop Extension Homeobox (TALE) class proteins are classified by their presence of three extra amino acids situated between the first and second alpha helices of their homeodomain [365-367]. The TALE family of genes contains six sub-gene families, which include Pre-B-cell leukaemia homeobox (PBX), Myeloid 
Ecotropic Viral Integration site 1 Homolog (MEIS) and PBX regulating protein (PREP). In mammals there are 5 PBX genes, including 1 pseudogene, 5 MEIS genes, including 2 pseudogenes and 2 PREP genes [368-370]. These can be seen in Table 
1.7.  
Table 1.7: Table listing PBX, MEIS and PREP proteins chromosome location and gene IDs. 
Gene 
Symbol 
Gene Name 
Chromosome 
Location 
Gene 
ID 
PBX1 Pre-B-cell leukaemia homeobox 1 1q23.3 5087 
PBX2 Pre-B-cell leukaemia homeobox 2 6p21.32 5089 
PBX2P1 Pre-B-cell leukaemia homeobox 2 pseudogene 1 3q24 5088 
PBX3 Pre-B-cell leukaemia homeobox 3 9q33.3 5090 
PBX4 Pre-B-cell leukaemia homeobox 4 19p13.11 80714 
MEIS1 Myeloid Ecotropic Viral Integration site 1 Homolog 1 2p14 4211 
MEIS2 Myeloid Ecotropic Viral Integration site 1 Homolog 2 15q14 4212 
MEIS3 Myeloid Ecotropic Viral Integration site 1 Homolog 3 19q13.32 56917 
MEIS3P1 Myeloid Ecotropic Viral Integration site 1 Homolog 3 pseudogene 1 17p12 4213 
MEIS3P2 Myeloid Ecotropic Viral Integration site 1 Homolog 3 pseudogene 2 17p11.2 257468 
PREP1 PBX regulating protein 1 21q22.3 5316 
PREP2 PBX regulating protein 2 11q24.2 63876 
TALE proteins mainly function as co-factors, with HOX proteins being their primary binding partners. PBX 1-4 bind anterior HOX proteins 1-10 while MEIS 1-3 bind to posterior HOX 9-13 [371]. HOX proteins can form dimers with PBX/MEIS, and trimers with any combination of PBX/MEIS/PREP and putative 
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tetramers with a combination of all three TALE proteins. The different combination of HOX/TALE proteins changes the DNA specificity, providing evidence that HOX transcription targeting is contextual and not one-dimensional. The final subclass of TALE genes is the PREP family consisting of PREP1 and PREP2. PREP proteins don’t directly bind to HOX proteins, but rather bind to PBX and MEIS proteins. PBX/MEIS-PREP dimers can bind to DNA independently to HOX, but can also form a trimer with HOX proteins [372].  
In addition to the conserved TALE homeodomain, TALE proteins have a further conserved domain known as the MEINOX domain [373]. This is believed to be derived from an ancient MEINOX domain that predates the plant animal divergence. The domain is split into two subdomains with a flexible linker, which forms an alpha helix [366]. PBX MEINOX subdomains are denoted PBC-A and PBC-B. A third subdomain downstream from the homeodomain is called PBC-C, also known as the hexapeptide motif [374]. This PBC-C domain is composed of a highly conserved 15 amino acid residue forming a hydrophobic pocket essential for binding with anterior HOX proteins on DNA [366]. MEIS and PREP proteins also feature split domains called homology region 1 (HR1) and homology region 2 (HR2). MEIS has further domains known as MEIS C, MEIS D and MEIS N, which are not present on PREP proteins, and are important for correct binding with posterior HOX proteins [366]. Figure 1.21 illustrates the basic structure of TALE proteins.  
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Figure 1.21: Diagram depicting the structure of TALE proteins. Phylogenesis and structure of TALE 
family proteins. The MEINOX domain is conserved between protein subclasses, however, different 
proteins have family specific regions such as PBX’s PBC-C domain and MEIS’s MEIS C, D and N domains. 
1.5.1.1 Regulation of PBX Sub-Cellular Localisation  TALE proteins primarily function as transcription factors or co-factors to other homeobox transcription factors. As transcription factors regulate gene transcription by direct DNA interactions, their ability to enter the nucleus is essential for them to exert their function. PBX proteins have 2 nuclear export and import signals, while PREP and MEIS have a single nuclear import signal. PBX monomers have a broad cellular distribution, but once bound to MEIS or PREP, PBX translocates to the nucleolus. This is due to binding between PBX’s PBC-A domain and the HR1 domain of MEIS and PREP through an evolutionary conserved LFPLL motif in HR1 [374, 375]. This interaction also provides protein stability and reduces ubiquitination and subsequent proteasome degradation of PBX, MEIS and PREP [376].  
PBX’s first nuclear localisation signal (NLS), RRKRR, is located between amino acids 234-239 on the N-terminal arm of the homeodomain, while the second NLS, 
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KRIRYKKNI, is located between amino acids 285-294 of the third helix of the homeodomain [377]. PBX’s nuclear export signal (NES) are positioned between amino acids 45-72 and 73-90 of the PBC-A domain [378]. These signals interact with the PBX’s homeodomain N-terminus region masking the NLS. The interaction between PBX and MEIS/PREP, through binding between the PBC-A and HR1 domains, causes a conformational change in PBX exposing the NLS signals while also inhibiting its NES [377]. This allows PBX to localise and stay in the cells nucleus as stable heterodimers [378, 379].  Figure 1.22 illustrates mechanisms involved in modulating PBX subcellular distribution.  
1.5.1.2 TALE Protein Functions Independent of HOX Though TALE proteins most characterised interaction is with HOX proteins, they have been reported to bind and modulate various other homeodomain and non-homeodomain containing proteins [380]. PBX1 and PREP1 bind either Smad2, 3 or 4 to form a trimeric complex, which is able to bind to follicle-stimulating 
hormone beta (FSHβ) promoter in response to activin [381]. The transcription and translation of FSHβ is an important step in the stimulation and formation of gametes. PBX-MEIS complexes have been shown to the bind to myogenin promoter, recruiting myogenic differentiation (MyoD) and SWItch/Sucrose Non-Fermentable (SWI/SNF) enzymes of the chromatin remodelling complex [382]. This facilitates binding of further regulators, leading to the transcription of the 
myogenin gene. PREP’s binding with PBX/MEIS has been shown to increase protein stability, with the loss of PREP leading to increased degradation. 
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Figure 1.22: Illustration showing the mechanisms that control PBX’s subcellular distribution. PBX can auto-inhibit nuclear localisation through folding and internalising 
NLS. Unfolded PBX proteins can shuttle between the nucleus and cytoplasm. Exportation from the nucleus is assisted via binding to exportin 1 (XPO1). Once PBX binds to 
PREP/MEIS, through their PBC-A and HR1 domains, the PBX-PREP/MEIS complex rapidly localises to the cells nucleus.  
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1.5.2 HOX Genes 
HOX genes, also known as homeotic genes, are part of the ANTP gene family which derives it’s named after the Drosophila gene Antennapedia. HOX genes were first discovered in 1921 by Morgan and Bridges, who identified two gene clusters, the Antennapedia complex (ANT-C) and Bithorax (BX-C) that control the body plan during embryogenesis along the rostral-caudal axis of Drosophila Melanogaster. Genetic experiments in D.Melanogaster discovered how aberrant HOX expression causes morphological abnormalities known as homeotic mutations. The 
antennapedia mutation causes antennae to change for an additional pair of legs, while for the bithorax mutation, the haltere is converted into a wing segment [383]. Figure 1.23 depicts homeotic mutations in D.Melanogaster.  
 
Figure 1.23: Diagram showing the mutation in D.Melanogaster. A| Antennapedia mutation causes an 
additional pair of legs to replace antennae, while the bithorax mutation leads to the formation of extra 
wings. B| Scanning electron microscope image of an antennapedia mutation in D.Melanogaster. 
Adapted from Grier et al (2005).   
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This work proved how essential HOX genes are in providing a developmental blueprint for proper patterning of the rostral-caudal axis. It was not until 1990, that two independent groups proved the existence of HOX genes in humans [385, 386]. Mammals have 39 HOX genes arranged in 4 clusters denoted A, B, C and D [387]. The HOX clusters are believed to have been derived from a single gene that underwent tandem duplications from the ancestral homeotic complex (HOM-C) [388]. In D.Melanogaster the HOM-C is comprised of the ANT-C homeobox genes: 
Labial (Lab), Proboscipedia (Pb), Deformed (Dfd), Sex comb reduced (Scr), 
Antennapedia (Antp), and the BX-C homeobox genes: Ultrabithorax (Ubx), 
Abdominal-A (abd-A) and Abdominal-B (abd-B). Each cluster is on average 100 Kb in length, and found on different chromosomes, with HOXA at 7p15.3, HOXB at 17p21.3, HOXC at 12q13.3 and HOXD at 2q31 [389]. Figure 1.24 [390] displays the similarities between D.Melanogaster and human HOX genes. 
HOX proteins primarily function as transcription factors that are essential in the patterning of the anterior and posterior axis during embryonic development and determine tissue fate. This is achieved by a highly conserved 60 amino acid helix-turn-helix, the homeodomain, that binds DNA [391]. The homeodomain motif is positioned in exon 2 of HOX genes, which leads to its expression in the C-terminal segment of HOX proteins. Typically 3’ HOX genes are expressed in anterior tissue whilst 5’ genes will be expressed in posterior tissue [392]. This is known as spatial distribution. In addition to this, temporal distribution dictates that 3’ prime HOX genes are expressed first, and that expression proceeds posteriorly. Spatial-temporal colinearity is accompanied by posterior prevalence, wherein posterior 
HOX gene products are dominant over anterior genes [393].  
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Figure 1.24: Diagram showing the similarities between D.Melanogaster and human HOX genes. 
Human’s 39 HOX genes are derived from tandem duplication of the ancestral HOM-C cluster. A high 
degree of homology can be seen between D.Melanogaster and human HOX genes, illustrated by colour 
conservation between paralog groups. Vertebrate HOX groups 1, 2, 4, 5, 6, 7, and 8 are most similar to 
Drosophila labial (lab), proboscipedia (Pb), deformed (Dfd), sex combs reduced (Scr), antennapedia 
(Antp), ultrabithorax (Ubx), and abdominal-A (abd-A), respectively. Vertebrate HOX paralogues 9-13 
are related to the Drosophila abdominal-B (abd-B). However, the Drosophila does not have a group 3 
corresponding HOX gene. Adapted from Mark et al (1997).  
1.5.2.1 HOX-TALE Protein Interactions HOX proteins have the capacity to bind to DNA as monomers through TAAT sequences, but their binding specificity and efficiency is greatly increased when bound to TALE member co-factors [369, 394, 395]. Important HOX protein co-factors include PBX1-4, MEIS1-2 and PREP1-2 [368-370]. These co-factors 
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influence DNA binding selectivity by improving recognition of larger, and more complex, binding motifs in gene promoters compared to HOX monomers, and facilitate nuclear entry [396-398]. All members of the PBX family bind to anterior HOX paralog proteins 1-10 via a highly conserved motif located in the PBC-C domain [374, 399]. While MEIS family members bind posterior HOX paralog proteins 9-13. However, HOXA6 has been shown to bind MEIS1, which alludes to the possibility that MEIS binding is not simply limited to posterior HOX proteins [400]. Figure 1.25 maps the HOX paralog groups that bind to PBX and MEIS.  
 
Figure 1.25: Diagram showing the varying HOX paralog groups that bind PBX and MEIS. PBX1-4 (Red 
box) are able to bind to HOX paralog groups 1-10, while MEIS1-3 (Black box) binds to paralog groups 
9-13. This binding increases DNA selectivity as well as provides increases protein stability and 
reduced rates of degradation. Adapted from Mark et al (1997).   
PBX’s binding motif, also referred to as the PBX Interaction Domain (PID), forms a hydrophobic pocket in its tertiary structure. The small tryptophan residue, also known as the hexapeptide motif, within HOX proteins, binds to PBX’s PID forming a ‘clasp shaped’ complex able to bind opposing faces of DNA. HOX’s hexapeptide motif sequence is highly conserved between paralog groups [399]. Figure 1.26 depicts the conserved hexapeptide sequence of HOX paralog groups 1-8. Experiments have shown that the tryptophan (W) in the hexapeptide motif is 
  
PBX MEIS 
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essential for efficient binding to PBX’s PID [401, 402]. Mutation at this position alone is enough to abolish any PBX-HOX binding [395, 403].  
HOX1     TFDWMKVKRN*PK 
HOX2   PEFPWMKEKK***K 
HOX3 KQIFPWMKES*Q**K*K 
HOX4  VVYPWMKKhHh******Y 
HOX5 PQIYPWMrKLHh*H******KR 
HOX6     hYPWMQRMNS*****fG***R*R 
HOX7    RIYPWMRS*G*D 
HOX8      hfPWM 
Figure 1.26: Diagram illustrating the conserved hexapeptide sequence in HOX paralog groups 1-8. The 
hexapeptide motif is highly conserved between HOX paralog groups. Capital letters denote conserved 
amino acids, based on the standard International Union of Biochemistry (IUB) amino acid codes. 
Amino acids coloured in red represent the hexapeptide motif of HOX paralog groups. Figure code: ‘f’ 
denotes either arginine (R) or lysine (K), ‘h’ is a hydrophobic amino acid and ‘*’ indicates that the 
amino acid at that position is not conserved but the spacing is. Figure adapted from [399]. 
1.5.2.2 Function of HOX Genes in Adult Tissues The role of HOX genes is not restricted to the patterning of the anterior-posterior axis during embryogenesis. Adult tissues express HOX genes in a collinear, organ specific pattern, reminiscent to that seen in the developing embryo [404, 405]. 
Figure 1.27 [406] shows the expression levels of HOX genes in various adult tissue types via Real Time-Quantitative Polymerase Chain Reaction (RT-qPCR). Adult tissue can be broadly divided into one of three groups: HOX high group comprised of tissue such as testis, prostate, colon, placenta and kidneys, HOX low group which includes heart, salivary gland and brain, and HOX moderate group which contains lung, bone marrow and thymus tissue [406]. 
.        .       . 
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Figure 1.27: HOX mRNA levels determined by RT-qPCR and normalised to GAPDH in various adult tissue. Adult organs present a specific collinear pattern. Anterior organs 
had low HOX expression compared to posterior organs. 3’ HOX genes were shown to be expressed at higher frequencies compared to 5’ HOX genes. Adapted from Takahashi 
et al (2004). 
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Generally, organs in the HOX low group were found in anterior areas of the body whereas HOX high organs were found more posteriorly. Furthermore, anterior 
HOX paralog groups were expressed more frequently compared to posterior genes.  Adult tissues utilise HOX genes to modulate various cellular functions such as cellular proliferation, differentiation, apoptosis, haematopoiesis, organogenesis, cellular motility, angiogenesis and cell-to-cell and cell-to-ECM interactions [392, 396, 407]. The male and female reproduction tract expresses 
HOXA9, HOXA10, HOXA11 and HOXA13. In men this is important in regulation of spermatogenesis and in women the remodelling of the endometrium during the menstrual cycle and pregnancy [408, 409]. Adult breast tissue expresses HOX genes conserved from their developmental precursor cells, with HOXA9 and 
HOXB9 expression decreasing during lactation [410]. HOX3 paralogs are important for tissue remodelling. HOX3 paralogs are induced by cytokines following tissue injury, and stimulates angiogenesis and wound repair [411, 412].                      
1.5.3 HOX/TALE Genes in Disease  HOX and TALE protein expression and interactions are tightly regulated during and after embryogenesis. However, mutation, loss or aberrant expression can lead to embryo termination, birth defects, and various diseases. To date a total of 10 
HOX genes have been implicated in human non-cancer conditions. Truncation mutations in human HOXA1 have been shown to cause developmental defects in the inner ear, brainstem and cardiovascular system [413]. Mutation in HOXA2 causes an autosomal recessive microtia in affected individuals. A frame shift mutation in exon 2 of the HOXA13 gene causes an amino acid change in the homeodomain of HOXA13 protein. This mutation has been shown to cause hand-foot-genital syndrome, characterised by limb malformations and urogenital 
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defects, and Guttmacher syndrome, which share similar limb malformations and urogenital defects, with the addition of postaxial polydactyly. Mutations in 
HOXB1’s homeodomain causes various conditions including congenital facial palsy, hearing loss, speech delay and facial defects such as an upturned nose, midface retrusion and posteriorly rotated ears [414]. Ectodermal dysplasia 9 is caused by homozygous loss-of-function HOXC13 mutation caused by a novel truncation mutation in exon 1 [415]. A missense mutation in the HOXD4 gene causes haematological malignancies with or without skeletal abnormalities [416]. A similar missense mutation has been identified in the HOXD10 gene causing cerebral venous thrombosis or charcot-marie tooth disease alone, and in some cases both [417]. Various HOXD13 mutations have been associated with several severe limb and genital abnormalities such as Synpolydactyly type II, Brachydactyly types D and E, Syndactyly type V, Brachydactyly-Syndactyly and VACTERL. Figure 1.28 [413] depicts synpolydactyly caused by HOXD13 mutation. 
TALE genes PBX and MEIS have been shown to play a role in congenital heart disease [418]. Though these mutations can occur in small numbers, and at times are confined to individual families, it highlights how various HOX genes are linked to a multitude of diseases and syndromes.  
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Figure 1.28: Various cases of synpolydactyly caused by polyalanine expansion in HOXD13. A| 
Syndactyly between finger digits 3 and 4. B| Syndactyly between fingers 3 and 4 with an additional 
digit. C| Duplicated 3rd distal phalanges accompanied by binding third proximal phalanx and 
hypoplastic 5th middle phalanx. D| Duplicated 3rd distal, middle and proximal phalanges accompanied 
by bifid third metacarpal, hypoplastic 5th middle phalanx and radially deviated thumb with short 1st 
metacarpal. Adapted from Stankunas et al (2008).  
1.5.4 HOX/TALE Genes in Cancer  It has been over 70 years since Bridges et al discovered the primary function of 
HOX genes, but still to date their role in malignancy is yet to be fully discovered. 
HOX genes are known to possess the ability to act as both oncogenes and tumour suppressors, with some contextually possessing both abilities [369]. HOX deregulation has been seen in numerous cancers including: lung, prostate, breast, colon, bladder, melanoma, myeloma, kidney, non-small cell lung, thyroid, and ovarian, in addition to various brain tumours including GBM [154, 370, 419-422]. In these cancers HOX genes have been shown to influence an increase in proliferation, invasion, metastasis, angiogenesis and to mediate DNA repair.  
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Abate-Shen proposed three mechanisms of HOX deregulation in cancer [363]. First is ‘temporospatial deregulation’, in which HOX gene expression in malignant cells is distinctly different to its normal counterpart. The second mechanism is ‘gene dominance’, whereby HOX genes are overexpressed in malignant tissue compared to their normal parent tissue. The third mechanism is ‘epigenetic deregulation’, resulting in down regulation and possibly silencing of HOX genes by promoter methylation, miRNA expression or direct protein-protein inhibition. These mechanisms lead to the modulation of various oncogenic pathways. These pathways are detailed below: 
Induction and Maintenance of Proliferation| In leukaemia the overexpression of HOXA and HOXB paralog groups has been shown to increase rates of proliferation in both parental and progenitor cells [423]. The Nucleoporin 98 (NUP98)-HOXA9 fusion protein drives proliferation in leukaemia cells in AML patients [424]. However, NUP98-HOXA9 fusion protein requires, joint or individual, up-regulation of MEIS or PBX to affect proliferation rates. HOXA9 overexpression has also been shown to up regulate insulin-like growth factor 1 receptor (IGF1R) in B cell lineage leukaemia cells, sensitising them for external proliferative signalling [425]. HOX genes implication in proliferation is not limited to haematopoietic malignancies. Overexpression of HOXC9 and 
HOXD10 in lung cancer has been shown to increase proliferation rates, while down regulation of HOXD10 in breast cancer and HOXB13 in colorectal cancer has similar effects [426, 427]. In prostate cells, the induced expression of HOXB13 suppresses hormone-mediated transactivation of androgen receptors, leading to reduced rates of proliferation [428, 429].  
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Inhibition of Apoptosis| Increased rates of proliferation alone is not sufficient to induce tumourgenesis, with loss of apoptotic regulation needed for proper tumour initiation. Primary breast tumours and breast cell lines have been shown to have high HOXA5 promoter methylation status, resulting in low HOXA5 protein levels, which correlated with low p53 expression levels [430]. Further in vitro investigations identified HOXA5 binding sites in the TP53 promoter, and that transient re-expression of HOXA5 caused increased rate of apoptosis. An independent group later identified that HOXA5 can trigger apoptosis in breast cancer cells by inducing caspase 2 and caspase 8 independently of p53 activity [431]. Futhermore, HOXA10 has been shown to modulate TP53 expression, in a similar manner to HOXA5, and the loss of HOXA10 expression leads to the loss of p53 expression in breast cancer cells and reduced rates of apoptosis [432].  
High HOXC9 expression in neuroblastoma patients is associated with favourable patient outcomes, and reported in cases of spontaneous regression [433]. This is due to the ability of HOXC9 to induce apoptosis. Re-expression of HOXC9 in three neuroblastoma cell lines lead to reduced cell viability and tumour growth in neuroblastoma xenografts by the activation of the intrinsic apoptosis pathway [433].  
Aberrant Differentiation| During normal embryogenesis tissue-specific HOX genes are expressed, acting as tumour suppressors by inducing mature morphogenesis and terminal differentiation [392]. The loss of expression can lead to the failed cellular differentiation, leading to cells maintaining developmental cellular properties in a 
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pseudo-embryonic cell state. Neuroblastoma tumours cells, both in vivo and in 
vitro, express minimal to undetectable HOX gene levels. However, when subjected to retinoic acid, HOX genes HOXC6, HOXD1 and HOXD8 increase leading to cellular differentiation [434, 435]. In addition, neuroblastoma GOTO cells expososed to 5-bromo-2’-deoxyuridine (BrdU) up regulate HOXC6 and HOXC11, leading to differentiation into Schwann cells, accompanied by expression of S100B, a Schwann cells differentiation marker [436]. Prostate tumours are shown to over express HOXC4, HOXC5, HOXC6 and HOXC8 when compared to normal human prostate tissue [437]. Overexpression of these HOX genes has been shown to correlate with loss of differentiation, and androgen-independent proliferation [438].  
In normal ovarian surface epithelium, 5’ HOXA genes are undetectable. However, all ovarian carcinoma subtypes, express varying levels of HOXA7 and HOXA9, while 
HOXA10 is uniquely expressed in endometrioid and mucinous subtypes and 
HOXA11 in mucinous subtypes [439]. The individual ovarian carcinoma subtypes share histological similarities with sections of the reproductive tract that share similar HOX expression. As these cells have different embryonic origins, and that the HOX expression is acquired with aberrant temporospatial expression, these findings highlight the importance of HOX expression in differentiation. In addition, this might allude to the potential that spatially incorrect differentiation might drive tumourgenesis [392]. In haematopoietic malignancies aberrant HOX expression can either impair normal differentiation, such as 3’ HOXA and HOXB genes that drive myeloid leukaemogenesis and impair normal lymphoid differentiation, while expression of HOXC4 can promote lymphoblastic differentiation [440, 441].  
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HOX Mediated Epithelial-Mesenchymal Transition and Invasion| Breast cancer cells have been shown to overexpress HOXB7 when compared to normal breast tissue, with a further elevation in expression seen in bone metastases. The overexpression of HOXB7 induces characteristics of EMT such as; the loss of adhesion molecules, changes in morphology, and cytoskeleton rearrangement [442]. In addition, HOXB9, has been shown to mediate the expression of ErbB ligands, production of transforming growth factor-beta (TGF-
β) and several angiogenic factors, which cause invasion, EMT and angiogenesis [443]. Overexpression of HOXD9 in hepatocellular carcinoma promotes EMT and significantly enhancing metastasis, whereas silencing HOXD9 inhibits these processes [444]. HOX gene expression can also act as suppressors, inhibiting EMT and invasion. In ovarian cancer epithelial cells, the expression of HOXA4 increases the expression of β1-integrin protein levels leading to increased cell-cell adhesion [445].  
TALE proteins mediate the above functions by acting as HOX co-factors. In addition to this, TALE proteins can function independently, acting as oncogenes and tumour suppressors in a tissue specific manner in various cancer types. PBX1 expression has been shown to correlate with platinum resistance in ovarian cancer cells, and is overexpressed in ovarian cancer stem cells [446]. Silencing of 
PBX1 in platinum resistant cells re-sensitised cells to platinum based treatments and reduced their stem-like properties [446]. This study showed that PBX1 proteins directly bind to the STAT3 promoter and positively regulates its transcription. In breast cancer, PBX1 has been shown to be essential for estrogen 
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receptor alpha (ERα) mediated tumour functions [447]. Depletion of PBX1, in cells with functioning ERα, leads to cellular quiescence, with cells desensitised to estrogen proliferate stimulation. Furthermore, patients with metastatic breast cancer were shown to have elevated levels of PBX1 expression when compared to non-metastatic patients [448]. This metastatic phenotype is accredited to PBX1-Forkhead box protein A1 (FOXA1) dimers regulating pro-metastatic gene transcription.  
Other TALE member such as MEIS1 have been implicated as oncogenes in various cancers. In pancreatic cancer cells, MEIS1 proteins have been shown to bind to H-strand mitochondria promoter regions, positively up-regulating mitochondrial genes [449]. Inhibition of these genes proper transcription, leads to loss of mitochondrial functions, such as reduced biosynthesis, proliferation and possible apoptosis [450]. MEIS2 proteins have been shown to be essential for cellular survival and proliferation in neurobastoma cells [451]. Silencing of MEIS2 caused M phase arrest, leading to mitotic catastrophe. Overexpression of MEIS2 significantly enhanced proliferation, anchorage-independent growth and tumourgenicity. MEIS2 was shown to be a key regulator of the MuvB-myeloblastosis-related protein B (B-MYB)-Forkhead box protein M1 complex which controls DNA replication, G2-M checkpoint control and M-phase progression [451]. The final TALE member to be implicated in cancer oncogenesis is PREP1. Transforming growth factor beta exposure (TGF-β) was shown to induce 
PREP1 expression in non-small cell lung adenocarcinoma [452]. PREP1 proteins were shown to stabilise PBX1 proteins, while also increasing Fos-related antigen 
1 (Fra-1) expression, resulting in loss of E-cadherin and EMT.  
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1.5.5 HOX/TALE Genes in Glioblastoma   Extensive research has discovered aberrant HOX expression in nearly all solid and haematopoietic malignancies, with more potentially to follow. HOX dyregulation has been reported in GBM. A study performed by Abdel-Fattah et al analysed HOX gene expression in normal human astrocytes (NHA), GBM cell lines and GBM tissue. In this study NHA expressed undetectable levels of HOX genes: A6, A7, A9, A13, B13, D4, C6, C8, D9, D10 and D13, while remaining HOX genes were expressed at an extremely low level [453]. Figure 1.29 [453] illustrates HOX gene expression in NHA. In contrast, all the aforementioned HOX genes were expressed at higher levels in both the GBM cell line and tissue samples, revealing aberrant HOX expression in all four clusters [453]. 
 
Figure 1.29: HOX RT-qPCR expression pattern in NHA. Black shading represents genes with low 
expression levels, while white shading represents silent HOX genes. Adapted from Abdel-Fattah et al 
(2006) 
In 2010, Costa et al used a set of 100 GBM samples to show similarly that HOX gene dysregulation is present in all four HOX clusters [454]. In addition, this study also highlighted that HOX expression did not resemble the collinear expression seen 
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during normal embryonic brain development [454]. It is worth noting the position of known oncogenic genes in relation to HOX clusters. In respect to this, GBM 
amplified genes (7p12), EGFR (7p12) are close to the HOXA cluster (7p15.3), 
protein kinase C alpha (PKX-α) (17q22) is found close to the HOXB cluster (17p21.3), while MDM-2 (12q14.3) is located near to the HOXC cluster (12q13.3) and finally low density lipoprotein receptor-related protein 1B (LRP1B) (2q21.2) located near the HOXD cluster (2q31) [453]. This may indicate mechanisms that up-regulate these known oncogenes could also play a role in HOX activation. 
1.5.5.1 HOXA Cluster Expression in GBM The HOXA cluster has provided the greatest amount of interest in GBM research, exhibiting the most extensive overexpression compared to all other HOX clusters. This domination of the HOX signature is due to two distinct mechanisms. First is the gain of additional chromosome 7 copies, which harbours HOXA cluster, and secondly the activation of the PI3K/AKT pathway. Overexpression of HOXA3, A4, 
A5, A6, A7, A9, A10 and A11 has been reported in various studies looking at both primary GBM tumours and cell lines [453, 455] 
Though aberrant HOXA gene signatures have been reported in numerous GBM studies, limited knowledge of how individual HOXA genes contribute to GBM tumourgenicity is known. HOXA3 has been shown to play an important role in angiogenesis in numerous solid tumours including GBM, providing spatial information for neoangiogenesis [456]. HOXA6 overexpression has been reported to drive invasive behaviour in GBM cells. Silencing of HOXA6 in these cells resulted in a marked reduction in invasive potential [457]. Overexpression of HOXA7 has 
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been linked to increased rates of proliferation in GBM by up-regulation of EGFR expression [458, 459].  
High HOXA9 expression in GBM has been shown to be an indicator of poor prognosis and reduced survival time [454]. Patients found to have a high HOXA9 promoter methylation phenotype were found to survive on average 9.6 months longer than patients with a methylation status below the median level [460]. HOXA9 has been cited as a potent anti-apoptotic regulator and a promoter of proliferation [454, 461]. In a study performed by Murat et al HOXA9 was proposed to be fundamental in the maintenance of a CSC phenotype [340]. Di Vinci et al showed that HOXA9 overexpression could be independent of tri/tetrasomy of chromosome 7, or surprisingly, the amplification of its constituent gene [460]. A more likely explanation is that upstream mechanisms drive HOXA9 up regulation. It has now been proposed that the AKT enhancers PIKE-A and PIKE -L cause an increase in PI3K levels and thus HOXA9 expression [462]. Both PIKE-A and PIKE-L, are encoded by the CENTG1 gene located within 12q13-q14 and is closely associated with the HOXC cluster [462]. The activation of PI3K in GBM has been associated with increase in tumour grade, suppression of apoptosis, the promotion of invasion through EMT and correlates to poor prognosis [463]. This can be accounted for, at least in part, by the up regulation of HOXA9 expression by PI3K, as the PI3K inhibitor LY294002 can silence HOXA9 expression [454]. Furthermore, overexpression of HOXA9 in GBM cell lines or immortalised NHA cells, results in increased rates of proliferation and resistance to apoptosis [454]. It is also important to note that Gfi1 has binding sites that overlap the HOXA9 promoter, thus providing a competitor inhibitor and causing alternative translational outcomes [461]. It is also notable that there is significantly less Gfi1 
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protein in GBM specimens compared to normal astrocytes, and that Gif1 levels are inversely correlated with HOXA9 expression [461]. GBM neurospheres have been shown to express high levels of HOXA9, with expression correlating with nestin expression. Transcription repression of HOXA9 in neurospheres leads to a significant drop in stem cell associated genes, while over expression significantly increases the number and size of neurosphere compared to control cells [454, 464].  
HOXA10, similarly to HOXA9, has been implicated as a major oncogene in GBM, driving multiple tumorigenic functions [465]. Di Vinci et al found that patients had on average a 4 month survival benefit if they had an above average methylation level of the HOXA10 gene [460]. Arguably the most important clinical finding associated with HOXA10 is its presence in neurosphere cultures derived from GBM samples [340, 465]. A study by Gallo et al documented the signalling pathway up and down stream of HOXA10 [465]. This study reported a strong correlation between Histone-lysine N-methyltransferase HRX (MLL) and HOXA10 [465].  MLL is a histone methyltransferase that catalyzes the methylation of histone 3 at lysine 4, causing a series of complex epigenetic modifications leading to positive regulation, ‘genome unzipping’, resulting in an up regulation of target genes, many of which have been associated with self-renewal and differentiation [466, 467]. MLL has been shown in various studies to contribute to both normal and malignant stem cell function. MLL has a binding site approximately 1,380 bp upstream of the HOXA10 translational start site, presenting a potential link between MLL expression and HOXA10 transcription [465]. This was proved, as the silencing of MLL results in a reduction of HOXA10 expression in GBM [465]. Further analysis of MLL/HOXA10 positive GBM cells showed strong expression of 
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CD15 and SOX2 when compared with NHA cells and low MLL/HOXA10 expressed GBM cells [465]. It was also noted that GBM cell lines cultured in hypoxic conditions had a higher expression of MLL compared to their normoxic counterparts [468]. To further strengthen the link of MLL/HOXA10 expression in GBM stem cells, previous studies have shown that culturing GBM cells in hypoxic conditions enriches their stem cell populations, and provides another mechanism which contributes to the ‘stemness’ of GBM cells that is distinct from the HIF-1-α pathway [469]. Identified HOXA10 targets are TERT, FGF17, JAG2 and NODAL, all of which have established oncogenic functions [465]. Other HOXA10 targets include HOXA7, HOXC10 and CBX6 [465]. This suggests a possible positive feedback loop between HOX proteins, which may account in part for the sporadic activation found in GBM cells compared to their astrocytic counterparts. Silencing of HOXA10 expression causes a marked reduction in proliferation both in vitro and 
in vivo. HOXA10 knockdown in xenograph mice provided an increase in survival time comapared to control mice, with some cell lines unable to form tumours following inoculation [465]. Murat et al discovered a correlation between high 
HOXA10 expression and poorer outcomes in patients receiving TMZ or concomitant TMZ/RT treatment [340]. This explains HOXA10’s ability to modulate DNA repair pathways through the maintainance of all Rec-A like Protein 51 (RAD51) isoforms, as well as, increases in gamma-H2A histone family member X (Υ-H2AX) formation at double-strand DNA damage sites [469]. 
HOXA11, unlike the previously discussed HOX proteins, acts primarily as a tumour suppressor, and is expressed in normal human tissue and down regulated in cancer. Martinez et al showed that 52 of 100 GBMs showed HOXA11 promoter hypermethylation, causing a decrease in HOXA11 expression [470]. A further 
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independent study reported HOXA11 promoter hypermethylation in GBM tumours. Methylation status positively correlated with increasing patient age, and a robust marker of poor patient prognosis [471]. HOXA11 has been associated with cellular migration and invasion and is believed to be a suppressor of EMT [470]. Tumour cells treated with either TMZ or RT, were shown to be enriched for 
HOXA11 negative or low expressing cells when compared to parental tumour cells [472]. This highlights HOXA11 importance in acquired treatment resistance in GBM.  
Duan et al, using a 306 sample set, discribed high HOXA13 expression in glioma compared to normal brain tissue, with HOXA13 expression levels increasing from low to high grade gliomas [473]. In addition to this, HOXA13 expression was associated with poor patient prognosis and a decreased surival time. The mechanisms contributing to HOXA13 oncogenic potential is still ongoing. However, associated pathways include focal adhesion and cell cycle control, as well as, TGF-β and Wnt signalling [473]. This provided evidence for HOXA13 enhancing glioma proliferation, invasion and migration. Silencing of HOXA13 has been shown to reduce GBM cells invasive potential and cause G0-G1 cell cycle arrest in vitro; while in vivo a loss of tumorigenicity is seen [473].  
1.5.5.2 HOXB Cluster Expression in GBM The HOXB cluster has received the least amount of attention in glioma research, with minimal published journals in the current literature. Han et al analysed 
HOXB1 expression in low and high grade gliomas compared to normal brain tissue [474]. A significant reduction in expression was seen in glioma tissue compared to normal brain tissue, with low HOXB1 expression linked to poor patient 
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prognosis [474]. Furthermore, differential expression was observed between low grade gliomas (LGG) and high grade gliomas (HGG) [474]. The role of HOXB1 as a tumour suppressor was supported when HOXB1 expression was silenced in GBM cell lines, resulting in an increase in cellular proliferation and invasion potential, while also inhibiting apoptosis. [474]. Overexpression of HOXB13 has been reported in GBM cell lines compared to NHA, as well as patient tissue [453, 457, 462]. Knockdown of HOXB13 by antisense-introduction, lead to a significant reduction in invasion compared to mock treated GBM cells [457]. Further work is on going to determine the mechanism behind HOXB13’s control over invasion.  
1.5.5.3 HOXC Cluster Expression in GBM In NHA the HOXC cluster expressed at minimal levels, with HOXC6, HOXC8 and 
HOXC10 unexpressed, while all of these genes are expressed in GBM cell lines and tissue [453]. Wide spread HOXC cluster expression has been reported in GBM cell lines with high HOXC4, HOXC10, HOXC11 and HOXC13 expression seen in TMZ resistant cell lines [462]. HOXC4 and HOXC6 have been shown to be differentially expressed in CD133 high tumours compared to CD133 low tumours [475]. Further analysis has also shown that high HOXC4 and HOXC6 expression is associated with shortened patient survival, and was an independent prognostic marker to CD133 [475]. HOXC4’s implication in GBM tumourgenicity is yet to be determined, but 
HOXC6 expression has been linked with high invasive potential in GBM cells.  This was supported by silencing HOXC6, using antisense-introduction, which resulted in a reduction in cellular invasion [457].  
High HOXC9 expression has been linked to poor prognosis in GBM patients, with expression shown to increase with tumour grade and be a positive marker of 
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patient progression [476, 477]. In addition to this, HOXC9 is overexpressed in CD133+ GBM cells, and co-expressed with E2F Transcription Factor 2 (E2F2). In GBM, E2F2 has been reported to induce Bcl-2 expression by transactivating promoter elements [478]. Short hairpin ribonucleic acid (shRNA) knockout of 
HOXC9 reduces cellular proliferation and invasion potential in GBM cell lines in 
vitro, while reducing orthotopic tumour volume in vivo [477]. Interestingly, shRNA knockout of HOXC9 has been shown to induce death-associated protein kinase 1 (DAPK1) mediated autophagy, and not apoptosis [477].   
1.5.5.4 HOXD Cluster Expression in GBM NHA expressed low levels of HOXD3, HOXD8, HOXD11 and HOXD12, while HOXD1, 
HOXD4, HOXD9, HOXD10 and HOXD13 are silent [453]. In contrast, GBM tissue and cell lines overexpressed HOXD1, HOXD4, HOXD9 and HOXD13 [453, 479]. Buccoliero et al reported universal overexpression of HOXD1 and HOXD12 in paediatric glioma tumours compared to NHA, with variable expression of HOXD4, 
HOXD9 and HOXD10 [480]. Interestingly, HOXD3 was found to be expressed at low levels in paediatric glioma compared to NHA, indicating a possible role as a tumour suppressor [480]. Minimal work has been performed on the effect of overexpression of anterior HOXD cluster expression; with only HOXD1 expression being associated with chemoresistance in GBM tissue [462]. 
HOXD9 has been shown to have a role in maintaining the CSC phenotype [481]. HOXD9 is crucial for early embryonic segmentation and limb bud patterning [482, 483]. After embryonic development, HOXD9 expression is limited to the normal spleen, kidney, bladder, testis, colon and placenta [481]. Extremely low or no expression in normal brain tissue is observed, but varying levels has been 
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reported in GBM tissue [484]. HOXD9 promotes the survival and proliferation of GBM cells [481]. Tabuse et al showed that there was a strong correlation between the expression of HOXD9 and the stem cell marker SOX2 [481]. In addition to this, higher levels of HOXD9 mRNA was detected in GBM CSCs compared to parental GBM cells[481], further supporting a role for HOXD9 in maintaining the GBM CSC phenotype [481]. It has been shown that siRNA- silencing of HOXD9 results in a marked reduction in proliferation as well as increased apoptosis in both the parental GBM and CSCs populations [481]. It is important to trace both the up and down stream pathways from HOXD9. It has been reported that HOXD9 is induced by Wnt signaling, which in turn is important for many developmental functions including maintenance of NSCs and neural crest cells [485-487]. This further supports the notion that HOXD9, induced by Wnt, is important in CSC maintenance, and potentially in the maintenance of NSCs and neural crest cells. HOXD9 has been shown to up regulate expression of Bcl-2 in GBM cells providing a survival benefit and anti-apoptotic stimuli [481]. However, if HOXD9 is silenced by siRNA, there is a significant reduction in Bcl-2 levels leading to apoptosis [481].  
Conflicting reports have been published in regards to expression of HOXD10 in normal brain tissue, with some reporting negative expression, while others detectable levels. Hu et al showed HOXD10 was frequently down regulated in glioma tissue when compared to matched adjacent tissue [488]. Low HOXD10 expression correlates with poor patient survival in GBM [489]. An inverse correlation between expression of HOXD10 and miRNA-23a was observed in glioma tissue and cell lines [488]. Inhibition of miRNA-23a in GBM cell lines resulted in a increase of HOXD10 protein levels, and a marked reduction in invasion potential [488]. This increase of HOXD10 was accompanied by a 
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reduction in matrix metalloproteinase-14 (MMP-14) expression, an important enzyme involved in the breakdown of ECM, an essential process for cellular invasion [488, 490]. Additional miRNAs, miRNA-10a and miRNA-10b, have been shown to target HOXD10 [489, 491-493]. Like miRNA-23a, miRNA-10a and miRNA-10b target HOXD10 causing a significant increase in MMP-14, as well as urokinase receptor (uPAR), promoting cellular invasion [489, 491]. Inhibition of miRNA-10b restored HOXD10 protein levels, resulting in a loss of MMP-14 and uPAR expression [489, 491]. Figure 1.30 depicts the known pathways both up and downstream of HOX signalling, while Figure 1.31 summarises the aberrant expression of HOX genes in GBM.  
 
Figure 1.30: Schematic diagram showing the pathway network connecting HOX proteins. An 
autoregulation loop can be seen between HOXA10, HOXC proteins and HOXA9. HOX genes up regulate 
a wide array of proteins involved in proliferation, invasion, angiogenesis and the suppression of 
apoptosis. 
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Figure 1.31: Diagram depicting aberrant expression of HOX genes in GBM. A total of 21 overexpressed and 4 under expressed HOX genes have been reported in GBM. The 
HOXA cluster has the highest aberrant expression pattern, while the HOXB cluster shows the least.   
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1.6 Targeting HOX-PBX Dimers The widespread aberrant HOX protein expression in cancer, and the key pathways they exert influence over has provided much interest as potential therapeutic targets. Various independent groups have targeted individual HOX genes with siRNA and miRNA, to varying degrees of success. This therapeutic approach is neither seen as especially effective, mainly due to functional redundancy of HOX proteins, and the limited application of siRNAs and miRNAs in the clinical setting. An alternative approach is to target and inhibit the interaction between HOX and PBX proteins, disrupting HOX paralog groups’ 1-10 functionality. This interaction is mediated by a small tryptophan-containing motif, which incorporates a highly conserved hexapeptide region located within the HOX protein. This hexapeptide motif binds to a hydrophobic pocket positioned in the PBX’s tertiary structure known as the PID [380, 397-399]. A previous attempt at targeting this interaction with a small molecular inhibitor has been published, but with its dissociation constants (Kd) in the micromolar range, the experimental drug was abandoned [494]. Independently an alternative approach was developed utilising a peptide-based drug named HXR9. 
1.6.1 Peptide therapies: HXR9, CXR9 and HTL00-1 HXR9 is an 18 amino acid synthetic peptide consisting of a hexapeptide sequence connected to a short polyarginine sequence [368, 391, 420-422]. The hexapeptide motif mimics the same amino acid sequence found in HOX proteins, thus allowing it to bind to PBX1-4 and inhibiting its dimerization to HOX [370, 419-422]. Figure 
1.32 shows computer modelling of HOXA9-PBX1 inhibition by HXR9.  
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Figure 1.32: Computer modelling based on X-ray crystallography of HXR9 binding to PBX1 PID, 
inhibiting the dimerization with HOXA9 and HOXB1.  
The polyarginine repeat promotes the cellular uptake of HXR9, via endocytosis, by binding to the extra cellular protein heparin sulphate [420-422, 495-497]. HXR9 was initially proved to be cytotoxic on melanoma cell lines and primary melanoma tumour cells, and was shown to reduce growth of B16F10 murine melanoma cells in an orthotopic model [419].  Subsequent experiments have shown HXR9 to be cytotoxic in numerous cancers including myeloma, mesothelioma, meningioma, melanoma, prostate cancer, breast cancer, non-small cell lung cancer and ovarian cancer both in vitro and in vivo [369, 370, 391, 421, 498-500]. CXR9 is a control peptide that is identical to HXR9, but with the exception of a one amino acid substitution. This substitution renders the peptide inert and has been shown to have no cytotoxic effect on both healthy and malignant cells both in vitro and in 
vivo [369, 370, 391, 421, 498-500]. The half-life of both peptides in serum has been shown to be around 12 hours [419].  
Hexapeptide HOXA9 – red HOXB1 – yellow PBX1 – cyan 
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HTL00-1 is a 2nd generation synthetic peptide based on similar therapeutic principals of it predecessor HXR9. As with HXR9, HTL00-1 comprises an identical polyarginine cell penetration sequence, as well as a modified hexapeptide motif and an additional linker sequence. These changes were implemented with the hope of increasing Kd, improving solubility and cytotoxicity as well as producing a peptide with a more neutral potential of hydrogen (pH).   
1.6.1.1 HXR9 and HTL00-1 Proposed Mechanism of Action HXR9 has been shown to induce apoptosis in all but one cancer type when used in 
vitro and in vivo [369, 370, 419, 498, 500]. The single outlier is renal cancer, which has been shown to undergo a mixture of apoptosis and necrosis [420]. Miccroarray analysis revealed 22 genes that were significantly increased (P<0.05) between HXR9 and CXR9 treated tumours [419]. Of these genes Fos Proto-
Oncogene AP-1 Transcription Factor Subunit (C-Fos), Jun Proto-Oncogene AP-1 
Transcription Factor Subunit (C-Jun), dual specific phosphatase 1 (DUSP1), 
activating transcription factor 3 (ATF3), kruppel like factor 4 (KLF4), mothers 
against decapentaplegic (MAD) and death-associated protein kinase-related 
apoptosis protein kinase 2 (Drak2) were all deemed of high interest. 
The main mechanism by which HXR9 causes cell death has been associated to a sharp increase in C-Fos. C-Fos, as well as C-Jun, is a member of the Basic Leucine Zipper domain (bZIP) superfamily of transcription factors, characterised by a leucine zipper region within its DNA-binding domain [501]. The silencing of C-Fos can be used to partially block HXR9 mediated death both in vitro and in vivo [419, 498]. C-Fos has been shown to have both oncogenic and tumour suppressive potential in a variety of solid tumour types. This is potentially due to the temporal 
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expression determining its functionality, but an alternative explanation is that C-Fos binding partners might act as the oncogenic/tumour suppressor ‘switch’. A third possibility is that a mixture of the two previous hypotheses are utilised.  
The immediate early gene Atf3 is a member of the activating transcription factor (ATF)/cyclic AMP-response element binding protein (CREB) family, whose expression is induced by a variety of cellular stress including DNA damage, cellular injury, oxidative stress and viral infection [502]. Atf3 induction in response to cellular stress causes a drop in migratory potential and reduction in proliferation and survival [502]. Atf3 tumour suppressor functions are mediated by its ability to block ubiquitination, and thus stabilise p53 protein levels [503]. In addition to this Atf3 has been shown to prevent translocation of NF-κB and the phosphorylation of signal transducer and activator transcription 3 (STAT3) [504]. MAD is a tumour suppressor protein able to block proto-oncogene C-Myc (C-Myc), causing a reduction in proliferation, migration and invasion [505, 506]. KLF4 is another known tumour suppressor shown to inhibit C-Myc activity, as well as beta catenin (β-catenin) [507-509]. Suppression of these genes leads to reduction in proliferation and invasion, increased rates of apoptosis and reduced tumourgenicity in vivo [507-509]. Drak2 is a serine/threonine kinase shown to share a high degree of sequence and function homology with death-associated protein kinases (DAPK). Drak2 expression, whether stress induced or transiently overexpressed, induces apoptosis in cancer and healthy cells [510, 511]. Figure 
1.33 [512] depicts the potential pathways modulated by HXR9 and HTL00-1 treatment. DUSP1 function as enzymes that dephosphorylates serine, threonine and tyrosine residues in a variety of proteins. DUSP1 targets include MAPKs, such as mitogen-activated protein kinases 1 (MEK) and extracellular signal-regulated 
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kinase (ERK) [513, 514]. DUSP1 dephosphorylation of MEK and ERK leads to their inactivation, and in turn the silencing of RAS signalling pathway [515, 516].  
 
Figure 1.33: Diagram showing the potential downstream pathways modulated by HXR9 and HTL00-1 
treatment. Unhindered HOX-PBX dimers are able to translocate and enter the nucleus, thus 
transcribing and repressing their target genes. Potential repressor targets are DUSP1, ATF3 and C-Fos. 
HXR9 mediated inhibition of HOX-PBX causes an increase in DUSP1, ATF3 and C-Fos expression. The 
current consensus is that increased C-Fos protein levels activate Fas ligand (FasL) transcription. FasL 
protein in turn binds and activates Fas receptor (FasR) triggering the extrinsic apoptosis pathway. 
ATF blocks ubiquitination of p53, which promotes mitochondria mediated apoptosis and blocks 
proliferation through cell cycle arrest. DUSP1 dephosphorylates MEK and ERK, causing a loss of RAS 
mediated signalling. Adapted from Morgan et al (2017). 
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1.6.2 Small Molecule Therapies: E4 and ICT9119 E4 is a 300 Da, small molecule mimic of HXR9, created using computer based modelling and based off the basic structure of tryptophan. E4 was selected from a panel of potential small molecule inhibitors for its cytotoxic ability and its rapid cellular absorption rates.  E4 is believed to be cytotoxic as it has the potential to bind to PBX1-4, blocking their ability to interact with HOX proteins. E4 is lipophilic and passes through the phospholipid bilayer in a passive manner [517, 518].  
ICT9119 is a second-generation small molecular mimic of HXR9. ICT9119 was designed off the ‘molecular skeleton’ of E4, and was part of a second stage screening process. This screening process contained 19 putative HOX/PBX inhibitors, 8 commercial manufactured (Chemspace, UK), and 8 developed ‘in-house’ at the University of Bradford. X-ray crystallography data confirmed that the binding of PBX1 and HOXA9 was dependent on a conserved tryptophan residue in the HOX hexapeptide sequence. Computer modelling showed that ICT9119 had the potential to bind to PBX proteins (Figure 1.34), thus inhibiting HOX/PBX dimerization. An interaction map of PBX and ICT9119’s molecular interactions can be seen in Figure 1.35. Much like E4, ICT9119 is lipophilic and enters cells by passive diffusion through the phospholipid bilayer [517, 518].  
1.6.2.1 E4 and ICT9119 Proposed Mechanism of Action As E4 and ICT9119 are both based off HXR9, it is believed that both small molecules will induce cell death through similar pathways as HXR9. These proposed pathways include, DUSP1 mediated RAS inhibition, C-Fos activation of FasL signalling, as well as ATF3 stabilisation p53. These proposed pathways can be seen in Figure 1.33. 
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Figure 1.34: Computer modelling of the interaction of ICT9119 (Green) to PBX (Blue), which is bound 
to DNA (Grey). Adapted from Morgan (2006).    
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Figure 1.35: Interaction map for binding of ICT9119 to PBX. Key interactions include the binding of 
leucine, at position 256, to ICT9119’s synthetic tryptophan group, lysine to the benzyl group, and 
asparagine, at position 258, to ICT9119’s sulphur group. Adapted from Morgan (2006).     
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1.7 Introduction Summary  Advances in GBM treatment has not progressed at a similar rate to other solid malignancies. This is mainly due to its rarity, restricted access to tissue, the complexity of designing adequate in vivo tumour models, the reduced ability for drug delivery due to the protective effects of the BBB and inherent aggressive nature.  
Previous research has identified HOX dysregulation between healthy brain tissue and brain tumours. In addition to this, GBM CSC’s have been shown to exhibit a distinct HOX expression pattern. HOX targeting is a relatively untouched area of research in GBM and CNS tumours. Independent groups have used various RNA mediated silencing treatments with varying degrees of success. Given the high level of HOX dysregulation in GBM, and the sensitivity of other solid malignancies to the HXR9, there is a clear opportunity to target HOX dysregulation in GBM.  Any future drug developed for GBM must meet 3 key characteristics: 
1.  The ability to cross the BBB. 2. Specifically target cancer cells. 3. Effectively kill both the ‘parental’ GBM cells as well as the more resistant CSCs.   With these criteria in mind there is evidence that HXR9/HTL00-1, and their small molecule counterparts, have the potential to provide an alternative treatment regime for both paediatric and adult GBM patients. We also propose that HOX/PBX inhibition could be used in conjunction with conventional chemotherapy or RT.   
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1.8 Study Hypothesis and Objectives   Our first hypothesis was that dispruption of HOX-PBX dimers in GBM parental CSCs is cytotoxic both in vitro and in vivo. Objectives of Chapter 3 are as follows: 
• Verify HOX and TALE gene dysregulation in adult GBM tissue, cell lines, both parental and CSC, as well as NHA.  
• To assess HXR9’s cytotoxic and cytostatic potential in adult GBM parental and CSC cell line in vitro.  
• To determine HXR9’s mode of Death. 
• To evaluate HXR9’s ability to retard tumour growth in vivo. 
Secondly, we hypothesised that paediatric glioma cells would also be susceptible to both HXR9 and HTL00-1 treatment. We further hypothesised that HTL00-1 would induce similar cell death pathways as HXR9. Objectives of Chapter 4 are as follows: 
• To evaluate normal paediatric brain HOX and TALE gene expression, as well as paediatric glioma cell lines gene expression. 
• To assess HXR9 and HTL00-1’s cytotoxic potential in paediatric glioma cell lines in vitro. 
• To determine HTL00-1’s mode of Death. 
• To establish HTL00-1’s cell death pathway. 
Our final hypothesis was that E4 and ICT9119 could inhibit HOX-PBX dimerization and be cytotoxic in vitro. In addition, we hypothesised that ICT9119 would induce the same cell death pathway as HXR9. Finally, we proposed that ICT9119 could act synergistically with RT in the treatment of adult GBM cells. Objectives of Chapter 
5 are as follows: 
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• To compare HXR9, E4 and ICT9119’s cytotoxic potential on adult GBM cell lines in vitro.  
• To evaluate ICT9119’s cell death pathway. 
• To asses the potential of ICT9119 with RT’s synergy. 
• To determine the mechanisms behind potential ICT9119 and RT synergy. 
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Chapter 2 
Materials and Methods 
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2 Materials and Methods 
2.1 Tissue Culture 
2.1.1  Tissue Culture Reagents  
Table 2.1 lists all the supplements and media used in tissue culturing. 
Table 2.1: A table listing all the media and supplements used in tissue culturing. 
Media and Supplements Abbreviation Supplier 
Minimal Essential Medium Eagle (With Earle’s salts, non-essential amino acids and sodium bicarbonate) MEME Sigma-Aldrich, UK Dulbecco's Modified Eagle's Medium (With 4500 mg L-glucose, 110 mg L-sodium pyruvate, pyridoxine hydrochloride and sodium bicarbonate) DMEM Sigma-Aldrich, UK Kaighn’s Modification of Ham’s F-12 Medium (2mM L-glutamine and 1500 mg/L sodium bicarbonate) F-12K Gibco, UK RPMI-1640 Medium RPMI Sigma-Aldrich, UK Neurobasal-A Medium Neuro-A Gibco, UK McCoy’s 5A (Modified) Medium McCoy’s Gibco, UK Foetal Bovine Serum FBS Gibco, UK Penicillin-Streptomycin (10,000 units of penicillin and 10 mg/ml streptomycin in 0.9% NaCl) Pen/Strep Sigma-Aldrich, UK L-Glutamine 200mM L-Glu Sigma-Aldrich, UK Minimal Essential Medium Non-Essential Amino Acids NEAA Gibco, UK Sodium Pyruvate 100mM NaP Sigma-Aldrich, UK N-2 Supplement 100x N-2 Gibco, UK B-27 Supplement 50x (minus vitamin A) B27 Gibco, UK Heparin Salt Solution 0.2% Hep StemCell Tech, UK 
Epidermal Growth Factor 100μg EGF Invitrogen, UK Basic Fibroblast Growth Factor 50μg FGF Gibco, UK Hanks Balanced Salt Solution HBSS Sigma-Aldrich, UK Bovine Serum Albumin BSA Sigma-Aldrich, UK 
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2.1.2 Cell Lines  
Table 2.2 lists all cell lines used during this study and their origin and source.  
Table 2.2: A summary of all cell lines used in this study, including their origin and source.  
Cell Line Organism Origin Source 
U87-MG Homo Sapien A GBM cell line from the tumour resection of a 44-year-old Caucasian male. ATCC, USA 
U251-MG Homo Sapien A cell line derived from GBM cells from a human patient by explant technique. ECACC, UK 
LN18 Homo Sapien Established in 1976 from the right temporal lobe of a human 65-year-old Caucasian male. This cell line is a grade IV glioma (GBM). ECACC, UK 
XXXCSC Homo Sapien All above glioblastoma cell lines were used for CSC enrichment, and identified using the CSC suffix. - 
GBM1UCL Homo Sapien A primary derived GBM CSC cell lines, established from a tumour resection. Cell line established using protocol described by Pollard et al [520]. UCL, UK 
GBM4UCL Homo Sapien A primary derived GBM CSC cell lines, established from a tumour resection. Cell line established using protocol described by Pollard et al [520]. UCL, UK 
KNS42 Homo Sapien A paediatric GBM cell line established in 1987 from a 16 year old male with a right frontoparieral malignant. ICR, UK 
SF188 Homo Sapien A paediatric GBM cell line established from a tumour resection of an 8-year-old male.  ICR, UK 
RES186 Homo Sapien A grade I paediatric pilocytic astrocytoma.  ICR, UK 
A549 Homo Sapien Originates from a biopsy from the lung of a human 58-year-old Caucasian male. Cells have an epithelial morphology. ATCC, USA 
HT29 Homo Sapien A colorectal adenocarcinoma cell line derived from a 44-year-old Caucasian female. ATCC, USA  
Cell lines U87-MG, A549 and HT29 were purchased from the American Type Culture Collection (ATCC) and U251-MG and LN18 were purchased from the European Collection of Cell Culture (ECACC). Cell lines KNS42, SF188 and RES186 were kindly gifted by Professor Chris Jones (Institute of Cancer Research, UK) GBM1UCL and GBM4UCL were provided by Professor Sebastian Brander (University College London, UK) and Dr Heiko Wurdak (University of Leeds, UK) respectively.  
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Commercially available cell lines were authenticated using short tandem repeat (STR) profiling (LGC, UK), and compared to authenticated STR profiles, with a threshold of ≥80% confirmed as a match.  
All cell lines were adherent lines, cultured in a Nuaire In-VitroCell incubator (Nuaire, USA) at 37°C with 5% CO2, and 25% O2. Cells were regularly passaged and weren’t allowed to pass 90% confluence. Media was changed every 3-5 days as needed. Mycoplasma testing was carried out prior to and after cryopreservation, and regularly thereafter on all cell lines using MycoAlert™ Mycoplasma Detection Kit (Lonza, UK). 
2.1.3  Preparation of Laminin and Extracellular Matrix Flasks and 
Plates Laminin coated flasks were prepared by first diluting lyophilised poly-L-ornithine (Sigma-Aldrich, UK) in tissue culture grade water (Sigma-Aldrich, UK) to a final concentration of 10 μg/ml. Then 10ml of diluted poly-L-ornithine was added per T175 Helena Bioscience flasks (Helena Bioscience, UK) and incubated for one hour at room temperature. Poly-L-ornithine was aspirated off, and flasks were washed 3 times with sterilised water. Lyophilised laminin was diluted in tissue culture grade phosphate buffer saline (PBS)(Thermo Scientific, UK) to a concentration of 2 μg/ml. Then 10ml of diluted laminin was added per flask and incubated at room temperature overnight. Laminin solution was aspirated and flasks washed 3 times with sterilised water. Flasks not used immediately were stored at -20°C after being wrapped in a protective layer of Nescofilm (Thermo Scientific, UK). To laminin coat 96 well plates (Thermo Scientific, UK), 20μl of 10 μg/ml poly-L-ornithine was pipetted per well and incubated for one hour at room temperature. 
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Poly-L-ornithine was aspirated off, and plates were washed 3 times with sterilised water. Then 20μl of 2μg/ml laminin per well and incubated at room temperature overnight. Laminin solution was aspirated and plates washed 3 times with sterilised water. Plates not used immediately were stored at -20°C after being wrapped in a protective layer of Nescofilm (Thermo Scientific, UK). GBM1UCL and GBM4UCL were cultured in laminin coated flask and plates.  
To coat a T75 Helena Bioscience flask with ECM coating, 5ml of Dilution media (Gibco, UK) was added before directly pipetting 50μl of Coating Matrix (Gibco, UK) into the Dilution media. The flask was gently rocked to mix reagents before being left to incubate at room temperature for 30 minutes. Coating Matrix solution was aspirated off prior to washing flask with HBSS. To coat 96 well plates with extracellular matrix protein, 5ml of Dilution media was mixed with 50μl of Coating Matrix and gently vortexed. 50μl of Coating Matrix solution was pipetted per well and incubated for 30 minutes. Coating Matrix solution was aspirated off prior to washing flask with HBSS. All reagents used in ECM coating protocol were supplied in Gibco’s Coating Matrix Kit (Gibco, UK). U87-MGCSC, U251-MGCSC and LN18CSC enriched cell lines were all cultured in pre-coated extracellular matrix flasks.  
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2.1.4 Cell Lines and Their Culture Media and Conditions  
Table 2.3 lists the culture conditions and media used for individual cell lines.  
Table 2.3: A table of culture media, with additional added supplements and growth conditions used 
to culture cell lines. 
Cell Line Culture Conditions  Media and Supplements 
U87-MG 37°C, 5% CO2, 25% O2 MEME + 10% FBS, 100 U/ml Pen/Strep, 1mM NaP 
U251-MG 37°C, 5% CO2, 25% O2 MEME + 10% FBS, 100 U/ml Pen/Strep, 1% NEAA, 1mM NaP 
LN18 37°C, 5% CO2, 25% O2 DMEM + 5% FBS, 100U/ml Pen/Strep, 2mM/L L-Glu  
CSC 37°C, 5% CO2, 25% O2 Neuro-A + 100 U/ml Pen/Strep, 2mM/L L-Glu, 1% N2, 2% B27, 0.0002% Hep, 20ng/ml EGF, 10ng/ml FGF 
GBM1 UCL 37°C, 5% CO2, 25% O2 F-12:DMEM (1:1) + 100 U/ml Pen/Strep, 2% B27, 0.0002% Hep, 20ng/ml EGF, 20ng/ml FGF 
GBM4 UCL 37°C, 5% CO2, 25% O2 F-12:DMEM (1:1) + 100 U/ml Pen/Strep, 2% B27, 0.0002% Hep, 20ng/ml EGF, 20ng/ml FGF 
KNS42 37°C, 5% CO2, 25% O2 F-12:DMEM (1:1) + 10% FBS, 100 U/ml Pen/Strep 
SF188 37°C, 5% CO2, 25% O2 F-12:DMEM (1:1) + 10% FBS, 100 U/ml Pen/Strep 
RES186 37°C, 5% CO2, 25% O2 F-12:DMEM (1:1) + 10% FBS, 100 U/ml Pen/Strep 
A549 37°C, 5% CO2, 25% O2 F-12K + 10% FBS, 100 U/ml Pen/Strep 
HT29 37°C, 5% CO2, 25% O2 McCoy’s + 10% FBS, 100 U/ml Pen/Strep  
2.1.5 Passaging of Adherent Non-CSC Cell Lines The following tissue culture work was all performed in a sterile class II biosafety cabinet with a double high-efficiency particulate air (HEPA) filter (Kendro, UK).  Media was first aspirated off, before the adherent cell monolayer was washed with HBSS to remove any foetal calf serum and dead cells. Cells were mobilised by adding 10ml 0.5% trypsin 0.2% ethylenediaminetetraacetic acid (EDTA) (Sigma-
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Aldrich, UK) for 5-10 minutes at 37°C. Once cells had been mobilised, 10ml of fresh media containing foetal calf serum was added to quench the trypsin EDTA. The cell suspension was then centrifuged at 1500 rpm for 3 minutes. The cell pellet was then resuspended in the appropriate media, as listed in Table 2.3, and then split into the required dilutions and seeded into new flasks. Cell lines were cultured for no more than 30 passages from the passage number they were received from tissue banks or STR authentication. Once the 30 passage threshold had been reached, cells were discarded and replaced by stock of a lower passage number. 
2.1.6 Enrichment of Cancer Stem Cells  CSC cell lines were produced from parental cell lines, U87-MG, U251-MG and LN18, by culturing the parental cell in CSC media, as listed in Table 2.3, in uncoated cell culture flasks. Neurospheres were mechanically disassociated by gently pipetting spheres through increasingly smaller pipette tips until a single cell suspension was achieved. Cells were split in a 1:5 ratio and suspended in fresh CSC media. Cells underwent 3 consecutive neurosphere passages before being mechanically disassociated one final time prior to cell seeding in a pre-coated extracellular matrix flask. Cells were only classified as CSCs once they had passed through this enrichment process and were assessed for their ability to positively express CSC markers.  
2.1.7 Passaging of Adherent CSC Cell Lines The following tissue culture work was all performed in a sterile class II biosafety cabinet with a double heap filter (Kendro, UK). CSC’s were passaged by first aspirating off media, before adding 10ml of StemPro® Accutase (Gibco, UK) to 
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mobilise cells. Once cell had mobilised HBSS was added to dilute and terminate cell disassociation reaction. The cell suspension was then centrifuged at 1500 revolutions per minute (rpm) for 3 minutes. The cell pellets were then resuspended in the appropriate CSC media, as listed in Table 2.3, and then split into the required dilutions and seeded into new pre-coated flasks.  
2.1.8 Cryopreservation and Storage of Cell Lines Cells in log phase of growth were harvested either with 0.5% trypsin 0.2% EDTA or StemPro® Accutase before being spun at 1500 rpm for 3 minutes to form a cell pellet. The supernatant was removed and the cell pellet was then resuspended at 106 or 107 cell/ml in appropriate complete media, with the addition of 10% DMSO (Sigma-Aldrich, UK). Cells were then transferred in 1ml aliquots, under sterile conditions, into labelled cryovials. Cryovials were initially frozen overnight using a Mr Frosty Freezing Container (Thermo Scientific, UK) containing 250ml of isopropanol (Fisher Scientific, UK) which has a temperature drop of 1°C/minute. The following day the cells were transferred to liquid nitrogen storage. 
2.1.9 Cell Recovery from Cryopreservation Cryovials were removed from liquid nitrogen and rapidly thawed in a water bath at 37°C. Once cells were thawed, they were diluted in 9ml of fresh warm media and then centrifuged at 1500 rpm for 3 minutes. The supernatant was discarded to remove traces of DMSO. Cell pellets were resuspended in 10ml of media and transferred to a T75 flask and incubated at 37°C. Media was removed and replaced the next day once cells had adhered.  
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2.1.10 Evaluation of Cell Number Cell suspension was diluted 1:10 with typan blue (Sigma-Aldrich, UK) and from this 10μl was loaded onto the grid of a Neubauer haemocytometer (Merck-Millipore, UK). Viable cells will remain unstained and appear clear, as trypan blue is membrane impermeable and only able to stain, membrane compromised, dead cells. Viable cells found in the outer four corner squares of the haemocytometer were counted, as illustrated in Figure 2.1. 
 
 
 
 
 
  
 
Figure 2.1: A haemocytometer diagram indicating the four corner squares, circled in red, which were 
used for determining cell number. Only cells able to exclude typan blue staining were counted.  The following formula determined the cell number:  
Mean No. of cells per quadrant × Dilution factor × 104 = No. of cells/mL  
2.1.11 Collection and Storage of Primary Brain Tissue The National Institute of Health NeuroBioBank provided brain tissue from healthy children and adolescents. Consent was provided and all appropriate Material Transfer Agreement (MTA) and Human Tissue Act (HTA) documents were filled and completed. Samples were stored at -80°C before being processed and stored 
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at either -20°C for DNA, or -80°C for RNA. The author would like to acknowledge and thank The University of Maryland, Brain and Tissue Bank, and The University of Miami Health System, Brain Endowment Bank, for their contribution of tissue for this study.  
2.2 Bright-Field Imaging of Glioblastoma Neurospheres GBM CSCs potential to form neurospheres was assessed by seeding 1.5x105 cells/well in an un-coated 6 well plate in CSC media. Cell were cultured at 37°C with 5% CO2, and 25% O2 for 72 hours. Cells were imaged using a Nikon GIGITAL SIGHT DS-5M camera (Nikon, UK) connected to a Nikon ECLIPSE TS100 inverted microscope (Nikon, UK). 
2.3 Evaluation of Stem Cell Markers via Flow Cytometry 
2.3.1 Extracellular Flow Cytometry: CD133 Cells were harvested using a 5mM solution of EDTA (Sigma-Aldrich, UK) before being washed with PBS. Cells were resuspended in 100µl of PBS/1% bovine serum albumin (BSA) (Sigma-Aldrich, UK) and mouse anti-CD133 (Miltenyi Biotec, UK) at a 1:10 dilution in a flow cytometry tube. Cells were incubated for 30 minutes at room temperature before being centrifuged at 2000 rpm for 2 minutes. Supernatant was removed and the cell pellet was then washed 3 times with 200µl of cold PBS before being centrifuged again at 2000 rpm for 2 minutes. The supernatant was again removed, before the cell pellet was resuspended with a goat-anti mouse IgG1 Alexa flourochrome 488 (Life Technologies, UK) at a 1:200 dilution in 100µl of PBS/1% BSA. Cells were incubated in the dark for 30 minutes at room temperature. Cells were then centrifuged at 2000 rpm for 2 minutes and subsequently washed 3 times with cold PBS. Cells were resuspended in 200µl of 
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PBS prior to being analysed on a MACSQuant® Analyzer 10 (Miltenyi Biotec, UK). A negative, no primary antibody control accompanied all tests. Primary antibody dilution was determined with a positive titre using the HT29 cell line. Primary and secondary antibodies used are listed in Table 2.4. 
2.3.2 Intracellular Flow Cytometry: SOX2 Cells were harvested using a 5mM solution of EDTA before being washed with PBS. Cells were resuspended in 100µl of Fixation medium (Invitrogen, UK) in a flow cytometry tube and incubated for 15 minutes at room temperature. Cells were centrifuged at 2000 rpm for 2 minutes. Supernatant was removed and the cell pellet was then resuspended in 100µl of Permeabilization medium (Invitrogen, UK) with primary antibody, rabbit anti-SOX2 (Abcam, UK), at a 1:100 dilution. Cells were incubated for 20 minutes at room temperature before being washed 3 times in cold PBS. The supernatant was removed, and the cell pellet was resuspended with a goat-anti rabbit IgG Alexa flourochrome 546 (Life Technologies, UK) at a 1:200 dilution in 100µl of Permeabilization medium. This was incubated in the dark for 30 minutes at room temperature, before being washed again 3 times in cold PBS. The supernatant was removed and the cells were resuspended in 200µl of PBS prior to being analysed on a MACSQuant® Analyzer 10 machine. A negative, no primary antibody control accompanied all tests. Primary antibody dilution was determined with a positive titre on the cell line A549. All products used for intracellular staining from Invitrogen were provided in the FIX & PERM® Cell Fixation and Permeabilization kit (Invitrogen, UK). Primary and seconday antibodies used are listed in Table 2.4. 
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Table 2.4: Table listing the primary and secondary antibodies, their dilution and isotypes, used for 
flow cytometry CSC analysis. 
Primary Antibodies 
Antibody Isotype Dilution Supplier 
Mouse anti-CD133 IgG1, Monoclonal 1:10 Miltenyi Biotec, UK 
Rabbit anti-SOX2 IgG, Polyclonal 1:100 Abcam, UK 
Secondary Antibodies 
Antibody Isotype Dilution Supplier 
Goat anti-Mouse Alexa 488 IgG, Polyclonal 1:200 Life Technologies, UK 
Goat anti-Rabbit Alexa 488 IgG, Polyclonal 1:200 Life Technologies, UK 
2.4 Synthesis of HXR9 and HTL00-1 HXR9 is an 18 amino acid peptide consisting of an active hexapeptide sequence, a linker region and a poly-arginine tail that facilitates cellular entry through binding to heperan sulphate. N- and C-terminal amino acids were synthesised in D-isomer conformation to extend peptide half-life by limiting proteasome degradation. CXR9 is a control peptide with a single amino acid substitution, tryptophan for alanine, which renders it inactive. Peptides were synthesised by conventional column-based chemistry and purified to at least 80% purity by Biosynthesis Inc, USA.  
HTL00-1 is a second-generation peptide based off HXR9’s amino acid sequence. HTL00-1 differs from HXR9 as it has a proline substituted for a lysine. Computer modeling determined this substitution increased binding affinity, due to additional hydrogen bonds and increased hydrophobic interactions.  The addition of 2 alanines to the linker region of HTL00-1, provide a peptide kink, which 
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reduces steric hindrance in binding to PBX. N- and C-terminal amino acids were synthesised in D-isomer conformation. Peptides were synthesised by conventional column-based chemistry and purified to ≥95% purity by Sigma-Aldrich, UK. Peptide sequences are as follows: 
HXR9:       WYPWMKKHHRRRRRRRRR (2718.23 Da) 
CXR9:        WYPAMKKHHRRRRRRRRR (2603.09 Da)  
HTL00-1: WYKWMKKAARRRRRRRRR (2617.16 Da) 
X=Changes     
2.5 Synthesis of ICT9119 ICT9119 was synthesised by first dissolving 31mg (0.128 mmol) of dissolving 2-(1H-indol-3-yl)-2-(thiophen-2-yl)ethan-1-amine in  3ml of tetrahydrofuran (THF). This mixture was gently stirred while 22μl (18mg, 0.128mmol) of N, N-Diisopropylethylamine (DIPEA) and 20μl (18 mg, 0.128 mmol) of hexyl isothiocyanate was added. Reaction mixture was then heated to reflux for 21.5 hours. The mixture was cooled to room temperature, and concentrated in vacuo, and purified by flash column chromatography (Ethyl acetate:Polyethylene, 1:2) to yield 34mg of ICT9119 as a brown oil. ICT9119 has molecular weight of 386.1711 Da. ICT9119 was synthesised at the University of Bradford, Institution of Cancer Therapeutics, under the supervision of Professor Richard Morgan. Molecular structure can be seen in Figure 2.2.  
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Figure 2.2: Chemical structure of ICT9119. Key functional groups are: A| a tryptophan group, B| a C=S 
amide bond connected to C| a linear alkane sequence. Adapted from Morgan (2016). 
2.6 HL00-1 Fluorescent Cell Penetration Images To prove the ability of HTL00-1 to penetrate cell’s membranes, and to identify its subcellular localisation, a fluorescent-tagged HTL00-1 peptide was synthesised (AltaBioscience, UK). This peptide had an almost identical amino acid sequence to untagged HTL00-1 peptide, but with the addition of 2 glycine amino acids to act as a linker, attached to 5(6)-carboxyfluorescein (5(6)-FAM) fluorescent tag. Tagged peptides were purified to >90% purity and analysed via mass spectrometry to confirm peptide integrity by manufacturer.  Peptide sequence can be seen below: 
5(6)-FAM-HTL00-1:.5(6)-FAM-GGWYKWMKKAARRRRRRRRR (3089 Da)  Cells were plated at 1x104/chamber in a Falcon™ 8 Chambered Cell Culture slide (Falcon®, Netherlands) and incubated overnight at 37°C. 5(6)-FAM-HTL00-1 was diluted to a final concentration of 2µM in FluroBrite™ DMEM media (Gibco, UK) supplemented with 10% FBS before 300µl was pipetted per chamber. Cells were 
  
C 
B 
A 
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incubated for 30 minutes at 37°C in the dark before 200µl of pre-diluted NucBlue™ Live ReadyProbes™ Reagent (Life Technologies, UK) was added per chamber. NucBlue™ Live ReadyProbes™ diluted solution was prepared by mixing 2 drops of NucBlue™ Live ReadyProbes™ Reagent with 1ml of FluroBrite™ DMEM media. Cells were incubated for a further 20 minutes before being visualised using a Nikon Eclipse TE2000-S inverted fluorescent microscope (Nikon, UK) connected to a CoolLED pE-300white illumination unit (CoolLED, UK). Images were captured using a Micropix GigE 4.2 Mega Pixel camera (Micropix, UK) and analysed using the Micropix Cytocam V1.3.5.0.    
2.7 Radiotherapy Treatment RT was performed by a Gulmay D330 orthovoltage X-ray therapy system (Gulmay Medical, UK), at the Royal Surrey County Hospital. The Gulmay D330 produces 250 kilovolt (Kv) photons directed through filter 9 with a 15cm by 15cm applicator field (Applicator I). Plates were placed on a 6cm tissue equal Solid Water Slab to reduce photon backscatter. Monitor units (MU) used to delivery set Gy dosages for 96 and 6 well plates can be seen in Table 2.5. Once cells were irradiated with various Gy’s, they were incubated for 120 hours at 37°C. Sequential synergy treatment was performed by either treating cells for 24 hours with ICT9119 or RT before the alternative treatment was applied, and cells were incubated for a further 120 hours at 37°C. Table 2.6 lists all the different treatment times and applications used in this study. The Gulmay D330 was calibrated before use by a physics technician. The author would like to acknowledge and thank the Royal Surrey County Hospital’s physic department for calculating the MUs needed to deliver the desired Gy’s for 96 and 6 well plates. 
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Table 2.5: Table listing the MUs used to delivery set Gy’s to 96 and 6 well plates. 
Dosage (Gy) 
Monitor Units (MU) 
6 Well Plate 96 Well Plate 1 100 97 2 200 193 4 400 385 8 800 770 16 800 x2 770 x2  
Table 2.6: Table listing the doses and incubations times used for RT treatments. 
Treatment  Dose Range Used (Gy) Incubation Time (Hours) 
Cytotoxicity Assay RT  1, 2, 4, 8, 16 RT 120 RT-ICT9119 2, 4 RT 24, ICT9119 120  ICT9119-RT 2, 4 ICT9119 24, RT 120 
Synergy Mechanisms  RT-ICT9119 1, 2, 4, 8 RT 24, ICT9119 120  ICT9119-RT 1, 2, 4, 8 ICT9119 24, RT 120 
2.8 Cell Viability Assay  Cell Titer 96® AQueous One Solution Cell Proliferation assay (Promega, UK), was used to evaluate viability of cells in a monolayer culture via a colormetric detection system. The assay contains a MTS tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium] (MTS) compound combined with an electron-coupling reagent phenazine ethosulfate (PES). PES has enhanced chemical stability that allows it to be combined with MTS to form a stable solution. The assay works by the incorporated MTS solution being bio-reduced in metabolically active cells with the use of dehydrogenase enzymes into the soluble formazan (Figure 2.3). The 
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quantity of formazan present, and thus the colour change, is directly proportional to the number of viable cells present.  
Figure 2.3: Chemical structures of the MTS tetrazolium compound and its formazan product once bio-
reduced by dehydrogenase enymes. Figure adapted from Promega’s CellTiter 96® Aqueous cell 
proliferation Assay manual: http://www.promega.co.uk/resources/protocols/technical-bulletins/ 
0/celltiter-96-aqueous-nonradioactive-cell-proliferation-assay-protocol/. 
Non-CSC and CSC cells were seeded at 3x103 cells/well in 96 well plates (Thermo Scientific, UK), with CSC cells seeded in either Laminin or ECM pre-coated plates. Plates were incubated at 37°C for 24 hours prior to treatment. After incubation, all media was removed and all blank and negative wells were replaced with 200μl of appropriate fresh media. All experimental drugs were pre-diluted in appropriate media to obtain desired final concentrations, Table 2.7. 200μl of pre-diluted drug was added to their respective test wells. The plates were then incubated at 37°C for optimum treatment time, Table 2.7. For plates used for RT work, all wells were aspirated and replaced with fresh media before undergoing various Gy’s of RT. Media from all wells was removed and replaced with 100µl of RPMI-1640 (Sigma-Aldrich, UK) plus 2% FBS and 10% of Cell Titer 96® AQueous One Solution in the dark before incubating at 37°C for between 1-4 hours, 
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depending on the cell line and treatment type. Following incubation with MTS solution, plates were measured for optical density (OD) absorption reading on a Varioskan® Flash Multimode Plate Reader (Thermo Scientific, UK) at wavelength 492nm. The data was analysed by subtracting the average OD of the background from the average OD of each sample. The cell survival percentage was then calculated relative to the untreated cells by using the formula below: 
𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂 𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐂𝐂 % = 𝐒𝐒𝐒𝐒𝐂𝐂𝐒𝐒𝐒𝐒𝐚𝐚𝐂𝐂 𝐎𝐎𝐎𝐎 𝐭𝐭𝐒𝐒𝐂𝐂𝐒𝐒𝐭𝐭𝐂𝐂𝐭𝐭 𝐬𝐬𝐒𝐒𝐬𝐬𝐬𝐬𝐂𝐂𝐂𝐂𝐬𝐬
𝐒𝐒𝐒𝐒𝐂𝐂𝐒𝐒𝐒𝐒𝐚𝐚𝐂𝐂 𝐎𝐎𝐎𝐎 𝐒𝐒𝐮𝐮𝐭𝐭𝐒𝐒𝐂𝐂𝐒𝐒𝐭𝐭𝐂𝐂𝐭𝐭 𝐬𝐬𝐒𝐒𝐬𝐬𝐬𝐬𝐂𝐂𝐂𝐂𝐬𝐬 × 𝟏𝟏𝟏𝟏𝟏𝟏 
IC50 and IC25 doses where calculated by the Excel (Microsoft® Office 365 v2013-2014, USA) add-in ED50 plus v1.0. This software was adapted by the author to analyse multiple non-linear regression curves to provide accurate IC50 and IC25 doses from multiple biological repeats. The fraction of dead cells affected by treatment was calculated using the formula below: 
𝐅𝐅𝐒𝐒𝐒𝐒𝐅𝐅𝐭𝐭𝐒𝐒𝐅𝐅𝐮𝐮 𝐅𝐅𝐨𝐨 𝐎𝐎𝐂𝐂𝐒𝐒𝐭𝐭 𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐬𝐬 𝐀𝐀𝐨𝐨𝐨𝐨𝐂𝐂𝐅𝐅𝐭𝐭𝐂𝐂𝐭𝐭 = 𝟏𝟏 − (% 𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂 𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐂𝐂 ÷ 𝟏𝟏𝟏𝟏𝟏𝟏) 
Fraction of dead cells affected was used for Bliss Synergy Analysis (Section 
2.16.3). 
Table 2.7: Table listing dose ranges, treatment times and MTS incubation times for all treatments 
used. * Drugs synthesised at the University of Bradford.  
Treatment Dose Range Treatment Time MTS Incubation Supplier 
HXR9 10-120μM 2 Hours 4 Hours Biosynthesis Inc, USA 
HTL00-1 10-120μM 2 Hours 4 Hours Sigma-Aldrich, UK 
E4 10-120μM 72 Hours 2 Hours * 
ICT9119 5-30μM, 10-120μM 72 Hours 2 Hour * 
Temozolomide 50-1000μM 72 Hours 2 Hours Sigma-Aldrich, UK 
RT 2-16 Gy 120 Hours 1 Hour - 
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2.9 Analysis of Cell Death  
2.9.1 Annexin V/7-Aminoactinomycin D Dual Staining  Apoptosis was initially assessed by measuring the membrane expression of phosphatidylserine with fluorescent conjugated annexin V, and membrane integrity via 7-Aminoactinomycin D (7-AAD) staining. The principal of this assay is based on the variable expression pattern of phosphatidylserine. Healthy cells asymmetrically express phosphatidylserine in the inner surface of the phospholipid bilayer with the help of aminophospholipid translocase (ATP10A) [521]. During the onset of apoptosis, phosphatidylserine is translocated to the outer membrane and acts as a receptor for macrophage mediated phagocytosis. Annexin V protein has a high binding affinity to phosphatidylserine, in a calcium ion (Ca2+) dependent manner. Conjugated annexin V-Phycoerythrin (PE) can be used to detect early signs of apoptosis via flow cytometry. In addition, the fluorescent chemical compound 7-AAD is used to test membrane integrity. 7-AAD has a high binding affinity for DNA, and unlike propidium iodide (PI), binds to RNA. As 7-AAD is not membrane permeable it can only stain cells that have been permeabilised. Thus cells can be split into 4 categories by Annexin V/7-AAD dual staining: 
1. Viable Cells - Annexin V Negative, 7-AAD Negative 2. Necrotic - Annexin V Negative, 7-AAD Positive 3. Early Apoptosis - Annexin V Positive, 7-AAD Negative 4. Late Apoptosis - Annexin V Positive, 7-AAD Positive  
Assay principals can be seen in Figure 2.4. Following appropriate drug treatment at their IC50 dosages, cells were washed 2 times with PBS before being mobilised using StemPro® Accutase. Cells were then resuspended in 200µl of 1X binding 
  129 
buffer (BD Biosciences, UK) with the addition of 10µl of Annexin V-PE antibody (BD Biosciences, UK) and 10µl of 7-AAD stain (BD Biosciences, UK). Following a 15 minute incubation in the dark, cells were washed 2 times with 1X binding buffer before being resuspend in 200µl of 1X binding buffer. The number of viable, apoptotic and necrotic cells was quantified by flow cytomety using the MACSQuant® Analyzer 10.  
 
 
 
Figure 2.4: Diagram showing the principals of the Annexin/7-AAD assay. Healthy viable cells are 
impermeable to 7-AAD dye and have no outer expression of phosphatidylserine. Similarly, necrotic 
cells do not express phosphatidylserine on their outer membrane, but are permeable to 7-AAD. Cells 
undergoing early apoptosis express phosphatidylserine, allowing for annexin V binding in a calcium 
dependent manner. Cells in late apoptosis express phosphatidylserine and are permeable to 7-AAD 
allowing for dual cellular staining. 
2.9.2 Caspase-Glo® 3/7 Assay Caspases are a family of protease enzymes that play a central role in various programmed cell death pathways. Caspases nucleophilically cleave target proteins at aspartic acid residues. Apoptotic caspases can be sub-divided into two distinct categories: 
1. Initiator Caspases – caspase-2, caspase-8, caspase-9 and caspase-10 2. Executioner Caspases – caspase-3, caspase-6 and caspase-7 
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Initiator caspases can be activated by either the intrinsic or extrinsic apoptotic pathway. Once activated, they in turn cleave and activate executioner caspases. Executioner caspases go-on to cleave and subsequently degrade cellular protein, with over 600 potential targets currently known [522]. Once executioner caspases are activated cells are irreversibly committed to undergoing programmed cell death. This underpins the reason why detection of these caspases are important in determining apoptotic cell death. 
 The Caspase-Glo® 3/7 Assay (Promega, UK) is based on a luminogenic caspase-3/7 substrate that contains a L-aspartyl-L-glutamyl-L-valyl-L-aspartic acid (DEVD) peptide. The DEVD is a tetrapeptide sequence that is only able to bind, and be subsequently cleaved, by the functional domain of cleaved caspase-3 and caspase-7 enzymes. Once the DEVD sequence is cleaved, the liberated aminoluciferin is bioreduced by UltraGlo™ Luciferase enzyme to produce a luminescent, light signal (Figure 2.5). Luminescent signal intensity is proportional to the amount of caspase activity present.  
 
 
 
 
Figure 2.5: Diagram showing the principals of the Caspase-Glo®-3/7 assay. Caspase-3 and caspase-7 
cleave the luminogenic substrate at its DEVD sequence releasing the attached aminoluciferin. 
UltraGlo™ Luciferase enzyme bioreduces aminoluciferin, which causes an emission of detectable 
luminescent signal. Figure adapted from Promega’s Caspase-Glo® 3/7 Assay manual: 
https://www.promega.com/ -/media/files/resources/protocols/technical-bulletins/101 / caspase-
glo-3-7-assay-protocol.pdf. 
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Cells were treated with appropriate drug at their IC50 dosages, with or without the use of carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]- fluoromethylketone (Z-VAD-FMK) at a concentration of 20µM, in a total volume of 100µL in white 96 well plates. Z-Vad-FMK is a cell permeable pan-caspase inhibitor, able to irreversibly bind to the catalytic site of caspase proteases, thus inhibiting apoptosis. Following treatment, 100µl of reconstituted Caspase-Glo® 3/7 substrate was added directly to each well and mixed using a plate shaker set at 300 rpm for 30 seconds. Cells were incubated at room temperature for 2 hours before luminescence was read by a Varioskan® Flash Multimode Plate Reader. The data was analysed by subtracting the average relative luminescent unit (RLU) of the background from the average RLU of each sample. Caspase-3/7 activity was calculated relative to the untreated cells by using the formula below:  
𝐂𝐂𝐒𝐒𝐬𝐬𝐬𝐬𝐒𝐒𝐬𝐬𝐂𝐂 𝟑𝟑/𝟕𝟕 𝐅𝐅𝐅𝐅𝐂𝐂𝐭𝐭 𝐂𝐂𝐂𝐂𝐒𝐒𝐮𝐮𝐚𝐚𝐂𝐂  = 𝐒𝐒𝐒𝐒𝐂𝐂𝐒𝐒𝐒𝐒𝐚𝐚𝐂𝐂 𝐑𝐑𝐑𝐑𝐑𝐑 𝐭𝐭𝐒𝐒𝐂𝐂𝐒𝐒𝐭𝐭𝐂𝐂𝐭𝐭 𝐬𝐬𝐒𝐒𝐬𝐬𝐬𝐬𝐂𝐂𝐂𝐂𝐬𝐬
𝐒𝐒𝐒𝐒𝐂𝐂𝐒𝐒𝐒𝐒𝐚𝐚𝐂𝐂 𝐑𝐑𝐑𝐑𝐑𝐑 𝐒𝐒𝐮𝐮𝐭𝐭𝐒𝐒𝐂𝐂𝐒𝐒𝐭𝐭𝐂𝐂𝐭𝐭 𝐬𝐬𝐒𝐒𝐬𝐬𝐬𝐬𝐂𝐂𝐂𝐂𝐬𝐬 − 𝟏𝟏 
2.9.3 CellEvent™ Caspase-3/7 Fluorescent Imaging CellEvent™ Caspase-3/7 Green ReadyProbes™ (Life Technologies, UK) were used to fluorescently label cells undergoing caspase-3 and/or caspase-7 mediated apoptosis. This assay uses a DEVD peptide conjugated to a non-auto-fluorescent dye by a linker region. If cleaved caspase-3 or caspase-7 proteins are present, the probes linker region is cleaved, separating the DEVD peptide and the fluorescent dye. This results in a green fluorescence emission detectable at 520nm.  
Cells were plated at 1x104/quadrant in a 35mm Cellview™ cell culture dish (Greiner Bio-One, UK). Once incubated overnight at 37°C, cells were treated for 90 minutes for peptides, and 72 hours for ICT9119, with 500µl/quadrant of 
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appropriate drug at their individual IC50 dosage. All drugs were diluted in FluroBrite™ DMEM media supplemented with 10% FBS. After 90 minutes of incubation, a single drop of NucBlue™ Live ReadyProbes™ Reagent and a single drop of CellEvent™ Caspase-3/7 Green ReadyProbes™ was added per quadrant and incubated for a further 30 minutes.  NucBlue™ Live ReadyProbes™ were used to counterstain cell nuclei blue for visualisation. Cells were visualised using a Nikon Eclipse TE2000-S inverted fluorescent microscope connected to a CoolLED pE-300white illumination unit. Images were captured using a Micropix GigE 4.2 Mega Pixel camera and analysed using the Micropix Cytocam V1.3.5.0.  
2.10 Bromodeoxyuridine Cell Proliferation Assay Bromodeoxyuridine (BrdU) is a synthetic analog of the DNA precursor thymidine (Figure 2.6 [523]). For cells to proliferate and divide, they must successfully pass through the S phase of the cell cycle, where DNA is replicated. As BrdU is a thymidine analog, it can be incorporated, in place of thymidine, in proliferating cells during S phase.   
 
 
 
 
Figure 2.6: Chemical structure of A| thymidine and B| BrdU. Thymidine and BrdU differ by the 
substitution of thymidine’s CH3 group for a bromine (Br) atom, circled in red, in BrdU. Adapted from 
Perez-Zamorona et al (2015). 
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Chemicon® BrdU Cell proliferation assay (Merck Millipore, UK) uses an enzyme-linked immunosorbent assay (ELISA) combined with a colorimetric detection system. The test principals’ centre around immunochemical detection using a mouse monoclonal anti-BrdU antibody to detect BrdU incorporated in partially denatured DNA. This is then targeted using a goat anti-mouse peroxidase conjugated secondary antibody. A 3,3’,5,5’-tetramethylbenzidine (TMB) peroxidase substrate is used to develop a colour change. The recorded OD is proportional to BrdU concentration in the sample, which in turn is proportional to the proliferation rate of the sample. All products used during the cell proliferation assay from Merck Millipore were supplied in the Chemicon® BrdU Cell proliferation assay kit. 
Cells were plated in pre-coated or un-coated 96 well plates and incubated overnight to allow cells to adhere. Cells were treated with either HXR9 or CXR9 at their relevant IC25 concentrations for 8 hours before being diluted 1:500 in BrdU label reagent (Merck Millipore, UK). This was directly added to test wells and incubated at 37°C for an additional 4 hours. Well contents were aspirated before cells were fixed and permeabilised, and their DNA partially denatured, by adding 200µl of Fixing Solution (Merck Millipore, UK) and incubated at room temperature for 30 minutes. Fixing Solution was aspirated before being washed 3 times with 1X Wash Buffer (Merck Millipore, UK) by completing filling wells, before inverting and gently tapping plates, then blotting plates on absorbent paper towels to dry. Cells were stained with 100µl/well of Anti-BrdU antibody for 1 hour at room temperature before 3 consecutive washes with 1X Wash Buffer was performed. Goat anti-mouse IgG peroxidase conjugate (Merck Millipore, UK) was diluted, 1:2000, in Conjugate Dilute (Merck Millipore, UK) and filtered using a 0.22µm 
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syringe filter (Merck Millipore, UK). Once filtered, 100µl/well of diluted goat anti-mouse IgG peroxidase conjugate (Merck Millipore, UK) was added and incubated for 30 minutes at room temperature. A final 3 consecutive wash steps were carried out with 1X Wash Buffer, before the entire plate was flooded and patted dry using absorbent paper towels. In the dark, 100µl/well of TMB peroxidase substrate (Merck Millipore, UK) was applied and incubated for 30 minutes at room temperature. The colour reaction was stopped by pipetting 100µl/well of Stop Solution (Merck Millipore, UK), which instantly caused positive blue wells to change to a bright yellow colour.  OD was quantified using a Varioskan® Flash Multimode Plate Reader set at dual wavelengths of 450/550nm. The data was analysed by subtracting the average OD of the background from the average OD of each sample. The cell proliferation percentage was then calculated relative to the untreated cells by using the formula below: 
𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂 𝐏𝐏𝐒𝐒𝐅𝐅𝐂𝐂𝐒𝐒𝐨𝐨𝐂𝐂𝐒𝐒𝐒𝐒𝐭𝐭𝐒𝐒𝐅𝐅𝐮𝐮 % = 𝐒𝐒𝐒𝐒𝐂𝐂𝐒𝐒𝐒𝐒𝐚𝐚𝐂𝐂 𝐎𝐎𝐎𝐎 𝐭𝐭𝐒𝐒𝐂𝐂𝐒𝐒𝐭𝐭𝐂𝐂𝐭𝐭 𝐬𝐬𝐒𝐒𝐬𝐬𝐬𝐬𝐂𝐂𝐂𝐂𝐬𝐬
𝐒𝐒𝐒𝐒𝐂𝐂𝐒𝐒𝐒𝐒𝐚𝐚𝐂𝐂 𝐎𝐎𝐎𝐎 𝐒𝐒𝐮𝐮𝐭𝐭𝐒𝐒𝐂𝐂𝐒𝐒𝐭𝐭𝐂𝐂𝐭𝐭 𝐬𝐬𝐒𝐒𝐬𝐬𝐬𝐬𝐂𝐂𝐂𝐂𝐬𝐬 × 𝟏𝟏𝟏𝟏𝟏𝟏 
2.11 Evaluation of Cellular Migration and Invasion Potential 
2.11.1 Transwell Migration Assay The Chemicon® InnoCyte™ Migration assay (Merck Millipore, UK) was used to model and assess cancer cell migration potential in vitro. The assay uses a non-coated cell culture insert with an 8µm pore size as a migration chamber. Cells suspended in serum free or growth factor free media are placed in the upper chamber of the cell culture insert. The insert is then placed in a well, referred to as the lower chamber, of a 24 well plate that contains media with either FBS or growth factors. Healthy cells are able to detect and migrate, via chemotaxis, to the 
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serum and growth factor containing media of the lower chamber. Evaluation of cell migration can be then assessed using a cell permeable fluorescent dye. The assay principal can be seen in Figure 2.7.  
 
 
 
 
 
 
 
 
 
  
 
Figure 2.7: Diagrammatic representation of the principles behind the transwell migration. Cells are 
seeded in the upper chamber in serum and growth factor free media. Healthy cells are stimulated, via 
chmemotaxis, to migrate through the 8µm pores to the lower chamber, which contains media with the 
addition of serum or growth factors.  
Cells were mobilised using StemPro® Accutase and then washed 3 times by centrifuging at 1500 rpm and then resuspending the cell pellet in PBS. This was to remove any residual culture media containing serum or growth factors. Cells were then treated with either HXR9 or CXR9 at their relevant IC25 concentration for 2 hours before 5 x105 cells were seeded in serum free media, for non CSC cells, or growth factor free media, for CSC cells, in the upper chamber of an 8µm pore size transwell insert (Merck Millipore, UK). 500µl of media containing either 10% FBS 
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or growth factors, EGF and FGF, was added to the lower chamber. Plates were then incubated for 12 hours at 37°C. Cell labelling/detachment solution was prepared by diluting, 1:300, Calcein-AM (Merck Millipore, UK) in Cell Detachment Buffer (Merck Millipore, UK). The migration chamber was transferred to a fresh well using sterile forceps, and all remaining media in the upper chamber discarded. Following this, 500µl of the cell labelling/detachment solution was added to the lower chamber, before incubating plates at 37°C for 20 minutes. To ensure complete removal of cells, forceps were used to gently tap each transwell insert against the bottom of the well. An additional 40 minutes of incubation at 37°C followed.  Once cells were stained, 200µl of fluorescently stained cell solution was transferred to a black 96 well plate (Thermo Scientific, UK) in triplicate. Fluorescent signal was measured using a Varioskan® Flash Multimode Plate Reader at an excitation wavelength of 485nm and an emission wavelength of 520nm. Results are represented as relative fluorescent units (RFU). The data was analysed by subtracting the average RFU of the background from the average RFU of each sample. The RFU of a sample is proportional to the number of migrating cells, hence the higher the RFU, the higher the migratory potential of the test cells. All products used during the transwell migration assay from Merck Millipore were supplied in the Chemicon® InnoCyte™ Migration assay kit. 
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2.11.2 Transwell Invasion Assay The Chemicon® InnoCyte™ Invasion assay (Merck Millipore, UK) was used to model and assess cancer cell invasion potential in vitro. Much like the transwell migration assay (Section 2.11.1). The assay uses a cell culture insert with an 8µm pore sized polycarbonate membrane. The upper surface of the polycarbonate membrane was coated with a uniform layer of pre-dried basement membrane matrix (BMM) solution. This layer prevents non-invasive cells from passing through the 8µm of the insert. Though invading and migrating cells have many similar characteristics, such as the ability to undergo cytoskeleton remodelling and the loss of adhesion molecules, invasive cells also need the ability to degrade basement membranes.  Thus only invasive cells will be able to move via chemotaxis to the lower chamber of the insert, where they will be quantified by a cell permeable fluorescent dye. The assay principal can be seen in Figure 2.7.  
The cell inserts were first left to warm to room temperature in a class II biosafety cabinet for 30 minutes.  Once warmed, the dried BMM was rehydrated with 400µl of warm serum-free media for an additional 30 minutes at 37°C. Cells were harvested using StemPro® Accutase and then washed 3 times centrifuging at 1500 rpm and then resuspension of the cell pellet in PBS. Cells were then treated with either HXR9 or CXR9 at their relevant IC25 concentration for 2 hours, before 5 x105 cells were seeded in serum free media, for non CSC cells, or growth factor free media, for CSC cells, in the upper chamber of a transwell insert (Merck Millipore, UK). 500µl of media containing either 10% FBS or growth factors, EGF and FGF, was added to the lower chamber. Plates were then incubated for 24 hours at 37°C. Cell labelling/detachment solution was prepared by diluting, 1:300, Calcein-AM (Merck Millipore, UK) in Cell Detachment Buffer (Merck Millipore, UK). The cell 
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insert was then transferred to a fresh well using sterile forceps, and all remaining media in the upper chamber discarded. Following this, 500µl of the cell labelling/detachment solution was added to the lower chamber, before incubating plates at 37°C for 30 minutes. To ensure complete removal of cells, forceps were used to gently tap each transwell insert against the bottom of the well. An additional 30 minutes of incubation at 37°C followed.  Once cells were stained, 200µl of fluorescently stained cell solution was transferred to a black 96 well plate (Thermo Scientific, UK) in triplicate. Fluorescent signal was measured using a Varioskan® Flash Multimode Plate Reader at an excitation wavelength of 485nm and an emission wavelength of 520nm. Results are represented as relative fluorescent units (RFU). The data was analysed by subtracting the average RFU of the background from the average RFU of each sample. The RFU of a sample is proportional to the number of invasive cells, hence the higher the RFU, the higher the invasion potential of the test cells. All products used during the transwell invasion assay from Merck Millipore were supplied in the Chemicon® InnoCyte™ Invasion assay kit. 
2.12 Cell Cycle Analysis Cell Cycle analysis was performed by first seeding 1.5x104 cells/well in a 6 well plate (Thermo Scientific, UK) and incubating over night at 37°C. Cells were then treated with various dosages of ICT9119 or Gy’s of radiation, and left to incubate for 24 hours at 37°C. StemPro® Accutase was used to mobilise cells, and washed 3 times with ice cold PBS. Cells were pelleted at 200 Xg and then resuspended in 300µl of ice cold PBS with 50% FBS. A 70% ethanol (Fisher Scientific, UK) solution was prepared in PBS, before 900µl was added to the cell suspension in a drop-wise 
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manner while gently vortexing. The cell solution was incubated overnight at 4°C, before being washed a further 2 times with ice cold PBS. 1 mg/ml of Ribonuclease A (RNase A) was added per sample to cleave and degrade sample RNA content. 50 µg/ml of PI (Thermo Scientific, UK) was then added to each sample and incubated for 1 hour at 37°C to stain DNA. Fluorescent signal was measured by flow cytomety using the MACSQuant® Analyzer 10 at an excitation wavelength of 533nm and an emission wavelength of 617nm. Fluorescent signal was then plotted against light scatter. 
2.13 Quantification of Gene Expression  
2.13.1 Homogenisation of Primary Brain Tissue All tissue used was stored in RNAlater® (Sigma-Aldrich, UK), or was snap frozen and stored at -20°C. Total RNA was extracted from tissue by first homogenising tissue using a gentleMACS™ dissociator (Miltenyi Biotech, UK). First 20-30mg of tissue was placed in a gentleMACS™ M Tube (Miltenyi Biotech, UK) with the addition of 600μl of Lysis Buffer RLT (Qiagen, UK) with 6μl (1%) of β-mecaptoethanol (Sigma-Aldrich, UK). GentleMACS™ M Tubes were sealed then inverted and lightly shaken to ensure tissue was displaced from the sides of the tube. Tubes were then placed in the gentleMACS™ dissociator and run on programme setting “RNA_01”. The tubes were then centrifuged at 200 Xg for 5 minutes. If tissue was not full homogenised it was re-run on the gentleMACS™ dissociator on programme setting “RNA_02”, and re-centrifuged. Supernatant was then transferred to a QIAshredder homogenizer column (Qiagen, UK), which was placed in a 2ml collecting tube (Qiagen, UK) and centrifuged at 10,000 rpm for 2 minutes. Supernatant flow through was retained and used for total RNA extraction (section 2.12.2). 
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2.13.2 Total RNA Extraction  For cell lines, cells were washed with HBSS before being mobilised with 0.05% trypsin EDTA or StemPro® Accutase. Cell suspension was then centrifuged at 1500 
rpm for 3 minutes. The cell pellet was then lysed using 600μl of Lysis Buffer RLT 
with 6μl (1%) of β-mecaptoethanol. RLT and β-mecaptoethanol amounts used varied upon size of cell pellet, however 1:100 reagent ratio was always maintained. Homogenised tissue samples continued from this point onwards. The Cell/ RLT mix was then transferred to a gDNA eliminator spin column (Qiagen, UK), which was placed in a 2ml collecting tube, and centrifuged for 30 seconds at 10,000 rpm. This ensured the removal of genomic DNA. The spin column was discarded, before 70% ethanol was added at a 1:1 ratio and mixed. The 1:1 mixture was then transferred to an RNeasy spin column (Qiagen, UK) placed in a 2ml collecting tube and centrifuged for 30 seconds at 10,000 rpm. The addition of ethanol enables RNA to bind to the silica membrane of the RNeasy spin column. The collecting tube containing the flow through was discarded and replaced with a fresh 2ml collecting tube. 700μl of Buffer RW1 (Qiagen, UK) was added to the RNeasy spin column and centrifuged at 10,000 rpm for 30 seconds. The collecting tube with flow through was discarded and again replaced with a new 2ml 
collecting tube. 500μl of complete Buffer RPE (Qiagen, UK), with ethanol added, was added to the RNeasy spin column and centrifuged at 10,000 rpm for 30 seconds. The collecting tube was discarded and replaced before an additional 
500μl of complete Buffer RPE was added to the RNeasy spin column and centrifuged at 10,000 rpm for 2 minutes. Buffer washes allowed contaminants to be washed away, while the RNA stayed bound to the silica membrane. Again the collecting tube was discarded and replaced before the RNeasy spin column was 
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centrifuged at 10,000 rpm for 1 minute to dry the membrane of residual buffer. The RNeasy spin column was then placed in a new 1.5ml collecting eppendorf (Qiagen, UK) with 30μl of RNase-free water (Qiagen, UK) added directly on the silica membrane of the RNeasy spin column. This was left for 1 minute at room temperature before being centrifuged at 10,000 rpm for 1 minute to elute the RNA. The RNeasy spin column was discarded and the collecting Eppendorf kept. This was then appropriately labelled and stored, following RNA quantification, at -80°C, unless immediately used for complementary DNA (cDNA) synthesis (Section 2.12.5). All products used during the RNA extraction from Qiagen were supplied in the RNeasy® Plus Mini Kit (Qiagen, UK). 
2.13.3 Quantification of RNA  Purified total RNA was quantified for RNA concentration and impurities using a NanoDrop® spectrophotometer ND-1000 (NanoDrop Technologies, USA). Absorption ratios at 260/280nm and 260/230nm were also analysed with a threshold of 1.8 used for ratios. Any sample that did not reach this threshold was discarded. A low 260/280nm ratio is an indication of protein or phenol contamination, while a low 260/230nm ratio indicates the presence of co-purified contaminants. Sample concentration (ng/ul) is based on absorbance at 260nm and the selected analysis constant as predicted by Beer’s Law. 
2.13.4 RNA Integrity Number Scoring  RNA integrity was tested using an Agilent 2100 Bioanalyzer (Agilent Technologies, USA) with samples prepared using the Agilent Technologies RNA 6000 Nano Reagent Kit (Agilent Technologies, USA). In short the assay principals are based on the use of interconnected microchannels, placed inside a RNA chip, 
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that separate RNA fragments based on their size by electrophoresis. All reagents used during RIN scoring from Agilent were supplied in the Agilent Technologies RNA 6000 Nano Reagent Kit. 
RNA ladder (Agilent Technologies, USA) was first prepared by transfering ladder dye to a sterile eppendorf before being heat denatured at 70°C in a pre-heated heat block (Thermo Scientific, UK) for 2 minutes. The ladder was then immediately cooled on ice. Assay gel matrix was prepared by pipetting 550μl of RNA gel matrix (Agilent Technologies, USA) into a spin filter (Agilent Technologies, USA) before centrifuging at 1500Xg for 10 minutes. RNA dye concentrate (Agilent, USA) was equilibrated to room temperature, before being vortexed to mix. Gel-dye mix was prepared by mixing 1μl of RNA dye concentrate with 65μl of filtered RNA gel matrix. Gel-dye mix was then vortexed before being centrifuged at 13000 Xg for 10 minutes. A RNA nano chip (Agilent Technologies, USA) was then secured to the base of the Chip Priming Station (Agilent Technologies, USA) before 9μl of gel-dye mix was pipetted to the well marked .G.. Chip Priming Station plunger was then pressed until held against the Chip Priming Station clip for 30 seconds, before releasing the clip to allow the plunger to re-pressurise to the 1ml position. Once full re-pressurised, 9μl of gel-dye mix was pipetted to the wells marked .G.. This was followed by pipetting 5μl of RNA marker (Agilent Technologies, USA) to all sample wells and the ladder well, prior to adding 1μl of sample to RNA test wells and 1μl of prepared RNA ladder. Well layout and contents can be seen in Figure 
2.8. RNA nano chips were then placed horizontally in an IKA® MS 3 Vortexer (IKA®, UK) and vortexed for 1 minute at 2400 rpm. RNA nano chips were then run in the Agilent 2100 Bioanalyzer to provide a RNA Integrity Number (RIN) score. 
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RIN score threshold was set at 7. Supplementary Figure 1 provides a RIN score report example. 
Figure 2.8: RNA nano chip well layout and contents.  
2.13.5 Complementary DNA Synthesis 
RNA was diluted to a final concentration of 1μg with a variable, sample dependent, amount of 0.1% diethylpyrocarbonate (DEPC) -treated water (Invitrogen, UK) to 
a final volume of 10μl. To this 4μl 5X cDNA Synthesis buffer, 1μl of 0.1M DTT (Invitrogen, UK), 2μl 10mM of deoxynucleotide triphosphate mix (dNTP) (Invitrogen, UK), 1μl 50μM Oligo (dT)20 primers (Invitrogen, UK), 1μl 15U/μl of Cloned AMV reverse transcriptase (Invitrogen, UK) and 1μl 40U/μl of RNaseOUT (Invitrogen, UK) was added to make a final volume of 20μl. This mixture was incubated at 50°C in a pre-heated heat block for 45 minutes. The cDNA synthesis reaction was terminated by incubating the sample at 85°C in a pre-heated heat block for 10 minutes. Alternatively, a thermal cycler (Applied Biosystems, UK) was used in place of heat blocks. Temperatures and incubation times were kept the same and no difference in cDNA product was detected between methods. Total 
volume was made up to 500μl by adding DEPC treated water. With the assumption 
.G. Wells: 9μl gel-dye mix 
Ladder Wells: 5μl RNA Marker 
1μl RNA Ladder 
. .G. Wells: 9μl gel-dye mix 
Sample Wells: 5μl RNA Marker 
1μl Sample RNA   
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that cDNA synthesis was 100% efficient, the final concentration of cDNA would be 2ng/μl. The cDNA samples were used immediately or stored at 20°C.  
All products used during the cDNA synthesis from Invitrogen were supplied in the Cloned AMV First-Strand Synthesis Kit (Invitrogen, UK). Normal astrocyte RNA used in cDNA synthesis was purchased from ScienCell Research Laboratories (ScienCell Research Laboratories, UK).  Normal astrocyte RNA was extracted using Qiagen RNeasy Mini Kit by supplier.  
2.13.6 Real Time-Quantitative Polymerase Chain Reaction  Real time-quantitative Polymerase Chain Reaction (RT-qPCR) was performed using the Stratagene Mx3005P qPCR system (Agilent Technologies, UK). The Stratagene Mx3005P machine measures PCR product accumulation, during the exponential phase of the reaction, by SYBR green fluorescent signal (Sigma-Aldrich, UK). A RT-qPCR master mix was prepared by mixing 12.5μl SYBR® Green JumpStart™ Taq ReadyMix™, 0.25μl 5-carboxy-ROX (ROX) Reference Dye (Sigma-
Aldrich, UK), 5.25μl RNase-free water (Qiagen, UK) and 2μl of 2ng/μl cDNA, making a final well reaction volume of 20μl. A primer stock was prepared by 
mixing 20μl of relevant forward and reverse primers with 160μl of RNase-free water to obtain a 10μM stock. Each experimental well was loaded with 20μl of RT-
qPCR master mix and 5μl of appropriate primer 10μM stock. A breakdown of reagents and reaction volumes of an individual well can be seen in Table 2.8. All qPCR reactions were carried out in either duplicate or triplicate in 96 well semi-skirted PCR plates (Agilent Technologies, UK) with optical Strip Caps (Agilent Technologies, UK). Plates were briefly spun to mix contents of wells. Beta-actin (β-
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actin) and Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) were used as the housekeeping genes (HKG) and thus the internal endogenous controls. 
Table 2.8: A breakdown of the reaction volumes for an individual well. 
Well Reagent Well Reaction Volume 
cDNA (2ng/μl) 2μl (4ng) Primers (Forward and Reverse) 5μl SYBR Green JumpStart Taq ReadyMix 12.5μl ROX Reference Dye 0.25μl Nuclease-free water 5.25μl 
Reaction conditions used were: Segment 1- 1 cycle at 95°C for 10 minutes to activate the polymerase enzyme. Segment 2 followed consisting of- 40 cycles of, 30 seconds at 95°C to denature cDNA, 1 minute at 60°C to allow for primer annealing, and 1 minute at 72°C to synthesise a new DNA strand prior to cycle threshold (Ct) data collected. The final segment was performed to obtain melt curves in order to check a single, pure, PCR product was being produced. This was achieved by 1 cycle of 1 minute at 95°C followed by a gradual decline in temperature to 55°C which is held for 30 seconds and a final cycle for 30 seconds at 95°C. The thermal profile can be seen in Figure 2.9.  
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Figure 2.9: Thermal profile for RT-qPCR. Segment 1 activated the polymerase enzyme, while segment 
2 synthesised new cDNA and collected Ct values. Segment 3 was used to collect melt cures. 
2.13.7 RT-qPCR Data Analysis The MxPro software (Agilent Technologies, UK) measures Ct for individual samples. Ct is defined as the number of PCR cycles required for the fluorescent signal to exceed sample background level, as determined by the reference dye ROX, and cross the detection threshold. Ct values are inversely proportional to the amount of PCR product produced in the sample. Results were analysed using the calculation derived from Livak’s comparative Ct calculation method [524]. The ΔCt relative quantification model calculates the fold difference of a gene of interest (GoI) between a treated and non-treated control sample. Assuming the PCR reaction is 100% efficient, and resulting in a 2-fold increase in PCR product per cycle, the ΔCt was multiplied by a factor of 2 (2(ΔCt)). The ΔΔCt relative quantification model was used as it calculates the fold difference of a GoI normalised against the HKG where ΔΔCt=(CtHKG-CtGoI) tumour-(CtHKG-CtGoI) control. An 
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arbitrary multiplication factor of 10,000 was used to scale up results. Below full equations used:  
𝐄𝐄𝐄𝐄𝐬𝐬𝐒𝐒𝐂𝐂𝐬𝐬𝐬𝐬𝐒𝐒𝐅𝐅𝐮𝐮 = [𝟐𝟐(−𝚫𝚫𝐂𝐂𝐭𝐭)] × 𝟏𝟏𝟏𝟏,𝟏𝟏𝟏𝟏𝟏𝟏 
𝐑𝐑𝐂𝐂𝐒𝐒𝐒𝐒𝐭𝐭𝐒𝐒𝐒𝐒𝐂𝐂 𝐄𝐄𝐄𝐄𝐬𝐬𝐒𝐒𝐂𝐂𝐬𝐬𝐬𝐬𝐒𝐒𝐅𝐅𝐮𝐮 = [𝟐𝟐(−𝚫𝚫𝚫𝚫𝐂𝐂𝐭𝐭)] × 𝟏𝟏𝟏𝟏,𝟏𝟏𝟏𝟏𝟏𝟏 
2.13.8 RT-qPCR Primer Design, Sequences and Validation Forward and reverse primers were designed using the Primer3web software version 4.0 or Primer-BLAST, both of which are web-based software. Primer sequences can be seen in Table 2.9. The following parameters were used, when possible, to design primers:  
1. A PCR product size of between 100 to 400 base pairs 2. A primer melting temperature between 55°C to 65°C 3. Primers that span exon-exon junctions 4. A primer length between 20 to 30 bases 5. A primer with a GC% of >55% 6. Self complementarity between 2 to 6 7. Self 3’ complementarity between 0 to 3 
All primers were purchased from Sigma-Aldrich, UK and were provided at a concentration of 100μM and desalted. Prior to delivery all primers are quality control checked by electrospray ionization mass spectrometry. Diluted and undiluted primers were stored at -20°C. All primers were assessed to prove single product amplification via melt curve analysis. In addition to this a ‘no template (cDNA) control’ was performed for all sets of primers to identify the possibility of primer dimer formation. Any primers that fail these validation tests were discarded and primers were redesigned. 
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Table 2.9: Table listing the forward and reverse primer sequences for all GoI quantified by RT-qPCR 
and their National Center for Biotechnology Information (NCBI) accession number.  
Gene Target Accession Number Forward and Reverse Primer Sequences Supplier 
HOXA1 NM_005522.4 F: 5’ CTGGCCCTGGCTACGTATAA 3’ R: 5’ TCCAACTTTCCCTGTTTTGG 3’ Sigma-Aldrich, UK 
HOXA2 NM_006735.3 F: 5’ TTCAGCAAAATGCCCTCTCT 3’ R: 5’ TAGGCCAGCTCCACAGTTCT 3’ Sigma-Aldrich, UK 
HOXA3 NM_030661.4 F: 5’ ACCTGTGATAGTGGGCTTGG 3’ R: 5’ ATACAGCCATTCCAGCAACC 3’ Sigma-Aldrich, UK 
HOXA4 NM_002141.4 F: 5’ CCCTGGATGAAGAAGATCCA 3’ R: 5’ AATTGGAGGATCGCATCTTG 3’ Sigma-Aldrich, UK 
HOXA5 NM_019102.3 F: 5’ CCGGAGAATGAAGTGGAAAA 3’ R: 5’ ACGAGAACAGGGCTTCTTCA 3’ Sigma-Aldrich, UK 
HOXA6 NM_024014.3 F: 5’ AAAGCACTCCATGACGAAGG 3’ R: 5’ TCCTTCTCCAGCTCCAGTGT 3’ Sigma-Aldrich, UK 
HOXA7 NM_006896.3 F: 5’ TGGTGTAAATCTGGGGGTGT 3’ R: 5’ TCTGATAAAGGGGGCTGTTG 3’ Sigma-Aldrich, UK 
HOXA9 NM_152739.3 F: 5’ AATAACCCAGCAGCCAACTG 3’ R: 5’ ATTTTCATCCTGCGGTTCTG 3’ Sigma-Aldrich, UK 
HOXA10 NM_018951.3 F: 5’ ACACTGGAGCTGGAGAAGGA 3’ R: 5’ GATCCGGTTTTCTCGATTCA 3’ Sigma-Aldrich, UK 
HOXA11 NM_005523.5 F: 5’ CGCTGCCCCTATACCAAGTA 3’ R: 5’ GTCAAGGGCAAAATCTGCAT 3’ Sigma-Aldrich, UK 
HOXA13 NM_000522.4 F: 5’ GGATATCAGCCACGACGAAT 3’ R: 5’ ATTATCTGGGCAAAGCAACG 3’ Sigma-Aldrich, UK 
HOXB1 NM_002144.3 F: 5’ TTCAGCAGAACTCCGGCTAT 3’ R: 5’ CCTCCGTCTCCTTCTGATTG 3’ Sigma-Aldrich, UK 
HOXB2 NM_002145.3 F: 5’ CTCCCAAAATCGCTCCATTA 3’ R: 5’ GAAAGGAGGAGGAGGAGGAA 3’ Sigma-Aldrich, UK 
HOXB3 NM_002146.4 F: 5’ TATGGCCTCAACCACCTTTC 3’ R: 5’ AAGCCTGGGTACCACCTTCT 3’ Sigma-Aldrich, UK 
HOXB4 NM-024015.4 F: 5’ TCTTGGAGCTGGAGAAGGAA 3’ R: 5’ GTTGGGCAACTTGTGGTCTT 3’ Sigma-Aldrich, UK 
HOXB5 NM_002147.3 F: 5’ AAGGCCTGGTCTGGGAGTAT 3’ R: 5’ GCATCCACTCGCTCACTACA 3’ Sigma-Aldrich, UK 
HOXB6 NM_018952.4 F: 5’ ATTTCCTTCTGGCCCTCACT 3’ R: 5’ GGAAGGTGGAGTTCACGAAA 3’ Sigma-Aldrich, UK 
HOXB7 NM_004502.3 F: 5’ CAGCCTCAAGTTCGGTTTTC 3’ R: 5’ CGGAGAGGTTCTGCTCAAAG 3’ Sigma-Aldrich, UK 
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HOXB8 NM_024016.3 F: 5’ GTAGGCTTCAGCTGGGACTG 3’ R: 5’ GGGAGCCTTTGCTTAAATCC 3’ Sigma-Aldrich, UK 
HOXB9 NM_024017.4 F: 5’ TAATCAAAGACCCGGCTACG 3’ R: 5’ CTACGGTCCCTGGTGAGGTA 3’ Sigma-Aldrich, UK 
HOXB13 NM_006361.5 F: 5’ CTTGGATGGAGCCAAGGATA 3’ R: 5’ CCGCCTCCAAAGTAACCATA 3’ Sigma-Aldrich, UK 
HOXC4 NM_014620.5 F: 5’ CGCTCGAGGACAGCCTATAC 3’ R: 5’ GCTCTGGGAGTGGTCTTCAG 3’ Sigma-Aldrich, UK 
HOXC5 NM_018953.3 F: 5’ CAGTTACACGCGCTACCAGA 3’ R: 5’ AGAGAGGAAAGGCGAAAAGG 3’ Sigma-Aldrich, UK 
HOXC6 NM_004503.3 F: 5’ AAGAGGAAAAGCGGGAAGAG 3’ R: 5’ GGTCCACGTTTGACTCCCTA 3’ Sigma-Aldrich, UK 
HOXC8 NM_022658.3 F: 5’ CTCAGGCTACCAGCAGAACC 3’ R: 5’ TTGGCGGAGGATTTACAGTC 3’ Sigma-Aldrich, UK 
HOXC9 NM_006897.2 F: 5’ AGACGCTGGAACTGGAGAAG 3’ R: 5’ AGGCTGGGTAGGGTTTAGGA 3’ Sigma-Aldrich, UK 
HOXC10 NM_017409.3 F: 5’ CGCCTGGAGATTAGCAAGAC 3’ R: 5’ GGTCCCTTGGAAGGAGAGTC 3’ Sigma-Aldrich, UK 
HOXC11 NM_014212.3 F: 5’ CGGAACAGCTACTCCTCCTG 3’ R: 5’ CAGGACGCTGTTCTTGTTGA 3’ Sigma-Aldrich, UK 
HOXC12 NM_173860.2 F: 5’ CAAGCCCTATTCGAAGTTGC 3’ R: 5’ GCTTGCTCCCTCAACAGAAG 3’ Sigma-Aldrich, UK 
HOXC13 NM_017410.2 F: 5’ GTGGAAATCCAAGGAGGACA 3’ R: 5’ TTGTTGAGGGACCCACTCTC 3’ Sigma-Aldrich, UK 
HOXD1 NM_024501.2 F: 5’ TTCAGCACCAAGCAACTGAC 3’ R: 5’ TAGTGGGGGTTGTTCCAGAG 3’ Sigma-Aldrich, UK 
HOXD3 NM_006898.4 F: 5’ CAGCCTCCTGGTCTGAACTC 3’ R: 5’ ATCCAGGGGAAGATCTGCTT 3’ Sigma-Aldrich, UK 
HOXD4 NM_014621.2 F: 5’ TCAAATGTGCCATAGCAAGC 3’ R: 5’ TCCATAGGGCCCTCCTACTT 3’ Sigma-Aldrich, UK 
HOXD8 NM_019558.3 F: 5’ TCAAATGTTTCCGTGGATGA 3’ R: 5’ GCTCTTGGGCTTCCTTTTTC 3’ Sigma-Aldrich, UK 
HOXD9 NM_014213.3 F: 5’ TCCCCCATGTTTCTGAAAAG 3’ R: 5’ GGGCTCCTCTAAGCCTCACT 3’ Sigma-Aldrich, UK 
HOXD10 NM_002148.3 F: 5’ GCTCCTTCACCACCAACATT 3’ R: 5’ AAATATCCAGGGACGGGAAC 3’ Sigma-Aldrich, UK 
HOXD11 NM_021192.2 F: 5’ GGGGCTACGCTCCCTACTAC 3’ R: 5’ GCTGCCTCGTAGAACTGGTC 3’ Sigma-Aldrich, UK 
HOXD12 NM_021193.3 F: 5’ CGCTTCCCCCTATCTCCTAC 3’ R: 5’ CTTCGGGCGCATAGAACTTA 3’ Sigma-Aldrich, UK 
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HOXD13 NM_000523.3 F: 5’ GGGGATGTGGCTCTAAATCA 3’ R: 5’ AACCTGGACCACATCAGGAG 3’ Sigma-Aldrich, UK 
PBX1 NM_002585.3 F: 5’ CAAGCTAACTCGCCCTCAAC 3’ R: 5’ GCTGCGAGTCCATCACTGTA 3’ Sigma-Aldrich, UK 
PBX2 NM_002586.4 F: 5’ CAGATGCAGCTGAAGCAGAG 3’ R: 5’ CACTTCTTGGCAAGCTCCTC 3’ Sigma-Aldrich, UK 
PBX3 NM_006195.5 F: 5’ CGGAAAAGGCGTAACTTCAG 3’ R: 5’ GCAGCATAGAGGTTGGCTTC 3’ Sigma-Aldrich, UK 
PBX4 NM_025245.2 F: 5’ GGATGAAGCCTGCTCTGTTC 3’ R: 5’ AGCTTGGCCCTGTAGTCAGA 3’ Sigma-Aldrich, UK 
MEIS1 NM_002398.2 F: 5’ AAGGTGATGGCTTGGACAAC 3’ R: 5’ TGTGCCAACTGCTTTTTCTG 3’ Sigma-Aldrich, UK 
MEIS2 NM_170677.4 F: 5’ CTTCTTCTTGGCGAGACCAC 3’ R: 5’ ACTTTGGGGAAAATGCCTCT 3’ Sigma-Aldrich, UK 
MEIS3 NM_020160.2 F: 5’ CAGCCTCCCAGACCAGAATA 3’ R: 5’ TCCTGGTCCAAGTCCTCATC 3’ Sigma-Aldrich, UK 
PREP1 NM_004571.4 F: 5’ GGTTTTGGCCTGATTCTATT 3’ R: 5’ GTGGGGAGGGAGTGGTG 3’ Sigma-Aldrich, UK 
PREP2 NM_022062.2 F: 5’ GCCACCAATATAATGCGTT 3’ R: 5’ GTGTTCCAAGCCCAGGTC 3’ Sigma-Aldrich, UK 
MELK NM_014791.3 F: 5'-CTTGGATCAGAGGCAGATGTTTGGAG-3' R: 5'-GTTGTAATCTTGCATGATCCAGG-3' Sigma-Aldrich, UK 
BMI1 NM_005180.8 F: 5'-GGAGACCAGCAAGTATTGTCCTTTTG-3' R: 5'-CATTGCTGCTGGGCATCGTAAG-3' Sigma-Aldrich, UK 
CD133 NM_006017.2 F: 5’ ACCAGGTAAGAACCCGGATCAA 3’ R: 5’ CAAGAATTCCGCCTCCTAGGACT 3’ Sigma-Aldrich, UK 
SOX2 NM_003106.3 F: 5’ AAATGGGAGGGGTGCAAAAGAGG 3’ R: 5’ CAGCTGTCATTTGCTGTGGGTGA 3’ Sigma-Aldrich, UK 
Nestin NM_006617.1 F: 5’ ATCGCTCAGGTCCTGGAA 3’ R: 5’ AAGCTGAGGGAAGTCTTGGA 3’ Sigma-Aldrich, UK 
Notch1 NM_017617.4 F: 5’ ACTGTGAGGACCTGGTGGAC 3’ R: 5’ TTGTAGGTGTTGGGGAGGTC 3’ Sigma-Aldrich, UK 
C-Fos NM_005252.3 F: 5’ CCAACCTGCTGAAGGAGAAG 3’ R: 5’ GCTGCTGATGCTCTTGACAG 3’ Sigma-Aldrich, UK 
EGR1 NM_001964.2 F: 5’ TGACCGCAAGAGTCTTTTCCT 3’ R: 5’ TGGGTTGGTCATGCTCACTA 3’ Sigma-Aldrich, UK 
C-Jun NM_002228.3 F: 5′-CCAAAGGATAGTGCGATGTTT-3′ R: 5′-CTGTCCCTCTCCACTGCAAC-3′ Sigma-Aldrich, UK 
Bcl-2 NM_000633.2 F: 5’ GATTGTGGCCTTCTTTGAG 3’ R: 5’ CAAACTGAGCAGAGTCTTC 3’ Sigma-Aldrich, UK 
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Bcl-XL NM_001289716.1 F: 5’ CAGAGCTTTGAACAGGTAG 3’ R: 5’ GCTCTCGGGTGCTGTATTG 3’ Sigma-Aldrich, UK 
β-Actin NM_001101.3 F: 5’ ATGTACCCTGGCATTGCCG 3’ R: 5’ GACTCGTCATACTCCTGCTTG 3’ Sigma-Aldrich, UK 
GAPDH NM_002046.5 F: 5’ ATGGGGAAGGTGAAGGTCG 3’ R: 5’ GAGATGATGACCCTTTTGGC 3’ Sigma-Aldrich, UK 
2.14 Protein Detection in Whole Cell Lysates 
2.14.1 Preparation of Whole Cell Lysate Cells were seeded in 6 well plates to provide a final confluence of 70%. Plates were incubated overnight to allow cells to adhere. Media was aspirated off before cells were washed 3 times with ice-cold PBS. A lysate master mix was prepared by mixing 6000 μl of radioimmunoprecipetation assay (RIPA) lysis buffer (Invitrogen, UK) with 60 μl of HALT™ Protease and Phosphatase Inhibitor Cocktail 100X (Life Technologies, UK) and 60 μl EDTA (Sigma-Aldrich, UK). Lysate master mix was briefly vortexed before adding 600 μl to each well. Plates were incubated on ice for 5 minutes, and occasionally rocked to mix. Cell lysates were then harvested using a cell scrapper and passed through a 25G fine needle (Greiner Bio-One, UK) to further homogenise before transferring to a 1.5ml eppendorfs.  Eppendorfs were then centrifuged at 13,000 rpm for 5 minutes at 4°C before decanting the supernatant into a fresh 1.5ml eppendorf. Cell lysates were stored at -80°C. 
2.14.2 Whole Cell Lysate Protein Quantification The amount of protein in whole cell lysate was determined using the Pierce™ Bicinchoninic Acid (BCA) Assay Kit (Life Technologies, UK) in accordance with the manufacturer’s instructions. In brief, albumin standards were prepared by diluting albumin in RIPA lysis buffer to obtain albumin concentrations ranging 
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from 2000 μg/ml to 0 μg/ml. 25 μl of whole cell lysate or albumin standards were pipetted in duplicate in a 96 well plate. A working reagent was prepared by mixing 50 parts of reagent A with 1 part of reagent B, before adding 200 μl of working reagent to each well. Plates were then incubated for 30 minutes at 37°C. The green working reagent reacts with sample protein producing a purple colour change, which was measured at 562nm on the Varioskan® Flash Multimode Plate Reader. The albumin standard was used to create a standard curve from which the unknown protein samples concentrations were interpolated.  
2.14.3 Sample Preparation and Protein Denaturing  Samples were diluted in RIPA buffer to obtain an equal protein concentration between all samples. In an eppendorf, 26 μl of sample was mixed with 10μl of NuPAGE™ lithium dodecyl sulphate (LDS) Sample Buffer 4X (Invitrogen, UK) and 4 
μl of NuPAGE™ Sample Reducing Agent 10X (Invitrogen, UK). Samples were briefly vortexed before being denatured on a pre-heated heat block for 10 minutes at 70°C. Protein denaturing allows proteins to be linearized to ensure all epitopes are exposed and allow for unobstructed movement during gel electrophoresis. 
2.14.4   Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) was used to separate proteins according to their electrophoretic mobility. A pre-cast NuPAGE™ polyacrylamide 1.5mm 4-12% Bis-Tris Gel (Invitrogen, UK) was inserted in a XCell Surelock™ Mini-Cell Electrophoresis tank and submerged in 800ml of diluted, 1:20, NuPAGE™ MOPS SDS Running Buffer 20X (Invitrogen, UK). This was used for low to mid molecular weight protein detection. For high molecular weight detection, NuPAGE™ polyacrylamide 1.5mm 3-8% Tris-Acetate 
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Gel were used in conjunction with in 800ml of diluted, 1:20, NuPAGE™  Tris-Acetate SDS Running Buffer 20X (Invitrogen, UK). Samples were briefly vortexed before 26 μl was loaded along with 10μl of Novex™ Sharp Pre-stained Protein Standards (Invitrogen, UK) or Spectra™ Multicolor High Range Protein Ladder, for low and high molecular weight gels respectively, into the appropriate wells of the gel. Gels were run at 60 volts (V) for 30 minutes, using a PowerPac (Bio-Rad, UK), before voltage was raised to 200V for approximately 30-40 minutes.  
2.14.5 Protein Transfer, Antibody Probing and Band Detection Following SDS-PAGE, proteins on low molecular weight gels were transferred to a Polyvinylidene difluoride (PVDF) membrane by electroblotting using an iBlot® 7-Minute Blotting System (Invitrogen, UK) in combination with iBlot™ 2 (PVDF) Transfer Stacks Mini (Invitrogen, UK) in accordance with the manufacturer’s instructions. Low molecular weight gels were transferred at 20V for 7 minutes. High molecular weight gels were pre-soaked in 20ml of diluted, 1:20, NuPAGE™ Transfer Buffer (Invitrogen, UK), 20% methanol (Fisher Scientific, UK) and, 1:1000, NuPAGE™ Antioxidant (Invitrogen, UK) for 10 minutes.  High molecular weight proteins were then transferred to a PVDF membrane by electroblotting using an iBlot® 7-Minute Blotting System in combination with iBlot™ 2 (PVDF) Transfer Stacks Mini at 20V for 9 minutes.  
Membranes were blocked with 20ml blocking buffer, 5% dried milk powder (Marvel, UK) dissolved in PBS/0.1% Tween-20 (sigma- Aldrich, UK), for 1 hour at room temperature while being gently shaken. Membranes were then probed with appropriate primary antibody, diluted in 20ml of blocking buffer, overnight at 4°C while being gently shaken. Following 4 consecutive 10 minutes washes with 
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PBS/0.1% Tween-20, membranes were incubated with appropriate secondary Horseradish Peroxidase (HRP) conjugated secondary antibody, diluted in 20ml of blocking buffer, for 2 hour at room temperature. Membranes were washed with PBS/0.1% Tween-20 for 3 consecutive 10 minutes washes. For protein visualisation, membranes were incubated with Pierce SuperSignal™ West Pico PLUS Chemiluminescent Substrate (Invitrogen, UK) or SuperSignal™ West Femto Maximum Sensitivity Substrate (Invitrogen, UK) in accordance with the manufacture’s instructions, before being visualised on a UVP ChemiDoc-IT2 Imager (UVP, UK). The molecular weight of protein bands were identified by direct comparison with protein ladder. Membranes were then stored in PBS/0.1% Tween-20 and stored at 4°C, while being gently shaken, for membrane stripping (Section 2.14.6) at a later date. All primary and secondary antibodies used can be seen in Table 2.10. 
2.14.6  Membrane Stripping and Antibody Re-Probing (Loading Control) To ensure uniform protein concentrations were loaded per sample, membranes were stripped and re-probed to detect loading controls GAPDH and β-Actin. Membranes were washed 3 consecutive times with PBS/0.1% Tween-20 for 10 minutes, before being immersed in 15ml of Restore™ PLUS Western Blot Stripping Buffer (Thermo Scientific, UK) for 15 minutes at room temperature. Membranes were then washed in reverse osmosis (RO) filtered water for 1 minute before being washed with PBS/0.1% Tween-20 for 3 times for 5 minutes. Membranes were blocked, re-probed and visualised using the same protocol outlined in 
Section 2.13.5. Loading control antibodies can be seen in Table 2.10.
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Table 2.10: Table listing the primary and secondary antibodies used for western blotting. 
Primary Antibodies 
Antibody Isotype Dilution Molecular Weight (kDa) Chemiluminescent Substrate Exposure Time (Seconds) Supplier 
Mouse anti-SOX2 Monoclonal IgG2A 1:1000 34 Femto 60 R&D Sysrems, UK 
Mouse anti-Nestin Monoclonal IgG1 1:1000 220 Pico 180 R&D Sysrems, UK 
Goat anti-HOXA3 Polyclonal IgG 1:200 54 Pico 600 Santa Cruz Biotechnology, USA 
Mouse anti-HOXA10 Monoclonal IgM 1:100 55 Pico 600 Santa Cruz Biotechnology, USA 
Mouse anti-HOXC4 Monoclonal IgG1 1:100 36 Pico 600 Santa Cruz Biotechnology, USA 
Goat anti-HOXD9 Polyclonal IgG 1:500 39 Pico 600 Santa Cruz Biotechnology, USA 
Rabbit anti-PBX2 Polyclonal IgG 1:1000 51 Pico 600 Santa Cruz Biotechnology, USA 
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Rabbit anti-PBX3 Polyclonal IgG 1:1000 51 Pico 600 Santa Cruz Biotechnology, USA 
Mouse anti-C-Fos Monoclonal IgG1 1:1000 41 Femto 60 Abcam, UK 
Rabbit anti-EGR1 Monoclonal IgG 1:1000 80 Femto 90 Abcam, UK 
Rabbit anti-C-Jun Polyclonal IgG 1:2000 36 Femto 30 Abcam, UK 
Mouse anti-Bcl-2 Monoclonal IgG1 1:500 26 Pico 120 Abcam, UK 
Rabbit anti-Bcl-XL Monoclonal IgG 1:1000 26 Pico 60 Abcam, UK 
Mouse anti-β-Actin Monoclonal IgG 1:5000 42 Femto 60 Sigma-Aldrich, UK 
Mouse anti-GAPDH Monoclonal IgG 1:2000 37 Femto 60 OriGene, USA 
Secondary Antibodies 
Antibody Isotype Dilution Supplier 
Goat anti-rabbit conjugated HRP Polyclonal IgG 1:5000 Abcam, UK 
Goat anti-mouse conjugated HRP Polyclonal IgG 1:5000 OriGene, USA 
Donkey anti-goat conjugated HRP Polyclonal IgG 1:1000 Jackson ImmunoReseach, USA 
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2.15 Detection of Proteins in Tissue by Enzymatic 
Immunohistochemistry Staining 
2.15.1  Fixation, Sectioning and Mounting of Tissue Sections Enzymatic immunohistochemistry (IHC) staining was used to determine the presence and location of proteins of interest in intact tissue sections. Tumours excised from in vivo subcutaneous mouse models were fixed in 10% neutral buffered formalin (Sigma-Aldrich, UK) for a minimum of 24 hours before being embedded in paraffin. Paraffin embedded samples were then cut into 4 μm sections using a Leica RM2125RT microtome (Leica Biosystems, UK). Sections were then mounted onto flex-coated microscope slides (Dako, UK). Slides were dried overnight at room temperature and then baked for 1 hour at 60°C. Tissue microarray was purchased from US Biomax, USA, and contained:  
GL806d: 32 cases of glioblastoma, 3 cases of anaplastic astrocytoma and 5 normal brain tissue cores. All cases are placed in duplicate. TMA slides were sectioned by supplier and stored at 4°C. Malignancy, grade and quality checked via IHC and haematoxylin and eosin (H&E) staining by supplier. TMA slide was baked for 30 minutes at 60°C prior to deparaffinization.  
2.15.2  Deparaffinization and Antigen Retrieval  Paraffin was removed from slides by first submerging slides in 100% xylene (Sigma-Aldrich, UK) for 5 minutes. This was repeated 3 times with fresh 100% xylene each time. This was followed by 10 dips in 100% ethanol (Fisher Scientific, UK).  To block endogenous peroxidase, slides were placed in methanol (Sigma-Aldrich, UK) containing 0.3% hydrogen peroxide (Sigma-Aldrich, UK) for 20 minutes. Sides were then rehydrated by dipping slides 10 times in decreasing 
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concentration of ethanol (Fisher Scientific, UK), from 100%, 70% and 50%. Slides were then placed in distilled water for 1 minute. For antigen retrieval, slides were placed in boiling 0.01M citrate buffer (pH 6.0)(sigma-Aldrich, UK) or tris buffer (pH 9.0) (sigma-Aldrich, UK) and then microwaved for 12 minutes on full power. Once heated, slides were left to cool at room temperature in 0.01M antigen retrieval buffer for between 1-2 hours until cool. Once cooled to room temperature, slides were washed in distilled water for 3 minutes, followed by 2 consecutive 3 minutes washes in PBS.  Antigen retrieval works by breaking the methylene bridges that are formed during fixation, helping to expose antigen sites for antibodies to bind to.  
2.15.3 Blocking of Non-Specific Binding Sites and Antibody Staining  An ImmEdge pen (Vector Laboratories, UK) was used to draw a hydrophobic barrier around tissue sections. Slides were then placed in a moist chamber, before 3 drops of normal horse serum (Vector Laboratories, UK) were added to slides. Slides were incubated in the moist chamber for 15 minutes, before being knocked off, and replaced with 3 drops of Avidin D solution (Vector Laboratories, UK). Slides were incubated for 15 minutes, and then washed once in PBS, before a further 3 drops of biotin solution (Vector Laboratories, UK) was added per slide for 15 minutes. Biotin solution was knocked off, and replaced with 200μl of appropriate primary antibody diluted in PBS/0.1% BSA and incubated in the moist chamber over night (Table 2.11). A negative, 200μl PBS/0.1% BSA alone, control accompanied each stain. Slides were then washed 3 times for 3 minutes in PBS, before 3 drops of universal secondary antibody (Vector Laboratories, UK) was added per slide for 30 minutes. The universal secondary antibody has a 
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composite of biotinylated anti-mouse IgG and anti-rabbit IgG, able to react with both mouse and rabbit primary antibodies. All products used during tissue staining and blocking from Vector Laboratories were supplied in either the Avidin/Biotin blocking kit (Vector Laboratories, UK) or the RTU Vectastain® Universal Elite® ABC Kit (Vector Laboratories, UK). 
Table 2.11: Table listing the primary antibodies used for IHC staing. 
Antibody Isotype Dilution Supplier 
Mouse anti-HOXC4 Monoclonal IgG2b 1:200 OriGene, USA 
Mouse anti-PBX1/2/3/4 Monoclonal IgG1 1:20 Santa Cruz Biotechnology, USA 
Rabbit anti-C-Fos Monoclonal IgG 1:5000 Sigma-Aldrich, UK 
Rabbit anti-Cleaved Caspase 3 Monoclonal IgG 1:50 Cell Signalling Technology, USA 
2.15.4 Staining of Biotinylated Proteins and Nuclear Counter Staining  Following secondary staining, 3 consecutive 3 minute washes in PBS was performed. ABC reagent was prepared by mixing 2 drops of REAGENT A (Vector Laboratories, UK), 2 drops of REAGENT B (Vector Laboratories, UK) in 5ml of ABC buffer (Vector Laboratories, UK). Then 3 drops of ABC reagent were added per slide and incubated in a moist chamber for 30 minutes. 3,3’-Diaminobenzidine (DAB) substrate solution was prepared by mixing 4 drops of DAB Peroxidase substarate solution (Vector Laboratories, UK) in 5ml of distilled water. Following 3 further 3 minute PBS washes, 3 drops of diluted DAB substrate solution was adder per slide and incubated for 2-10 minutes. Slides were then immersed in distilled water for 5 minutes. Slides were counter stained with 3 drops of the nuclear stain haematoxylin (Vector Laboratories, UK) for between 30-45 seconds. Once stained slides were immediately washed under a running tap for 5 minutes. 
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All products used during tissue staining and blocking from Vector Laboratories were supplied in RTU Vectastain® Universal Elite® ABC Kit. 
2.15.5 Dehydration and Scoring of Tissue Sections Tissue sections were dehydrated in a series of alcohol washes by dipping slides 10 times in increasing concentrations of ethanol from 50%, 70% to 100%. Slides were then dipped 10 times in fresh 100% ethanol 2 times, before dipping 10 times in fresh 100% xylene 3 times. Fresh ethanol and xylene was used for each wash step. Slides were then left to air dry for between 30-50 minutes. Once completely dried, 1 drop of Vector mounting media (Vector Laboratories, UK) was added per slide and a glass coverslip (VWR International, USA) was added directly on top of each section. Any bubbles formed were lightly pressed out. Slides were dried on an Electrothermal Slide Drying Rack (Electrothermal, UK) for 30 minutes and later stored at room temperature, before being scored under a ZEISS Primo Star (ZEISS, Germany). The following scores were used: 0 = Negative, +1 = Weak Positive, +2 = Moderate Positive, +3 = Strong Positive. Pictures were taken using a Micorpix Macro-Imager (Micropix, UK) and analysed using the Micropix Cytocam V1.3.5.0 (Micropix, UK).  
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2.16 In Vivo Subcutaneous Mouse Model  Female BALB/c SCID nude mice (Charles River, UK) were used for all in vivo experiments. BALB/c mice have a homozygous mutation of the forkhead box N1 (Foxn1) gene, resulting in defects in hair follicle development and thymus epithelium. These defects result in their distinct nude appearance and their immunodeficiency as animals lacking a thymus are unable to produce mature functional T lymphocytes.  Mice were kept in positive pressure, individual ventilated, cages in 12 hour light/dark cycles, with food and water available ad 
libitum.  
Mice were acclimatised for one week, before being inoculated subcutaneously with 1x106 U87-MG or 1x106 U87-MGCSC suspended in PBS/Matrigel (Sigma-Aldrich, UK) in a 1:1 mix. U87-MG and U87-MGCSC’s were tested for the presence of various common murine pathogens (Surrey Diagnostics LTD, UK) before being used for in vivo experiments. Murine pathogen results can be seen in 
Supplementary Figure 2. Tumour sizes were measured three times per week using callipers. Once tumours had reached volumes of approximately 50mm3, mice were equally divided into two treatment groups. Mice were then injected intratumourally with 50 mg/Kg of HXR9 or an equal volume of PBS as a control. Subsequent dosing was scheduled at days 2 and 5 with 50 mg/Kg of HXR9 or PBS. Mice were monitored daily for signs of distress, including behavioural changes and weight loss. Mice were culled once tumour dimension reached ≥1500mm or when adverse healthy effects were encountered. Experiments were carried out under Professor Hardev Pandha Home office project license PBE74785E. The University of Surrey’s Animal Welfare and Ethical Review Body (AWERB) 
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approved and oversaw all in vivo experiments. Tumour volume was calculated using the formula below: 
𝐓𝐓𝐒𝐒𝐬𝐬𝐅𝐅𝐒𝐒𝐒𝐒 𝐕𝐕𝐅𝐅𝐂𝐂𝐒𝐒𝐬𝐬𝐂𝐂 = (𝐂𝐂𝐂𝐂𝐮𝐮𝐚𝐚𝐭𝐭𝐂𝐂 𝐄𝐄 𝐰𝐰𝐒𝐒𝐭𝐭𝐭𝐭𝐂𝐂 𝐄𝐄 𝐰𝐰𝐒𝐒𝐭𝐭𝐭𝐭𝐂𝐂)
𝟐𝟐
 
2.17 Product Quality Assurance All products used were accompanied with appropriate Certificate of Analysis (CoA). The Author holds either physical or electronical copies of all CoAs, which are presentable on request.  
2.18  Statistical Analysis  
2.18.1  Significance Level All values are given as the mean of three independent experiments, with error bars showing standard deviation (SD) of the mean. Significant values were calculated using GraphPad Prism® Version 7.0 (GraphPad Software, USA). Differences with a p value <0.05 were considered to be significant. The following symbol indices were used in result figures to show levels of significance: P*<0.05, P**<0.01, P***<0.001, P****<0.0001. 
2.18.2  Comparing Statistical Difference Between Two or More Groups   Statistical difference between % cell survival between 2 or more treatments was calculated using two-way ANOVA with Tukey’s post-hoc test. Experiments included are: HXR9, HTL00-1, E4, ICT9119, TMZ and RT treatments with subsequent MTS assay. Multiple unpaired student’s t-test with Benjamini, Krieger and Yekutieli correction was used to calculate statistical difference between defined two means. Experiments included are: Annexin V/7-AAD assay, Caspase-
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Glo® 3/7 assay, BrdU Cell proliferation assay, RT-qPCR and in vivo growth curve analysis. 
2.18.3  Bliss Synergy Analysis Bliss Independence Analysis spreadsheet (MedImmune LLC, USA) was provided by Professor Kevin Harrington with permission from MedImmune LLC. Fraction of dead cells affected by RT (Eradio) and ICT9119 therapy (EICT) was used to calculate the combined expected effect (Eexp) using the complete additivity probability theory (Bliss Independence equation) [525, 526]: 
𝐄𝐄𝐂𝐂𝐄𝐄𝐬𝐬 = (𝐄𝐄𝐒𝐒𝐒𝐒𝐭𝐭𝐒𝐒𝐅𝐅 + 𝐄𝐄𝐈𝐈𝐂𝐂𝐓𝐓) − (𝐄𝐄𝐒𝐒𝐒𝐒𝐭𝐭𝐒𝐒𝐅𝐅  ×  𝐄𝐄𝐈𝐈𝐂𝐂𝐓𝐓 ) 
To determine synergy or antagonism using Bliss analysis, a second equation was performed to determine difference in effect (ΔE) between the observed effect (Eobs) and the Eexp: 
𝚫𝚫𝐄𝐄 = 𝐄𝐄𝐅𝐅𝐨𝐨𝐬𝐬 − 𝐄𝐄𝐂𝐂𝐄𝐄𝐬𝐬 
If the ΔE and its 95% confidence interval (CI) was equal to zero, meaning the observed effect (Eobs) was equal to the Eexp, then the result infers Bliss independence, or additive effect. If the ΔE and its 95% CI was greater than zero, the combination therapy was deemed synergistic. If the ΔE and its 95% CI was less than zero, the combination therapy was below expected joint effect, and was thus antagonistic. Bliss analysis results are presented as a percentage of ΔE with the upper and lower CI in a table format. Accompanying this is a colour coded contour 
map of the ΔE values.   
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3 Investigating HOX and TALE Expression in Adult 
Glioblastoma, and Their Susceptibility to HXR9 
Treatment 
3.1 Chapter 3 Introduction  GBM is an extremely aggressive, highly specialised malignancy, accounting for the majority of brain tumour cases in adults. Standard of care treatment combines surgery with adjuvant TMZ and RT, providing a meadian survival of just 15 months [24, 25, 152]. Patients who survive beyond 15 months have less than 10% chance of surviving 5 years. Relapse of disease, and subsequent poor outcomes have been largely accredited to a subpopulation of GBM cells known as CSCs. These cells have been shown to have increased tumorigenic properties, and specialised survival mechanisms, able to endure and progress through all conventional treatment modalities. In view of this situation, new therapeutic agents, and treatment strategies are urgently needed. In addition to this, new ways of accurately profiling CSC populations in patients is needed for diagnostic purposes.  
Previous HOX expression studies have been performed on GBM tissue and cell lines as described in Section 1.5.5. However, the vast majority of these studies investigated individual HOX genes, and their oncogenic and/or tumour suppressor functions. To date, there are limited published studies investigating 
TALE expression in GBM and no studies looking jointly into HOX and TALE gene expression together. This oversight comes at great surprise as studies from developmental biology have highlighted the importance of HOX-TALE protein interaction in target gene transcription and repression. Furthermore, previous 
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work has associated high HOX expression signature to GBM CSC’s, but have not assessed the functional importance of this elevated expression. 
With previously reported high HOX expression in GBM, independent groups have studied the therapeutic effect of silencing individual HOX genes both in vitro and 
in vivo. Though these studies have had varying degrees of success, their application to a clinical setting has not been feasible. Much of this is due to their targeting methods, mostly siRNAs and shRNA, and the inherent functional redundancy between HOX proteins [527, 528]. HOX DNA binding specificity is reliant on binding to TALE co-factor members. With this in mind, targeting this interaction presents an attractive treatment opportunity. 
HXR9 is a peptide based therapy designed to disrupt the formation of HOX-PBX dimers. This is achieved by HXR9 binding to PBX’s PID motif, which is essential for HOX-PBX interactions. As HXR9 specifically inhibits HOX-PBX binding, only anterior HOX proteins are affected. Anterior HOX protein such as HOXA6, HOXA7, HOXA9, HOXA10, HOXC6, HOXC9 and HOXD9 have all been implicated in various malignant functions such as anti-apoptosis, pro-invasion and pro-migration. As HXR9 is able to target all aforementioned proteins, it is believed that HXR9 treatment can be used both in vitro and in vivo as a cytotoxic and cytostatic agent. Furthermore, if CSCs are functionally more reliant on HOX-PBX dimers, their sensitivity to HXR9 could be increased compared to parental cells. This would finally provide a therapeutic agent able to effectively target both tumour populations in GBM patients. 
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3.2 Chapter 3 Objectives The main objective of this chapter was to determine the therapeutic potential of HXR9 treatment on adult GBM and GBM CSC cell lines in vitro and in vivo. In order to test this, the following experiments were performed: 
1. Validation of CSC cell lines by analysis of CSC markers via RT-qPCR, flow cytometry and western blot. 2. Measurement of HOX and TALE expression in GBM cell lines and primary tissue by RT-qPCR and western blot. 3. Determination of HXR9 IC50 values, on a panel of adult GBM and GBM CSC cell lines, in vitro by MTS assay. 4. Analysis of HXR9’s cell death using annexin V/7-AAD dual staining and caspase 3/7 activity assays. 5. Assessment of HXR9’s cytostatic potential at IC25 dosages using transwell migration/invasion assays, as well as BrdU proliferation assays. 6. Assessment of HXR9’s ability to inhibit GBM and GBM CSC tumour growth 
in vivo using BALB/c flank model, with intratumoural injections.  
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3.3 Chapter 3 Results 
3.3.1 Production and Maintenance of GBM CSC Cell Lines  To be able to compare parental cells to CSC’s, a panel of CSC cell lines had to be established. These cell lines were formed through CSC enriched from parental cell lines U87-MG, U251-MG and LN18. Once established, CSC cell lines were then subsequently validated using a series of experiments.   
CSC cell lines were produced from parental cell lines by creating a selective pressure through serum deprivation, coupled with, increased mitotic stimulus through various supplements, and the use of growth factors (Section 2.1.6.). Parental cell lines are primarily populated by ‘normal’ GBM cells, which express CSC genes or markers at low or undetectable levels. However, they do contain a small subpopulation of cells that possess a stem-like phenotype. Stem cell enrichment media provides a survival benefit for any CSCs that reside in the parental cell line. Survival benefits include, increased rate of proliferation, as well as elimination of ‘normal’ parental GBM cells [31]. The absence of foetal calf serum has previously been shown to cause terminally differentiated cells to die, whilst precursor and CSCs are able to survive with the aid of additional supplements and a forced mitotic stimulus provided by growth factors. 
Cells underwent 3 consecutive passages before being assessed for their ability to form neurospheres (Figure 3.1). Only after this process was successfully completed were CSC cell lines used for further experiments. All CSC cell lines showed a significant reduction in cell numbers after 24 hours once transferred to CSC media. After 72 hours cell numbers had increased and neurospheres had started to form. Figure 3.1 shows neurospheres formed after 72 hours. All CSC cell lines produced neurospheres with varying sizes and sphere density. 
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Figure 3.1: A panel of brightfiels images of GBM neurospheres. All CSC cell lines showed the ability to 
form neurospheres when grown in stem cell media with no extracellular matrix coating. A| LN18CSC, 
B| U87-MGCSC, C| U251-MGCSC. Images taken using a Nikon GIGITAL SIGHT DS-5M camera connected to 
a Nikon ECLIPSE TS100 inverted microscope. Magnification X10 and X20. Scale bars 100μM.  
x10 x20 
A| 
B| 
C| 
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3.3.2 Validation of CSC Cell Lines 
CSC cell lines enriched with serum free media express CSC marker mRNA at 
significant higher levels compared to their parental cell lines. Once parental cell lines had undergone 3 consecutive stem cell passages and capable of forming neurospheres, they were evaluated for CSC marker expression via RT-qPCR (Section 2.13.6) (Figure 3.2). Elevated levels of expression of all CSC markers were found in CSC cell lines compared to their parental cell lines. LN18CSC showed a significant up regulation of stem cell markers MELK, CD133, SOX2 and 
nestin (Figure 3.2 |A). In contrast there was no significant difference in BMI1 and 
Notch1 expression. Similarly, U87-MGCSC expressed stem cell markers MELK, 
CD133, SOX2, nestin and BMI1 at significantly higher levels than their parental counterparts (Figure 3.2 |B). U251-MGCSC exhibited significantly higher expression levels of MELK, BMI1, SOX2 and nestin, when compared to their parental cells (Figure 3.2 |C). However, CD133 and Notch1 expression levels compared to parental cells was not significantly increased.  Of the 6 CSC markers examined, MELK, SOX2 and nestin were highly expressed in all CSC cell lines when compared to their respective parental cells (Figure 3.2 |D). CD133, Notch1 and 
BMI1 expression were elevated in CSC cell lines, but no at statistically significant levels. All parental cell lines expressed CSC markers at low to undetectable levels. LN18CSC had the highest overall expression level of CSC markers, whereas expression in U87-MGCSC was only marginally lower than that of U251CSC.  
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Figure 3.2: Bar charts showing CSC mRNA marker expression in parental and GBM CSC G cells. 
Expression of CSC markers for both parental and CSCs for A| LN18, B| U87-MG and C| U251-MG. CSC 
cell lines exhibited elevated expression levels of CSC markers when compared to their parental cells. 
The expression of each gene is presented relative to the house keeping gene β-actin (x10,000). Each 
test was performed in triplicate and error bars represent standard deviation of the mean. *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001 comparing CSC and parental expression.   
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CSC cell lines have elevated protein levels of selected CSC markers compared 
to their parental cell lines.  To validate the PCR results, and to confirm the protein expression of CSC markers, CD133 and SOX2 were selected for further analysis via flow cytometry (Section 
2.3). SOX2 was selected because of its reported correlation with high HOXA10 and 
HOXD9 expression [465, 481]. While CD133 expression was selected because of it positive correlation with high HOXC4, HOXC6 and HOXC9 expression [475, 478]. Results showed extremely low CD133 expression, less than 1% of cells, in all parental cell lines (Figure 3.3 A|, B|, C|). In contrast, all CSC cell lines expressed high CD133 protein levels. CSC expression levels were 8.98%, 22.61% and 18.57% for LN18CSC, U87-MGCSC and U251-MGCSC respectively (Figure 3.3 A|, B|, C|). Similar to CD133, SOX2 protein expression was shown to be low, less than 0.5%, in all parental cell lines (Figure 3.4 A|, B|, C|). However, CSC expression levels were much higher with expression levels of 16.05%, 20.71% and 13.94% for LN18CSC, U87-MGCSC and U251-MGCSC respectively (Figure 3.4 A|, B|, C|). Overall U87-MGCSC’s had the highest expression of CD133 and SOX2. LN18CSC had the lowest expression of CD133, while U251-MGCSC had the lowest SOX2 expression. Comparing RT-qPCR and flow cytometry results shows no correlation between mRNA expression and protein expression. LN18CSC has the highest mRNA expression for both SOX2 and CD133 (Figure 3.2 |D) out of all cell lines, but is only ranked second and third for SOX2 and CD133 protein expression (Figure 3.3 
A| and Figure 3.4 A|). U87-MGCSC has low mRNA expression for both CSC markers (Figure 3.2 |D), but has the highest expression percentage compared to all other cells (Figure 3.3 B| and Figure 3.4 B|).  
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Figure 3.3: Histogram plots depicting protein expression of CSC marker CD133 in parental and CSC 
cell lines via flow cytometry. Both parental and CSC cell line for A| LN18, B| U87-MG and C| U251-MG 
were used. Results show that CD133 expression increases in CSC cell lines when compared to 
parental cells. Tests were performed in triplicate and are presented compared to appropriate 
isotype controls.  
 
A| LN18                                                                              LN18CSC  
B| U87-MG                                                                        U87-MGCSC 
C| U251-MG                                                                      U251-MGCSC 
0.87% 22.61% 
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Figure 3.4: Dot plots depicting protein expression of CSC marker SOX2 in parental and CSC cell lines 
via flow cytometry. Both parental and CSC cell line for A| LN18, B| U87-MG and C| U251-MG were used. 
Results show that SOX2 expression increases in CSC cell lines when compared to parental cells. Tests 
were performed in triplicate and are presented compared to appropriate isotype controls. 
A| LN18                                                                              LN18CSC  
B| U87-MG                                                                        U87-MGCSC 
C| U251-MG                                                                      U251-MGCSC 
0.87% 
8.98% 0.13% 
16.05% 
0.32% 20.71% 
0.40% 13.94% 
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As flow cytometry results were not in accordance with pre-published data, further protein analysis of CSC markers was performed using western blot. Originally it was planned to use both CD133 and SOX2, however, a validated CD133 antibody for western blot could not be sourced so nestin was used as a replacement marker. Nestin was selected as it is positively expressed in high HOXA9 GBM cells [288, 461]. Furthermore, nestin’s specific expression pattern makes it a good indicator of cells differential state, as only stem-like cells have nestin protein expression [288].  
Low to undetectable levels of SOX2 and nestin protein was seen in parental cell lines (Figure 3.5). CSC cell lines showed a clear increase in both SOX2 and nestin expression when compared to their parental cells (Figure 3.5). U87-MG was shown to have the lowest expression of nestin in all the cell lines, and was the only cell line to have undetectable levels of SOX2. These results match mRNA expression levels reported in RT-qPCR. U251-MGCSC expressed the highest protein levels of SOX2 and nestin, and had the second and first highest mRNA expression levels respectively. LN18 parental cell line had the highest mRNA expression of SOX2 and Nestin compared to all other parental cell lines, but this did not correlate to having the highest protein expression. The same trend can be seen for LN18CSC cell line.  
The short passaged primary derived CSC cell lines GBM1UCL and GBM4UCL were used to compare expression levels and drug sensitivity of primary CSC cell lines to high passaged commercial cell lines. Both primary CSC cell lines showed similar expression profiles with SOX2 being the most highly expressed CSC marker (Figure 3.6). When directly compared, GBM1UCL has higher CSC marker mRNA 
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levels than GBM4UCL. General expression profiles of primary derived CSC cell lines were similar to CSC cell lines enriched from parental cell lines.   
 
Figure 3.5: Protein expression of SOX2 and Nestin via western blot analysis. SOX2 and Nestin were 
both up regulated at the protein level in CSC cell lines compared to parental cell lines. U87-MG had the 
lowest expression of both SOX2 and Nestin, whereas U251-MGCSC had the highest protein expression 
for both SOX2 and nestin. 
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Figure 3.6: Expression of CSC markers for GBM1UCL and GBM4UCL. The expression of each gene is 
presented relative to the house keeping gene β-actin (x10,000). Each test was performed in triplicate 
and error bars represent standard deviation of the mean. 
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3.3.3 Evaluation of HOX Gene Expression in Adult GBM and GBM CSC 
Enriched Cell Lines  
HOX genes are dysregulated in GBM cell lines compared to NHAs All 39 HOX genes were evaluated for gene expression using RT-qPCR in parental GBM cells and their respective GBM CSCs. In addition to this, primary derived CSC cell lines GBM1UCL and GBM4UCL were also included with a NHA sample. Analysis of results shows that there were extremely low or undetectable levels of HOX expression across all 39 genes in NHA (Figure 3.7 A|). In contrast all tumour derived cell lines, both parental and CSC, showed elevated levels of HOX gene expression across all 4 clusters (Figure 3.7 B|, C|, D|, E|, F|, G|). In particular, the 
HOXA and HOXD clusters are the most pronounced in all parental cell lines while a universal expression pattern across all clusters can be seen in CSC cell lines. LN18 has a more dominant posterior HOXA expression pattern (Figure 3.7 B|), while LN18CSC has universal up regulation of HOX genes with prominent HOXA cluster expression (Figure 3.7 C|). U87-MG showed high central HOXC cluster expression with high posterior HOXD expression (Figure 3.7 D|). In contrast, U87-MGCSC has no distinct HOX cluster expression (Figure 3.7 E|). U251-MG had overexpression in all HOX clusters (Figure 3.7 F|), but its enriched U251-MGCSC cell line showed distinct high HOXD posterior expression, with a mainly posterior dominant expression pattern across all other HOX clusters (Figure 3.7 G|).   All CSC cell lines showed a significant increase in HOX expression through all clusters when compared to their parental cells. In both the parental and CSC cell lines, LN18 showed the highest expression of all 39 HOX genes compared to U87-MG and U251-MG. Supplementary Table 1 lists P values comparing CSC cell lines to their parental cells for all HOX genes.  
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Figure 3.7: Expression levels of all 39 HOX genes for A| NHA, B| LN18, C| LN18CSC, D| U87-MG, E| U87-
MGCSC, F| U251-MG and G| U251-MGCSC.  All cell lines showed increased HOX expression compared to 
NHA. CSC cell lines showed a further increase in expression when compared to their parental cell lines. 
The expression of each gene is presented relative to the house keeping gene β-actin (x10,000). Each 
test was performed in triplicate and error bars represent standard deviation of the mean. 
No visibly distinct HOX expression pattern was seen across all parental and CSC cell lines. Neither was there a single predominate HOX gene or HOX cluster that was universally expressed by all cell lines. However, HOXA3, HOXA5, HOXB9, 
HOXC4 and HOXD9 showed the most consistent over expression across all parental and CSC cell lines (Figure 3.8).  All these genes are expressed at higher level than that seen in NHA.  
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Figure 3.8: Expression levels of HOXA3, HOXA5, HOXB9, HOXC4 and HOXD9 in all parental and CSC cell 
lines. Predominantly expressed HOX genes are evenly spread across all HOX clusters. The expression 
of each gene is presented relative to the house keeping gene β-actin (x10,000). Each test was 
performed in triplicate and error bars represent standard deviation of the mean. 
In a similar manner to the parental and the enriched CSC lines, primary CSC cell line GBM1UCL and GBM4UCL exhibited elevated HOX gene expression compared to NHA (Figure 3.9 A|, B|).  GBM1UCL had a distinct expression pattern, with overexpression of the HOXA and HOXD clusters, but with extremely low or undetectable expression in the HOXB and HOXC clusters (Figure 3.9 A|). GBM4UCL showed high HOX expression across all 4 clusters, with prominent expression of central HOX genes in each cluster (Figure 3.9 B|).  
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Figure 3.9: Expression levels of all 39 HOX genes for A| GBM1UCL and B| GBM4UCL. All cell lines showed 
increased HOX expression compared to NHA. The expression of each gene is presented relative to the 
house keeping gene β-actin (x10,000). Each test was performed in triplicate and error bars represent 
standard deviation of the mean.     
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Much like the commercial cell lines and the CSC enriched cell lines, GBM1UCL and GBM4UCL had no shared HOX expression pattern, nor a predominate HOX gene or 
HOX cluster that is universally expressed by both cell lines. Though, HOXA9, 
HOXA10, HOXB9, HOXC4, HOXC9 and HOXD9 were the most consistently overexpressed HOX genes in GBM1UCL and GBM4UCL (Figure 3.10).  
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Figure 3.10: Expression levels of HOXA5, HOXA9, HOXA10, HOXB9, HOXC4 and HOXD9 in GBM1UCL and 
GBM4UCL. The expression of each gene is presented relative to the house keeping gene β-actin 
(x10,000). Each test was performed in triplicate and error bars represent standard deviation of the 
mean.  
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3.3.4 Detection of HOX Proteins in Adult GBM and GBM CSC cell lines 
GBM CSC’s have elevated HOX protein expression when compared to their 
parental cell lines. Elevated HOX protein levels were indicated by western blot assays (Section 2.14). HOXA3, C4 and D9 were selected in view of the RT-qPCR results for commercial parental and CSC cell lines (Figure 3.11). Similar to data obtained by RT-qPCR, all HOX proteins were shown to be present in all CSC enriched cell lines, though only selectively expressed in parental cell lines. HOXA3 was shown to be expressed only in LN18 while U87-MG and U251-MG had no detectable levels, though all CSC enriched cells lines exhibited varying levels of protein expression. HOXC4 was shown to be expressed in all cell lines, both parental and CSC, but had a higher expression in LN18 and LN18 CSC cell lines. HOXD9 was detected in all CSC enriched cell lines, but only expressed in LN18 but not in U87-MG and U251-MG. From the three HOX proteins tested, HOXD9 had the highest expression levels in CSC cell lines, while HOXA3 had the lowest. The overall trend for HOX protein expression mirrored mRNA levels previously identified by RT-qPCR, showing all HOX proteins having a higher expression level in CSC cell lines compared to their parental cell lines.  
Primary derived CSC cell lines GBM1UCL and GBM4UCL were assessed for their protein levels for HOXA10 and HOXD9 (Figure 3.12). Both cell lines expressed HOX proteins at varying levels, with GBM4UCL expressing both HOXA10 and HOXD9 at higher levels compared to GBM1UCL. Expression levels were equatable to mRNA levels detected by RT-PCR, and comparable to HOX protein levels seen in CSC enriched cell lines.  
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Figure 3.11: Protein expression of HOXA3, HOXC4 and HOXD9 in adult GBM and GBM CSC cell lines. 
Low to undetectable levels of HOX proteins was found in parental cell lines, while high levels were 
seen in their enriched CSC cell lines.   
      
Figure 3.12: Protein expression of HOXA10 and HOXD9 in GBM1UCL and GBM4UCL. GBM4UCL had the 
highest expression of both HOXA10 and HOXD9.   
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3.3.5 Assessment of TALE Gene Expression in Adult GBM and GBM CSC 
Enriched Cell Lines 
NHA and GBM cell lines differential expression TALE genes The importance of HOX-TALE binding in the modulation of target genes transcription has been widely recognised. With this in mind, it was deemed essential to determine TALE gene expression in NHA and GBM parental and CSC cell lines. NHA possessed a distinct pattern with higher PBX1 and PREP1 expression, with minimal to undetectable levels of all other TALE genes (Figure 
3.13). A general trend showed down regulation of PBX1, PREP1 and PREP2 in all GBM, parental and CSC, cell lines compared to NHA (Figure 3.13 A|, B|, C|). In contrast TALE genes PBX2, PBX3, MEIS2 and MEIS3 were up regulated compared to NHA. PBX4 and MEIS1 showed no observable difference between GBM cell lines and NHA. A general trend shows increased TALE gene expression in CSC cell lines when compared to their parental cell. U87-MG and U87-MGCSC had the highest expression of PBX3, MEIS2 and MEIS3 when compared to all commercial cell lines. LN18CSC had the highest PBX2 expression. U251-MG and U251-MGCSC had the lowest TALE expression of all cell lines tested. Furthermore, unlike cell lines LN18 and U87-MG, U251-MG parental and CSC cell lines showed no observable difference in expression. Supplementary Table 2 lists P values comparing CSC cell lines to their parental cells for all TALE genes.  
Primary CSC cell lines GBM1UCL and GBM4UCL had similar expression patterns to other GBM cell lines, with high PBX2, PBX3, MEIS2 and MEIS3 expression but low or similar PBX4, MEIS1, PREP1 and PREP2 (Figure 3.13 D|). Interestingly, PBX1 expression in GBM1UCL was slightly lower than NHA, while GBM4UCL was 
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marginally higher. GBM4UCL had in general higher TALE gene expression compared to GBM1UCL, with the exception of MEIS1 and MEIS3 genes.  
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 Figure 3.13: Expression levels of all 9 TALE genes in NHA and A| LN18 and LN18CSC, B| U87-MG and 
U87-MGCSC, C| U251-MG and U251-MGCSC and D| GBM1UCL and GBM4UCL. The expression of each gene is 
presented relative to the house keeping gene β-actin (x10,000). Each test was performed in triplicate 
and error bars represent standard deviation of the mean.  
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3.3.6 Evaluation of PBX Protein Expression in GBM and GBM CSC Cell 
Lines  
GBM cell lines express varying protein levels of PBX2 and PBX3, with CSC cell 
lines expressing PBX proteins at higher concentrations compared to their 
parental cells. As PBX2 and PBX3 were shown to be almost universally overexpressed in GBM cell lines, they were selected for protein quantification via western blot assay. This confirmed that almost all GBM cell lines contained both PBX2 and PBX3 proteins (Figure 3.14). The only exceptions were LN18, U87-MG and U87-MGCSC, which had undetectable levels of PBX2, while U251-MG had undetectable levels of PBX3. All CSC enriched cell lines showed increased levels of both PBX2 and PBX3 compared to their parental cell lines. LN18CSC and U251CSC showed the highest levels of both PBX proteins compared to other commercial cell lines. U87-MG had the lowest general expression of PBX proteins with only low levels of PBX3 detected. Primary CSC cell lines GBM1UCL and GBM4UCL both expressed high levels of both PBX2 and PBX3 (Figure 3.14). These levels were higher than that seen in CSC enriched cell lines. 
 
Figure 3.14: Protein expression of PBX2 and PBX3 in adult GBM, CSC enriched and primary CSC cell 
lines. PBX3 was the highest expressed across cell lines tested.  
GBM
1
U
CL 
GBM
4
U
CL 
LN
18 
LN
18
CSC 
U
251-M
G
CSC 
U
251-M
G 
U
87-M
G
CSC 
U
87-M
G 
PBX2 
PBX3 
GAPDH 
  190 
3.3.7 Assessment of HOX and PBX Expression in Primary GBM 
Tumours 
GBM tumour tissue displays high HOX gene expression compared to 
matched adjacent tissue. Three primary tumours, GBM 50, 56 and 57, with their matched adjacent tissue were used to establish if HOX gene expression in cell lines was representative of GBM tumours. All tumour tissue showed universal up regulation of HOX genes when compared to their matched adjacent tissue (Figure 3.15). Tumour sample, GBM 50, displayed high HOX expression spread across all 4 HOX clusters (Figure 
3.15 A|). GBM 56 presented with the lowest HOX expression between the three tested samples (Figure 3.15 B|). However, GBM 56 expression profile revealed clear HOXA cluster dominance, with posterior expression seen in HOX cluster A, C and D. GBM 57 presented with the highest HOX expression seen from any tumour tissue or cell line tested (Figure 3.15 C|). Much like GBM 50, tumour sample GBM 57 showed high HOX expression across all HOX clusters when compared to its matched adjacent tissue.  
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Figure 3.15: Expression levels of all 39 HOX genes for A| GBM 50, B| GBM 56 and C| GBM 57. All tumour 
tissue tested displayed widespread overexpression of HOX genes when compared to their matched 
adjacent tissue. The expression of each gene is presented relative to the house keeping gene β-actin 
(x10,000). Each test was performed in triplicate and error bars represent standard deviation of the 
mean.   
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Further analysis highlighted a number of HOX genes with conserved overexpression across all tumour tissue (Figure 3.16). However, though these genes were conserved, neither a distinct pattern of HOX expression, nor a single predominate HOX gene or HOX cluster was not identifiable. Supplementary 
Table 3 lists P values comparing tumour tissue with matched adjacent tissue for all HOX genes. Multiple unmatched student’s t-test analyses revealed that all tissue samples showed significant increase in HOXA cluster expression compared to match adjacent tissue. However, interpatient variations were seen, with GBM 50 and GBM57 displaying significant overexpression of genes compared to match adjacent tissue over all HOX clusters, while GBM 56 expression was limited to the 
HOXA cluster, with a single gene in the HOXC cluster. 
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Figure 3.16: Bar chart of relative fold change between tumour tissue and matched adjacent tissue for 
HOXA5, HOXA9, HOXA11, HOXC4, HOXC5, HOXC8, HOXD9, HOXD10 and HOXD13. The expression of each 
gene is presented normalised to the house keeping gene β-actin (x10,000) before being calculated 
relative to matched adjacent tissue. Each test was performed in triplicate and error bars represent 
standard deviation of the mean.  
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GBM tumour tissue expresses varying combinations of TALE genes, with 
general overexpression compared to matched adjacent tissue. 
TALE gene expression was determined via RT-qPCR, revealing widespread TALE gene dysregulation present in all primary tumours (Figure 3.17). GBM 50 tumour tissue showed significantly increased expression of PBX1 and PBX2 compared to matched adjacent tissue (Figure 3.17 A|). GBM 56 tumour tissue showed significantly increased expression of PBX1, PBX2, PBX3 and MEIS2 compared to matched adjacent tissue (Figure 3.17 B|). Conversely, PREP1 was significantly increased in matched adjacent tissue compared to tumour tissue. GBM 57 tumour tissue showed significantly increased expression of PBX2, PBX4 and MEIS1 compared to matched adjacent tissue (Figure 3.17 C|). However, PBX1 was significantly increased in matched adjacent tissue compared to tumour tissue.  
PBX2 was the only TALE gene with significant increase expression shared across all tumour samples. Supplementary Table 4 lists P values comparing tumour tissue with matched adjacent tissue for all TALE genes. 
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Figure 3.17: Expression levels of all 9 TALE genes in A| GBM 50, B| GBM 56 and C| GBM 57. Tumour 
tissue displayed a mixture of overexpressed and under expressed  TALE genes. The expression of each 
gene is presented relative to the house keeping gene β-actin (x10,000). Each test was performed in 
triplicate and error bars represent standard deviation of the mean. *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001 comparing tumour and matched adjacent tissue.   
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3.3.8 Determination of HOXC4 and PBX1-4 protein levels in GBM via 
IHC  
GBM and normal brain tissue express high protein levels of PBX1-4, while 
normal brain expresses low HOXC4 levels compared to GBM tissue. TMA’s containing 32 cases of GBM, 3 cases of anaplastic astrocytoma, and 5 normal brain tissue specimens, all in duplicate, was purchased from US Biomax. These TMA’s were used to further assess the differences between HOX and TALE expression in normal and malignant brain tissue. Antibodies were first optimised using a serial dilution method on slides of normal human placenta as recommended by antibody suppliers (Data not shown). Negative controls were obtained by performing the IHC staining protocol but in the absence of primary HOXC4 or PBX1/2/3/4 antibody. Negative controls displayed no positive brown staining and only blue colouration as a result of the haematoxylin counter staining. 
Matching TMA’s were stained with either anti-HOXC4 or anti-PBX1/2/3/4 antibodies to assess protein expression in tissue (Section 2.15). A scoring system was used whereby two investigators independently scored tissue cores as either 0, +1, +2, +3 or +4 depending on the intensity of brown staining. Scores were complied and any discrepancies were rescored. Two cores from the same patient were lost on both TMA’s stained during the staining protocol these were positioned at number B5 and B6.  
From a total of 31 GBM patients only 2 (6%) stained dual negative for HOXC4 (Supplementary Figure 3). Of the 3 anaplastic astrocytoma’s only 1 (33%) stained dual negative for HOXC4. Analysis revealed 36 (58%) of the 62 cores stained were scored either +3 or +4. Though most duplicates from patients were scored with similar intensity scores, + or – 1, some cases showed larger variations 
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in scoring intensities. HOXC4 staining was distinctly nuclear in all positive cases. The majority of positively stained cores presented with a mixture of negative and positively stained cells. Examples of 0, +1, +2, +3 or +4 HOXC4 intensity staining are shown in Figure 3.18. From the 5 normal brain tissue cases, 3 (60%) were negative for HOXC4, while the remaining 2 cases were scored low, +1, or moderately, +2, respectively. Demographic details for the tissues on the GL806d array are shown in Supplementary Table 5, including the IHC HOXC4 intensity score. 
From the 31 GBM cases, only 3 (10%) stained dual negative for PBX1-4 (Supplementary Figure 4). Of the 3 anaplastic astrocytoma’s only 1 (33%) stained dual negative for PBX1-4. 37 (60%) of the 62 cores stained were scored either +3 or +4. Though most duplicates from patients were scored with similar intensity scores, + or – 1, some cases showed larger variations in scoring intensities. Much like HOXC4, the majority of positively stained cores presented with a mixture of negative and positively stained cells. Examples of 0, +1, +2, +3 or +4 HOXC4 intensity staining are shown in Figure 3.19. All the normal brain tissue cases stained highly, +3 or +4, for PBX1-4 proteins. No correlation was seen between HOXC4 and PBX1-4 staining intensity scores. Demographic details for the tissues on the GL806d array are shown in Supplementary Table 5, including the IHC PBX1-4 intensity score. 
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Figure 3.18: Examples of HOXC4 protein expression from cores taken from TMA slide GL806d. 
Intensity staining score is indicated as either 0= negative, +1 weak positive, +2 moderate positive, +3 
strong positive and +4 very strong positive. Normal tissue shows negative expression levels for HOXC4 
proteins. HOXC4 positive staining was seen exclusively in the nucleus of the cells. Images were taken 
at x20 and x40 magnification using a ZEISS Primo Star light microscope attached to a Micorpix Macro-
Imager, and analysed using the Micropix Cytocam V1.3.5.0.  
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Figure 3.19: Examples of PBX1/2/3/4 protein expression from cores taken from TMA slide GL806d. 
Intensity staining score is indicated as either 0= negative, +1 weak positive, +2 moderate positive, +3 
strong positive and +4 very strong positive. Normal tissue shows highly positive, +4, expression levels 
for PBX1-4 proteins. PBX1-4 positive staining was seen exclusively in the nucleus of the cells. Images 
were taken at x20 and x40 magnification using a ZEISS Primo Star light microscope attached to a 
Micorpix Macro-Imager, and analysed using the Micropix Cytocam V1.3.5.0. 
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3.3.9 Determination of Adult GBM Cell Lines Sensitivity to HXR9 
Treatment 
CSC cell lines are more sensitive to HXR9 treatment compared to their 
parental cell lines. All primary and established cell lines were treated with varying concentrations of HXR9 and CXR9 to determine IC50 values (Table 3.1). All cells lines showed dose dependent cytotoxicity following HXR9 treatment, but low to no cytotoxicity to the control peptide CXR9 (Section 2.8) (Figure 3.18 A|, B|, C|, D|). All CSC cell lines were significantly more sensitive to HXR9 treatment when compared to their parental cells. LN18 was the least sensitive cell line tested (IC50 62μM), while U87-MGCSC was the most sensitive (IC50 25μM). Primary derived CSC cell lines GBM1UCL and GBM4UCL were highly sensitive, IC50 3μM and 5μM respectively, to HXR9 treatment. No correlation was observed between sensitivity to HXR9 and expression of either HOX or TALE genes.  
Table 3.1: IC50 concentration for GBM cell lines treated with HXR9, with HOX and TALE gene expression 
scoring. 
Cell Line HXR9 IC50 (μM) HOX Gene Expression PBX Gene Expression LN18 62 Moderate Low LN18CSC 53 High High U87-MG 31 Low Moderate U87-MGCSC 25 Moderate High U251-MG 47 Low Low U251-MGCSC 28 Moderate Low GBM1UCL 3 Low High GBM4UCL 5 Moderate High    
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Figure 3.20: HXR9 and CXR9 dose response curves for A| LN18 and LN18CSC, B| U87-MG and U87-MGCSC, 
C| U251-MG and U251-MGCSC and D| GBM1UCL and GBM4UCL. All cell lines were sensitive to HXR9, with 
no notable cytotoxicity seen with CXR9 treatment. P****<0.0001 comparing CSC and parental HXR9 
treatments. 
3.3.10 Determination of HXR9 Mode of Death  
HXR9 treatment causes changes in membrane marker expression and 
membrane integrity reminiscent of apoptotic cells. To determine whether HXR9 induced cell death through apoptosis, an initial annexin V/7-AAD dual staining assay was performed (Section 2.9.1). This assay detects changes in the cell membrane expression of phosphatidylserine with a fluorescently labelled annexin V protein, and membrane integrity using the DNA-binding dye 7-AAD. All cell lines, both parental and CSCs, showed significantly increased levels of apoptosis following HXR9 treatment compared to both untreated and CXR9 treated cells (Figure 3.19 A|, B|). All CSCs showed increased apoptosis when compared to their parental cells. There was no significant difference in apoptosis between untreated and CXR9 treated cells for all cell lines. 
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Figure 3.21: Bar graphs showing the percentage of annexin V/7-AAD dual positive (apoptosis) cells 
for A| LN18, U87-MG, U251-MG parental and CSC and B| GBM1UCL and GBM4UCL. All cell lines showed 
significantly increased levels of apoptosis following HXR9 treatment compared to both untreated and 
CXR9 treated cells. Error bars show standard deviation of the mean. P*<0.05, P**<0.01, P***<0.001, 
P****<0.0001 comparing CXR9 treatment with HXR9 treatment. 
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HXR9 induces increased caspase 3 and caspase 7 activity in GBM parental 
and CSC cell lines. Further analysis of apoptosis was performed using a Caspase-Glo® 3/7 assay (Section 2.9.2). Cells were treated with HXR9 and CXR9 at their respective IC50 concentrations for 2 hours before being assessed for cytoplasmic cleaved caspase 3/7 activity. The pan caspase inhibitor Z-VAD-FMK was used to evaluate whether cells could be rescued from caspase mediated death by pre-treating cells. All cell lines displayed significantly increased levels of caspase 3/7 activity following HXR9 treatment compared to both untreated and CXR9 treated cells (Figure 3.20 
A|, B|). Caspase 3/7 activity in Z-VAD-FMK pre-treated cells significantly dropped when compared to HXR9 treated cells. Caspase activity did not correlate with HXR9 sensitivity.  
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Figure 3.22:  Caspase 3/7 activity in A| LN18, U87-MG, U251-MG parental and CSC and B| GBM1UCL and 
GBM4UCL after HXR9 and CXR9 treatment. Pan caspase inhibitor Z-VAD-FMK was used in combination 
with HXR9 treatment. All cell lines displayed significantly increased levels of caspase 3/7 activity 
following HXR9 treatment. Caspase 3/7 activity in pre-treated Z-VAD-FMK cells was significantly 
reduced. Error bars show standard deviation of the mean. P*<0.05, P**<0.01, P***<0.001, 
P****<0.0001 comparing HXR9 treatment with HXR9 + Z-Vad treated cells.   
Adult GBM cells displayed fluorescent staining for cleaved caspase 3 and 
caspase 7 proteins when treated with HXR9, but not for CXR9 treatment. All parental GBM cell lines were assessed for caspase 3 and caspase 7 activity using CellEvent™ Caspase-3/7 Green ReadyProbes™ (Section 2.9.3). CSC cell lines were not used because an effective way to coat glass dishes with either laminin or ECM protein was not found. NucBlue™ Live ReadyProbes™ was used to counter stain cell nuclei blue for better visualisation. All parental GBM cells treated with HXR9 displayed green fluorescent staining, indicating caspase activity in both the 
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cytoplasm and nucleus of cells (Figure 3.21 A|, B|, C|). No caspase activity was detected in CXR9 treated cells. Bright field images showed the appearance of healthy cells in CXR9 treated cells, while HTL00-1 cells have characteristic appearance of cells undergoing apoptosis. 
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Figure 3.23: Caspase 3 and caspase 7 activity visualised by fluorescent probes in A| LN18, B| U87-MG 
and C| U251-MG. HXR9 treated cells showed caspase 3 and caspase 7 activity, while none was seen in 
CXR9 treated cells (Green fluorescent stain). Blue stain indicates cell nuclei. Magnification 20x. 
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3.3.11 Evaluation of HXR9’s Cytostatic Potential  
The use of IC25 HXR9 concentrations causes a reduction in cellular 
proliferation in GBM cell lines.  The anti-proliferative potential of HXR9 was assessed using a BrdU incorporation assay (Section 2.10). All cell lines showed a significant decrease in proliferation after treatment with HXR9 compared to untreated cells (Figure 3.21 A|, B|).  CXR9 treatment had no observable effect on proliferation rate. Primary CSC cell lines were more sensitive to HXR9 induced cell cycle arrest compared to parental and CSC enriched cell lines. No significant difference in proliferation was seen between untreated and CXR9 treated cells. 
 
A| 
LN
18
 Un
t
LN
18
 CX
R9
LN
18
 HX
R9
LN
18
 CS
C U
nt
LN
18
 CS
C C
XR
9
LN
18
 CS
C H
XR
9
U8
7-M
G 
Un
t
U8
7-M
G 
CX
R9
U8
7-M
G 
HX
R9
U8
7-M
G 
CS
C U
nt
U8
7-M
G 
CS
C C
XR
9
U8
7-M
G 
CS
C H
XR
9
U2
51
-M
G 
Un
t
U2
51
-M
G 
CX
R9
U2
51
-M
G 
HX
R9
U2
51
-M
G 
CS
C U
nt
U2
51
-M
G 
CS
C C
XR
9
U2
51
-M
G 
CS
C H
XR
9
0
20
40
60
80
100
120
140
B
rd
U
 In
co
rp
or
at
io
n 
(%
 C
on
tr
ol
) *
* **
*
*
*
  211 
 
 
 
 
 
 
 
 
 
Figure 3.24: BrdU incorporation percentage in A| LN18, U87-MG, U251-MG parental and CSC and B| 
GBM1UCL and GBM4UCL. All cell lines showed a reduction in proliferation after IC25 HXR9 treatment. 
CXR9 was shown to have no significant effect on proliferation. Error bars show standard deviation of 
the mean. P*<0.05, P**<0.01 comparing HXR9 treated and CXR9 treated cells.  
IC25 concentrations of HXR9 reduces GBM cells migration potential, but has 
limited anti-invasion effects. A transwell migration assay was used to assess the anti-migratory/invasion potential of HXR9 (Section 2.11). Migration potential of CSC cell lines were shown to be higher compared to their parental cells. All cell lines treated with an IC25 dose of HXR9 significantly decreased migration compared to untreated cells (Figure 
3.22 A|, B|). CXR9 treatment was shown to have no effect on cellular migration. Similar to migration results, CSC cell lines were shown to have higher invasion potential compared to their parental cells.  All cell lines treated with an IC25 dose of HXR9 showed minor decreases in invasion rate when compared to untreated 
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and CXR9 treated cells (Figure 3.22 C|, D|). U87-MGCSC was the only cell line to have a statistically significant reduction in cell invasion following HXR9 treatment.  
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Figure 3.25: Anti-migration potential of HXR9 IC25 dosages on A| LN18, U87-MG, U251-MG parental 
and CSC and B| GBM1UCL and GBM4UCL. All cell lines showed a significant decrease in migration 
potential when compared to untreated and CXR9 treated cells. Anti-invasion potential of HXR9 IC25 
dosages on C| LN18, U87-MG, U251-MG parental and CSC and D| GBM1UCL and GBM4UCL. U87-MGCSC cell 
line showed the only significant decrease in invasion potential following HXR9 treatment. Error bars 
show standard deviation of the mean. P*<0.05, P**<0.01 comparing HXR9 treated and CXR9 treated 
cells.  
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3.3.12 Evaluation of HXR9’s Anti-Tumour Potential in Vivo 
Tumours grown from CSC cells maintain their CSC marker expression in vivo.  Mice were subcutaneously injected with either U87-MG parental cells or U87-MGCSC cells to assess variations of tumour growth rates betweem cell types. Tumours were resected and total RNA was extracted and RT-qPCR was performed to determine stem cell marker expression in vivo. Results revealed that tumours formed from U87-MGCSC cell line retained expression of CSC markers in vivo (Figure 3.26). Parental tumour’s CSC markers were expressed at lower levels, in line with parental cells in vitro expression, with the exception of MELK, which was more highly expressed. CSC marker expression profiles were highly varied between individual tumours within parental and CSC groups.  
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Figure 3.26: RT-qPCR CSC markers expression for U87-MG and U87-MGCSC tumours grown in vivo. 
Tumours derived from U87-MGCSC mice showed a higher expression of stem cell markers compared 
to parental mice tumours. CSC marker expression for both parental and CSC tumours were similar to 
expression profiles seen in vitro. The expression of each gene is presented relative to the house 
keeping gene β-actin (x10,000). Each test was performed in triplicate and error bars represent 
standard deviation of the mean. 
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HXR9 reduces in vivo tumour growth in SCID mice, with CSC tumours more 
sensitive to HXR9 treatment compared to parental tumours.  Mice were subcutaneously injected with either U87-MG parental cells or U87-MG CSC cells and allowed to form tumours of approximately 50mm3 (Section 2.16). Once this volume had been reached the mice were randomly grouped and either received an intratumoural control injection of PBS or 50 mg/Kg of HXR9 on days 0, 2 and 5. U87-MG parental and CSC tumours grown in mice exhibited a marked decrease in growth when treated with HXR9 (Figure 3.27 A|, B). CSC tumours had a significantly improved response to HXR9 treatment when compared to parental U87-MG tumours (Figure 3.27 C|). Mice with parental U87-MG tumours were euthanized prematurely because of tumour dimensions exceeding ethical limits. In contrast, U87-MGCSC tumours formed dome shaped tumours allowing for measurable endpoints to be reached. No seriously adverse side effects were induced by HXR9 treatment.   
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Figure 3.27: Average tumour volume of A| U87-MG PBX and HXR9 treated tumour, B| U87-MGCSC PBX 
and HXR9 treated tumour and C| U87-MG and U87-MGCSC HXR9 treated tumours compared. Tumours 
treated with HXR9 showed a significant reduction in growth when compared to PBS treated tumours. 
U87-MGCSC tumours showed a significantly greater response compared to the parental tumours. Error 
bars show standard deviation of the mean. P**<0.01, P***<0.001 comparing HXR9 and PBX treated 
mice and U87-MG HXR9 and U87-MGCSC  treated tumours. 
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HXR9 treated tumours express elevated levels of cleaved caspase 3, C-Fos 
and DUSP1 when compared to PBS control tumours.  Once mice were euthanized, their tumours were excised and fixed in formalin before being embedded in paraffin blocks. Sections were cut and mounted on slides before being stained for cleaved caspase 3, C-Fos and DUSP1. Antibodies were first optimised using a serial dilution method on slides of normal human placenta for DUSP1 and tonsil for cleaved caspase 3 and C-Fos as recommended by antibody suppliers (Data not shown). Negative controls were obtained by performing the IHC staining protocol but in the absence of primary antibodies. Negative controls displayed no positive brown staining and only blue colouration as a result of the haematoxylin counter staining. 
A scoring system was used whereby two investigators independently scored tumour slides as either 0, +1, +2 or +3 dependent on intensity of brown staining. Scores were compiled, and any discrepancies were rescored. Tumours used to optimise seeding density and to assess growth rates were used to identify natural background cleaved caspase 3 staining. These results were used to normalise cleaved caspase 3 results, with only staining above these being stores +1 or above. The pathology department of the Royal Surrey County Hospital performed H&E staining for all tumour slides. 
H&E staining revealed high levels of tissue disruption, characteristic of cellular death in parental and CSC HXR9 treated tumours (Figure 3.28). These characteristics included small round apoptotic bodies, condensed chromatin and loss of cell to cell contact. This tissue destruction was not visible in PBS treated tumours, with normal tumour architecture seen throughout tumour sections. Parental and CSC treated tumours both stained for low to undetectible levels of 
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cleaved caspase 3 and C-Fos proteins. However, HXR9 treated tumours positively stained for high levels of both cleaved caspase 3 and C-Fos (Figure 3.28). Staining for both proteins was localized around areas of the aforementioned tissue destruction, and known delivery sites for HXR9. Furthermore, a strong correlation was seen between cells jointly expressing cleaved capase 3 and C-Fos proteins. Staining intensity was higher in parental tumours compared to CSC tumours, although this is mostly likely due to parental tumours being excised earlier due to tumours reaching their ethical size limits.  
All except one PBS control tumours, and both parental and CSC, stained negative for DUSP1 proteins (Figure 3.29). In contrast HXR9 treated tumours all stained strongly, +3, for DUSP1. Further analysis showed that the vast majority of DUSP1 staining localized in areas where cells highly expressed cleaved caspase 3 and C-Fos. Unlike cleaved caspase 3 and C-Fos staining, DUSP1 staining was either scored at negative, 0, or strong positive, +3. This alludes to DUSP1 activation and subsequent expression as more an ‘on/off switch’ rather than a ‘slider’ response dependent on dose. Individual tumour staining for all antibodies used can be seen in Supplementary Figure 5. Intensity staining scores for all antibodies used for individual PBS and HXR9 parental and CSC tumours can be seen in Table 3.2.  
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Figure 3.28: A| Parental tumours and B| CSC tumours, treated with either PBS or HXR9, stained for cleaved caspase 3 and C-Fos. PBS tumours stained weakly or negatively 
for cleaved caspase 3 and C-Fos. HXR9 tumours stained strongly for both cleaved caspase 3 and C-Fos. Positive staining correlated at area of visual tissue destruction. 
Images were taken at x10 and x20 magnification using a ZEISS Primo Star light microscope attached to a Micorpix Macro-Imager, and analysed using the Micropix Cytocam 
V1.3.5.0. 
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Figure 3.29: A| Parental tumours and B| CSC tumours, treated with either PBS or HXR9, stained for DUSP1. Parental and CSC PBS treated tumours stained negatively for 
DUSP1, while HXR9 treated tumours stained strong positively, +3. Images were taken at x10 and x20 magnification using a ZEISS Primo Star light microscope attached to 
a Micorpix Macro-Imager, and analysed using the Micropix Cytocam V1.3.5.0. 
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Table 3.2: Intensity scoring table for parental and CSC tumours treated with either PBS or HXR9. 
Staining scores for cleaved caspase 3, C-Fos and DUSP1.  
Parental 
No. Treatment 
Intensity Score 
Cleaved Caspase 3 C-Fos DUSP1 T1 PBS 0 1 0 T2 PBS 0 1 0 T3 PBS 1 1 0 T4 PBS 1 1 0 T5 PBS 2 2 0 T6 PBS 0 1 0 T1 HXR9 2 2 3 T2 HXR9 3 3 3 T3 HXR9 1 1 0 T4 HXR9 3 3 3 T5 HXR9 2 3 3 T6 HXR9 3 2 3 
Cancer Stem Cells 
No. Treatment Intensity Score 
Cleaved Caspase 3 C-Fos DUSP1 T1 PBS 0 1 0 T2 PBS 0 1 0 T3 PBS 1 1 0 T4 PBS 1 1 1 T1 HXR9 3 2 3 T2 HXR9 2 2 3 T3 HXR9 2 2 3 T4 HXR9 3 3 3 
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3.4 Chapter 3 Discussion The key objectives of this chapter were to first fully document HOX and TALE expression in adult GBM and GBM CSC, and to identify whether any aberrant expression was therapeutically targetable by HXR9 treatment. To achieve this a robust method of enriching parental cell lines to form CSCs, coupled with the ability to validate enriched CSC was imperative. This was accomplished by formulating various media ‘recipes’ to be used to enrich parental cell lines for CSC. Though multiple of these formed neurosphere cultures, only one was deemed to be suitable for use with all cell lines selected. The culturing of parental GBM cells in this media not only resulted in the formation of non-adherent neurospheres, but increased the expression of CSC markers. The differential expression pattern of selected CSC markers highlights the vast heterogeneity of CSC, and the various CSC pathways utilised by GBM cells to obtain stem cell phenotypes. We propose that the CSCs enriched from parental cell lines more closely resemble that of the neuronal stem cells type C or D. This is due to the similar expression pattern of stem cell markers, the dual ability to form neurospheres, as well as the similar division times.  
HOX gene dysregulation in cancer is now a widely recognised phenomenon, with numerous solid and haematological malignancies reported to show aberrant HOX expression. Despite a high level of functional redundancy between HOX proteins, in this study we showed that glioblastoma cell lines and primary tumours show a universal up regulation of HOX genes across all 4 clusters, whilst NHAs showed very low or no expression. This is in contrast to findings in other normal adult cells, as for example there is a high level of HOXA5 in normal breast tissue, HOXA11 in gastric tissue, and HOXB13 in colon and prostate tissue [426, 428, 430, 
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529]. However, low to undetectable levels of HOX gene expression in NHA has been previously reported [453]. As previously addressed many normal tissues express certain HOX genes, and utilise them as tumour suppressors. This tumour suppressor function can be independent of HOX regulation, but normally is due to suppression of other HOX genes. The absence of this HOX autoregulation mechanism in brain tissue can allude to increased sensitivity to HOX gene activation, and thus HOX driven malignancies.  
HOX gene dysregulation was evaluated in both immortalised glioblastoma cell lines and their enriched CSC counterparts. These neurosphere forming cells expressed elevated HOX gene levels when compared to their parental counterparts. This is in agreement with previous findings that HOX genes play a role in the formation and maintenance of glioma CSCs [465, 481]. This high HOX gene signature is also present in patient derived CSCs, indicating that it is not a result of in vitro culture. Immortalised long-term cultured cell lines and their CSC enriched cell lines, shared high levels of HOXA3, HOXA5, HOXB9, HOXC4 and 
HOXD9. Primary derived CSC cell lines shared expression of HOX genes HOXA5, 
HOXA9, HOXA10, HOXB9, HOXC4, HOXC9 and HOXD9.  
HOX proteins can bind to DNA as monomers, but their binding specificity and efficacy is greatly increased when bound to TALE proteins such as PBX and MEIS [369, 394, 395]. These co-factors influence DNA binding selectivity and facilitate nuclear entry [396-398]. Our results show that PBX2-3 expression is elevated in both established and patient derived cell lines compared to NHA. PBX expression is elevated in CSCs compared to their parental counterparts, suggesting a possible positive feedback loop between HOX and PBX genes.  
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Primary GBM tissue samples were assessed to obtain full HOX and TALE gene expression profiles. Wide spread HOX gene dysregulation was seen across all 4 
HOX clusters when compared to matched adjacent tissue. This mirrored previous findings in cell lines. Commonly overexpressed HOX genes included HOXA5, 
HOXA9, HOXA10, HOXA11, HOXC4, HOXC5, HOXC8, HOXD9, HOXD10 and HOXD13. Taken together with previous studies, our findings indicate that the HOX genes 
HOXA5, HOXB9, HOXC4 and HOXD9 are the strongest candidates for biomarkers and treatment targets for GBM and GBM CSCs. HOXC4 protein levels were assessed in 32 GBM cases. Of these 31 cases, 29 (94%) stained positive for various levels of HOXC4. In contrast to this, normal healthy brain tissue was found to express low levels of HOXC4 or no expression at all. In addition to this HOX paralog groups 4, 5 and 9 overexpression was seen in all cell lines and primary tissue tested. This indicated the potential importance of these HOX genes for GBM cell survival.  
TALE gene expression was assessed in primary GBM tissue to determine whether cell lines results were due to culture conditions. Results revealed high expression of TALE genes PBX1, PBX2, PBX3, MEIS1 and MEIS2. This, with the exception of 
PBX1, is identical to the TALE gene expression profiles seen in parental and CSC cell lines. This strongly indicates, that like cell lines, primary GBM tumours utilise HOX-PBX complexes for genomic transcription and repression. This was further strengthened when TMA staining showed that 90% of GBM cases tested for PBX proteins 1-4 were positive. It was also revealed that normal brain tissue also expressed PBX proteins. This is mostly due to the alternative functions PBX monomers possess, as well as their ability to bind independently to other proteins independently of HOX proteins [380].  
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With the identification of both HOX and PBX proteins present in both primary tissue and cell lines, it was hypothesised that HOX-PBX disruption could be used therapeutically. The hexapeptide drug HXR9 was shown to rapidly cause GBM-derived cell lines to undergo cell death, and that CSCs derived from these lines were even more sensitive to this treatment. Apoptosis was proven to be the mode of death through identification of membrane expression changes characteristic of apoptosis, and the activation of caspases 3 and 7. We found no correlation between HOX-PBX expression and sensitivity to HXR9. Although it must be noted this was based on the measurement of HOX and PBX RNA, and not protein expression, as an indicator of the level of HOX-PBX dimers in the cell. An assay that can quantify the total level of HOX/PBX dimers is yet to be developed, but remains an important goal as it is likely to be a better predictor of sensitivity to HOX/PBX inhibition. 
HOX genes have been shown to influence a variety of cellular functions including cell migration and proliferation in both normal and malignant cells [498, 530, 531]. Our findings demonstrate that HXR9 has anti-proliferative and anti-migratory effects. As HXR9 targets multiple HOX and PBX proteins, it is not possible to establish which specific set or sets of HOX-PBX dimers are required for these activities, although the high level of functional redundancy amongst HOX proteins would indicate that a broad disruption of dimer formation is necessary. However, previous studies have shown that loss of HOXD9 expression reduces cellular proliferation, while suppression of HOXD10 causes an increase in invasion and migration [481, 488]. In addition, HOX genes HOXA6 and HOXA9 have been linked to increased invasion and migration, and HOXA7, HOXA9 and HOXC9 are all implicated in cellular proliferation (Figure 3.30). Notably these are all targetable 
  227 
by HXR9 therapy. Further assessments of the mechanism behind HXR9’s anti-proliferative and migratory abilities are to be explored but the broad suppressive effects of HXR9 on HOX proteins, as well as their inherent functional redundancies, seriously hamper the likeliness of success. 
 
 
 
 
 
 
 
 
Figure 3.30: Diagram depicting the effect of HOX protein suppression by HXR9 in GBM tumours. HOX 
protein such as HOXA6, HOXA7, HOXA9, HOXC9 and HOXD9 have been linked to increased 
proliferation rates as well as increased migration and invasion potentials. HXR9 is able to block HOX-
PBX dimers, which in turn suppresses proliferation and invasion/migration.  
Investigations into HXR9’s anti-invasion potential were regrettably inconclusive. This came as a surprise as HOX proteins have been implicated in the regulation of various MMPs. A potential explanation for this result is the short half-life of HXR9. HXR9’s half-life in serum has been calculated to be 12 hours [419]. Though it must be noted that HXR9 incubated with cells will be actively ubiquitinated and degraded. Thus the half-life on cells will be low. With this in mind the 12 hour time point for the migration assay will provide positive results as by the time the assay 
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end point is reached less HXR9 would be degraded compared to invasion assay, 24 hours, which would have almost no active HXR9 left. This would mean that once HXR9 had been degraded, HOX suppression would be lower allowing for cells to invade. The potential addition of a second IC25 dose of HXR9 at the 12 hour time point for invasion assay might have resulted in more positive outcome, and is currently under investigation.  
Before HXR9’s anti-tumour potential could be tested, a robust parental and CSC in 
vivo model had to be established and validated. Parental and CSC cells were grown subcutaneously in the flanks of mice, and resulting tumours were excised for RNA extraction and CSC marker RT-qPCR. Results indicated that tumour cells formed from CSC cells maintained their CSC marker expression, and thus their stem cell phenotype. This came as some surprise as it was expected that once cells were relieved from their selective pressure from in vitro culture, they would differentiate into parental cells losing their CSC markers. A possible explanation is that though serum deprivation is lost, murine growth factors are able to bind to human receptors helping maintain stem cell phenotypes. This explanation is strengthened as previous work has proved the cross reactivity of mouse, rat and human growth factor ligand/receptor binding [532, 533].  
Parental and CSC tumours treated with HXR9 experienced significant reduction in tumour growth when compared to PBS control mice. In addition to this, CSC tumour growth was reduced at a significantly increased rate compared to parental tumours. This further indicates that phenotypically parental and CSC tumours differ. This confirmed that in vitro results are translatable to in vivo, and that CSC targeting in patients is a possibility. Further experiments looking at different use 
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of injection time points might reveal increased efficacy if injections were more spaced out, or additional injections were used. This is under consideration and will likely be addressed in future work.  
HXR9 treatment was shown to induce expression of cleaved caspase 3, C-Fos and DUSP1 in parental and CSC tumours. This indicates that HXR9 induces apoptosis through caspase 3 activation, as seen in vitro. In addition to this, results showed correlation of C-Fos, DUSP1 and cleaved caspase 3 staining, indicating that the 3 molecules are interconnected, and that C-Fos and DUSP1 could have either a joint or opposing apoptotic effect on HXR9 treated cells (Figure 3.31). This is further analysed in Chapter 6 Discussion.   
 
 
 
 
 
 
 
 
 
Figure 3.31: Diagram showing the potential interactions between C-Fos, DUSP1 and Caspase 3. HXR9 
treatment causes an increase in C-Fos and DUSP1 protein levels. C-Fos and DUSP1 activation and or 
suppression of caspase 3 ensue. In addition to this, C-Fos and DUSP1 transactivation and suppression 
is also possible.  
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3.5 Chapter 3 Conclusion Our results reveal widespread HOX dysregulation across all HOX clusters in GBM cells, with a further up regulation seen in CSC when compared to parental cells. This dysregulation is consistent with evaluation of primary tissue, which also exhibits high HOX expression. In contrast, NHA express low to undetectable levels of HOX genes, confirming that HOX expression seen in GBM tumours is acquired during malignant transformation. HOX co-factors PBX and MEIS are both up regulated in adult GBM tissue and cell lines. This supports the notion that HOX-PBX/MEIS dimers are present in GBM tumours, and drive oncogenic functions. Furthermore, CSCs have increased expression levels of TALE genes over parental cells, which accompanies the elevated HOX expression previously mentioned.  
 HOX-PBX dimers were speculated to be potential targets for therapeutic treatment.  HXR9, the HOX-PBX inhibitor, has potent cytotoxic effects on adult GBM cells both in vitro and in vivo. Furthermore, the CSC component of GBM is particularly sensitive to HXR9-mediated cell killing. HXR9’s anti-tumour capabilities extend beyond cell kinging, with anti-migratory and anti-proliferative effects. 
With all this in mind, treatment that includes an inhibitor of HOX-PBX dimers could increase the efficacy of GBM treatment, and reduce the likelihood of CSC-mediated recurrence.  In addition to this the differential expression profile of HOX and PBX can be potentially used as diagnostic markers, as well as markers for the overall CSC population a patient possesses.  
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4 Comparing HXR9 and HTL00-1 Cytotoxic 
Potential in Paediatric Glioma Cell Lines 
4.1 Chapter 4 Introduction The vast majority of previous studies investigating HOX gene expression in GBM have been performed on adult GBM tissue and cell lines. Currently there are no published studies detailing complete HOX and/or TALE gene expression in paediatric GBM. Although adult and paediatric GBM cases share some similar genetic pathways, they are generally considered genetically distinct from one another. Nonetheless, there is enough preliminary data from low grade gliomas, and other brain tumour subtypes, to indicate potential HOX and TALE gene dysregulation in paediatric GBM cells. Furthermore, it is not unreasonable to predict that HOX gene reactivation can potentially be more robust in paediatric GBM cells than that already seen in adult tissue.  
 HOX genes are primarily developmental genes, expressed during embryonic patterning, and are expressed at low levels in adults. However, there is currently no published data detailing HOX or TALE expression in children and adolescents. If potential HOX and TALE dysregulation is to be targeted, a better understanding of their expression in normal young children and adolescent brains is needed. With this knowledge appropriate treatment planning and age thresholds can be set to ensure no cognitive damage to prospective patient’s normally growing brains by HOX-PBX targeted therapies.  
Building on the previous success of HXR9, a second-generation peptide drug was developed. The resulting peptide, HTL00-1, was based on the amino acid sequence of its predecessor (Section 2.4).  With the aid of computer modelling, an amino 
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acid substitution of lysine for proline was made to enhance target-binding affinity. In addition to this, 2 alanine amino acids were substituted for the 2 histidines to form a new linker region. This new linker region provides a peptide kink, which reduces steric hindrance in peptide binding to PBX’s hydrophobic pocket. In addition to this, HTL00-1 was shown to have an increased half-life in serum, a more neutral pH, and improved solubility at high molecular concentration. 
Previous work by Morgan et al identified a putative HXR9 signature that includes 
C-Fos and DUSP1 [419]. Additional work has helped formulate potential mechanisms that mediate HXR9 induced cell death. A proposed cell death mechanism is that C-Fos proteins activate FasL transcription causing FasL mediated cell death. In addition, DUSP1 induction following HXR9 treatment results in dephosphorylation of MEK and ERK. This dephosphorylation silences RAS signalling leading to apoptosis. An alternative mechanism, proposed by the author, is that C-Fos dimerises with C-Jun to form a complex known as Activator protein 1 (AP-1). AP-1 has been shown to cause apoptosis through a variety of mechanisms [534-536]. One mechanism of interest is the AP-1/Bcl-2/Bcl-XL pathway. AP-1 complexes are shown to indirectly suppress Bcl-2 and/or Bcl-XL, in a tissue dependent manner, leading to apoptosis [537-540]. In addition to this, C-Jun monomers have been shown to promote Bcl-2 expression [541]. An additional protein of interest is EGR1. EGR1 gene expression has been shown to be up-regulated by more than 20 fold following HXR9 treatment [421]. EGR1 has been shown to induce apoptosis via numerous pathways. One such mechanism is inhibition of Bcl-2 expression [542]. With the current uncertainties, and newly proposed mechanisms, a more in-depth look into the death mechanism induced by HOX-PBX inhibition was deemed necessary.   
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4.2 Chapter 4 Objectives  The main objective of this chapter was to determine the viability of using HXR9 or HTL00-1 as a therapeutic agent in the treatment of paediatric GBM. In order to test this, the following experiments were performed: 
1. Quantification of HOX and TALE expression in healthy children and adolescent brain tissue via RT-qPCR. 2. Assessment of HOX and TALE expression in paediatric GBM cell lines by RT-qPCR. 3. Comparison of HXR9 vs HTL00-1’s IC50 values, on a panel of paediatric GBM cell lines, in vitro by MTS assay. 4. Analysis of HTL00-1 cell death using annexin V/7-AAD dual staining and caspase 3/7 activity assays.  5. Assessment of HTL00-1 death pathway via RT-qPCR and western blot assay. 
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4.3 Chapter 4 Results 
4.3.1 Complete analysis of HOX and TALE Gene Expression in Healthy 
Children Brain Tissue  
High HOX expression is evident in young children, but rapidly drops with 
increase in age. Analysis of HOX gene expression was assessed on 20 healthy children and adolescent brain samples via RT-qPCR. Samples were selected from patients who had died from causes not related to direct brain trauma or brain related diseases. Samples were equally separated (n=5) into 4 age groups. Results showed a distinct high HOX expression across all clusters in patients aged between 0-4 years (Figure 4.1). This high expression rapidly decreases in patients aged between 5-9 years of age. A further reduction is seen in age groups 10-14 and 15-20.  The highest expression in age group 0-4 is seen in the HOXA and HOXC clusters. This high expression is spread across both anterior and posterior genes and does not correlate with HOX genes expressed in foetal brains (Red Line). 
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Figure 4.1: Complete HOX gene expression in healthy paediatric brains. Children aged between 0-4 
showed high HOX gene expression across all 4 gene clusters. HOX gene expression decreases across 
all clusters from ages 5 onwards. Red lines indicate HOX genes expressed in foetal brain during 
embryonic development. The expression of each gene is presented relative to the house keeping gene 
β-actin (x10,000). Each test was performed in triplicate and error bars represent standard deviation 
of the mean.  
To compare HOX expression between healthy paediatric brains, HOX expression data from healthy paediatric brains was compared to HOX expression data from NHA (Figure 4.2). Results showed, as previously stated, that high HOX expression is seen at early ages and rapidly drops off with age. High expression clusters can be seen in age group 0-4 years old at, HOXA9-HOXA13, HOXB4-HOXB6 and HOXC11-
HOXC13. Using NHA HOX expression as an adult comparison, it is clear that HOX genes are silenced to ‘adult’ expression levels from the age of 5 onwards. 
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Figure 4.2: Gene expression heat map detailing expression of all 39 HOX genes in paediatric and 
adolescent healthy brains from ages 0-20, with an adult NHA sample. HOX expression rapidly 
decreases from high expression at age group 0-4, to low levels at 5 onwards. This low expression is 
comparable to expression levels seen in adult NHA samples. The expression of each gene is presented 
relative to the house keeping gene β-actin (x10,000). Each test was performed in triplicate and error 
bars represent standard deviation of the mean.  
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Healthy paediatric brains express high levels of MEIS3 gene activity when 
compared to adult NHA’s. Healthy paediatric brains generally expressed similar levels of TALE gene expression across all 4 age groups (Figure 4.3). PBX1, PBX2 and PBX3 were all expressed at similar levels to each other, while there was limited to undetectable levels of PBX4 in all samples. MEIS1 was expressed at lower levels than that seen in PBX1-3. MEIS2 was expressed at higher levels than the previously mentioned genes, but no significant difference in expression could be seen between age groups. In contrast, MIES3 had the highest levels of gene expression seen between all TALE genes tested. Age group 0-4 had the highest expression of MEIS3, while the 15-20 age group the lowest. A clear trend showed MEIS3 expression decreases with age.   
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Figure 4.3: Expression of TALE genes in healthy paediatric and adolescent brains. PBX1-3, MEIS1-2 
showed varying levels of expression, but were equally expressed across all age groups. MEIS3 was 
highly expressed in the 0-4 age group with expression decreasing with an increase in age. The 
expression of each gene is presented relative to the house keeping gene β-actin (x10,000). Each test 
was performed in triplicate and error bars represent standard deviation of the mean. 
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TALE expression between healthy paediatric brains, with expression from adult NHA was compared using a gene expression heat map (Figure 4.4). Results showed that expression of PBX1-4 and MEIS1-2 were generally comparable with that seen in adult NHA. The exception to this was MEIS3, which was shown to be highly expressed in healthy paediatric samples compared to adult NHA.  
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Figure 4.4: Gene expression heat map detailing expression of all TALE genes in paediatric and 
adolescent healthy brains from ages 0-20, with an adult NHA sample. TALE expression was similar 
between paediatric and NHA samples, with the exception of MEIS3, which was highly expressed in 
paediatric samples. The expression of each gene is presented relative to the house keeping gene β-
actin (x10,000). Each test was performed in triplicate and error bars represent standard deviation of 
the mean. 
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4.3.2 Evaluation of HOX Expression in Paediatric Glioma Cell Lines 
Paediatric glioma cell lines show widespread HOX gene dysregulation across 
all HOX gene clusters. Paediatric cell lines KNS42 and SF188, both grade IV gliomas, with RES186, a grade I glioma, were investigated for HOX gene expression via RT-qPCR. All cell lines tested showed HOX gene expression at varying levels across all 4 HOX clusters (Figure 4.5 A|, B|, C|). KNS42 had the highest total HOX gene expression compared to all tested cell lines (Figure 4.5 A|). This high expression is predominantly in HOX clusters B and D. Low gene expression was seen in the 
HOXA cluster, with low to undetectable levels in the HOXC cluster.  SF188 displayed high HOXB and HOXC cluster expression, with low HOXA and HOXD expression with the exception of a few posterior genes (Figure 4.5 B|). RES186 presented with the lowest overall HOX expression of the 3 cell lines tested (Figure 
4.5 C|). Low HOX expression is seen in all HOX clusters with the exception of 
HOXB7 and HOXD10.  
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Figure 4.5: Expression levels of all 39 HOX genes for A|KNS42, B| SF188, C| RES186. GBM cell lines 
KNS42 and SF188 showed high HOX gene expression. Grade I glioma, RES186, showed the lowest HOX 
gene expression. The expression of each gene is presented relative to the house keeping gene β-actin 
(x10,000). Each test was performed in triplicate and error bars represent standard deviation of the 
mean.   
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In a similar trend with adult GBM cell lines, a distinct pattern of HOX expression was not visible in all paediatric glioma cell lines. Neither was there a single predominant HOX gene universally expressed as the highest HOX gene by all cell lines. However, high HOXB cluster expression was present in all tested cell lines. 
HOXB4, HOXB5, HOXB7, HOXB9, HOXD10 and HOXD13 were the most consistently over expressed genes across all cell lines (Figure 4.6). Compared to adult GBM cell lines, paediatric glioma cell lines showed generally higher HOXB cluster expression. Adult GBM cell lines generally were more HOXA, HOXC and HOXD cluster dominant. 
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Figure 4.6: Expression levels of HOXB4, HOXB5, HOXB7, HOXB9, HOXD10 and HOXD13 in all paediatric 
glioma cell lines. All cells lines show dominant HOXB cluster expression. The expression of each gene 
is presented relative to the house keeping gene β-actin (x10,000). Each test was performed in 
triplicate and error bars represent standard deviation of the mean.   
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4.3.3 TALE Gene Expression in Paediatric Glioma Cell Lines 
Paediatric glioma cell lines express high levels of PBX1, PBX2 and MEIS3 
TALE gene expression in paediatric glioma cell lines was determined via RT-qPCR. Initial analysis shows a clear trend of high PBX1, PBX2 and MEIS3 expression shared between all cell lines (Figure 4.7 A|, B|, C|). KNS42 showed the highest expression of TALE genes between all cell lines (Figure 4.7 A|). This high expression is seen in PBX1-3 and MEIS3. Extremely low to undetectable levels of 
PBX4, PREP1 and PREP2 were seen, with moderate expression of MEIS1 and 
MEIS2. SF188 displayed high PBX1, PBX2, MEIS2 and MEIS3 expression, while low expression of the remaining TALE genes (Figure 4.7 B|). RES186 had the lowest overall TALE gene expression of the cell lines tested (Figure 4.7 C|). Moderate expression of TALE genes PBX1-3 and MEIS3 was evident, while low to undetectable expression of all remain TALE gene was observed.  
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Figure 4.7: Expression levels of all 9 TALE genes in paediatric glioma cell lines A| KNS42, B| SF188, C| 
RES186. All cell lines displayed high expression of TALE genes PBX1, PBX2 and MESI3. Expression of 
remaining TALE genes was cell line dependent. The expression of each gene is presented relative to 
the house keeping gene β-actin (x10,000). Each test was performed in triplicate and error bars 
represent standard deviation of the mean. 
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4.3.4 HTL00-1 Cellular Penetration  
HTL00-1 was able to penetrate all paediatric cell lines, and was distributed 
in the cell cytoplasm and nucleus.  To prove cellular penetration of HTL00-1, all paediatric glioma cell lines were treated with 20µM of HTL00-1 conjugated with the fluorescent probe 5/6-FAM (green fluorescent stain) (Section 2.6). Cells were then counterstained with NucBlue™ Live ReadyProbes™ to visualise cell’s nucleus (blue fluorescent stain). Images indicate that HTL00-1 is able to rapidly penetrate the cellular membrane and is evenly distributed in the cytoplasm and nucleus (Figure 4.8 A|, B|, C|). A visible trend shows the green fluorescent intensity, which is proportional to HTL00-1 concentration, is directly correlated to sensitivity to HTL00-1. RES186 is the most sensitive to HTL00-1, and thus shows the highest fluorescent intensity (Figure 4.8 A|), while KNS42 is the least sensitive and displays the lowest fluorescence (Figure 4.8 B|). In addition to this, KNS42 cells showed a higher cytoplasmic distribution of HTL00-1 compared to the more sensitive cell lines SF188 and RES186. Bright field images show signs characteristic of apoptosis, such as, cellular rounding, membrane blebbing and chromosome condensing.  
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Figure 4.8: Fluorescent imaging of A| KNS42, B| SF188 and B| RES186 cells treated with HTL00-1 
conjugated to 5/6-FAM. All cell lines showed HTL00-1 penetration within 1 hour of HTL00-1 
treatment. KNS42 showed the lowest green fluorescent intensity per cell while RES186 showed the 
highest. This trend showed a correlation between concentration of HTL00-1 per cell, green florescent 
intensity, to sensitivity to HTL00-1. Bright field images show signs characteristic of apoptosis, such as, 
cellular rounding, membrane blebbing and chromosome condensing.     
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4.3.5 Comparing Sensitivity of HXR9 and HTL00-1 treatment in 
Paediatric Glioma Cell Lines 
All paediatric cell lines were more sensitive to HTL00-1 treatment 
compared to HXR9 treatment.  Sensitivity to varying concentrations of HXR9 and HTL00-1 treatment was determined via MTS assay, and was used to provide IC50 values (Table 4.1). All paediatric glioma cells lines showed dose dependent cytotoxicity following HXR9 or HTLOO-1 treatment, but low to no cytotoxicity to the control peptide CXR9. All cell lines were significantly more sensitive to HTL00-1 treatment when compared to HXR9 treatment (Figure 4.9 A|, B|, C|). KNS42 was the least sensitive to both HTL00-1 and HXR9 treatment (IC50 41 and 64μM respectively), while RES186 was the most sensitive to both HTL00-1 and HXR9 treatment (IC50 24 and 15μM respectively). No correlation was observed between sensitivity to HXR9 and expression of either HOX or TALE genes. Further analysis showed no correlation between general HOX expression and sensitivity. However, a correlation between 
TALE expression and sensitivity for both HTL00-1 and HXR9 was visible. KNS42 was the most resistant cell line tested and had the highest PBX expression, whilst the most sensitive cell line, RES186, expressed the lowest levels of general PBX expression. 
Table 4.1: IC50 concentration for Paediatric glioma cell lines treated with HXR9 or HTL00-1, with HOX 
and TALE gene expression scoring. 
Cell Line HXR9 IC50 (μM) 
HTL00-1 IC50 
(μM) 
HOX Gene 
Expression 
PBX Gene 
Expression 
KNS42 64 41 Moderate High 
SF188 39 17 High Moderate 
RES186 24 15 Low Low 
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Figure 4.9: HTL00-1, HXR9 and CXR9 dose response curves for A| KNS42, B| SF188 and C| RES186. All 
cell lines were sensitive to HTL00-1 and HXR9, with no notable cytotoxicity seen with CXR9 treatment. 
P**<0.01, P****<0.0001 comparing HTL00-1 and HXR9 treatments.  
4.3.6 Determination of HTL00-1 Induced Mode of Death 
HTL00-1 treatment causes changes in membrane marker expression and 
membrane integrity characteristic of apoptotic cells. An initial annexin V/7-AAD dual staining assay was performed on HTL00-1 treated cells to determine if mode of death was similar to that of HXR9’s. All cell lines showed a significant increase in apoptosis when treated with HTL00-1 compared to both CXR9 treated and untreated cells (Figure 4.10 A|, B|, C|). High levels of dual annexin V/7-AAD staining was detected in all cell lines, signifying the majority of cells were in late stages of apoptosis. No significant difference in apoptosis between untreated and CXR9 treated cells was observed for all cell lines. 
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Figure 4.10: FACs plots of annexin V/7-AAD, single and dual positive cells, for A| KNS42, B| SF188 and 
B| RES186. All cell lines showed significantly increased levels of cells in late apoptosis following 
HTL00-1 treatment, compared to both untreated and CXR9 treated cells. No significant difference in 
apoptosis, both early and late, between untreated and CXR9 treated cells.    
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HTL00-1 induces caspase 3 and caspase 7 activity in paediatric glioma cell 
lines. Caspase activity was analysed using a Caspase-Glo® 3/7 assay. Cells were treated with HTL00-1, with and without Z-VAD-FMK, and CXR9 at their relevant IC50 concentrations for 2 hours before being assessed for cytoplasmic cleaved caspase 3/7 activity. All cell lines displayed significantly increased levels of caspase 3/7 activity following HTL00-1 treatment compared to both untreated and CXR9 treated cells (Figure 4.11). Caspase 3/7 activity in Z-VAD-FMK pre-treated cells significantly dropped when compared to HTL00-1 treated cells. Caspase activity directly correlated to HTL00-1 sensitivity. 
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Figure 4.11: Caspase 3/7 activity in Paediatric glioma cell lines after HTL00-1 and CXR9 treatment. All 
cell lines displayed significantly increased levels of caspase 3/7 activity following HTL00-1 treatment. 
Caspase 3/7 activity in pre-treated Z-VAD-FMK cells was significantly reduced. Error bars show 
standard deviation of the mean. P**<0.01, P***<0.001 comparing HTL00-1 treatment with HTL00-1 + 
Z-VAD-FMK treated cells.   
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KNS42 cells stained positively for cleaved caspase 3 and caspase 7 proteins 
when treated with HTL00-1, but not for CXR9 treatment. All paediatric glioma cell lines were originally assessed for caspase 3 and caspase 7 activity using fluorescent probes. However, NucBlue™ Live ReadyProbes™ in combination with CellEvent™ Caspase-3/7 Green ReadyProbes™ were found to be cytotoxic to SF188 and RES186 cell lines. Therefore, only KNS42 was used for caspase visualisation. KNS42 cells treated with HTL00-1 displayed green fluorescence, indicating caspase activity, in both the cytoplasm and nucleus of cells (Figure 4.12). No caspase activity was detected in CXR9 treated cells. Bright field images show the appearance of healthy cells in untreated and CXR9 treated cells, while HTL00-1 cells have characteristic appearance of cells undergoing apoptosis. 
Figure 4.12: Caspase 3 and caspase 7 activity visualised by fluorescent probes in KNS42. HTL00-1 cells 
showed caspase 3 and caspase 7 activity, while none was seen in untreated and CXR9 treated cells 
(Green fluorescent stain). Blue stain indicates cell nucleus. Magnification 20x. 
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4.3.7 Determination of HTL00-1 Death Pathway 
Treatment of HTL00-1 causes an up regulation in C-Fos gene expression, 
accompanied by a down regulation of Bcl-2 expression. Genes C-Fos, EGR1 and C-Jun were selected from a panel of genes previously shown to be up regulated following HXR9 treatment [419]. Bcl-2 and Bcl-XL were added to the list of selected genes because of their interconnection with aforementioned genes in the role of apoptosis. RT-qPCR results showed that post HTL00-1 treatment, C-Fos expression is rapidly induced in all paediatric glioma cell lines (Figure 4.13). KNS42 displayed the lowest fold change (1.03) in C-Fos expression while, SF188 (5.6) and RES186 (9.5) showed more dramatic induction of C-Fos expression. In contrast to this, Bcl-2 expression was shown to decline once cells were treated with HTL00-1. All cells showed significant down regulation of Bcl-2 gene expression when compared to untreated cells. EGR1 expression was not significantly different between HTL00-1 treated cells and HTL00-1 treated cells for all cell lines. However, KNS42 and RES186 showed small increases in EGR1 expression following HTL00-1 treatment. This increase was not evident in SF188 cells. Much like EGR1 expression, C-Jun and Bcl-XL was shown to neither significantly increase nor decrease following HTL00-1 treatment. Further analysis highlighted a direct correlation between the increase in C-Fos expression and the decrease in Bcl-2 expression. In spite of this, gene expression changes of C-Fos and 
Bcl-2 did not correlate with sensitivity to HTL00-1 treatment.  
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Figure 4.13: Gene expression of C-Fos, EGR1, C-Jun, Bcl-2 and Bcl-XL in paediatric glioma cell lines 
treated with HTL00-1 or CXR9. All cell lines displayed a distinct up regulation of C-Fos expression, 
accompanied by a down regulation in Bcl-2 expression following HTL00-1 treatment. No significant 
difference in EGR1, C-Jun or Bcl-2 expression was observed. The expression of each gene is presented 
relative to the house keeping gene β-actin (x10,000). Each test was performed in triplicate and error 
bars represent standard deviation of the mean. P**<0.01, P***<0.001 comparing HTL00-1 treated 
with untreated cells.   
C-Fos protein levels increase, whilst Bcl-2 protein decreases following 
HTL00-1 treatment in paediatric glioma cell lines. Proteins levels of C-Fos, EGR1, C-Jun, Bcl-2 and Bcl-XL were determined via western blot assay. C-Fos protein levels were shown to be up regulated in all cell lines following HTL00-1 treatment compared to untreated and CXR9 treated cells (Figure 4.14). This up regulation was accompanied by a reduction in Bcl-2 expression in HTL00-1 treated cells compared to untreated and CXR9 treated cell. This generally followed the trend seen in gene expression, but there was no direct correlation between gene expression levels and proteins levels neither Bcl-2 nor 
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C-Fos. No changes in protein levels were seen for C-Jun, EGR1 or Bcl-XL. Interestingly, all cells expressed varying levels of the C-Fos binding partner, C-Jun, in untreated cells.  
 
 
Figure 4.14: Protein expression of C-Fos, C-Jun, EGR1, Bcl-2 and Bcl-XL in paediatric glioma cell lines 
following CXR9 or HTL00-1 treatment. C-Fos protein levels increased in all cell lines following HTL00-
1 treatment. This increase was accompanied by a decrease in protein expression for Bcl-2. No 
detectable change in EGR1, C-Jun or Bcl-XL was observed.  
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4.4 Chapter 4 Discussion  The main objective of this chapter was to determine the effectivness of using HXR9 or HTL00-1 as a therapeutic agent in the treatment of paediatric GBM. Before this was assessed it was deemed essential to identify HOX gene expression postnatally. This was due to the concern that any potential HOX-PBX inhibition could cause cognitive impairment if used in the treatment of paediatric glioblastoma.  
Results showed high HOX gene expression spread across all clusters in children aged 0-4 years, with moderate to low PBX expression but high MEIS2 and MEIS3 expression. HOX expression rapidly dropped off from 4-years onwards, while 
MEIS3 expression persisted throughout adolescence. This indicates that HOX genes not utilised in foetal brain development are reactivated postnatally. This reactivation could be due to continual brain development. Synaptic density rapidly increases after birth and peaks between the age of 2-4 years of age [543]. This is then followed by neural ‘pruning’. Furthermore HOX monomers have been shown to exert control over the Epherin/Eph receptor ligand system [544]. The Epherin/Eph receptor ligand system is crucial for neurone migration and adhesion, as well as cell-to-cell communication during postnatal brain development [545]. MEIS protein expression has previously been shown to be expressed at greater levels compared to PBX in the developing regions of the brain [546]. This might explain why MEIS3 expression is dominant over PBX1-4 expression in paediatric brains. It must also be noted that HOX, PBX and MEIS proteins have DNA binding abilities as monomers and have alternative binding partners.  These results indicate that though HXR9 or HTL00-1 treatment might not be appropriate for children aged 4 and below, but might potentially be used on older children and adolescents.  
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All paediatric glioma cell lines tested aberrantly expressed HOX genes. This aberrant expression was cell line specific with each cell line displaying a unique 
HOX profile. Grade I glioma, RES186, had the lowest HOX expression profile when compared to grade IV cell lines KNS42 and SF188. With low sample population, it is impossible to definitively state that HOX gene expression increases with tumour grade, however, these results provide a possible indicator to base future work. To further this notion, previous work compiled at this laboratory has shown HOX expression increases between low and high grade ovarian tumours. Glioma cell lines shared a selection of HOX genes that were expressed across all cell lines. High 
HOXC cluster expression was shared between all cell lines, though other HOX cluster expression was varied across cell lines. This highlights the functional redundancy that is present between HOX genes. 
Paediatric glioma cell lines shared high expression of TALE genes PBX1-3 and 
MEIS2-3. This is unlike healthy paediatric brain tissue which expresses moderate to low levels of PBX1-4 and MEIS1-2, with high MEIS3 expression. Comparisons indicate that TALE genes are overexpressed in cancer, while MEIS3 expression is maintained. This overexpression is important as it accompanied the overexpression of its binding partner HOX. This provides further evidence that a potential positive feedback loop is present between HOX and TALE genes.  
HXR9 has previously been shown to penetrate cells using a FITC label peptide [421, 498]. To establish if HTL00-1 had similar properties, a 5/6-FAM tagged HTL00-1 peptide was used to visualise peptide cell penetration. All cell lines were susceptible to peptide entry with staining visible in both the nucleus and cytoplasm of the cells. IC50 results revealed all cell lines were sensitive to both 
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HXR9 and HTL00-1 at sub 70μM concentrations. Results showed a direct correlation between HTL00-1 sensitivity and cell peptide accumulation. HXR9 and HTL00-1 both use a polyarginine penetration sequence that requires heparin sulphate for cellular entry [420-422, 495-497]. This could mean that, at least in part, sensitivity is linked to membrane heparin sulphate expression, and thus the peptides ability to penetrate cells. Comparisons between HXR9 and HTL00-1 sensitivity revealed a clear increase in cytotoxicity between 1st and 2nd generation peptides. No correlation was found between HOX expression and HXR9 or HTL00-1 sensitivity. However, correlations between TALE gene expression and HXR9 and HTL00-1 sensitivity were proven.  
Previously published work, as well as work completed in this thesis showed HXR9 induced apoptosis in cancer cells [369, 410, 419, 498, 519]. To verify HTL00-1 induces similar mode of death a series of assay were performed. Annexin V, Caspase-Glo® 3/7 and Caspase3/7 immunofluorescence assays unanimously showed that HTL00-1 induced mode of death was apoptosis mediated through caspase 3 and caspace 7 activity. In addition to this CXR9 was shown to exert no cytotoxic effect on paediatric glioma cells.  
Our current understanding is that antagonism of HOX-PBX dimerization cause apoptosis through various death pathways (Figure 1.30). To further investigate this a panel of known and unknown HOX-PBX sensitive genes were assessed post HTL00-1 treatment. Results showed that HTL00-1 caused a significant increase in 
C-Fos mRNA and protein expression post treatment. This was accompanied by a decrease in Bcl-2 mRNA and protein expression. No changes in C-Jun, EGR1 or Bcl-
XL were detected.  These results show a link between C-Fos and Bcl-2 expression. 
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Currently no direct binding sites have been found between C-Fos or Bcl-2. Therefore the mechanism that represses Bcl-2  is believed to be transcriptionally based as Bcl-2 mRNA levels decrease following C-Fos induction. Current literature has shown direct HOX protein activity at Bcl-2 promoter sites, directly linking HOX expression with Bcl-2 expression [478, 481, 547, 548]. A potential mechanism is that loss of HOX-PBX dimers results in the loss of Bcl-2 expression leading to apoptosis. In addition to this, the increase in C-Fos causes dimerization with C-Jun to form the AP-1 complex. This complex can then directly or indirectly inhibit Bcl-
2 transcription. An alternative or additive pathway is the inhibition of C-Jun mediated Bcl-2 transcription. C-Jun in the absence of C-Fos is a Bcl-2 transcription factor [541]. Thus once C-Fos transcription increases, and AP-1 complex forms, C-Jun mediated Bcl-2 transcription is lost. The exact mechanism by which HOX-PBX inhibition results in increased C-Fos expression is not addressed in this work. C-
Fos is an early response gene induced in response to many different types of cellular stress. Recent evidence has shown HOX-PBX complexes directly suppress 
C-Fos expression through promoter inhibition, and indirectly by miRNA up regulation [391]. Figure 4.15 depicts the potential new additions to the proposed death pathway induced by HOX-PBX inhibition. Further work is needed to fully understand the dynamic signalling mechanisms that are utilised once HOX-PBX dimerization is inhibited.  
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Figure 4.15: Diagram showing the proposed mechanism of action of HTL00-1. HOX-PBX dimers promote and suppress target genes such as C-Fos and Bcl-2 respectively. C-
Fos suppression is mediated by miRNAs. Once HOX-PBX dimerization is inhibited, C-Fos expression is increased leading to dimerization with C-Jun to form the AP-1 
complex. AP-1 indirectly inhibits Bcl-2 expression, while loss of C-Jun monomers also contributes to loss of Bcl-2 expression. Loss of Bcl-2 leads to loss of mitochondria 
membrane integrity and activation of caspase 3/7, leading to apoptosis.   
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4.5 Chapter 4 Conclusion Aberrant HOX expression has been reported in paediatric glioma. However, to date no study has comprehensively investigated expression of all 39 HOX genes. We present results that details aberrant HOX expression in paediatric cell lines across all HOX clusters. This is accompanied by overexpression of TALE genes such as PBX1-3 and MEIS2-3. This aberrant expression is targetable with HOX-PBX inhibitors HXR9 and HTL00-1, resulting in apoptotic cell death. This apoptotic cell death is mediated through caspase 3 and caspase 7 activation, as seen for adult GBM cells treated with HXR9. HTL00-1, our 2nd generation peptide therapy, is a more potent therapeutic agent when compared to HXR9. This is deemed to be due to its improved solubility, more neutral pH and its reduction of steric hindrance of polyarginine repeat sequence using a linker region.  
Young children, aged 0-4 year, were found to express high levels of HOX genes. This expression was spread across all HOX clusters, with expression patterning not resembling that seen in the developing foetus. General TALE expression was low in all age groups, with the exception of MEIS3, which persisted into early adulthood. As HOX and TALE gene expression profiles do not match, it is believed that HOX-PBX dimers are being utilised by the developing brain, and rather HOX monomers, and MEIS3 HOX independent complex are used instead. HOX and MEIS protein functionality in the developing brain is yet to be fully determined, but work, though not currently planned, might be able to reveal their importance. With HXR9 and HTL00-1 unable to bind MEIS3, its functions will be unhindered by prospected peptide therapy. In addition, the knowledge that certain neural functions are influenced by HOX monomers alone allows for HXR9 and HTL00-1 therapy to be regarded as a potential novel agent in the treatment of paediatric 
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gliomas. In the unlikely event that HOX-PBX inhibition is detrimental to cognitive development, a treatment cut off of 4 years can be implemented, still allowing for older children and adolescents to benefit from the therapeutic benefits offered by HXR9 and HTL00-1.  
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5 Investigating ICT9119 Cytotoxic Capability in 
Adult GBM Cell Lines, and It’s Synergistic 
potential with Radiotherapy 
5.1 Chapter 5 Introduction  HXR9 has been successfully proven to be a potent cytotoxic agent in the treatment of various cancers both in vitro and in vivo [369, 370, 391, 421, 498-500]. Furthermore, work detailed in this thesis has demonstrated cytotoxic and cytostatic potential of HXR9, both in vitro and in vivo, in the treatment of adult and paediatric GBM. Peptide therapeutics generally share key benefits such as high target binding specificity, low to no side effects, low production costs, and low to no patient acquired resistance [549-551]. However, major obstacles in the development of peptides still persist. Obstacles include; the potential to elicit an immune response against themselves, the need for special storage, short half-life due to rapid degradation by proteolytic enzymes of the digestive system and blood plasma, rapid clearance from blood circulation by the liver and kidneys, high conformational flexibility and low oral bioavailability [549, 550]. Low oral bioavailability is due to the main molecular distribution pathways: 
Intravenous Injection: Right ventricle (heart), lungs, left ventricle (heart) followed by organ delivery (brain, liver, intestines, muscles, kidneys etc [552].  
Orally Administered: Stomach, intestine, liver, blood, kidneys then tissues and organs [552].  
Intravenous or intratumoural injections require trained staff, incurring increased costs of treatment and potential need for hospitalisation of patients. The short half-life of peptides also indicates the need for frequent administration of 
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treatment, further increasing the cost. Oral administration subjects peptides to strongly acidic gastric environments, high intestinal proteolytic activities and high intestinal permeability barriers [553]. Figure 5.1 [551] shows Strength, 
Weakness, Opportunity, Treats (SWOT) analysis for peptide therapies.  
Figure 5.1 [551]: SWOT analysis of peptide therapies.  
Though efforts have been made to reduce these shortfalls in the development of HXR9 and HTL00-1, certain inherent issues will always persist. Such issues include short half-life, which is known to be around 12 hours in serum [419], and their inability to be delivered orally. These drawbacks are due to degradation by proteolytic enzymes. Table 5.1 lists the potential enzymes able to target HXR9 and HTL00-1. A solution to this would be to develop a small molecular mimic of HXR9 and HTL00-1. This has been previously attempted by an independent group, but due to poor Kd values, the drug development was abandoned [494].  
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Table 5.1: Table listing all potential enzymes able to cleave HXR9 and HTL00-1. 
HXR9 
Enzyme Number of Cleavage Sites Position of Cleavage Sites Arg-C proteinase 9 10, 11, 12, 13, 14, 15, 16, 17, 18 BNPS-Skatole 2 1,4 Cyanogen Bromide 1 5 Chymotrypsin-high 1 1 Chymotrypsin-low 4 1, 5, 8, 9 Clostripain 9 10, 11, 12, 13, 14, 15, 16, 17, 18 Iodosobenzoic acid 2 1, 4 Lysyl endopeptidase  2 6, 7 Peptidyl-Lys metalloendopeptidase  2 5, 6 Pepsin 2 2, 3 Proteinase K 3 1, 2, 4 Thermolysin 1 4 Trypsin 4 6, 7, 10, 18 
HTL00-1 
Enzyme Number of Cleavage Sites Position of Cleavage Sites Arg-C proteinase 9 10, 11, 12, 13, 14, 15, 16, 17, 18 BNPS-Skatole 2 1,4 Cyanogen Bromide 1 5 Chymotrypsin-high 2 1, 2 Chymotrypsin-low 3 1, 2, 5 Clostripain 9 10, 11, 12, 13, 14, 15, 16, 17, 18 Iodosobenzoic acid 2 1, 4 Lysyl endopeptidase  3 3, 6, 7 Peptidyl-Lys metalloendopeptidase  3 2, 5, 6 Pepsin 4 1, 2, 3, 4 Proteinase K 5 1, 2, 4, 8, 9 Thermolysin 3 4, 7, 8 Trypsin 5 3, 6, 7, 10, 18   
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Small molecules E4 and ICT9119 were designed to build off the original success of HXR9 and HTL00-1, but without any of the draw backs associated with peptide therapies. This means it is essential that any potential small molecule possess comparable IC50 values, a similar cellular death pathway, and a similar mode of death.  
Standard therapy used in the treatment of malignant gliomas, grade III-IV, consists of surgical resection followed by adjuvant RT and TMZ treatment [25, 152]. This treatment regime provides a mean life expectancy for GBM patients of 15 months. With clinical use as the major goal for any new cancer therapeutic, it is important to identify potential treatment combinations and regimes. Without this no drug would gain Food and Drug Administration (FDA), or National Institute for Health and Clinical Excellence (NICE) approval. With this in mind, it is essential to identify potential synergistic partners for HOX-PBX inhibitors, as well as determine the most effect treatment regime. Furthermore, if any synergy were established, it would be beneficial to identify the exact mechanism utilised.  With this vital information it then would be possible to identify further potential synergistic partners.  
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5.2 Chapter 5 Objectives The main objective of this chapter was to compare the cytotoxic potential of ICT9119 and E4 with HXR9 as therapeutic treatment for adult GBM. In order to test this, the following experiments were performed: 
1. Comparison of ICT9119 and E4 vs HXR9 IC50 values, on a panel of adult GBM cell lines, in vitro by MTS assay. 2. Analysis of ICT9119’s cell death using annexin V/7-AAD dual staining and caspase 3/7 immunofluorescent staining.  3. Assessment of ICT9119 and HXR9’s death pathway via RT-qPCR and western blot assay. 4. Comparison of TMZ vs RT IC50 values, on a panel of adult GBM cell lines, to determine the best potential synergistic partner for ICT9119. 5. To establish if any potential synergy is possible between RT and ICT9119 treatment via MTS assay.  6. To investigate any potential mechanism between potential synergy between RT and ICT9119 treatment.  
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5.3 Chapter 5 Results 
5.3.1 Comparing ICT9119, E4 and HXR9 Cytotoxicity in GBM Cell Lines  
Small molecule targeting of HOX-PBX dimers in adult GBM cells is more 
effective than HXR9. To determine sensitivity to small molecules E4 and ICT9119, adult parental cell lines were treated with varying doses of drug to determine their IC50 values (Table 
5.2). All cell lines showed dose dependent cytotoxicity following E4 and ICT9119 treatment (Figure 5.2 A|, B|, C|). ICT9119 displayed the highest cytotoxicity in all cell lines with the lowest IC50 values when compared to HXR9 and E4. LN18 had the greatest increase in cytotoxicity between HXR9 and E4 sensitivity, IC50 62μM and 56μM respectively, when compared to ICT9119, IC50 14μM (Figure 5.2 A|). In a similar fashion, U87-MG HXR9 IC50, 31μM, and E4 IC50, 31μM, was higher than ICT9119 IC50 at 20μM (Figure 5.2 B|). U251-MG follows this general trend with ICT9119’s IC50 value, 41μM, being the lowest, however the difference between HXR9, 47μM, and E4, 49μM, was not as dramatic (Figure 5.2 C|). Two-way ANOVA tabular results indicate P****<0.0001 between column factors in all cell lines. Two-way ANOVA statistical results can be seen in (Figure 5.2 A|, B|, C|). No solvent control, DMSO, cytotoxicity was seen (Data not shown). 
Table 5.2: IC50 concentrations for GBM cell lines treated with HXR9, E4 or ICT9119 
Cell Line HXR9 (μM) E4 (μM) ICT9119 (μM) 
LN18 62 56 14 
U87-MG 31 54 20 
U251-MG 47 49 41 
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LN18 Dose (μM) Tukey's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value 
5 
E4 vs. ICT9119 24.07 20.93 to 27.21 Yes **** <0.000001 E4 vs. HXR9 -5 -8.144 to -1.856 Yes *** 0.000645 ICT9119 vs. HXR9 -29.07 -32.21 to -25.93 Yes **** <0.000001 
10 
E4 vs. ICT9119 31.16 28.01 to 34.3 Yes **** <0.000001 E4 vs. HXR9 1.08 -2.064 to 4.224 No ns 0.69726 ICT9119 vs. HXR9 -30.08 -33.22 to -26.94 Yes **** <0.000001 
15 
E4 vs. ICT9119 44.49 41.34 to 47.63 Yes **** <0.000001 E4 vs. HXR9 2 -1.144 to 5.144 No ns 0.292605 ICT9119 vs. HXR9 -42.49 -45.63 to -39.34 Yes **** <0.000001 
20 
E4 vs. ICT9119 67.8 64.66 to 70.95 Yes **** <0.000001 E4 vs. HXR9 0 -3.144 to 3.144 No ns >0.999999 ICT9119 vs. HXR9 -67.8 -70.95 to -64.66 Yes **** <0.000001 
25 
E4 vs. ICT9119 75.45 72.31 to 78.6 Yes **** <0.000001 E4 vs. HXR9 4 0.8561 to 7.144 Yes ** 0.008346 ICT9119 vs. HXR9 -71.45 -74.6 to -68.31 Yes **** <0.000001 
30 
E4 vs. ICT9119 67.71 64.56 to 70.85 Yes **** <0.000001 E4 vs. HXR9 -0.4192 -3.563 to 2.725 No ns 0.946964 ICT9119 vs. HXR9 -68.13 -71.27 to -64.98 Yes **** <0.000001 
60 
E4 vs. ICT9119 41.29 38.15 to 44.44 Yes **** <0.000001 E4 vs. HXR9 -10.15 -13.3 to -7.011 Yes **** <0.000001 ICT9119 vs. HXR9 -51.45 -54.59 to -48.3 Yes **** <0.000001 
80 
E4 vs. ICT9119 25.69 22.55 to 28.84 Yes **** <0.000001 E4 vs. HXR9 -12.36 -15.5 to -9.212 Yes **** <0.000001 ICT9119 vs. HXR9 -38.05 -41.19 to -34.9 Yes **** <0.000001 
100 
E4 vs. ICT9119  17.64 14.5 to 20.78 Yes **** <0.000001 E4 vs. HXR9 -12.9 -16.04 to -9.752 Yes **** <0.000001 ICT9119 vs. HXR9 -30.54 -33.68 to -27.39 Yes **** <0.000001 
120 
E4 vs. ICT9119  5.032 1.888 to 8.176 Yes *** 0.00059 E4 vs. HXR9 -20.96 -24.11 to -17.82 Yes **** <0.000001 ICT9119 vs. HXR9 -25.99 -29.14 to -22.85 Yes **** <0.000001  
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B| U87-MG 
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U87-MG  Dose (μM) Tukey's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value 
10 
E4 vs. ICT9119 13.05 8.711 to 17.38 Yes **** <0.000001 E4 vs. HXR9 -13.42 -17.76 to -9.084 Yes **** <0.000001 ICT9119 vs. HXR9 -26.47 -30.81 to -22.13 Yes **** <0.000001 
20 
E4 vs. ICT9119 43.06 38.72 to 47.4 Yes **** <0.000001 E4 vs. HXR9 10 5.663 to 14.34 Yes **** <0.000001 ICT9119 vs. HXR9 -33.06 -37.4 to -28.72 Yes **** <0.000001 
30 
E4 vs. ICT9119 60.85 56.51 to 65.18 Yes **** <0.000001 E4 vs. HXR9 38.66 34.32 to 43 Yes **** <0.000001 ICT9119 vs. HXR9 -22.19 -26.52 to -17.85 Yes **** <0.000001 
40 
E4 vs. ICT9119 58.62 54.28 to 62.96 Yes **** <0.000001 E4 vs. HXR9 34 29.66 to 38.34 Yes **** <0.000001 ICT9119 vs. HXR9 -24.62 -28.96 to -20.28 Yes **** <0.000001 
50 
E4 vs. ICT9119 48.46 44.12 to 52.8 Yes **** <0.000001 E4 vs. HXR9 26 21.66 to 30.34 Yes **** <0.000001 ICT9119 vs. HXR9 -22.46 -26.8 to -18.12 Yes **** <0.000001 
60 
E4 vs. ICT9119 35.96 31.63 to 40.3 Yes **** <0.000001 E4 vs. HXR9 27.08 22.74 to 31.42 Yes **** <0.000001 ICT9119 vs. HXR9 -8.884 -13.22 to -4.547 Yes **** 0.000008 
80 
E4 vs. ICT9119 24.38 20.04 to 28.71 Yes **** <0.000001 E4 vs. HXR9 15.01 10.67 to 19.35 Yes **** <0.000001 ICT9119 vs. HXR9 -9.365 -13.7 to -5.028 Yes **** 0.000002 
100 
E4 vs. ICT9119 10.08 5.739 to 14.41 Yes **** <0.000001 E4 vs. HXR9 3.863 -0.4742 to 8.2 No ns 0.091805 ICT9119 vs. HXR9 -6.214 -10.55 to -1.876 Yes ** 0.00246 
120 
E4 vs. ICT9119 1.243 -3.094 to 5.581 No ns 0.777347 E4 vs. HXR9 -3.658 -7.995 to 0.6789 No ns 0.11696 ICT9119 vs. HXR9 -4.902 -9.239 to -0.5646 Yes * 0.022324   
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C| U251-MG 
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U251-MG  Dose (μM) Tukey's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value 
10 
E4 vs. ICT9119 -12.95 -17.02 to -8.89 Yes **** <0.000001 E4 vs. HXR9 6.846 2.783 to 10.91 Yes *** 0.00028 ICT9119 vs. HXR9 19.8 15.74 to 23.86 Yes **** <0.000001 
20 
E4 vs. ICT9119 -34 -38.07 to -29.94 Yes **** <0.000001 E4 vs. HXR9 4 -0.06293 to 8.063 No ns 0.054708 ICT9119 vs. HXR9 38 33.94 to 42.07 Yes **** <0.000001 
30 
E4 vs. ICT9119 -23.53 -27.6 to -19.47 Yes **** <0.000001 E4 vs. HXR9 -1.071 -5.134 to 2.992 No ns 0.808269 ICT9119 vs. HXR9 22.46 18.4 to 26.53 Yes **** <0.000001 
40 
E4 vs. ICT9119 2.64 -1.423 to 6.703 No ns 0.277412 E4 vs. HXR9 5 0.9371 to 9.063 Yes * 0.011285 ICT9119 vs. HXR9 2.36 -1.703 to 6.423 No ns 0.357931 
50 
E4 vs. ICT9119 41.86 37.8 to 45.92 Yes **** <0.000001 E4 vs. HXR9 5 0.9371 to 9.063 Yes * 0.011285 ICT9119 vs. HXR9 -36.86 -40.92 to -32.8 Yes **** <0.000001 
60 
E4 vs. ICT9119 35.15 31.09 to 39.21 Yes **** <0.000001 E4 vs. HXR9 -2.286 -6.349 to 1.777 No ns 0.38141 ICT9119 vs. HXR9 -37.43 -41.5 to -33.37 Yes **** <0.000001 
80 
E4 vs. ICT9119 29.66 25.6 to 33.72 Yes **** <0.000001 E4 vs. HXR9 -2.228 -6.291 to 1.834 No ns 0.399846 ICT9119 vs. HXR9 -31.89 -35.95 to -27.82 Yes **** <0.000001 
100 
E4 vs. ICT9119 19.93 15.86 to 23.99 Yes **** <0.000001 E4 vs. HXR9 -1.761 -5.824 to 2.302 No ns 0.563153 ICT9119 vs. HXR9 -21.69 -25.75 to -17.63 Yes **** <0.000001 
120 
E4 vs. ICT9119 2.856 -1.207 to 6.919 No ns 0.223418 E4 vs. HXR9 -14.74 -18.81 to -10.68 Yes **** <0.000001 ICT9119 vs. HXR9 -17.6 -21.66 to -13.54 Yes **** <0.000001 
Figure 5.2: E4, ICT9119 and HXR9 dose response curves and two-way ANOVA analysis table for A| LN18, B| U87-MG, C| U251-MG. P*<0.05, P**<0.01, P***<0.001, 
P****<0.0001 comparing HXR9, E4 and ICT9119 treatments.  
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5.3.2 Determination of ICT9119 Mode of Death 
ICT9119 treatment causes changes in membrane marker expression and 
membrane integrity characteristic of apoptosis. To determine whether ICT9119 induces cell death through apoptosis, an initial annexin V/7-AAD dual staining assay was performed. All cell lines showed a significant increase in apoptosis when treated with ICT9119 compared to both DMSO treated and untreated cells (Figure 5.3). High levels of dual annexin V/7-AAD staining was detected in all cell lines, signifying the majority of cells were in late stages of apoptosis. No significant difference in apoptosis between untreated and DMSO treatment for all cell lines was seen.  
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Figure 5.3: The percentage of annexin V/7-AAD dual positive (apoptosis) cells for LN18, U87-MG, 
U251-MG. All cell lines showed significantly increased levels of apoptosis following ICT9119 
treatment compared to both untreated and DMSO treated cells. Error bars show standard deviation 
of the mean. P**<0.01, P***<0.001, P****<0.0001 comparing ICT9119 treatment with untreated cells. 
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Adult GBM cells positively stain for cleaved caspase 3 and caspase 7 proteins 
when treated with ICT9119. All parental adult GBM cell lines were assessed for caspase 3 and caspase 7 activity using CellEvent™ Caspase-3/7 Green ReadyProbes™. NucBlue™ Live ReadyProbes™ was used to counter stain cell nuclei blue for visualisation. All parental adult GBM cells treated with ICT9119 displayed green fluorescent staining, indicating caspase 3/7 activity, in both the cytoplasm and nucleus of cells (Figure 5.4 A|, B|, C|). No caspase activity was detected in DMSO treated cells. NucBlue™ staining caused some necrosis in cell lines but need not induce false positive caspase 3/7 staining. Bright field images showed the appearance of healthy cells in DMSO treated cells, while ICT9119 cells have characteristic appearance of cells undergoing apoptosis. 
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Figure 5.4: Caspase 3 and caspase 7 activity visualised by fluorescent probes in A| LN18, B| U87-MG and C| U251-MG. ICT9119 treated cells displayed caspase 3 and caspase 
7 activations following treatment (Green fluorescent stain), while no caspase activation was seen in DMSO treated cells. Blue stain indicates cell nuclei. Magnification 20x.  
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5.3.3 Comparison Between ICT9119 and HXR9 Death Pathway 
ICT9119 and HXR9 treatment causes up regulation of C-Fos gene expression, 
and a down regulation of Bcl-2 expression. Immediate early genes C-Fos, EGR1 and C-Jun were selected from a panel of genes previously shown to be up regulated following HXR9 treatment and for their relevance shown in HTL00-1 mediated death (Section 4.3.7)[419]. Anti-apoptotic genes Bcl-2 and Bcl-XL were included because of their interconnection with the aforementioned genes in the role of apoptosis. RT-qPCR results showed that following ICT9119 and HXR9 treatment, C-Fos expression is rapidly induced in all adult GBM cell lines (Figure 5.5). No correlation was present between C-Fos expression post treatment, and sensitivity to HXR9 or ICT9119 treatment. Cell lines U87-MG and U251-MG expressed significantly increased levels of EGF1 mRNA post HXR9 and ICT9119 treatment when compared to untreated cells. LN18 did not show any changes in EGR1 expression post treatment. In contrast, all cell lines showed significant down regulation of Bcl-2 gene expression post HXR9 and ICT9119 treatment when compared to untreated cells. No correlation between Bcl-2 expression change and sensitivity to HXR9 or ICT9119 was evident. However, an inverse relation between the amount of C-Fos induction and Bcl-2 suppression is present. C-Jun and Bcl-XL was unaltered following HXR9 or ICT9119 treatment.  
     
  281 
C-
Fo
s
EG
R1
C-
Ju
n
Bc
l-2
Bc
l-X
L
0
100
200
300
400
N
or
m
al
is
ed
 to
β-
ac
tin
***
**
**
**
**
**
***
**
**
**
****
***
***
**
****
LN18 Unt
LN18 ICT9119
LN18 HXR9
U87-MG Unt
U87-MG ICT9119
U87-MG HXR9
U251-MG Unt
U251-MG ICT9119
U251-MG HXR9
 
Figure 5.5: Gene expression of C-Fos, EGR1, C-Jun, Bcl-2 and Bcl-XL in adult GBM cell lines treated with 
HXR9 or ICT9119. All cell lines displayed a distinct up regulation of C-Fos expression, accompanied by 
a down regulation in Bcl-2 expression following HXR9 or ICT9119 treatment. No significant difference 
in C-Jun or Bcl-2 expression was observed. The expression of each gene is presented relative to the 
house keeping gene β-actin (x10,000). Each test was performed in triplicate and error bars represent 
standard deviation of the mean. P**<0.01, P***<0.001, P****<0.0001 comparing HXR9 or ICT9119 
treated cells with untreated cells.   
HXR9 and ICT9119 treatment causes an increase in C-Fos protein 
expression, while Bcl-2 protein levels decrease.  Proteins levels of C-Fos, EGR1, C-Jun, Bcl-2 and Bcl-XL were determined via western blot assay. C-Fos protein levels were shown to be up regulated in all cell lines following HXR9 and ICT9119 treatment compared to untreated cells (Figure 
5.6). This up regulation was accompanied by a reduction in Bcl-2 expression in HXR9 and ICT9119 treated cells compared to untreated cells. This generally followed the trend seen in gene expression, but there was no correlation between gene expression levels and proteins levels for either Bcl-2 or C-Fos. EGR1 
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expression increased in both U87-MG and U251-MG cell lines following treatment. No change in EGR1 expression was seen in LN18. C-Jun and Bcl-XL protein levels remained stable post HXR9 and ICT9119 treatment. All cells expressed varying levels of C-Fos binding partner, C-Jun, in untreated cells.  
 
Figure 5.6: Protein expression of C-Fos, C-Jun, EGR1, Bcl-2 and Bcl-XL in adult GBM cell lines following 
HXR9 or ICT9119 treatment. C-Fos protein levels increased in all cell lines following HOX-PBX 
inhibition. This increase was accompanied by a decrease in protein expression of Bcl-2. No detectable 
change C-Jun or Bcl-XL was observed. 
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5.3.4 Evaluation of a Potential Synergistic Partner for ICT9119 
Radiotherapy provides a more suitable synergistic partner for ICT9119 
treatment compared to TMZ ICT9119 was selected for synergy assays as it demonstrated increased cytotoxicity compared to HXR9, with the additional benefit of increased long-term stability. With RT and TMZ treatment currently the most widely utilised treatment modalities, they were selected as potential synergistic partners for ICT9119. First adult GBM cell lines were assessed for their sensitivity to TMZ and RT treatment. MTS assay was used to determine cell line IC50 values. (Table 5.3). Cell lines LN18, IC50 243μM, and U251-MG, IC50278μM, showed sensitivity to TMZ treatment alone, while U87-MG was shown to be highly resistant, IC50 823μM (Figure 5.7 A|). CSC cell lines were tested for TMZ sensitivity and were found to be more resistant to TMZ treatment alone when compared to their parental cell lines (Supplementary 
Figure 6). All adult GBM cell lines were sensitive to RT treatment (Figure 5.7 B|). As TMZ resistance was seen in U87-MG and all cell lines were shown to be sensitive to RT treatment, it was decided to use RT as a potential synergistic partner for HOX-PBX inhibition. As cells need to undergo a 120 hour incubation time, and HXR9 has been shown to have a half life of approximately 12 hours, it was decided ICT9119 was the most appropriate treatment to use.    
Table 5.3: IC50 values for GBM cell lines treated with TMZ or RT 
Cell Line TMZ (μM) RT (Gy) LN18 243 4 U251-MG 278 8 U87-MG 823 8 
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Figure 5.7: Dose response curves for adult GBM cell lines treated with A| TMZ and B| RT. LN18 and 
U251-MG were shown to be sensitive to TMZ treatment, while U87-MG was highly resistant. All cell 
lines tested were sensitive to RT treatment.  
A| 
B| 
50 10
0
30
0
60
0
80
0
10
00
0
20
40
60
80
100
120
Temozolomide (µM)
%
 S
ur
vi
va
l
LN18
U87-MG
U251-MG
0 1 2 4 8 16
0
20
40
60
80
100
120
Dose (Gy)
%
 S
ur
vi
va
l
LN18
U87-MG
U251-MG
  285 
5.3.5 Investigating Potential Synergy Between Radiotherapy and 
ICT9119 
ICT9119 is a moderate radiosensitiser, with low levels of synergy seen when 
GBM cells are pre-treated before irradiation.  Initial synergy experiments were designed using ICT9119 as a potential radiosensitiser. This was due to current literature reporting contribution of individual HOX genes in the repair of DNA in response to various genomic stresses [392, 554, 555]. To test this, cells were pre-treated with ICT9119 for 24 hours prior to RT. A general trend emerged showing ICT9119-RT treatment was generally antagonistic, though randomly distributed pockets of low synergy was seen in all cells (Figure 5.8, 5.9, 5.10). LN18 displayed the lowest amount of synergy between cell lines tested (Figure 5.8, Table 5.4). This low synergy was visible only when cells were pre-treated with 20, 25 or 30μM of ICT9119, and with 1 Gy of RT. The highest level of synergy in LN18 was between 30μM of ICT9119 and 1 Gy of RT. U87-MG displayed the highest synergy, with 2 clear ‘veins’ of synergy seen (Figure 5.9, Table 5.5). These synergy ‘veins’ are observed between RT 2 Gy and all ICT9119 doses, bar 20μM, and ICT9119 30μM with RT 1, 2, and 4 Gy. Highest levels of synergy were between ICT9119 30μM and RT 2 Gy, while highest antagonistic effect was between ICT9119 20μM and RT 2 Gy. U251-MG had 2 clear pockets of synergy between ICT9119 and RT (Figure 5.10, Table 5.6). 
These pockets are visible at 20μM of ICT9119 with RT 2 and 4 Gy, and another pocket at 50 and 60μM with RT 1, 2 and 4 Gy. All cell lines had individual synergy profiles. However, U87-MG and U251-MG both shared synergy around ICT9119 
doses 20 and 30μM. A growth rebound was present at 30μM of ICT9119 in cell lines LN18 and U251-MG.  
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Figure 5.8: Combination treatment for LN18 with varying ICT9119 doses 24 hours prior to RT. A| dose response curves for LN18 cells treated with ICT9119 prior to RT. B| 
Contour map plotting the ΔE values determined via Bliss Analysis to visualise synergistic and antagonistic combinations. Results indicate synergy is only present at RT 1 
Gy with ICT9119 at 20, 25 and 30μM. 
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Table 5.4: Interaction between ICT9119 and RT was assessed via Bliss Analysis. ΔE values and upper and lower confidence intervals are displayed and colour coded to 
show levels of synergy.  
 ICT9119 (μM) 
5 10 15 20 25 30 
Ra
di
ot
he
ra
py
 (G
y)
 
1 
ΔE -14.45% -11.73% -3.14% 0.85% 1.65% 15.13% 
Upper CI -8.65 -0.95 3.59 22.24 8.63 21.84 
Lower CI -20.13 -22.51 -9.87 -20.54 -5.33 8.42 
2 
ΔE -18.26% -11.84% -12.64% -12.69% -7.52% -12.46% 
Upper CI -11.22 -7.21 -0.97 1.67 -1.9 1.74 
Lower CI -25.3 -16.47 -24.31 -27.05 -13.14 -26.66 
4 
ΔE -9.09% -18.48% -12.72% -16.24% -8.64% -11.15% 
Upper CI -3.66 -14.26 0.59 -8.44 -1.82 -2.37 
Lower CI -14.52 -22.7 -26.03 -24.04 -15.46 -19.93   
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Figure 5.9: Combination treatment for U87-MG with varying ICT9119 doses 24 hours prior to RT. A| dose response curves for U87-MG cells treated with ICT9119 prior to 
RT. B| Contour map plotting the ΔE values determined via Bliss Analysis to visualise synergistic and antagonistic combinations. Results indicate synergy is present at RT 2 
Gy with ICT9119 at 10, 30, 40, 50 and 60μM.  
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Table 5.5: Interaction between ICT9119 and RT was assessed via Bliss Analysis. ΔE values and upper and lower confidence intervals are displayed and colour coded to 
show levels of synergy. 
 
ICT9119 (μM) 
10 20 30 40 50 60 
Ra
di
ot
he
ra
py
 (G
y)
 
1 
ΔE -1.23% -7.53% 4.55% -1.65% -1.09% -0.55% 
Upper CI  4.21 -0.14% 17.7 4.77 4.26 1.88 
Lower CI -6.67 -14.92 -8.6 -8.07 -6.44 -2.98 
2 
ΔE 7.04% -21.50% 11.99% 0.07% 0.63% 0.51% 
Upper CI 14.03 -11.26 20.68 4.58 1.7 0.83 
Lower CI 0.05 -31.74 3.3 -4.44 -0.44 0.19 
4 
ΔE -11.78% -17.29% 7.20% 0.74% -2.07% 5.05% 
Upper CI -2.19 -12.68 11.59 7.83 1.44 8.46 
Lower CI -21.37 -21.9 2.81 -6.35 -5.58 1.64 
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Figure 5.10: Combination treatment for U251-MG with varying ICT9119 doses 24 hours prior to RT. A| dose response curves for U251-MG cells treated with ICT9119 prior 
to RT. B| Contour map plotting the ΔE values determined via Bliss Analysis to visualise synergistic and antagonistic combinations. Synergy is present at all RT doses with 
ICT9119 at 20, 50 or 60μM. 
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Table 5.6: Interaction between ICT9119 and RT was assessed via Bliss Analysis. ΔE values and upper and lower confidence intervals are displayed and colour coded to 
show levels of synergy. 
 
ICT9119 (μM) 
10 20 30 40 50 60 
Ra
di
ot
he
ra
py
 (G
y)
 
1 
ΔE -11.23% -3.10% -28.07% -1.35% 2.25% -0.15% 
Upper CI -5.95 5.9  -20.37 3.63 7.78 1.18 
Lower CI -16.51 -12.1 -35.77 -6.33 -3.28 -1.48 
2 
ΔE -28.25% 1.50% -28.33% -10.85% 0.55% 0.35% 
Upper CI -21.45 11.84 -8.26 -5.64 7.11 1.19 
Lower CI -35.05 -8.84 -48.4 -16.06 -6.01 -0.49 
4 
ΔE -28.21% 16.28% -38.84% -7.23% 7.55% 10.30% 
Upper CI -23.62 24.09 -30.15 -0.54 8.09 10.42 
Lower CI -32.8 8.47 -47.53 -13.92 7.01 10.18  
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Radiotherapy sensitises cells for ICT9119 treatment, producing high levels 
of synergy. Following the inconclusive results of ICT9119-RT synergy assays, it was decided to reverse treatment sequences to test whether RT sensitises cells to ICT9119 treatment. To investigate this, cells were initially irradiated and then followed 24 hours after with ICT9119 treatment. All cell lines exhibited high levels of synergy across all dosages when sequentially treated with RT-ICT9119 (Figure 5.11, 5.12, 
5.13). LN18 had the lowest synergy compared to other tested cell lines, but showed almost universal synergy across all RT and ICT9119 combinations (Figure 5.11, Table 5.7). Highest synergy was obtained using RT 4 Gy combined with ICT9119 between 5-25μM. High levels of synergy was seen in U87-MG cells treated with all doses of RT and ICT9119 (Figure 5.12, Table 5.8). A clear divide in synergy profiles show that high RT was more synergistic with low ICT9119 dose and vice versa. U251-MG displayed the highest levels of synergy between RT and ICT9119 (Figure 5.13, Table 5.9). Similar for U87-MG, the highest level of synergy was reached when opposing levels or RT and ICT9119 was combined. All cell lines treated have the best synergy when combining various doses of ICT9119 with RT 4 Gy (Table 5.10).  
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Figure 5.11: Combination treatment for LN18 cells with varying RT Gy 24 hours prior to ICT9119 doses. A| dose response curves for LN18 cells treated with RT prior to 
ICT9119. B| Contour map plotting the ΔE values determined via Bliss Analysis to visualise synergistic and antagonistic combinations. High synergy is present at all RT 
doses with ICT9119, with the exception of RT 1 Gy ICT9119 at 15μM. 
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Table 5.7: Interaction between ICT9119 and RT was assessed via Bliss Analysis. ΔE values and upper and lower confidence intervals are displayed and colour coded to 
show levels of synergy. 
 
ICT9119 (μM) 
5 10 15 20 25 30 
Ra
di
ot
he
ra
py
 (G
y)
 
1 
ΔE 3.29% 1.77% -4.57% 1.97% 5.49% 5.07% 
Upper CI 10.39 7.39  2.98 10.21 11.53 9.86 
Lower CI -3.81 -3.85 -12.12 -6.27 -0.55  0.28 
2 
ΔE 18.41% 7.21% 5.25% 4.06% 5.64% 7.37% 
Upper CI 25.07 13.22 7.57 7.32  9.23 8.57 
Lower CI 11.75 1.2 2.93 0.8 2.05 6.17 
4 
ΔE 34.00% 34.79% 33.88% 41.01% 29.08% -0.95% 
Upper CI 44.46 42.11 36.36 48.42 29.64  1.06 
Lower CI 23.54 27.47 31.4 33.6 28.52 -2.97   
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Figure 5.12: Combination treatment for U87-MG cells with varying RT Gy 24 hours prior to ICT9119 doses. A| dose response curves for U87-MG cells treated with RT prior 
to ICT9119. B| Contour map plotting the ΔE values determined via Bliss Analysis to visualise synergistic levels between various treatment combinations. High synergy is 
present at all RT doses with ICT9119. RT 2 Gy ICT9119 high dose, and RT 4 Gy ICT9119 low dose provided the best synergy. 
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Table 5.8: Interaction between ICT9119 and RT was assessed via Bliss Analysis. ΔE values and upper and lower confidence intervals are displayed and colour coded to 
show levels of synergy. 
 
ICT9119 (μM) 
10 20 30 40 50 60 
Ra
di
ot
he
ra
py
 (G
y)
 
1 
ΔE 8.39% 22.30% 27.89% 35.16% 38.93% 37.41% 
Upper CI 25.53 33.63 32.77 44.31 42.39 41.35 
Lower CI -8.75 10.97 23.01 26.01 35.47 33.47 
2 
ΔE 32.36% 35.40% 38.90% 41.58% 49.14% 47.43% 
Upper CI 36.99 43.26 53.04 52.03 56.62 51.46 
Lower CI 27.73 27.54 24.76 31.13 41.66 43.4 
4 
ΔE 46.85% 55.70% 42.91% 38.42% 36.03% 47.14% 
Upper CI 82.52 91.04 48.77 45.39 48.91 49.11 
Lower CI 11.18 20.36 37.05 31.45 23.15 45.17   
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Figure 5.13: Combination treatment for U251-MG cells with varying RT Gy 24 hours prior to ICT9119 doses. A| dose response curves for U251-MG cells treated with RT 
prior to ICT9119. B| Contour map plotting the ΔE values determined via Bliss Analysis to visualise synergistic levels between various treatment combinations. High synergy 
is present at all RT doses with ICT9119. Highest synergy was achieved at RT 4 Gy combined with ICT9119 10 or 20μM. 
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Table 5.9: Interaction between ICT9119 and RT was assessed via Bliss Analysis. ΔE values and upper and lower confidence intervals are displayed and colour coded to 
show levels of synergy. 
 
ICT9119 (μM) 
10 20 30 40 50 60 
Ra
di
ot
he
ra
py
 (G
y)
 
1 
ΔE 44.53% 39.06% 30.34% 35.42% 42.33% 45.43% 
Upper CI 54.82 55.45 44.48 49.33 56.24 51.23 
Lower CI 34.24 22.67 16.2 21.51 28.42 39.63 
2 
ΔE 56.25% 64.47% 40.37% 44.42% 56.36% 59.20% 
Upper CI 61.69 72.46 47.17 54.78 66.25 61.32 
Lower CI 50.81 56.48 33.57 34.06 46.47 57.08 
4 
ΔE 69.84% 66.48% 44.62% 43.24% 23.75% 62.43% 
Upper CI 94.43 99.79 85.44 80.84 56.06 64.5 
Lower CI 45.25 33.17 3.8 5.64 -8.56 60.36 
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Table 5.10: Table listing the overview of the synergistic and antagonistic ranges of RT and ICT9119 
treatment.   
Treatment 
Sequence 
Range Best Synergy 
Combination 
Predominant 
Effect Antagonism Synergy 
LN18 
ICT9119-RT -18.48%- -2.14% 0.85%- 15.13% RT 1Gy- ICT 30μM Antagonistic 
RT-ICT9119 -4.57%- -0.95% 1.77%- 41.01% RT 4Gy- ICT 20μM Synergistic 
U87-MG 
ICT9119-RT -21.50%- -0.55% 0.07%- 11.99% RT 2Gy- ICT 30μM Antagonistic 
RT-ICT9119 - 8.39%- 55.70% RT 4Gy- ICT 20μM Synergistic 
U251-MG 
ICT9119-RT -38.84%- -0.15% 0.35%- 16.28% RT 4Gy- ICT 20μM Antagonistic 
RT-ICT9119 - 30.34%- 69.84% RT 4Gy- ICT 10μM Synergistic 
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5.3.6 Identifying Synergistic and Antagonistic Mechanisms Between 
RT-ICT9119 and ICT9119-RT Treatments 
Synergy of RT treatment pre ICT9119 could be due to RT inducing G2/M 
phase cell cycle arrest. Cell cycle synchronisation modulated by RT and ICT9119 was initially analysed to determine whether synergistic and antagonistic mechanisms were cell cycle dependent. To assess this, cells were treated with either 1 or 4 Gy of RT, or IC50 dose of ICT9119, and then analysed for their cell cycle distribution via flow cytometry. For analysis only singlet cells were gated with doublets excluded. 
Supplementary Figure 7 depicts how cells were gated to achieve this.  
All untreated cell lines had similar cell cycle distribution profiles, with the majority of cells in G0/G1 (Figure 5.14 A|, B|, C|). Once treated with either 1 or 4 Gy of RT, cell cycle distribution changes in all cell lines with a reduction of cells in G0/G1 phase, and an increase in cells at G2/M phase. All cell lines, with the exception of U87-MG, showed a dose dependent increase in G2/M phase increase with RT treatment. LN18 displayed the largest change in cell cycle distribution post RT, while U251-MG the least (Figure 5.14 A|, C|). Cells treated with ICT9119 showed a similar shift in cell cycle distribution to RT treated cells. All cell lines had an increase in cells in G2/M phase of the cell cycle, with a decrease in cells in G0/G1. Again LN18 showed the biggest change in cell cycle distribution post ICT9119 treatment, whereas U251-MG had the smallest change (Figure 5.14 A|, C|).  
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Figure 5.14: Cell cycle analysis 24 hours post 1 Gy or 2 Gy of RT, or IC50 dose of ICT9119, for A| LN18, B| U87-MG and C| U251-MG. RT and ICT9119 treatment cause cell cycle 
redistribution in all cell lines tested. This redistribution causes a reduction of cells in G0/G1 phase, accompanied by an increase of cells in G2/M phase. Gates set from left 
to right: Apoptosis, G0-G1, S, G2-M.  
Untreated RT 1 Gy RT 4 Gy ICT9119 
1.72 53.54 21.63 22.63 2.96 52.07 19.42 25.43 0.92 46.84 24.29 27.77 0.77 57.10 18.82 23.18 
C| 
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Synergist effects of RT pre-treatment could be due to a mixture of induction 
and suppression of HOX gene expression. To establish if synergy was due to RT pre-treatment directly affecting HOX transcription, gene expression was assessed post RT treatment. Cells were irradiated with either 1 or 4 Gy of RT before their total RNA was collected at 24 and 72 hours after treatment.  Once collected, HOX gene expression was assessed via RT-qPCR. Initial assessment of results reveals very little change in HOX gene expression with 1 or 4 Gy RT at either 24 or 72 hours post treatment (Figure 5.15, 
5.16, 5.17). However, more in depth analysis showed that statistically significant changes were present (Table 5.11, 5.12).  
LN18 cells show no statistical difference in HOX expression when irradiated with 1 or 4 Gy at 24 hours (Figure 5.15 A|). However, at 72 hours statistically significant changes are present at both 1 and 4 Gy (Figure 5.15 B|, Table 5.12). Down regulated genes include HOXA5, A10, B9 and C10, while up regulated genes include HOXC10 and D10.  U87-MG cells showed a mixture of up regulation and down regulation of HOX genes at both 24 and 72 hours post RT (Figure 5.16 A|, 
B|). Statistical increases and decreases in HOX genes expression are present at both 1 and 4 Gy (Table 5.11, 5.12). Though these changes are present, fluctuating expression patterns are present. HOX genes A5, D10 and D13 all show initial decrease in expression at 24 hours followed by an increase at 72 hours. HOXB4 has irregular expression with both an increase and decrease in expression at 24 hours with 1 and 4 Gys. U251-MG displays the highest changes in HOX genes post RT (Figure 5.17 A|, B|). Statistical changes are present with HOX genes A2, A5, A6, 
B7, B9, C4, C9, C10, C13 and D8 (Table 5.11, 5.12). HOXA5 and C9 both exhibit an initial down regulation at 24 hours followed by an up regulation at 72 hours. -
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HOXA5 and C9 shared dysregulation post RT across all cell lines. However, the manner of expression change is cell specific.  
 
Figure 5.15: Expression levels of all 39 HOX genes for LN18 post RT at A| 24 hours and B| 72 hours. 
Statistically significant changes in HOX gene expression were only present at 72 hours post treatment. 
The expression of each gene is presented relative to the house keeping gene β-actin (x10,000). Each 
test was performed in triplicate and error bars represent standard deviation of the mean. 
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Figure 5.16: Expression levels of all 39 HOX genes for U87-MG post RT at A| 24 hours and B| 72 hours. 
Statistically significant changes in HOX gene expression were present at both 24 and 72 hours post 
treatment. HOX genes A5, D10 and D13 all show and initial decrease in expression at 24 hours followed 
by an increase at 72 hours. The expression of each gene is presented relative to the house keeping 
gene β-actin (x10,000). Each test was performed in triplicate and error bars represent standard 
deviation of the mean.  
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Figure 5.17: Expression levels of all 39 HOX genes for U251-MG post RT at A| 24 hours and B| 72 hours. 
Statistically significant changes in HOX gene expression were present at both 24 and 72 hours post 
treatment. HOXA5 and C9 both exhibit an initial down regulation at 24 hours followed by an up 
regulation at 72 hours. The expression of each gene is presented relative to the house keeping gene 
β-actin (x10,000). Each test was performed in triplicate and error bars represent standard deviation 
of the mean. 
A| 
B| 
a1 a2 a3 a4 a5 a6 a7 a9 a1
0
a1
1
a1
3 b1 b2 b3 b4 b5 b6 b7 b8 b9 b1
3 c4 c5 c6 c8 c9 c1
0
c1
1
c1
2
c1
3 d1 d3 d4 d8 d9 d1
0
d1
1
d1
2
d1
3
0
5
10
15
20
HOX gene
N
or
m
al
is
ed
 to
β-
ac
tin 0 Gy1 Gy
4 Gy
a1 a2 a3 a4 a5 a6 a7 a9 a1
0
a1
1
a1
3 b1 b2 b3 b4 b5 b6 b7 b8 b9 b1
3 c4 c5 c6 c8 c9 c1
0
c1
1
c1
2
c1
3 d1 d3 d4 d8 d9 d1
0
d1
1
d1
2
d1
3
0
5
10
15
20
HOX gene
N
or
m
al
is
ed
 to
β-
ac
tin 0 Gy1 Gy
4 Gy
  
307 
Table 5.11: Two-way ANOVA analysis table for HOX gene changes at 24 hours in U87-MG and U251-MG cells treated with 0, 1 or 4 Gy of RT. P*<0.05, P**<0.01, P***<0.001, 
P****<0.0001 comparing 1 and 4 Gy RT treated cells with O Gy, untreated cells. 
HOX Gene Tukey's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value 
U87-MG 
A5 0 Gy vs. 1 Gy 1.098 0.3422 to 1.854 Yes ** 0.002579 0 Gy vs. 4 Gy -0.4386 -1.195 to 0.3176 No ns 0.380805 
B4 0 Gy vs. 1 Gy 0.8454 0.08925 to 1.602 Yes * 0.024885 0 Gy vs. 4 Gy -0.8871 -1.643 to -0.1309 Yes * 0.017637 
C4 0 Gy vs. 1 Gy -0.1989 -0.9551 to 0.5572 No ns >0.999999 0 Gy vs. 4 Gy -1.025 -1.781 to -0.2688 Yes ** 0.005197 
C8 0 Gy vs. 1 Gy -1.23 -1.987 to -0.4743 Yes *** 0.000672 0 Gy vs. 4 Gy -0.3727 -1.129 to 0.3834 No ns 0.530705 
D8 0 Gy vs. 1 Gy 2.189 1.433 to 2.945 Yes **** <0.000001 0 Gy vs. 4 Gy 4.627 3.871 to 5.383 Yes **** <0.000001 
D10 0 Gy vs. 1 Gy 1.183 0.4267 to 1.939 Yes ** 0.001105 0 Gy vs. 4 Gy 0.03327 -0.7229 to 0.7894 No ns >0.999999 
D13 0 Gy vs. 1 Gy 1.378 0.6221 to 2.134 Yes *** 0.000132 0 Gy vs. 4 Gy 1.558 0.8023 to 2.315 Yes **** 0.000016 
U251-MG 
A2 0 Gy vs. 1 Gy -0.2398 -1.577 to 1.097 No ns >0.999999 0 Gy vs. 4 Gy -1.714 -3.051 to -0.3774 Yes ** 0.008613 
A5 0 Gy vs. 1 Gy -0.1397 -1.476 to 1.197 No ns >0.999999 0 Gy vs. 4 Gy -11.18 -12.51 to -9.841 Yes **** <0.000001 
A6 0 Gy vs. 1 Gy 1.65 0.3129 to 2.986 Yes * 0.011886 0 Gy vs. 4 Gy -0.7208 -2.058 to 0.6159 No ns 0.44652 
C9 0 Gy vs. 1 Gy -1.095 -2.432 to 0.2415 No ns 0.13066 0 Gy vs. 4 Gy -6.773 -8.11 to -5.436 Yes **** <0.000001 
C10 0 Gy vs. 1 Gy 0.8066 -0.5302 to 2.143 No ns 0.346591 0 Gy vs. 4 Gy 2.09 0.7528 to 3.426 Yes ** 0.001114 
C13 0 Gy vs. 1 Gy -1.91 -3.247 to -0.5736 Yes ** 0.003065 0 Gy vs. 4 Gy -1.697 -3.033 to -0.3598 Yes ** 0.009414 
D8 0 Gy vs. 1 Gy -2.245 -3.582 to -0.9083 Yes *** 0.000441 0 Gy vs. 4 Gy -2.702 -4.039 to -1.365 Yes **** 0.000023 
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Table 5.12: Two-way ANOVA analysis table for HOX gene changes at 72 hours in LN18, U87-MG and U251-MG cells treated with 0, 1 or 4 Gy of RT. P*<0.05, P**<0.01, 
P***<0.001, P****<0.0001 comparing 1 and 4 Gy RT treated cells with O Gy, untreated cells. 
HOX Gene Tukey's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value 
LN18 
A5 
0 Gy vs. 1 Gy 1.098 0.3422 to 1.854 Yes ** 0.002579 0 Gy vs. 4 Gy -0.4386 -1.195 to 0.3176 No ns 0.380805 
A10 
0 Gy vs. 1 Gy 0.8454 0.08925 to 1.602 Yes * 0.024885 0 Gy vs. 4 Gy -0.8871 -1.643 to -0.1309 Yes * 0.017637 
B9 
0 Gy vs. 1 Gy -0.1989 -0.9551 to 0.5572 No ns >0.999999 0 Gy vs. 4 Gy -1.025 -1.781 to -0.2688 Yes ** 0.005197 
C9 
0 Gy vs. 1 Gy -1.23 -1.987 to -0.4743 Yes *** 0.000672 0 Gy vs. 4 Gy -0.3727 -1.129 to 0.3834 No ns 0.530705 
C10 
0 Gy vs. 1 Gy 2.189 1.433 to 2.945 Yes **** <0.000001 0 Gy vs. 4 Gy 4.627 3.871 to 5.383 Yes **** <0.000001 
D10 
0 Gy vs. 1 Gy 1.183 0.4267 to 1.939 Yes ** 0.001105 0 Gy vs. 4 Gy 0.03327 -0.7229 to 0.7894 No ns >0.999999 
U87-MG 
A5 0 Gy vs. 1 Gy -2.271 -2.986 to -1.557 Yes **** 0.0001 0 Gy vs. 4 Gy -3.064 -3.778 to -2.35 Yes **** 0.0001 
C8 0 Gy vs. 1 Gy -1.049 -1.763 to -0.3343 Yes ** 0.0026 0 Gy vs. 4 Gy -1.467 -2.181 to -0.7526 Yes **** 0.0001 
C9 0 Gy vs. 1 Gy -0.4988 -1.213 to 0.2157 No ns 0.2089 0 Gy vs. 4 Gy -1.07 -1.785 to -0.3557 Yes ** 0.0021 
D8 0 Gy vs. 1 Gy 9.599 8.885 to 10.31 Yes **** 0.0001 0 Gy vs. 4 Gy 10.33 9.614 to 11.04 Yes **** 0.0001 
D10 0 Gy vs. 1 Gy -1.562 -2.276 to -0.8474 Yes **** 0.0001 0 Gy vs. 4 Gy -2.724 -3.439 to -2.01 Yes **** 0.0001 
  
309 
D13 0 Gy vs. 1 Gy 0.1112 -0.6032 to 0.8257 No ns 0.9154 0 Gy vs. 4 Gy -0.8055 -1.52 to -0.09108 Yes * 0.0244 
U251-MG 
A5 0 Gy vs. 1 Gy -0.5826 -1.261 to 0.0963 No ns 0.102741 0 Gy vs. 4 Gy 2.649 1.97 to 3.327 Yes **** 0.0001 
A6 
0 Gy vs. 1 Gy 0.6851 0.006155 to 1.364 Yes * 0.047637 0 Gy vs. 4 Gy 1.374 0.695 to 2.053 Yes **** 0.0001 
B7 0 Gy vs. 1 Gy -0.7142 -1.393 to -0.03535 Yes * 0.037568 0 Gy vs. 4 Gy 0.1091 -0.5698 to 0.788 No ns 0.910105 
B9 0 Gy vs. 1 Gy -1.46 -2.139 to -0.7811 Yes **** 0.0001 0 Gy vs. 4 Gy -0.5847 -1.264 to 0.09419 No ns 0.101276 
C4 0 Gy vs. 1 Gy 1.363 0.6839 to 2.042 Yes **** 0.0001 0 Gy vs. 4 Gy 2.597 1.919 to 3.276 Yes **** 0.0001 
C9 0 Gy vs. 1 Gy 0.2632 -0.4157 to 0.9421 No ns 0.592023 0 Gy vs. 4 Gy 1.52 0.8413 to 2.199 Yes **** 0.0001 
C10 0 Gy vs. 1 Gy -0.3294 -1.008 to 0.3495 No ns 0.448985 0 Gy vs. 4 Gy 2.937 2.258 to 3.616 Yes **** 0.0001 
C13 0 Gy vs. 1 Gy -2.087 -2.766 to -1.408 Yes **** 0.0001 0 Gy vs. 4 Gy 0.07453 -0.6044 to 0.7534 No ns 0.956726 
D8 0 Gy vs. 1 Gy -1.286 -1.965 to -0.6069 Yes **** 0.0001 0 Gy vs. 4 Gy 1.429 0.7503 to 2.108 Yes **** 0.0001    
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RT pre-treatment causes an increase in C-Jun gene expression, potentially 
enhancing synergist effects with ICT9119 treatment. With the importance of C-Fos expression in ICT9119 death pathway being established, it was hypothesised that RT synergy could be due to additional induction of C-Fos expression. C-Jun expression has previously been shown to be induced post RT treatment in various solid malignancies [556-558]. With this in mind we further hypothesised that C-Jun induced expression post RT could potentially be part of the synergistic mechanism used in RT-ICT9119 treatment. To test this, RT-qPCR was used to quantify changes in gene expression post 1 and 4 Gy of RT at 24 and 72 hours. 
LN18 was the only cell line to have a significant increase in C-Fos expression (Figure 5.18 A|). On the other hand, C-Jun expression increased at both 24 and 72 hours at both 1 and 4 Gy (Figure 5.18 A|, B|). This increase in expression was higher at 4 Gy when compared to 1 Gy, showing direct correlation with RT dose and the amount of C-Jun induction. U87-MG had no significant changes in C-Fos expression post RT at either 24 or 72 hours (Figure 5.19 A|, B|). However, an increase in C-Jun expression is present at both 1 and 4 Gy at 24 and 72 hour time points. U251-MG also has an increase in C-Jun expression post 1 and 4 Gy or RT at 24 hours (Figure 5.20 A|), but at 72 hours C-Jun expression is reduced in RT treated cells when compared to untreated cells (Figure 5.20 B|). No change in C-
Fos expression was seen at either 24 or 72 hours post RT. Similar to LN18, both U87-MG and U251-MG showed a direct correlation between RT dose and level of 
C-Jun gene induction.  
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Figure 5.18: Expression levels of C-Fos and C-Jun genes for LN18 post RT at A| 24 hours and B| 72 hours. 
A statistically significant increase in C-Fos expression was seen at 24 hours post RT at 1 Gy. No other 
dose or time point showed a significant change in C-Fos expression. C-Jun expression increased at both 
1 and 4 Gy compared to untreated cells at both 24 and 72 hours post RT. The expression of each gene 
is presented relative to the house keeping gene β-actin (x10,000). Each test was performed in 
triplicate and error bars represent standard deviation of the mean. P***<0.001, P****<0.0001 
comparing untreated (0 Gy) with 1 and 4 Gy treated cells. 
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Figure 5.19: Expression levels of C-Fos and C-Jun genes for U87-MG post RT at A| 24 hours and B| 72 
hours. C-Jun expression increased at both 1 and 4 Gy compared to untreated cells, at both 24 and 72 
hours post RT. No significant changes were present with C-Fos gene expression. The expression of 
each gene is presented relative to the house keeping gene β-actin (x10,000). Each test was performed 
in triplicate and error bars represent standard deviation of the mean. P**<0.01, P***<0.001, 
P****<0.0001 comparing untreated (0 Gy) with 1 and 4 Gy treated cells.  
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Figure 5.20: Expression levels of C-Fos and C-Jun genes for U251-MG post RT at A| 24 hours and B| 72 
hours. No statically significant changes in C-Fos expression were observed post RT treatment. An 
initial increase in C-Jun Expression was present at both 1 and 4 Gy at 24 hours. This trend reverses 
with a decrease in C-Jun gene expression at 72 hours. The expression of each gene is presented 
relative to the house keeping gene β-actin (x10,000). Each test was performed in triplicates and error 
bars represent standard deviation of the mean. P* <0.05, P**<0.01, P****<0.0001 comparing 
untreated (0 Gy) with 1 and 4 Gy treated cells.  
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5.4 Chapter 5 Discussion  The key objectives of this chapter were to compare the effectiveness of peptide treatment, HXR9, with small molecule treatments, ICT9119 and E4, and then to identify a potential synergistic partner for HOX-PBX inhibitors. To achieve this a direct comparison of cytoxicity between HXR9 and ICT9119 was performed. These results showed that cytoxicity to HXR9 and E4 were cell specific, with some being more sensitive to peptide therapy while to others E4. However, all cell lines were highly sensitive to treatment. The increase in sensitivity between ICT9119 and E4 can in part be explained by the increased solubility of ICT9119. In addition to this the changes in molecular structure of ICT9119 should increase binding affinity to the PBX PID. Peptide drugs generally have a higher binding affinity and target selectivity when compared to small molecule drugs [559]. However, they provide poorer stability when compared to small molecules. This could account for the increase in cytotoxicity of cells to ICT9119 compared to HXR9.  
ICT9119 mode of death was identified as apoptosis via annexin V/7-AAD assay and caspase 3/7 immunofluorescent staining. This coincides with results from 
Section 3.3.10 that showed HXR9 mediated cell death was in part due to apoptosis. Cell death pathway analysis highlighted that HOX-PBX inhibition, whether peptide or small molecule mediated, results in the activation of identical pathways. The pathway results in the activation of C-Fos expression, which causes the loss of Bcl-2 expression. This loss of and gain of gene expression is visible at the protein level. This gene and protein expression pattern is identical of that seen in paediatric gliomas treated with HTL00-1. However, one variation is the modest induction of EGR1 visible in U87-MG and U251-MG cells treated with HXR9 and ICT9119. This variation in expression is deemed to be due to the difference in how 
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adult and paediatric cell lines react to HOX-PBX inhibition, rather than difference between peptide generations or small molecule treatment.  
EGR1 is a dual function gene with oncogenic and tumour suppressor functions. Previous research has identified EGR1 binding sites within the promoter of C-Fos [560]. Furthermore, induction of EGR1 expression has been shown to cause a direct down regulation of Bcl-2 expression [542, 561]. As only 2 of the 3 cell lines tested expressed EGR1 post treatment, this pathway may be supplementary to the main C-Fos/Bcl-2 death pathway present in all cell lines tested.  
 In summary, results indicate that HOX-PBX binding leads to the increased expression of Bcl-2. C-Jun proteins binding to Bcl-2’s promoter sites, independent of C-Fos, further drives this increase in transcription. In addition to this, HOX-PBX complexes may suppress expression of C-Fos, either directly or indirectly through miRNAs. Once HOX-PBX binding is antagonised, a rapid induction in C-Fos expression ensues, accompanied by a decrease in Bcl-2 expression. This is believed to be due to loss of direct HOX-PBX Bcl-2 transcription, as well as the loss of C-Jun driven transcription. Loss of C-Jun promoter activity is a direct result of C-Fos and the formation of the AP-1 complex. The AP-1 complex causes further transcriptional repression of Bcl-2. If activation of EGR1 expression is present, this further represses Bcl-2 expression. This culminates in loss of Bcl-2 family pro-apoptotic suppression, leading to mitochondria membrane loss. This in turn leads to the formation of the apoptosome and the activation of caspase 3 and caspase 7, leading to apoptosis.  
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Figure 5.21: HXR9 and ICT9119 antagonism of HOX-PBX binding leads to similar downstream events seen in HTL00-1 treatment (Figure 4.15). To summarise, los of HOX-
PBX binding leads to loss of Bcl-2 expression and induction of C-Fos expression. The formation of the AP-1 complex further results in Bcl-2 transcriptional repression. An 
optional pathway results in the up regulation of EGR1. EGR1 then directly represses Bcl-2 expression, while further inducing C-Fos transcription. This optional pathway is 
marked in red.   
ICT9119 
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TMZ and RT were selected as possible synergistic partners for ICT9119 treatment. Adult GBM cell lines sensitivity to treatment was initially assessed via MTS. Results showed U87-MG cell lines were resistant to TMZ, while LN18 and U251-MG were shown to have varying degrees of sensitivity. RT was deemed to be the better synergistic partner as all cell lines showed sensitivity, and slopes of dose response curves allowed for better modelling via bliss analysis. 
Although TMZ was not used in synergistic experiments, its potential to be used in combination with ICT9119 should not be totally over looked. Cells treated with TMZ has been shown to be sequestered at the G2/M boundary [562]. Treating these cells once sequestered at the G2/M boundary with Bcl-2 inhibitors causes an increase in treatment sensitivity [563]. Furthermore, studies have reported the importance in Bcl-2 expression in TMZ resistance, as well as showing the synergistic potential of Bcl-2 inhibitors when combined with TMZ therapy [564, 565]. As ICT9119 has been shown to cause repression of Bcl-2 expression via various mechanisms, its potential to work synergistically with TMZ is evident. This also indicates various avenues of research in which known treatments shown to cause G2/M cell cycle arrest can be used in synergy with ICT9119, HXR9 or HTL00-1.  
Initial use of ICT9119 as a radiosensitiser resulted in antagonism rather than synergy in all cell lines tested. However, when the sequence of treatment was reversed, high levels of synergy across all cell lines was seen. This synergy was best observed when opposing levels of ICT9119 and RT doses were combined. In an effort to determine mechanisms behind sequence dependent synergy and antagonism, cell cycle analysis was first analysed. Results showed clear cell cycle 
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redistribution when cells were treated with either 1 or 4 Gy of RT. An increase in cells in G2/M phase was observed in all cell lines, which was accompanied by a decrease of cells in G0/G1. These results indicate that G2/M cell cycle arrest was induced, indicating that 24 hours post RT the ATM-CHK2-CDK1 pathway was either dominant over the ATM-p53-CDK4/5 and the ATM-ATR-CHK1-CDK2 pathways, or has a more rapid response time in GBM cells (Figure 5.22 [566]). 
 
Figure 5.22: Diagram detailing the DNA damage response patheways induced by ionising radiation. 
RT causes the formation of hydroxyl radicals causing single and double strand breaks. Detection of 
DNA damage triggers phosphorylation of ATM or ATR which in turn phosphorylates downstream 
targets. The inhibition of CDK2/4/6 causes G1/S arrest, while inhibition of CDK1 results in G2/M 
arrest. Adapted from Maier et al (2016). 
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Cell cycle G2/M arrest has previously been demonstrated to sensitise cells to Bcl-2 inhibitors [563]. Results detailed in Section 5.3.3 indicate that post ICT9119 treatment causes a significant loss of Bcl-2 expression. The combination of these results alludes to a possible mechanism of synergy between RT-ICT9119 treatments, based on the sensitising effect of RT synchronising cells in G2/M phase, for the Bcl-2 targeting effects of ICT9119. If this proposed mechanism is true, additional treatment combinations may provide new treatment avenues. One such combination is the use of Bcl-XL inhibitors in combination with RT-ICT9119 treatments. As previously demonstrated (Section 5.3.3) ICT9119 specifically down regulates Bcl-2 expression with no observable effect on Bcl-XL. Even though Bcl-XL is an isoform of Bcl-2, it has specific binding partners independent from Bcl-2. As Bcl-XL alone can suppress apoptosis, the joint targeting of Bcl-2, via ICT9119, and Bcl-XL, with or without RT, could provide further levels of synergy.  
Cell cycle results revealed that 24 hours post ICT9119 treatment cells were partially enriched in G2/M phase. Previous research has proved that cells are more sensitive to RT in G2/M phase, while less sensitive in G1 phase, and least sensitive in S phase [567]. This indicates that although ICT9119 treatment should theoretically sensitise cells to RT, other mechanisms are at work causing antagonistic results.  
Changes in HOX gene expression was hypothesised to be another potential synergistic mechanism that contributes to RT-ICT9119 synergy. As previously described HOX genes have been implicated in inducing DNA repair pathways post treatment [469]. Differential expression of HOX genes was observed in all cell lines following RT treatment at 24 and 72 hours. This sporadic change in expression 
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pattern can in part be due to the functional redundancy between HOX paralogs. It is conceivable that RT induced HOX expression utilised in DNA damage repair, is inhibited by ICT9119, increasing the cytotoxic ability of RT. Though this concept has basis, it does not help explain why ICT9119-RT treatment sequence is antagonistic.  
Furthermore, the early response gene and AP-1 subunits, C-Fos and C-Jun, were both assessed pre and post RT for expression level changes. C-Fos expression levels generally did not change post RT, while all cell lines displayed a significant increase in C-Jun expression. Changes in C-Jun have previously been reported in various cancers post RT [568-570]. The unilateral up regulation of C-Jun without the C-Fos, could potentially indicate that C-Jun proteins are functioning separately to C-Fos or as monomers. One possibility is that C-Jun induction post RT is part of the cellular stress response, leading to an increase in Bcl-2 expression. This could be part of the synergy mechanism involving ICT9119, as once treated C-Fos expression is increased. Once C-Fos is transcribed, it binds with C-Jun to form the AP-1 complex, thus reducing C-Jun driven Bcl-2 expression. A similar mechanism has been reported for PKC inhibitors used to block RT induced C-Jun expression with additive cytotoxic results [558].  
These results only partially explain why synergy is present between RT and ICT9119 treatment. Further mechanism behind synergy can be only speculated, however pose potential new avenues of research. One of these potential avenues centres around the MAPK/DUSP pathway. MAPK’s are a family of proteins that modulate target proteins behaviour via phosphorylation. This phosphorylation acts as an ‘on-off switch’ for a wide variety of cellular processes (Figure 5.23 
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[571]). DUSP family members act as phosphatase enzymes able to remove phosphate residues. Thus MAPK’s and DUSP’s family members are antagonistic in function and a careful balance is maintained in eukaryotic cells.  
 
Figure 5.23: schematic representation of the MAPK pathways. Various intra- and extracellular 
stresses induce MAPK activations through a variety of protein mediators. Once induced, MAPK’s have 
both anti- and pro-tumour functions in a situational dependent manner. Adapted from Dhillon et al 
(2007). 
MAPK’s are important mediators of cellular stress response to RT, with rapid induction once cells are exposed to ionising radiation [572, 573]. An important target of MAPK phosphorylation is C-Jun, which phosphorylates serine at positions 63 and 73 and/or threonine 91 and tyrosine 93 within its transactivation domain [574, 575]. Previous studies inducing expression of MAPK’s C-Jun N-terminus kinase (JNK) and ERK to activate C-Jun resulted in increased radiosensitivity [569]. JNK’s importance was further validated when an independent group suppressed JNK expression post RT, leading to a significant 
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reduction in C-Jun activity and apoptosis [570]. Furthermore, increase in EGR1 expression post RT has been widely reported, again being accredited to the activating abilities of MAPK’s [576, 577]. An additional piece to this puzzle is the importance of MAPK phosphorylation in the activation of C-Fos. MAPK’s, and in particular ERK, are important in the phosphorylation, and subsequent activation of C-Fos as a transcription factor [578-580]. Once both C-Jun and C-Fos are phosphorylated, they bind to form the active AP-1 complex, capable of promoting and repressing target genes [580, 581].  
As previously mentioned the DUSP family of phosphatases inhibit MAPK mediated phosphorylation, thus leading to a reduction in MAPK target gene transcription [582, 583]. DUSP1 is one of the initial 22 genes reported to be up regulated by HXR9 treatment [419]. DUSP1’s importance to MAPK response to radiation has been reported in regards to sensitivity. Elevated DUSP1 levels have been reported to increase resistance to MAPK induced death, while knockdown of DUSP1 increased sensitivity [583]. Compiling this information provides additional support for the potential synergy and antagonism behind sequential ICT9119 and RT treatment. RT-ICT9119 treatment leads to cell cycle arrest at G2/M phase, while increasing C-Jun mRNA expression. In addition to this pre-treatment by RT induces MAPK levels and phosphorylates C-Jun proteins priming cells for ICT9119 treatment. When treated with ICT9119, a spike in C-Fos expression ensues. C-Fos is then phosphorylated by the RT induced MAPK’s, leading to enhanced formation of the AP-1 complex. Though DUSP1 is induced by ICT9119, this effect is dampened by the pre-induced MAPK levels. When sequential treatments are reversed, ICT9119-RT, DUSP1 inductions provides a radioresistance mechanism as it provides dominance over the RT induced MAPK’s. This dominance over 
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MAPK reduces the ability of ICT9119 to arrest cells in the radiosensitive G2/M phase of the cell cycle. Figure 5.24 illustrates the possible MAPK/DUSP1 synergistic and antagonistic pathways proposed.  
 
 
 
 
 
 
 
             
A| 
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Figure 5.24: Diagram depicting the potential MAPK/DUSP antagonistic and synergistic pathways 
induced by RT. A| Ionising radiation causes the formation of ROS, which in turn activates the 
transcription of MAPKs ERK, JNK and p38. ERK and JNK phosphorylates C-Fos and C-Jun respectively, 
while p38 phosphorylates ATF2. C-Fos, C-Jun and ATF2 can all be dephosphorylated by DUSP1, which 
causes their inactivation. In addition to this, DUSP1 can dephosphorylate MAPKs causing their 
inactivation. Once C-Fos and C-Jun are phosphorylated, they bind to form the AP-1 complex. This 
directly inhibits Bcl-2, as well as transcribes additional pro-apoptotic genes. This culminates in the 
loss of mitochondrial membrane integrity and apoptosis. ATF2 has been associated with inducing 
apoptosis, though its direct mechanisms are unknown. B| pre-treating cells with ICT9119 causes an 
increase in DUSP1 expression. This suppresses the pro-apoptotic effects of MAPKs that is induced 
following RT. Thus if DUSP1 is induced first it is dominant over MAPKs and the combination of 
ICT9119 and RT is antagonistic. However, if treatment schedules are reversed, MAPKs are induced 
before DUSP1 and is then dominant. This leads to synergy between RT and ICT9119.  
5.5 Chapter 5 Conclusion Previous attempts to target HOX-PBX dimers by developing a small molecule based treatment failed, and was swiftly abandoned with no documented redesigns attempted [494]. Our attempts to develop a small molecular agent has proven to be successful with two generations already being developed and successfully used. When comparing these small molecular agents to HXR9, there is a clear increase in cytotoxicity, with ICT9119 being the most potent in all cell lines tested. ICT9119, much like its peptide counterparts HXR9 and HTL00-1, causes apoptotic cell death in GBM cells, mediated through activation of caspase 3 and caspase 7 activity. Furthermore, ICT9119 induced identical cell death pathways as seen in HXR9 and HTL00-1. Though GBM CSCs have not been treated with ICT9119, they 
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have however been targeted using E4 with increased sensitivity compared to parental cells (Supplementary Figure 8). This leads us to believe that ICT9119 would also prove to be effective against the CSC sub-population, and again with increased sensitivity compared to parental cells. This is currently under investigation.  
RT was deemed a more suitable synergistic partner for ICT9119 treatment with high levels of synergy seen in RT-ICT9119 treatment sequences. ICT9119-RT provided the opposite effect, with low to medium levels of antagonistic effects between treatments. Initial attempts to identify the mechanisms behind the conflicting effects of sequential treatment, has yet to identify definitive answers. We believe that a combination of selected cell cycle arrest and induction of opposing phosphorylation kinases and phosphatases may impact the outcome of potential antagonistic or synergistic effects. This is now our most proponent area of new research with additional mechanistic work planned, as well as the investigation of concomitant treatment effects and in vivo studies.  
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6 Thesis Discussion  HOX oncogenic research has expanded rapidly over the last decade with further advances still to be made. Here we have shown that HOX gene dysregulation is present at both the RNA and protein levels in adult and paediatric gliomas. This alone is a significant finding as adult and paediatric gliomas have been reported to have genetically very distinct gene expression profiles. With the discovery of shared HOX dysregulation, albeit with un-identical profile, provides an enticing therapeutic opportunity.  
HOX genes have been implicated in a variety of different haematological and solid neoplasms with GBM as no exception. Their aberrant expression in cancer reflects a variety of functions, ranging from potential oncogenic to tumour suppressor activities. The importance of HOX genes in modulating these functions in GBM has been reinforced with the results presented in this study. Here we have shown HOX-PBX inhibition can cause not just cellular death, but at sub-lethal IC25 doses, can provide anti-proliferative and anti-migratory benefits. With all this in mind 
HOX genes can, and should, be classified as driver mutations. This is because of their direct influence on several of the key hallmarks of cancer. Furthermore, 2 key genetic pathways, as described in Section 1.3.5, are directly influenced by HOX protein expression. The synergistic effects of HOXC9, and putatively other HOX proteins, help suppress the actions of E2F, driving the p16INK4a/Rb pathway. This reduces the degradation of Rb allowing for G1/S transition, and thus uncontrolled proliferation. In addition, the suppression of E2F increases cellular survival, as it promotes the up regulation of the pro-survival gene Bcl-2 [478]. Another key genetic pathway in GBM closely linked to HOX dysregulation is the 
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EGFR/PI3K/PTEN/AKT pathway. HOX9 paralog groups have been shown to be directly up regulated by PI3K and AKT proteins [584]. HOX9 paralog proteins have anti-apoptotic, pro-invasive and migration, pro-proliferative and pro-angiogenic effects. PTEN is a negative regulator of PI3K expression, and is frequently inactivated in GBM. This may help explain the observed high levels of the HOX9 paralog in GBM, and could be used as a potential marker for HOX expression. HOX gene involvement in these key genetic pathways further strengthens the proposed notion that HOX genes are driver and not passenger mutations. If this were correct, 
HOX gene activation would appear at early stages of glioma and increase with grade, potentially making them putative biomarkers for tumour grade and stage.  
Our study has revealed that both adult and paediatric glioma cell lines and tumours express elevated levels of HOX genes compared to normal brain tissue. However, we failed to identify key HOX genes shared by all cell lines. Though this has been possible in previous cancers, the functional redundancy of HOX genes would mean it is more likely that expression profiles are more likely to be shared. This has been identified by this study with sets of HOX genes sharing expression between adult and paediatric cell lines. It must be noted that this expression profile is limited to either adult cell lines or paediatric. With the functional redundancies between HOX proteins, the use of individual HOX genes as biomarkers potential has had limited success. We propose that using paralog groups as biomarkers may provide more success. This can already be potentially used in GBM, with HOXA9, HOXC9 and HOXD9 all proven to promote malignant processes. 
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The importance of accurately identifying GBM CSCs, and effectively targeting them, is widely recognised as an essential goal in the search for a GBM cure. Published studies have reported high HOX gene signatures in GBM CSCs [340]. Additional studies have shown high correlation between key CSC genes and HOX expression. These include SOX2 with HOXA5 and HOXD9, EGFR and HOXA7, Nestin and HOXA9 and HIF1-α and HOXA10 [174, 458, 461, 469, 481]. As expected, we have shown that HOX gene expression is higher in GBM CSCs compared to parental cells. Firstly, HOX genes are essential developmental genes that are highly expressed in embryonic and adult stem cells, allowing them to retain high levels of genomic plasticity. Secondly, they provide essential survival benefits to cells under extreme intrinsic and extrinsic stresses, as well as promoting many CSC functions. This is the most likely reason why CSCs were more sensitive to HOX-PBX inhibition. The differential expression pattern between CSCs and parental cells presents the opportunity to use a high HOX expression signature as a marker for CSC population size, and potentially as an inclusion criteria for patients to be treated with HOX-PBX inhibitors.  
HOX protein monomers have the ability to bind to simple TAAT sequences in target genes independently of TALE co-factors. This monomeric binding has been shown to mainly act as a genomic repressor, and hence utilising HOX proteins as tumour suppressors [585]. Monomeric HOX transcription repression has been shown in Drosophila [395]. This is further strengthened as a point mutation in PBX3’s PID totally abolishes HOXC6 binding, leading to direct HOXC9 repression by HOXC6 monomers [586]. Evidence shows that HOX genes promote various malignant processes, as well as the transcription of an abundance of oncogenic genes. This would suggest that rather than HOX monomers, it is HOX-TALE 
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complexes that are the active force driving HOX mediated oncogenic functions. This highlights the importance of gaining a full prospective of both HOX and TALE gene expression levels in patients. In this study, paediatric and adult glioma cell lines and tumours expressed varying levels of TALE genes. Genes such as PBX1, 
PBX2, PBX3 and MEIS2 and MEIS3 were all overexpressed in cancer when compared to normal brain tissue. This provides evidence that HOX-TALE dimers/complexes are present and thus active in GBM cells.  
PBX1-4 proteins bind anterior HOX proteins, while MEIS1-3 proteins bind posterior HOX proteins. Predominantly, anterior HOX genes have been implicated with overexpression, and linked to malignant behaviour. In contrast, posterior 
HOX genes have been reported to act mainly in a tumour suppressor capacity, for example HOXD10 and HOXA11[488, 587]. This strongly indicates that HOX-PBX dimers are the most advantageous target of the HOX-TALE complexes.  
Inhibition of HOX-PBX dimers by HXR9, HTL00-1 or ICT9119 induces apoptosis, and at sub-IC50 doses, causes reduced migration and proliferation in glioma and GBM cells. This is due to the inability of HOX-PBX dimers to bind to target sequences casing transcriptional repression or promotion. An alternative explanation is that at low levels HOX-PBX inhibitors cause cells to differentiate from CSCs to parental cells. Our results identified that HOX-PBX inhibition, whether peptide or small molecule based, causes identical cellular death pathways to be activated. Despite revealing addition proteins involved in this death pathway, there is still much to discover before a full definitive picture is obtained.  
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However, one can speculate on potential pathways and alternative mechanism being utilised. For example, HOX-PBX inhibition restricts dimerization by specifically binding to PBX1-4’s PID. This specifically causes loss of HOX-PBX dimerization, but does not stop binding of PBX with alternative binding partners. PBX proteins have been shown to bind, independently from HOX, GATA binding protein 1 (GATA1), FRA-1, MEIS1, PREP1, Jun-B Proto-Oncogene AP-1 Transcription Factor Subunit (B-Jun) and PBX interacting protein 1 (HPIP) to name a few. This poses the possibility that loss of HOX-PBX dimers increases alternative PBX binding leading to cellular death. Furthermore, the loss of anterior HOX-PBX binding will increase HOX monomeric binding, which as discussed earlier is mainly genomic repressive. This alternative-binding scenario could also lead to cell death.  
The complexities, as described above, highlight the many reasons why simple HOX and PBX expression rarely correlates with sensitivity to HOX-PBX inhibition. Additional explanations for this lack of correlation can be attributed to the importance of HOX paralog group 9 and 10. In glioma, and other solid and haematological malignancies, HOX genes such as HOXA9, HOXA10, HOXC9, HOXD9 and HOXD10 provide key oncogenic functions [427, 444, 454, 455, 462, 469, 476, 481]. This can be explained by its unique positioning along the HOX cluster axis, allowing them to bind both MEIS and PBX proteins. This unique property means that inhibition of HOX (9-10)-PBX binding does not fully restrict their functionality, as they are unimpeded in their ability to bind to MEIS proteins. This ‘escape’ mechanism becomes all the more important when you take into account the ability of HOX9 paralog’s ability to induce Bcl-2 expression through either co-operation with PBX or MEIS proteins. This is essential as Bcl-2 repression is a 
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major event in HOX-PBX mediated death. MEIS1 has also been shown to be able to bind anterior HOX genes, like HOXA6, showing that HOX-PBX inhibition may not completely silence anterior HOX-TALE target genes. 
Drug research and development is a slow and extremely expensive process. These processes can exceed 10 years, with expenses rising to 8 digit figures. Even with these completed, ethical and clinical trials have to be passed before full-scale production and distribution can take place. For any new therapeutic to be able to reach brain tumour patients they must meet the 3 key characteristics: 
1. The ability to cross the BBB. 2. Specifically target cancer cells. 3. Effectively kill both the ‘normal’ GBM cells as well as the more resistant CSCs.  Once the therapeutic potential of the drug has been proven, proper ethical usage of the therapeutic agent must be shown. For the NICE to approve a new drug it must meet 5 additional criteria:  
1. Have low toxicity. 2. Have minimal/manageable side effects. 3. Improved efficacy over pre-established treatments 4. Have the ability to work in conjunction with pre-established treatments 5. Cost effective delivery mechanism Work determining the ability of HOX-PBX inhibitors to cross the BBB is currently underway. This will be performed using the GL261 mouse cell line in a C57BL/6 mouse model, with and without intracranial lesions present. Pharmacology and toxicology has revealed no adverse effects of HOX-PBX treatments, with no offsite effects found. The high specificity of peptide treatments allows for high doses to be administered with low to no toxicity. In addition to this, the low HOX levels 
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detected in NHA, and normal brain tissue in general, further reduces the possibility of adverse effects or potential cognitive damage.  
The ability to target both parental and CSC populations in GBM tumours is the proverbial ‘holy grail’ to neuro-oncologists. Many treatment modalities are able to target parental cells, but without eradication of patient’s CSC populations, reoccurrence and subsequent death is inevitable. Our results show not just cytotoxicity and cytostatic effects in both cellular populations, but an increase in sensitivity to treatment in CSC’s. This has been shown both in vivo and in vitro, but additional work such as intracranial models and further work on primary cell lines is deemed necessary and is currently underway. In addition to HOX-PBX inhibitors dual cell targeting ability, this highlights its potentially improved efficacy over current treatments.  
This study has shown high levels of synergy between RT-ICT9119 treatments, with strong evidence that HOX-PBX inhibitors can be also provide synergy with TMZ treatment. We further believe that HOX-PBX inhibitors can be used in conjunction with surgery. In the form of ICT9119, surgical de-bulking supplemented with oral ICT9119 would provide systemic delivery, targeting tumours cells that had escaped resection margins and disseminated deep into the brain. This same method could be combined with HXR9 or HTL00-1, but with intravenous rather than oral delivery. Another potential combination with surgery is wafer or gel delivery. This would entail using wafer or gels that are infused with either HXR9 or HTL00-1. These could then be placed/injected into the resection cavity. This provides 4 benefits: circumventing the BBB, providing 
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direct delivery of drug, reduction of tumour re-infiltration to resection cavity and finally, slower release of drug.  
Many drugs fail to be cost effective as they don’t provide an increased efficacy over older cheaper drugs, are not widely applicable to wide patient populations, or have clear resistance mechanisms that are utilised by malignant cells. HOX-PBX inhibitors have putatively shown increased efficacy over the ‘gold standard’ GBM treatment TMZ. Its application in patients is wide with low to high grade gliomas expressing high HOX levels, leaving potential resistance mechanism as the final hurdle. As described in Section 1.3.7 glioma cells utilise a variety of drug resistance mechanisms to evade cellular death of anti-neoplastic therapies (Figure 6.1).  
 
 
 
 
 
 
 
 
  
Figure 6.1: A summary of key drug resistance mechanism utilised by cancer. These include up 
regulation of efflux pumps, changes in membrane permeability, increased proteasome activity, 
increase in DNA repair enzyme levels, mutations/loss of cellular target and alterations in membrane 
composition.  
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Major acquired drug resistance mechanisms in glioma are up regulation of efflux pumps (MRP and P-gp etc.) and DNA repair enzymes (MGMT and MMR etc.). HOX-PBX inhibitors pass through the phospholipid bilayer of cells by passive diffusion. There currently is no evidence that efflux pumps are able to actively remove HOX-PBX inhibitors from the cells. However, if they did, HOX-PBX inhibitors would simply re-enter the cells negating its effects. DNA repair expression levels would have no impact on cellular sensitivity to HOX-PBX inhibitors, as these drugs do not induce DNA damage. Other resistance mechanisms, such as drug compartmentalisation should also not be an issue. We only see 3 potential drug resistance mechanisms being induced by malignant cells in response to HOX-PBX inhibition. These are; increase proteasome activity, changes in phospholipid composition and down regulation of HOX/PBX.  
Neoplastic cells have been shown to induce expression of proteasomes to acquire multiple drug resistance [588-590]. This potential could allow GBM cells to acquire resistance to peptide therapies such as HXR9 and HTL00-1. It must be noted that ICT9119 should not be similarly affected. Proteasome activity could potentially affect cell sensitivity. Cells with high levels of proteasome activity could be more resistant to HXR9 and HTL00-1. If this is true, proteasome activity level could provide a ‘response to treatment’ marker for selecting patients by using biopsy tissue for proteasome activity analysis. This also could explain why cells sensitive to ICT9119 are not as sensitive to HXR9 treatment. This could provide a treatment opportunity by combining HXR9 or HTL00-1 with proteasome inhibitors for potential synergy. 
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Changes in phospholipid membrane composition have been reported in numerous cancers including GBM [591, 592]. Alteration in average lipid density per nanometre, and the compilation of different glycolipids, glycoproteins and cholesterol, can all lead to reduction in uptake of organic and inorganic molecules [591, 593]. In addition, increases in negatively charged lipids such as phosphatidyl serine slightly increase the alkalinity of the bilayer causing a decrease in electrostatic repulsion between polar groups [591]. This increases surface tension of the phospholipid bilayer reducing uptake of drugs through passive diffusion. We believe if drugs such as HXR9 or HTL00-1 encounter this phenomenon, their naturaly low pH should decrease surface tension and neutralise the alkaline pH locally allowing for cellular entry.  
The final potential resistance mechanism is the down regulation or mutation of HOX or PBX in malignant cells. Though this is a possibility, the loss of expression of HOX and PBX is highly unlikely. This is because of their importance in driving malignant cellular functions. The loss of these genes would most likely lead to cell death and therefore not be beneficial to the neoplastic cells. A mutation in the homeodomain of HOX proteins, or even the PID of PBX would render any inhibitor null, but would abolish any HOX-PBX interactions as well. This again would provide malignant cells with no survival benefit and actually be detrimental. 
We strongly believe that HOX-PBX inhibitors have already met the majority of the key characteristics and NICE criteria need to approve a new drug. Work is already planned to address outstanding points. We hope that once this work is completed a phase I clinical can swiftly commence. 
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7 Future Work This study has provided additional knowledge of HOX and TALE expression in healthy and malignant brains in adults and children. It has also demostrated that these interactions can be inhibited with potent cytostatic and cytotoxic results. However, there are still areas surrounding the body of work presented here which needs further investigation. Here we outline proposed future short and long term objectives we have currently set out to complete. Here we list additional work that has not been discussed previously in the Thesis Discussion. 
Short Term| A major benefit of ICT9119 treatment over HXR9 and HTL00-1 is its increased half-life and thus sustained reactivity. The addition of amino acids to HXR9 and HTL00-1 can help increase the half-life, but cannot be large enough to hinder peptide binding. Using the half-life prediction software ProtParam [594] which predicts that in mammalian cells, HXR9 and HTL00-1 have half-life’s of 2.8 hours. To improve this, we are currently trialling the use of a proline added to the N-terminus of HXR9 and HTL00-1. This theoretically should increase peptide half-life to >20 hours. Initial results have shown no change in cytotoxicity with the added proline, with additional experiments using mass spectrometry planned.  
The use of an additional N-terminus proline reduces proteasome activity. This again is seen as an important area of research. We currently plan on using a proteasome activity assay that utilises fluorescently tagged peptides to see if peptide sensitivity correlated with proteasome activity. If positive results are obtained, the use of proteasome inhibitors in combination with HXR9 and HTL00-1 will be explored.  
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The importance of DUSP1 and MAPK activity in response to ICT9119 and RT treatment has been previously discussed in Chapter 5 Discussion. We plan to test our ‘hypothesis’ that DUSP1 and MAPK activity influences potential synergy of HOX-PBX inhibits with RT. This will be achieved with various knockdown and overexpression assays in combination with RT and ICT9119 treatments. We also plan to explore the use of DUSP inhibitors with ICT9119-RT to rescue potential synergy between treatments in this sequence. Though HXR9 and HTL00-1 have been shown to have an identical death pathway to ICT919, their potential to replace ICT9119 in synergy treatments is questionable. This is mainly due to their shorter half-life, and the ability of ionising radiation to target and degrade them. Nonetheless additional therapeutic combination assays are planned including HOX-PBX inhibitors with TMZ. This will be evaluated both in vitro and in vivo.  
Work in this study has shown that CSCs express elevated levels of HOX and TALE genes compared to parental cells. This elevated expression equates to an increase in sensitivity to HOX-PBX inhibition. It must be noted that these CSC are enriched using growth factors and represent a unique type of GBM CSC. Hypoxia induced CSC’s express different genes compared to their growth factor counterparts, and also behave differently. We envision the use of a hypoxic chamber to enrich parental cell lines for hypoxia induced CSCs. We then plan to quantify full HOX and 
TALE profiles to be able to compare their expression pattern to both parental and growth factor induced CSCs. These hypoxic CSCs will also be assessed for sensitivity to HOX-PBX inhibitors, and results compared to those obtained from parental and growth factor enriched CSCs.  
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Finally, we are currently investigating HOX-PBX inhibitor immunogenicity and inflammatory potentials. Preliminary results show that HOX-PBX inhibitors do not induce inflammatory markers such as calreticulin, Fas ligand, Heat shock protein-70KDa (HSP-70), Programed death-ligand 1 (PD-L1), Cluster of differentiation 80 (CD80) and Human leucocyte antigen (HLA). Though these results are not definitive, if substantiated it demonstrates that HOX-PBX inhibitors are non-inflammatory. This is a highly revered characteristic in brain tumour research, due to the adverse effects of inflammation and oedema. Inflammation and oedema causes an elevation in intracranial pressure of the brain, potential resulting in loss of cognitive functions, and even death. In addition to this, oedema causes an increase in hydrostatic pressure of the tumour causing an increase in drug efflux from the tumour site. These positive preliminary results are currently being followed up with additional in vitro experiments, with in vivo experiments being scheduled.  
Long Term| Peptide based therapies contain unique properties as they are based from naturally occurring molecules.  These properties include high target specificity, low off site binding, low toxicities, but targeted degradation by proteasomes. As previously described, the latter point means that the half-life of peptide therapies is lower than that seen from inorganic compounds. This can be overcome by peptide modifications, modulation of the cell’s proteasome activity, or by providing patients with multiple drug doses. We propose that viral based drug delivery could provide a more enticing opportunity. The use of a virus such as herpes simplex virus (HSV), can be genetically manipulated with exogenous genes inserted. This could allow for an engineered gene encoding HXR9 or HTL00-1 to 
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be inserted into the virus. Once the virus enters the cancer cell, it shuts down cellular process, and ‘hijacks’ them for the production of new viral components. Once these are produced, the newly inserted HXR9 and HTL00-1 gene will be transcribed and translated. This would allow newly formed peptides to target HOX-PBX dimers, causing cellular death (Figure 7.1).   
 
Figure 7.1: Diagram illustrating the potential use of viruses to deliver HXR9 o HTL00-1. Genes 
encoding HXR9 or HTL00-1 can be inserted in virus vectors such as HSV. These modified viruses can 
then be used to transfect neoplastic cells. Once inside host cells, viruses utilise host’s cellular 
machinery to transcribe viral genes. HXR9/HTL00-1 molecules will be transcribed and translated, 
and then go on to target HOX-PBX dimers. If viral particles are able to full replicate before host cell 
death, they will be released and allowed to infect neighbouring cells.  
HXR9 and HTL00-1 are encoded by a relatively small gene allowing for individual viruses to be able to contain thousands or possibly millions of copy numbers. Furthermore, it is possible to insert HXR9 or HTL00-1 genes into late cycle gene 
  342 
loci, allowing for virus particles to be able to fully replicate before transcribing peptide drugs. This would have the added benefit of continuing the viral cycle, allowing new viral particles to infect neighboring neoplastic cells, thus starting a new cycle by replicating additional viral particles and peptide agents. This concept is still under review, with preliminary tests commencing in the near future.   
We hope that once our short term research goals are sufficiently completed, phase I clinical trials can commence. Currently clinical trials for renal cancer, and unilateral prostate cancer patients will start in 2018, with patient recruitment planned for the first quarter. Once these are completed we envisage an adult glioma clinical trial to follow, with phase I and II trials to be completed in quick succession. Further clinical trials using combination therapy between ICT9119 and RT and TMZ are also part of our long term plans.  
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8 Thesis Conclusion There have been no significant advances in GBM treatment for over a decade, with the mean survival time for patients still only 15 months. This highlights the urgent need for new therapeutic targets to be identified, and new treatments to be developed. 
Here we have shown that HOX and TALE gene dysregulation is present in both paediatric and adult gliomas, while being absent in NHAs. This aberrant expression is targetable by the use of HOX-PBX inhibitors with both cytostatic and cytotoxic results. Differential expression patterns between parental and CSCs presents the opportunity to use HOX and TALE expression signatures to quantify CSC population in tumours. This increase in gene expression directly relates to increased sensitivity to HOX-PBX inhibitors. This provides evidence that HOX-PBX inhibitors are CSC targeting agents, with the added benefit of cytotoxicity towards parental cells.  
HTL00-1, our 2nd generation peptide inhibitor, has a significant improvement in cytotoxicity over its predecessor HXR9. Furthermore, we have successfully developed a small molecular mimic, ICT9119, which provides further improvement with regards to cytotoxicity and drug stability. Whether peptide or small molecule based, HOX-PBX inhibition has shown enourmous potential as a new therapy for glioma, either as a single therapeutic agent, or in combination with chemotherapy or RT.  
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Supplementary Results 
Supplementary Table 1: Multiple unmatched student’s t-test analysis table comparing CSC cell lines to 
their parental cells for all 39 HOX genes.  
HOX Gene Significant? P value Difference SE of difference t ratio 
LN18 
A1 No 0.411892 -8.65108 8.41259 1.02835 
A2 Yes 0.03352 -56.7097 10.6524 5.32367 
A3 Yes 0.000312 -1554.86 81.2514 19.1365 
A4 No 0.171651 -5.27155 2.52094 2.0911 
A5 Yes 0.004246 -116.423 19.8847 5.85489 
A6 Yes 0.009484 -560.457 54.9716 10.1954 
A7 No 0.993713 -0.081436 9.15875 0.00889161 
A9 No 0.35617 -51.1574 42.9911 1.18995 
A10 Yes 0.001197 -1976.57 68.4408 28.8799 
A11 No 0.17136 -40.7949 19.4869 2.09345 
A13 No 0.10414 -28.2979 9.92457 2.8513 
B1 No 0.163989 -13.5263 6.27763 2.15468 
B2 No 0.060432 -22.7238 5.85497 3.88112 
B3 No 0.098611 -169.505 57.5777 2.94394 
B4 No 0.085987 -10.5173 3.30084 3.18625 
B5 No 0.196434 -12.2798 6.43173 1.90925 
B6 No 0.126283 -4.67602 1.84084 2.54016 
B7 No 0.120264 -4.84847 1.8529 2.61669 
B8 No 0.207373 -46.7605 25.4341 1.8385 
B9 Yes 0.000002 -1292.34 30.3472 42.5851 
B13 Yes 0.039159 -65.599 13.3773 4.90377 
C4 Yes 0.006849 -201.65 39.3251 5.12777 
C5 No 0.080124 -33.0138 9.95336 3.31685 
C6 No 0.100514 -240.307 82.5446 2.91123 
C8 No 0.261724 -6.97996 4.5092 1.54794 
C9 No 0.347321 -105.846 86.8803 1.2183 
C10 Yes 0.016577 -95.5975 12.4638 7.67002 
C11 No 0.121563 -69.9442 26.9045 2.59972 
C12 No 0.118514 -14.4609 5.47772 2.63994 
C13 No 0.143578 -73.7631 31.4426 2.34596 
D1 No 0.249317 -257.569 160.288 1.60691 
D3 No 0.201487 -17.8646 9.52308 1.87593 
D4 Yes 0.040268 -2.86023 0.591992 4.83153 
D8 Yes 0.025346 -20.1717 3.27401 6.16117 
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D9 Yes 0.000128 -100.097 3.88018 25.7969 
D10 No 0.83317 -14.8166 61.92 0.239286 
D11 No 0.292352 -8.20009 5.78947 1.41638 
D12 Yes 0.027147 -4.76811 0.80203 5.94505 
D13 No 0.162207 -19.0827 8.79372 2.17004 
U87-MG 
A1 No 0.072949 -8.30984 2.37646 3.49673 
A2 Yes 0.011237 -2.78027 0.297239 9.35365 
A3 Yes 0.003836 -41.9207 5.13116 8.16982 
A4 No 0.10235 3.29083 1.14245 2.88051 
A5 Yes 0.000125 -50.8875 1.95998 25.9633 
A6 No 0.064679 -4.81553 1.28803 3.73869 
A7 No 0.386987 -0.0544532 0.0496256 1.09728 
A9 Yes 0.035604 -0.354383 0.0687175 5.1571 
A10 Yes 0.004456 -22.152 1.48371 14.9301 
A11 Yes 0.031773 -0.841828 0.153745 5.47549 
A13 No 0.552783 -0.0426219 0.0602759 0.707113 
B1 No 0.101053 -0.408009 0.140589 2.90214 
B2 Yes 0.032774 -0.542948 0.100787 5.38707 
B3 No 0.071076 -14.4396 4.06985 3.54794 
B4 Yes 0.030177 -20.8571 3.70768 5.62539 
B5 Yes 0.015748 -2.73768 0.347674 7.87429 
B6 Yes 0.029407 -1.39906 0.245362 5.70202 
B7 No 0.2654 -0.255408 0.166808 1.53114 
B8 No 0.096094 -7.24562 2.42443 2.98859 
B9 Yes 0.00182 -8.29891 0.786714 10.5488 
B13 Yes 0.030395 -33.5876 5.99323 5.60425 
C4 Yes 0.033573 -24.4875 4.60358 5.31922 
C5 No 0.666028 0.531725 1.06116 0.501079 
C6 No 0.066645 -12.3082 3.34713 3.67725 
C8 No 0.511218 3.2164 4.05936 0.79234 
C9 No 0.151404 -1.33937 0.590441 2.26843 
C10 Yes 0.002827 -3.6917 0.196714 18.7668 
C11 Yes 0.000432 -0.944763 0.019643 48.0968 
C12 Yes 0.020298 -0.579216 0.0838035 6.91159 
C13 No 0.120318 -1.27614 0.487826 2.61598 
D1 No 0.053012 -8.95015 2.14703 4.16862 
D3 Yes 0.014757 -0.538988 0.0662116 8.14039 
D4 Yes 0.030596 -1.90511 0.341111 5.585 
D8 No 0.071424 -21.7227 6.13933 3.53829 
D9 No 0.120342 -8.42362 3.22046 2.61566 
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D10 Yes 0.015051 -45.3649 5.62927 8.05875 
D11 Yes 0.010701 -0.125394 0.0130768 9.58905 
D12 No 0.290877 -0.151729 0.106677 1.42231 
D13 No 0.073949 -17.1649 4.94642 3.47018 
U251-MG 
A1 Yes 0.014617 -6.67154 0.815576 8.18016 
A2 Yes 0.002743 -2.64796 0.138963 19.0551 
A3 Yes 0.00363 3.02581 0.182792 16.5533 
A4 No 0.30328 -0.091242 0.0664276 1.37356 
A5 Yes 0.000566 -31.6064 0.752205 42.0184 
A6 Yes 0.000951 -24.656 0.76088 32.4045 
A7 Yes 0.020035 -3.46299 0.497673 6.95836 
A9 No 0.100396 -0.822448 0.282314 2.91324 
A10 Yes 0.012294 2.55 0.285376 8.93558 
A11 Yes 0.009971 -0.681769 0.068592 9.93947 
A13 Yes 0.00083 -21.0378 0.606509 34.6867 
B1 No 0.164016 0.0345323 0.0160284 2.15445 
B2 Yes 0.025247 0.0562997 0.00911916 6.17378 
B3 Yes 0.023777 -1.60122 0.251409 6.36897 
B4 Yes 0.001033 -2.69812 0.0867912 31.0874 
B5 Yes 0.004041 -2.73014 0.17407 15.6841 
B6 Yes 0.008983 -0.111993 0.0106868 10.4796 
B7 No 0.381413 -2.65444 2.38409 1.1134 
B8 Yes 0.03568 -0.0669147 0.0129899 5.1513 
B9 Yes 0.005576 -42.1217 3.15853 13.3359 
B13 Yes 0.019557 -6.14273 0.871872 7.04545 
C4 Yes 0.018281 -33.8609 4.6421 7.2943 
C5 Yes 0.001292 -3.17806 0.114333 27.7966 
C6 No 0.058083 -0.300468 0.0757548 3.96633 
C8 Yes 0.010866 -1.66764 0.175271 9.51466 
C9 Yes 0.003864 -19.791 1.23374 16.0414 
C10 Yes 0.002336 -4.0261 0.194916 20.6555 
C11 No 0.065949 0.0477773 0.0129174 3.69869 
C12 No 0.486315 0.0239552 0.028292 0.846711 
C13 Yes 0.010338 -31.8702 3.26588 9.75853 
D1 No 0.060204 -1.4968 0.384865 3.88917 
D3 No 0.522022 0.00946287 0.0122964 0.769563 
D4 Yes 0.000605 -19.7425 0.485627 40.6535 
D8 Yes 0.017465 -31.8699 4.26784 7.46746 
D9 Yes 0.005208 -35.3878 2.56383 13.8027 
D10 Yes 0.011659 -156.835 17.0841 9.18017 
  373 
D11 No 0.671009 -0.0178906 0.036312 0.49269 
D12 No 0.250165 0.02184 0.0136265 1.60276 
D13 Yes 0.002446 -6.95156 0.344436 20.1824  
Supplementary Table 2: Multiple unmatched student’s t-test analysis table comparing CSC cell lines to 
their parental cells for TALE genes. 
TALE Gene Significant? P value Difference SE of difference t ratio 
LN18 
PBX1 No 0.067504 -2.73526 1.09861 2.48973 
PBX2 Yes 0.014599 -61.7286 14.9787 4.12109 
PBX3 No 0.096281 5.36905 2.47922 2.16562 
PBX4 Yes 0.048328 -0.364691 0.129793 2.80978 
MEIS1 Yes 0.001069 -6.22135 0.735294 8.46104 
MEIS2 No 0.405013 -3.0666 3.29741 0.930004 
MEIS3 Yes 0.000746 -31.5141 3.3909 9.29373 
PREP1 No 0.28216 -0.112502 0.0905986 1.24177 
PREP2 No 0.067504 -2.73526 1.09861 2.48973 
U87-MG 
PBX1 No 0.000127 61.3545 4.19204 14.6359 
PBX2 No 0.519576 0.191002 0.26256 0.72746 
PBX3 No 0.006135 -17.9444 3.39308 5.28854 
PBX4 No 0.179894 -0.0874297 0.0538666 1.62308 
MEIS1 No 0.701702 0.321704 0.78151 0.411644 
MEIS2 Yes 0.000067 -21.0285 1.22459 17.1719 
MEIS3 No 0.001239 -44.1881 5.42864 8.13982 
PREP1 No 0.00133 34.7889 4.35351 7.991 
PREP2 No 0.000127 61.3545 4.19204 14.6359 
U251-MG 
PBX1 Yes 0.00047 44.5725 4.25669 10.4712 
PBX2 Yes 0.000092 -10.8803 0.684791 15.8885 
PBX3 Yes 0.01159 -11.9811 2.71612 4.41113 
PBX4 Yes 0.035302 0.177104 0.0566449 3.12656 
MEIS1 No 0.062281 -2.86068 1.1151 2.5654 
MEIS2 Yes 0.005305 -6.6002 1.19859 5.50662 
MEIS3 Yes 0.000209 -18.8371 1.46137 12.89 
PREP1 Yes 0.001321 34.8445 4.35337 8.00403 
PREP2 Yes 0.00047 44.5725 4.25669 10.4712  
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Supplementary Table 3: Multiple unmatched student’s t-test analysis table comparing tumour tissue 
to matched adjacent tissue for all 39 HOX genes. 
HOX Gene Significant? P value Difference SE of difference t ratio 
GBM 50 
A1 No 0.758708 34.109 110.651 0.308257 
A2 Yes <0.000001 -1270.75 110.651 11.4843 
A3 Yes <0.000001 -1655.76 110.651 14.9638 
A4 No 0.612984 56.1954 110.651 0.507861 
A5 Yes <0.000001 -2161.36 110.651 19.5331 
A6 No 0.785688 30.1914 110.651 0.272852 
A7 No 0.02881 -246.454 110.651 2.22731 
A9 Yes <0.000001 -1993.35 110.651 18.0148 
A10 Yes <0.000001 -3536.35 110.651 31.9595 
A11 Yes <0.000001 -993.416 110.651 8.97791 
A13 Yes <0.000001 -1567.75 110.651 14.1684 
B1 No 0.011422 -286.681 110.651 2.59085 
B2 No 0.921686 -10.9134 110.651 0.0986286 
B3 No 0.97025 -4.13996 110.651 0.0374146 
B4 No 0.004222 -326.158 110.651 2.94762 
B5 Yes <0.000001 -5791.06 110.651 52.3362 
B6 Yes <0.000001 -1196.14 110.651 10.8101 
B7 No 0.049967 -220.322 110.651 1.99114 
B8 No 0.290224 -117.828 110.651 1.06486 
B9 No 0.988817 -1.55585 110.651 0.0140608 
B13 Yes 0.000002 -576.065 110.651 5.20614 
C4 Yes <0.000001 -2250.39 110.651 20.3377 
C5 Yes <0.000001 -2119.63 110.651 19.156 
C6 No 0.521369 -71.2757 110.651 0.644149 
C8 Yes 0.000003 -560.444 110.651 5.06497 
C9 Yes <0.000001 -3644.71 110.651 32.9388 
C10 No 0.073069 -201.045 110.651 1.81693 
C11 No 0.951016 -6.81929 110.651 0.0616288 
C12 Yes <0.000001 -714.345 110.651 6.45583 
C13 Yes <0.000001 -2751.9 110.651 24.8701 
D1 Yes 0.000067 -466.125 110.651 4.21257 
D3 No 0.555154 -65.5734 110.651 0.592614 
D4 No 0.00744 -304.097 110.651 2.74825 
D8 No >0.999999 0 110.651 0 
D9 No 0.179418 -149.901 110.651 1.35472 
D10 Yes <0.000001 -2164.42 110.651 19.5608 
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D11 No 0.977915 -3.07304 110.651 0.0277724 
D12 No >0.999999 0 110.651 0 
D13 Yes <0.000001 -731.534 110.651 6.61118 
GBM 56 
A1 No 0.192248 -1.72172 0.888525 1.93773 
A2 Yes 0.035322 -20.1142 3.88395 5.17881 
A3 Yes 0.037564 -9.69 1.93296 5.01303 
A4 No 0.588859 -0.100431 0.157454 0.637844 
A5 Yes 0.004045 -106.092 6.76815 15.6752 
A6 Yes 0.001294 -76.452 2.75232 27.7773 
A7 No 0.141099 -13.155 5.54655 2.37174 
A9 Yes 0.015831 -53.8663 6.85932 7.85301 
A10 Yes 0.001195 -22.819 0.789597 28.8996 
A11 Yes 0.041624 -23.3032 4.90893 4.7471 
A13 No 0.206828 -19.3873 10.5257 1.8419 
B1 No 0.76746 -0.217697 0.643826 0.33813 
B2 No 0.507278 0.0369465 0.0461391 0.800764 
B3 No 0.42265 -0.0214588 0.0214588 1 
B4 No 0.35009 -0.787975 0.651574 1.20934 
B5 No 0.207965 -3.45182 1.88129 1.83481 
B6 No 0.518256 -0.476304 0.612649 0.777449 
B7 No 0.662899 -0.177471 0.350476 0.506371 
B8 No 0.418269 1.5909 1.57289 1.01145 
B9 No 0.369864 -0.33682 0.293482 1.14767 
B13 No 0.161031 -0.13333 0.061152 2.18031 
C4 No 0.099824 -31.5711 10.8009 2.92299 
C5 No 0.079789 -4.35572 1.3101 3.32472 
C6 Yes 0.029814 -0.728169 0.128624 5.66122 
C8 No 0.11687 -23.8217 8.94796 2.66225 
C9 Yes 0.010939 -56.9155 6.00219 9.48246 
C10 No 0.101678 -1.9038 0.658375 2.89166 
C11 No 0.42265 0.0492994 0.0492994 1 
C12 No 0.619374 0.568465 0.976574 0.582102 
C13 No 0.059599 -12.7025 3.24807 3.91077 
D1 No 0.997085 0.0048775 1.18334 0.0041218 
D3 No 0.776971 0.0578742 0.178866 0.323561 
D4 No 0.087615 -6.7698 2.14764 3.15221 
D8 - - - - - 
D9 Yes 0.039246 -8.28356 1.69121 4.89801 
D10 No 0.108653 -60.6722 21.819 2.7807 
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D11 No 0.42265 0.0332089 0.0332089 1 
D12 - - - - - 
D13 Yes 0.015176 -16.982 2.11619 8.02479 
GBM 57 
A1 No 0.42265 -4.25074 4.25074 1 
A2 Yes 0.021794 -5379.52 807.426 6.66255 
A3 Yes 0.001205 -3757.22 130.566 28.7763 
A4 No 0.171278 -3.36056 1.60477 2.09411 
A5 Yes 0.001681 -4892.73 200.827 24.3629 
A6 Yes 0.038704 -47.0862 9.54266 4.93429 
A7 Yes 0.033379 -815.932 152.926 5.33546 
A9 Yes 0.006505 -1943.4 157.51 12.3383 
A10 Yes 0.000203 -9825.53 140.118 70.1235 
A11 Yes 0.016535 -5440.56 708.406 7.68001 
A13 Yes 0.000375 -8130.19 157.514 51.6157 
B1 Yes 0.016771 -1311.36 171.996 7.62433 
B2 Yes 0.018373 -17.3619 2.38639 7.27539 
B3 No 0.058895 -32.263 8.19628 3.9363 
B4 Yes 0.015164 -2541.54 316.582 8.02805 
B5 Yes 0.004941 -5193.82 366.437 14.1738 
B6 Yes 0.007942 -2573.44 230.713 11.1543 
B7 Yes 0.000657 -889.84 22.82 38.9939 
B8 No 0.070346 -182.935 51.2649 3.56842 
B9 No 0.885 0.347275 2.12114 0.163721 
B13 Yes 0.004914 -774.398 54.4871 14.2125 
C4 Yes 0.000789 -2758.12 77.5321 35.5739 
C5 Yes 0.009127 -2937.13 282.544 10.3953 
C6 Yes 0.015375 -233.113 29.2433 7.97151 
C8 Yes 0.001007 -3687.6 117.103 31.4903 
C9 Yes 0.007015 -5735.44 482.927 11.8764 
C10 Yes 0.013131 -333.331 38.5781 8.64042 
C11 No 0.155629 -12.9644 5.81665 2.22884 
C12 Yes 0.000178 -3756.84 50.0907 75.0009 
C13 Yes 0.010542 -4836.26 500.533 9.66221 
D1 Yes 0.000109 -1455.31 15.1691 95.9389 
D3 Yes 0.008485 -135.726 12.5827 10.7867 
D4 Yes 0.03687 -1402.03 276.929 5.0628 
D8 - - - - - 
D9 Yes 0.009123 -1225.78 117.889 10.3977 
D10 Yes 0.00545 -5753.18 426.476 13.49 
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D11 No 0.889148 -0.20447 1.29624 0.157741 
D12 - - - - - 
D13 Yes 0.020466 -4696.51 682.392 6.88242  
Supplementary Table 4: Multiple unmatched student’s t-test analysis table comparing tumour tissue 
to matched adjacent tissue for TALE genes. 
TALE Gene Significant? P value Difference SE of difference t ratio 
GBM 50 
PBX1 Yes 0.000665 -131.871 3.40309 38.7505 
PBX2 Yes 0.006731 -151.141 12.4628 12.1274 
PBX3 No 0.243148 5.29219 3.23155 1.63766 
PBX4 No 0.019922 -11.3692 1.62917 6.97851 
MEIS1 No 0.03979 -21.977 4.51987 4.8623 
MEIS2 No 0.012947 -31.5364 3.62366 8.70294 
MEIS3 - - - - - 
PREP1 No 0.032868 10.9889 2.04294 5.37895 
PREP2 No 0.42265 -0.138477 0.138477 1 
GBM 56 
PBX1 Yes 0.00467 -129.219 8.86184 14.5815 
PBX2 Yes 0.000455 -89.1145 1.90147 46.8661 
PBX3 Yes 0.004642 -28.5947 1.95503 14.6262 
PBX4 No 0.624568 -0.125205 0.218567 0.572845 
MEIS1 No 0.055248 -12.4974 3.06605 4.07606 
MEIS2 Yes 0.000085 -23.44 0.215623 108.708 
MEIS3 - - - - - 
PREP1 No 0.051548 27.4717 6.49089 4.23234 
PREP2 Yes 0.00467 -129.219 8.86184 14.5815 
GBM 57 
PBX1 Yes 0.018656 67.2777 9.32024 7.21845 
PBX2 Yes 0.047174 -792.062 178.408 4.43961 
PBX3 No 0.346312 -4.0136 3.28555 1.22159 
PBX4 Yes 0.008594 -155.273 14.4878 10.7174 
MEIS1 Yes 0.001823 -100.794 4.30924 23.3902 
MEIS2 No 0.117475 -19.1126 7.2015 2.65398 
MEIS3 - - - - - 
PREP1 No 0.079853 8.06886 2.42802 3.32322 
PREP2 No 0.326796 -6.00024 4.66036 1.2875 
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Supplementary Table 5: Demographic data from TMA GL806d, with HOXC4 and PBX1/2/3/4 IHX intensity staining scores. 
No. Sex Age Organ Pathology Diagnosis Grade Type Intensity Score 
HOXC4 PBX1/2/3/4 
A1 M 38 Cerebrum Glioblastoma with necrosis 4 Malignant 1 1 
A2 M 38 Cerebrum Glioblastoma with necrosis 4 Malignant 2 2 
A3 M 31 Cerebrum Glioblastoma 4 Malignant 2 1 
A4 M 31 Cerebrum Glioblastoma 4 Malignant 3 1 
A5 M 20 Cerebrum Glioblastoma 4 Malignant 1 1 
A6 M 20 Cerebrum Glioblastoma 4 Malignant 2 0 
A7 F 19 Cerebrum Glioblastoma 4 Malignant 2 0 
A8 F 19 Cerebrum Glioblastoma 4 Malignant 0 0 
A9 M 43 Cerebrum Anaplastic astrocytoma 3 Malignant 0 0 
A10 M 43 Cerebrum Anaplastic astrocytoma 3 Malignant 0 0 
B1 F 59 Cerebrum Glioblastoma 4 Malignant 0 1 
B2 F 59 Cerebrum Glioblastoma (sparse) 4 Malignant 0 2 
B3 M 40 Cerebrum Glioblastoma 4 Malignant 4 0 
B4 M 40 Cerebrum Glioblastoma with necrosis 4 Malignant 4 0 
B5 M 24 Cerebrum Glioblastoma 4 Malignant Missing Missing 
B6 M 24 Cerebrum Glioblastoma 4 Malignant Missing Missing 
B7 M 1 Cerebrum Glioblastoma with necrosis 4 Malignant 2 1 
B8 M 1 Cerebrum Glioblastoma 4 Malignant 4 1 
B9 M 75 Cerebrum Glioblastoma 4 Malignant 3 0 
B10 M 75 Cerebrum Glioblastoma with necrosis 4 Malignant 2 0 
C1 F 41 
  
Cerebrum 
 
Glioblastoma with necrosis 4 Malignant 2 2 
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C2 F 41 Cerebrum Glioblastoma 4 Malignant 3 2 
C3 M 51 Cerebrum Glioblastoma 4 Malignant 3 4 
C4 M 51 Cerebrum Glioblastoma 4 Malignant 3 4 
C5 F 58 Cerebrum Glioblastoma 4 Malignant 1 4 
C6 F 58 Cerebrum Glioblastoma 4 Malignant 1 4 
C7 F 31 Cerebrum Glioblastoma 4 Malignant 1 3 
C8 F 31 Cerebrum Glioblastoma 4 Malignant 2 4 
C9 F 11 Cerebrum Glioblastoma 4 Malignant 3 4 
C10 F 11 Cerebrum Glioblastoma 4 Malignant 2 2 
D1 F 51 Cerebrum Glioblastoma 4 Malignant 2 4 
D2 F 51 Cerebrum Glioblastoma 4 Malignant 3 4 
D3 F 22 Cerebrum Glioblastoma 4 Malignant 2 3 
D4 F 22 Cerebrum Glioblastoma 4 Malignant 2 3 
D5 M 33 Cerebrum Glioblastoma 4 Malignant 3 3 
D6 M 33 Cerebrum Glioblastoma 4 Malignant 3 2 
D7 M 73 Cerebrum Glioblastoma 4 Malignant 3 3 
D8 M 73 Cerebrum Glioblastoma 4 Malignant 0 1 
D9 M 43 Cerebrum Glioblastoma 4 Malignant 4 2 
D10 M 43 Cerebrum Glioblastoma 4 Malignant 4 2 
E1 F 61 Cerebrum Glioblastoma 4 Malignant 4 3 
E2 F 61 Cerebrum Glioblastoma 4 Malignant 4 3 
E3 M 26 Cerebrum Glioblastoma 4 Malignant 4 4 
E4 M 26 Cerebrum Glioblastoma 4 Malignant Non-specific Non-specific 
E5 M 59 Cerebrum Glioblastoma 4 Malignant 0 4 
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E6 M 59 Cerebrum Glioblastoma 4 Malignant 4 4 
E7 F 40 Cerebrum Anaplastic astrocytoma 3 Malignant 3 3 
E8 F 40 Cerebrum Anaplastic astrocytoma 3 Malignant 1 4 
E9 M 34 Cerebrum Glioblastoma 4 Malignant 4 3 
E10 M 34 Cerebrum Glioblastoma 4 Malignant 4 3 
F1 F 33 Cerebrum Anaplastic astrocytoma 3 Malignant 1 2 
F2 F 33 Cerebrum Anaplastic astrocytoma 3 Malignant 1 3 
F3 M 40 Cerebrum Glioblastoma 4 Malignant 4 4 
F4 M 40 Cerebrum Glioblastoma with necrosis 4 Malignant 4 4 
F5 F 58 Cerebrum Glioblastoma 4 Malignant Non-specific Non-specific 
F6 F 58 Cerebrum Glioblastoma 4 Malignant 2 4 
F7 F 33 Cerebrum Glioblastoma 4 Malignant 4 4 
F8 F 33 Cerebrum Glioblastoma 4 Malignant 4 4 
F9 F 44 Cerebrum Glioblastoma 4 Malignant 3 3 
F10 F 44 Cerebrum Glioblastoma 4 Malignant 3 2 
G1 M 26 Cerebrum Glioblastoma 4 Malignant 3 4 
G2 M 26 Cerebrum Glioblastoma 4 Malignant 3 4 
G3 F 48 Cerebrum Glioblastoma 4 Malignant 2 3 
G4 F 48 Cerebrum Glioblastoma 4 Malignant 2 3 
G5 M 43 Cerebrum Glioblastoma 4 Malignant 4 2 
G6 M 43 Cerebrum Glioblastoma 4 Malignant 4 2 
G7 F 30 Cerebrum Glioblastoma 4 Malignant 4 3 
G8 F 30 Cerebrum Glioblastoma 4 Malignant 4 3 
G9 F 42 Cerebrum Glioblastoma 4 Malignant 4 4 
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G10 F 42 Cerebrum Glioblastoma 4 Malignant 4 4 
H1 F 50 Cerebrum Cerebral white matter tissue - Normal 2 4 
H2 F 50 Cerebrum Cerebral white matter and gray tissue - Normal 2 3 
H3 F 42 Cerebrum Cerebral gray matter tissue - Normal 0 3 
H4 F 42 Cerebrum Cerebral gray matter tissue - Normal 0 3 
H5 M 35 Cerebrum Cerebral white matter and gray tissue - Normal 0 4 
H6 M 35 Cerebrum Cerebral gray matter tissue - Normal 0 4 
H7 F 24 Cerebrum Cerebral white matter and gray tissue - Normal 0 4 
H8 F 24 Cerebrum Cerebral gray matter tissue - Normal 0 4 
H9 M 49 Cerebrum Cerebral white matter tissue - Normal 1 4 
H10 M 49 Cerebrum Cerebral white matter tissue - Normal 1 4        
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 Supplementary Figure 1: RIN Score reports depicts each sample’s peak profile and blots, with RIN 
score.    
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Supplementary Figure 2: Murine Level 4 Pathogen Screening Report for LN18, LN18CSC, U87-MG, U87-MGCSC, U251-MG and U251-MGCSC. Pathogen testing was performed 
prior to any in vivo work. All cell lines were negative for the complete panel of murine pathogens tested. 
  
384 
               
Supplementary Figure 3: TMA slide GL806d cores stained for HOXC4 protein. Images were taken at x10 magnification using a ZEISS Primo Star light microscope attached 
to a Micorpix Macro-Imager, and analysed using the Micropix Cytocam V1.3.5.0. 
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Supplementary Figure 4: TMA slide GL806d cores stained for PBX proteins 1-4. Images were taken at x10 magnification using a ZEISS Primo Star light microscope attached 
to a Micorpix Macro-Imager, and analysed using the Micropix Cytocam V1.3.5. 
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Supplementary Figure 5: Parental tumours and CSC tumours, treated with either PBS or HXR9, stained for cleaved caspase 3, C-Fos or DUSP1. Images were taken at x10 
and x20 magnification using a ZEISS Primo Star light microscope attached to a Micorpix Macro-Imager, and analysed using the Micropix Cytocam V1.3.5.0.  
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TMZ (μM) Significant? P value Difference SE of difference t ratio 
50 Yes 0.00109833973034 9.684 2.439 3.97 
100 Yes 0.000105692255368 14.94 2.925 5.106 
300 Yes 0.000000000000002 -46.94 1.591 29.51 
600 Yes 0.000000000001491 -28.92 1.488 19.43 
800 Yes 0.000000000000297 -28.26 1.31 21.57 
1000 Yes 0.000000000180428 -21.54 1.521 14.16         
TMZ (μM) Significant? P value Difference SE of difference t ratio 
50 No 0.183810442003474 -4.641 3.341 1.389 
100 No 0.771148304340602 -0.5512 1.863 0.2959 
300 No 0.267945828893143 -1.817 1.583 1.148 
600 Yes 0.000000015302674 -10.79 1.035 10.43 
800 Yes <0.000000000000001 -24.51 0.4479 54.72 
1000 Yes 0.000000000000098 -35.24 1.521 23.16 
B| U87-MG and U87-MG
CSC 
A| LN18 and LN18CSC 
0 50 10
0
30
0
60
0
80
0
10
00
20
40
60
80
100
120
Temozolomide (µM)
%
 S
ur
vi
va
l LN18
LN18 CSC
0 50 10
0
30
0
60
0
80
0
10
00
20
40
60
80
100
120
Temozolomide (µM)
%
 S
ur
vi
va
l U87-MG
U87-MG CSC
  397 
        
TMZ (μM) Significant? P value Difference SE of difference t ratio 
50 Yes 0.009245005168444 -11.76 3.974 2.959 
100 Yes 0.000060529199943 -14.41 2.675 5.387 
300 Yes 0.000000000000188 -18.93 0.8517 22.22 
600 Yes 0.000000032946201 -13.22 1.339 9.87 
800 Yes 0.000000000617419 -18.92 1.452 13.03 
1000 Yes 0.034311727288647 0.8068 0.3487 2.314 
Supplementary Figure 6: TMZ dose response curves and unmatched student t test’s analysis tables 
for: A| LN18 and LN18CSC, B| U87-MG and U87-MGCSC, C| U251-MG and U251-MGCSC.   
 
 
 
 
 
 
 
 
Supplementary Figure 7: Cell cycle analysis gating example. A single strand of singlets were gated to 
ensure no doublets, which would provided false positive results for cells in G2/M phase, were included 
in analysis.  
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0 50 10
0
30
0
60
0
80
0
10
00
20
40
60
80
100
120
Temozolomide (µM)
%
 S
ur
vi
va
l U251-MG
U251-MG CSC
  398 
 
  
     
E4 (μM) Significant? P value Difference SE of difference t ratio 
10 Yes 0.000043 -9.25373 1.66353 5.5627 
30 Yes <0.000001 23.4519 2.18914 10.7128 
60 Yes <0.000001 13.9875 1.65312 8.4613 
80 Yes <0.000001 8.187 0.560989 14.5939 
100 Yes <0.000001 12.9575 0.838729 15.4489 
120 Yes 0.00007 3.71915 0.700219 5.31141        
E4 (μM) Significant? P value Difference SE of difference t ratio 
10 Yes 0.017579 -6.09934 2.30432 2.64692 
30 No 0.175621 -3.80708 2.68646 1.41714 
60 Yes <0.000001 10.4058 1.16269 8.94976 
80 Yes <0.000001 11.5054 1.21862 9.44134 
100 Yes 0.000007 7.85273 1.2008 6.53957 
120 Yes 0.013874 -0.600566 0.217402 2.76246 
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E4 (μM) Significant? P value Difference SE of difference t ratio 
10 Yes <0.000001 24.8511 1.5361 16.1781 
30 Yes <0.000001 12.5669 0.935884 13.4279 
60 Yes 0.000013 7.90114 1.27872 6.17894 
80 Yes <0.000001 14.5571 0.542645 26.8262 
100 Yes <0.000001 9.8418 0.42925 22.9279 
120 Yes 0.000791 -1.40436 0.340327 4.12649 
Supplementary Figure 8: E4 dose response curves and unmatched student t test’s analysis tables for: 
A| LN18 and LN18CSC, B| U87-MG and U87-MGCSC, C| U251-MG and U251-MGCSC.  
 
 
 
 
C| U251-MG and U251-MGCSC 
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Conference Posters, Talks and Awards 
Posters| ‘Inhibiting HOX Protein Function in Glioma Stem Cells as a Novel Therapeutic Approach in Glioblastoma’- British Neuro-Oncology Society (BNOS) 2015, East Midlands Conference Centre, University of Nottingham, Nottingham UK. 
https://academic.oup.com/neuro-oncology/article/17/suppl_8/viii9/2472773/PO49INHIBITING-HOX-PROTEIN-
FUNCTION-IN-GLIOMA-STEM 
‘Targetting Developmental Proteins in Glioblastoma as a Novel Treatment’- Surrey Cancer Research Institute (SCRI) and King’s Health Partners Cancer Conference 2015, The Surrey Conferences Meeting Centre, University of Surrey, Guildford UK. 
‘Inhibiting PBX-HOX Binding in Paediatric Glioma Stem Cells as a Novel Therapeutic Treatment in Glioblastoma’- The International Symposium on Pediatric Neuro-Oncology (ISPNO) 2016, Arena and Convention Centre Liverpool, Liverpool UK. 
https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_3/iii56/2469250/HG-38INHIBITING-PBX-
HOX-BINDING-IN-PAEDIATRIC?rss=1 
‘Inbibiting HOX-PBX Dimers in Glioblastoma Cancer Stem Cells’- SCRI and King’s Health Partners Annual Cancer R&D Conference 2016, King’s Health Partners Comprehensive Cancer Centre, Guy’s Hospital, London UK.  
‘Targeting PBX-HOX Complexes in Glioblastoma’- The Prostate Project 10 Year Anniversary Conference 2016, The Surrey Conferences Meeting Centre, University of Surrey, Guildford UK. 
‘Targeting Developmental Proteins as a Novel Treatment in Glioblastoma’- European Association of Neuro-Oncology (EANO) 2016, Congress Centre Rosengarten, Mannheim Germany. 
https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv44/2222838/P08-17-Targeting-
developmental-proteins-as-a-novel?redirectedFrom=PDF 
‘Inhibiting HOX-PBX Binding in Paediatric Glioblastoma as a Novel Therapeutic Treatment’- Nactional Cancer Research Institute (NCRI) 2016, Arena and Convention Centre Liverpool, Liverpool UK. 
http://abstracts.ncri.org.uk/abstract/inhibiting-hox-pbx-binding-in-paediatric-glioblastoma-as-a-novel-
therapeutic-treatment/ 
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‘Small Molecular Targeting of HOX-PBX Binding in Glioblastoma as a Novel Therapeutic Treatment’- Society of Neuro-Oncology (SNO) 2016, Scottsdale Princess hotel, Scottsdale USA. 
https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_6/vi69/2542368/EXTH-48-SMALL-
MOLECULAR-TARGETING-OF-HOX-PBX 
Talks| ‘Inhibiting HOX-PBX Binding in Paediatric Glioblastoma as a Novel Therapeutic Treatment’- NCRI 2016, Arena and Convention Centre Liverpool, Liverpool UK. 
http://abstracts.ncri.org.uk/abstract/inhibiting-hox-pbx-binding-in-paediatric-glioblastoma-as-a-novel-
therapeutic-treatment/ 
Awards| ‘Inhibiting HOX-PBX Binding in Paediatric Glioblastoma as a Novel Therapeutic Treatment’- NCRI Talk 2016, Arena and Convention Centre Liverpool, Liverpool UK. Children’s Cancer and Leukaemia Group (CCLG) Award.  
 
   
